View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Acknowledgements<br />
We would like to acknowledge and thank our sponsors,<br />
whose contribution to <strong>Rheumatology</strong> 2012 ensure we deliver<br />
a quality scientific meeting, and give access to a range of<br />
quality educational symposia and an innovative exhibition<br />
Platinum sponsors<br />
Abbott | stand 38<br />
Treat to target symposium: the patient at the heart of treat to target<br />
New practical tools to optimise the consultation process<br />
Wednesday 2 May, 18.00 – 19.30<br />
Page 50<br />
Would like to thank <strong>for</strong> their generous support<br />
Platinum<br />
New developments in spondyloarthritis<br />
Diagnosis, management and clinical advances in axial SpA<br />
Thursday 3 May, 07.30 – 09.00<br />
Page 56<br />
Roche products Ltd | stand 98<br />
Assessing the evidence: the benefits of IL-6R Inhibition in RA<br />
Wednesday 2 May, 18.00 – 19.30<br />
Page 53<br />
Gold Sponsors<br />
Bristol-Myers Squibb Pharmaceuticals | stand 114<br />
Getting it right: optimising RA treatment strategies in the evolving NHS<br />
Wednesday 2 May, 07.30 – 09.00<br />
Page 34<br />
Silver Sponsors<br />
Cellestis GmbH | stand 64<br />
Screening of TB infection in pre TNF-alpha patients. How IGRA improves outcomes<br />
Wednesday 2 May, 07.30 – 09.00<br />
Page 37<br />
Gold<br />
Silver<br />
Pfizer Inc. | stand 34<br />
Emerging treatment directions: signalling changes in rheumatoid arthritis<br />
Tuesday 1 May, 17.45 – 19.15<br />
Page 30<br />
UCB | stand 26
Contents<br />
Presidents’ welcome 2<br />
General in<strong>for</strong>mation 4-5<br />
Floor plan 6-7<br />
BSR Prizes and awards 8-9<br />
BHPR Prizes and awards 10<br />
Keynote speakers 12-13<br />
Poster categories and tours 14<br />
<strong>Rheumatology</strong> 2013 15<br />
Meeting at a glance<br />
Meeting at a glance 17-19<br />
Additional meetings 20<br />
Programme:<br />
Tuesday 1 May 2012 21-32<br />
Programme:<br />
Wednesday 2 May 2012 33-52<br />
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 1<br />
Oral presentation of abstracts 67-78<br />
Poster viewing:<br />
Tuesday 1 May 2012 79-92<br />
Poster viewing:<br />
Wednesday 2 May 2012 93-108<br />
Poster viewing:<br />
Thursday 3 May 2012 109-124<br />
Exhibition<br />
Exhibitor list 126<br />
Exhibition floor plan 127<br />
<strong>Rheumatology</strong> 2012 exhibitors 128-133<br />
Abstract reviewers 134<br />
Prize and bursary assesors 135<br />
Notes 136-144<br />
Programme:<br />
Thursday 3 May 2012 53-66<br />
BSR, Bride House,<br />
18-20 Bride Lane, London EC4Y 8EE<br />
Telephone: +44 (0) 20 7842 0900<br />
Fax: +44 (0) 20 7842 0901<br />
Email: events@rheumatology.org.uk<br />
Website: www.rheumatology.org.uk/<strong>conference</strong><br />
A Company limited by guarantee with charitable status<br />
VAT No. 404 5637 66<br />
Company Reg. No. 3470316<br />
Charity Reg. No. 1067124<br />
Design and produced by: AD Design www.ad-design.uk.com<br />
®<br />
MIX<br />
From responsible<br />
sources<br />
FSC ® TT-COC-002846<br />
www.fsc.org
2 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
Presidents’ welcome<br />
Dear friends and colleagues,<br />
Welcome to <strong>Rheumatology</strong> 2012! We are delighted that you<br />
are able to join us at the UK’s leading rheumatology event.<br />
<strong>The</strong> <strong>conference</strong> offers an invaluable chance <strong>for</strong> the whole<br />
rheumatology team to come together to learn, network and<br />
hear about the latest developments in the field.<br />
We are all working in an increasingly challenging environment<br />
and so it is more important than ever that we come together as<br />
a community to support each other and raise the profile of the<br />
specialty.<br />
As always, we would love to hear your thoughts about the<br />
<strong>conference</strong>. You will receive an email inviting you to complete<br />
the <strong>conference</strong> survey and we would encourage you to give us<br />
your comments and suggestions to make sure that your<br />
<strong>conference</strong> gets better and better each year.<br />
Prof David L Scott and Mrs Lindsey Hawley<br />
‘Networking with colleagues in<br />
rheumatology is invaluable and the<br />
<strong>conference</strong> is the perfect opportunity<br />
to do just that’ Delegate 2011<br />
Connect with us via Twitter, Facebook or Linkedin:<br />
@<strong>Rheumatology</strong>UK<br />
⧣Rheum2012<br />
facebook.com/rheumatologyUK<br />
Search ‘Groups’:<br />
<strong>Rheumatology</strong> 2012
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 3<br />
Meet the BSR Events team<br />
<strong>The</strong> BSR Events team have worked hard to make sure that<br />
<strong>Rheumatology</strong> 2012 is as successful a <strong>conference</strong> as possible.<br />
If you have any problems at all while at the <strong>conference</strong>, please do<br />
come and speak to one of the team via the registration desk.<br />
Louis Bellintani James Glavin Saheeda Rahman Briony Wilson<br />
Education and Events Director of Events Senior Events Senior Events<br />
Officer and Marketing Officer Officer<br />
You can contact the Events team at<br />
events@rheumatology.org.uk
4 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
General in<strong>for</strong>mation<br />
Registration opening hours<br />
Monday 30 April 16.00-20.00<br />
Tuesday 1 May 08.00-19.30<br />
Wednesday 2 May 07.00-18.30<br />
Thursday 3 May 07.00-16.00<br />
Exhibition opening hours<br />
Tuesday 1 May 09.00-18.30<br />
Wednesday 2 May 09.00-17.00<br />
Thursday 3 May 08.45-14.30<br />
Abstract supplement<br />
All accepted abstracts have been published<br />
as a supplement in BSR’s journal<br />
<strong>Rheumatology</strong>. Abstracts are freely available<br />
online on the journal’s website at<br />
www.rheumatology.ox<strong>for</strong>djournals.org<br />
All <strong>conference</strong> delegates will receive a hard<br />
copy abstract book in their delegate bag<br />
and a lanyard featuring an integrated USB<br />
stick with an electronic version of the<br />
abstract book.<br />
Badges<br />
Your name badge gives you access to any<br />
session taking place on the days <strong>for</strong> which<br />
you have registered. Please wear your badge<br />
visibly when at <strong>Rheumatology</strong> 2012 –<br />
stewards will not allow people without badges<br />
to access sessions or the exhibition areas.<br />
CPD<br />
<strong>The</strong> <strong>conference</strong> is accredited by the Royal<br />
College of Physicians (up to 18 credits - six<br />
per day) and by the Royal College of Nursing<br />
(up to 19 study hours). A certificate of<br />
attendance is included in your delegate bag.<br />
Please ensure that your badge is scanned<br />
once each day that you are at the<br />
<strong>conference</strong> in order to receive your CPD<br />
points. Scanners will be available at the<br />
registration desks and at the entrance of<br />
the exhibition area in Hall 5.<br />
Please ensure that your<br />
badge is scanned once<br />
each day that you are at<br />
the <strong>conference</strong> in order to<br />
receive your CPD points<br />
First time at the <strong>conference</strong>?<br />
We want you to get the most out of<br />
your time at <strong>Rheumatology</strong> 2012<br />
so if there’s anything the BSR team can<br />
do to help come and find us at the<br />
registration desk or on the BSR Stand 32<br />
CPD <strong>for</strong> Essentials in <strong>Rheumatology</strong><br />
In order to receive CPD recognition <strong>for</strong><br />
attending the Essentials <strong>programme</strong>, please<br />
ensure that you are scanned in to the room<br />
be<strong>for</strong>e each session.<br />
Catering<br />
Your registration fee <strong>for</strong> the <strong>conference</strong><br />
includes lunch and tea and coffee <strong>for</strong> each<br />
day that you have registered. <strong>The</strong>re are<br />
multiple catering points located throughout<br />
the exhibition areas.<br />
Accommodation<br />
If you have booked through our appointed<br />
accommodation agents, Reservations<br />
Highway, you can contact them with any<br />
accommodation queries on<br />
(0)1423 525 577.
Connect with us via Twitter, Facebook or Linkedin:<br />
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 5<br />
@<strong>Rheumatology</strong>UK<br />
⧣Rheum2012<br />
facebook.com/rheumatologyUK<br />
Search ‘Groups’:<br />
<strong>Rheumatology</strong> 2012<br />
Speaker preview<br />
All speakers are asked to check in their<br />
presentation at the speaker preview room no<br />
later than two hours prior to your session<br />
start time. <strong>The</strong> speaker preview room is<br />
situated in Carron Room 2 (see venue map<br />
page 6/7). If your session is first thing in the<br />
morning, you may want to check in your<br />
presentation the night be<strong>for</strong>e. Speaker<br />
badges can be picked up from the<br />
registration desk in Hall 5.<br />
Cyber café<br />
<strong>The</strong> Cyber café, is situated in the exhibition<br />
area in Hall 5 and is free <strong>for</strong> all delegates<br />
to use. Check your emails and comment on<br />
BSR’s social media channels.<br />
Social Media<br />
We encourage your use of social media in<br />
and around <strong>Rheumatology</strong> 2012. Search on<br />
Twitter <strong>for</strong> the hashtag #Rheum2012 to<br />
follow the feed of tweets related to the<br />
<strong>conference</strong> and be sure to include<br />
#Rheum2012 in any tweets that you send<br />
out. Use social media to contact other<br />
attendees: suggest sessions to attend and<br />
posters to visit, plan to meet up in the<br />
Exhibition Hall or at the social events.<br />
Provide helpful feedback to <strong>The</strong> Events team,<br />
discuss topics of interest and/or speakers<br />
and make suggestions <strong>for</strong> next year’s<br />
meeting. Happy tweeting!<br />
Room capacities<br />
We have tried to allocate rooms to ensure<br />
that the room size is appropriate <strong>for</strong> the<br />
session, based on the in<strong>for</strong>mation given to us<br />
by delegates when they book. We apologise<br />
in advance if you are not able to attend a<br />
session due to the room being full.<br />
Press area<br />
<strong>The</strong> <strong>Rheumatology</strong> 2012 press area is<br />
situated next to the poster area in Hall 5<br />
(see exhibition floor plan page 127).<br />
Members of the press can use the area to<br />
issue press releases and as a meeting point.<br />
On request, the Events team can organise<br />
one-to-one interviews with key speakers and<br />
spokespeople at the <strong>conference</strong>, subject to<br />
availability.<br />
Property and cloakroom<br />
Delegates are responsible <strong>for</strong> their property<br />
at all times. Neither the BSR nor the venue<br />
can accept liability <strong>for</strong> loss or damage of<br />
personal items. Please keep bags and<br />
packages with you at all times or use the<br />
cloakroom provided. Unattended items can<br />
cause unnecessary security alerts.<br />
Business centre<br />
Delegates can use the Cyber café in the<br />
exhibition area (Hall 5) <strong>for</strong> accessing the<br />
internet and printing. <strong>The</strong> SECC also has a<br />
business centre where you can access a<br />
range of business services such as<br />
photocopying and faxing.<br />
Prayer space<br />
If you require a quiet space during the course<br />
of the <strong>conference</strong>, please contact a member<br />
of the Events team via the registration desk in<br />
Hall 5.<br />
First aid<br />
Trained first aiders will be on duty throughout<br />
the event. Please contact one of the Events<br />
team or one of the venue’s stewards in the<br />
event of an incident. <strong>The</strong>re is a first aid suite<br />
situated on the main SECC concourse staffed<br />
by qualified first aid staff.<br />
Smoking policy<br />
Smoking is not permitted anywhere within<br />
the <strong>conference</strong> venue.<br />
Disclaimer<br />
Please note that the BSR and BHPR accept<br />
no responsibility <strong>for</strong> views expressed by the<br />
speakers at the event.
6 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
DOOR 4.4<br />
F M<br />
Poster area<br />
F F M<br />
F<br />
Ground level<br />
ALL 4<br />
HALL 5<br />
OOR<br />
4C<br />
DOOR<br />
4B<br />
M<br />
M<br />
Exhibition<br />
Exit<br />
Registration<br />
Exhibition<br />
Entrance<br />
M<br />
F<br />
Concourse<br />
< MAIN ENTRANCE<br />
DOOR<br />
2A<br />
F M<br />
F<br />
M<br />
HALL 1<br />
M<br />
F<br />
Lomond<br />
Auditorium<br />
Alsh 1 Alsh 2<br />
Etive<br />
LOCH SUITE<br />
Fyne<br />
Café<br />
M<br />
F<br />
Boisdale Boisdale<br />
2 1<br />
Linked corridor to<br />
Clyde Auditorium<br />
CONFERENCE CENTRE<br />
Clyde Auditorium<br />
Gala 1 & 2<br />
(Upper Level)<br />
Forth<br />
(Ground Level)
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 7<br />
Upper level<br />
Katrine<br />
Leven<br />
Morar<br />
Ness<br />
M<br />
F<br />
Concourse<br />
M<br />
F<br />
Carron<br />
1<br />
Carron<br />
2<br />
Speaker preview<br />
LOCH SUITE<br />
Lomond<br />
Auditorium<br />
Upper Level<br />
Dochart<br />
2<br />
Dochart<br />
1<br />
Linked corridor to<br />
Clyde Auditorium
8 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
BSR Prizes and awards<br />
BSR is proud to recognise and celebrate achievements and innovations that change<br />
the face of rheumatology<br />
Michael Mason<br />
<strong>The</strong> esteemed Michael Mason Prize is awarded by the Heberden<br />
Committee <strong>for</strong> excellence in clinical or scientific research in the field<br />
of rheumatology, the winner receives: £1,000, the Michael Mason<br />
award, complimentary <strong>conference</strong> registration and the opportunity<br />
to present their work during the plenary session of that year.<br />
Dr Kimme Hyrich, University of Manchester, Manchester<br />
<strong>The</strong> silver standard: measuring treatment effects using<br />
observational data<br />
Tuesday 1 May, 14.00 – 16.00, Jewels in the Crown, page 30<br />
Garrod Prize<br />
<strong>The</strong> prestigious Garrod Prize is open to scientists with a non-clinical<br />
background currently working in rheumatology or a related discipline.<br />
<strong>The</strong> winner receives: £1,000, <strong>The</strong> Garrod award, complimentary<br />
<strong>conference</strong> registration and the opportunity to present their work<br />
during the plenary session of that year.<br />
Mrs Elizabeth Camacho, University of Manchester, Manchester<br />
<strong>The</strong> relationship between pregnancy and long-term functional<br />
disability in women with inflammatory polyarthritis: results from<br />
the Norfolk Arthritis Register (NOAR)<br />
Tuesday 1 May, 14.00 – 16.00, Jewels in the Crown, page 30<br />
Young Investigator Award<br />
Awarded to young investigative rheumatologists who have included<br />
an imaginative hypothesis with results that could advance knowledge<br />
within the field. Winners receive: complimentary registration to<br />
<strong>Rheumatology</strong> 2012, publication of the winning abstract in the<br />
BSR journal <strong>Rheumatology</strong> plus the opportunity to present the<br />
research at <strong>Rheumatology</strong> 2012.<br />
Miss Youridies Vattakuzhi, Kennedy Institute of <strong>Rheumatology</strong>,<br />
London<br />
Dual specificity phosphatase 1 is a crucial negative regulator<br />
of inflammatory osteolysis and a mediator of therapeutic effects<br />
of dexamethasone in collagen-induced arthritis<br />
Thursday 3 May, 14.00 – 15.30, Molecular mechanisms of disease:<br />
inflammatory arthritis II, page 63<br />
Dr Jennifer Humphreys, University of Manchester, Manchester<br />
Incidence of rheumatoid arthritis in the UK using the 2010<br />
ACR/EULAR classification criteria; and comparison with estimates<br />
using the 1987 ACR criteria<br />
Thursday 3 May, 09.00 – 10.30, Oral abstracts: epidemiology and<br />
outcomes, page 56<br />
Dr Joanna Cobb, University of Manchester, Manchester<br />
Analysis of the immunochip in a large cohort of oligo- and<br />
polyarthritis juvenile idiopathic arthritis cases confirms previous<br />
and identifies novel associations<br />
Thursday 3 May, 14.00 – 15.30, Oral abstracts: genetics, page 64<br />
Dr Amy Naylor, University of Birmingham, Birmingham<br />
<strong>The</strong> mesenchymal stromal cell marker cd248 regulates<br />
inflammatory arthritis and bone <strong>for</strong>mation<br />
Thursday 3 May, 14.00 – 15.30, Molecular mechanisms of disease:<br />
inflammatory arthritis II, page 63<br />
Dr Clare Warrell, Royal Free Hampstead Hospital NHS Trusts, London<br />
Is there an association between warfarin and survival in ssc-pah<br />
patients treated with first line bosentan monotherapy?<br />
Wednesday 2 May, 11.45 – 13.15, Oral abstracts: connective<br />
tissue diseases, page 42
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 9<br />
Every year the BSR runs a <strong>programme</strong> of prizes and awards<br />
to raise the profile of achievements within rheumatology and<br />
to encourage those working to improve patient care. To find<br />
out more about our popular range of bursaries, prizes and<br />
awards please visit www.rheumatology.org.uk/prizes<br />
Medical Student Bursaries<br />
Awarded to UK medical students whose abstract submission scored<br />
highly and was judged by the Heberden Committee to be of<br />
particularly good quality. Winners receive: complimentary<br />
<strong>conference</strong> registration, economy travel expenses, two nights’<br />
accommodation and the opportunity to present their work<br />
at <strong>Rheumatology</strong> 2012<br />
Mr Matthew Casey, University of Glasgow, Glasgow<br />
Can peer assisted learning delivered by medical<br />
students be useful in training senior colleagues in<br />
use of REMS technique <strong>for</strong> mss examination?<br />
A pilot study<br />
Poster 278, Thursday 3 May, 10.30 – 11.30, Poster viewing<br />
Ms Helen Monk, Keele University, Keele<br />
Are rheumatoid arthritis patients screened <strong>for</strong> cardiovascular<br />
disease in primary care?<br />
Wednesday 2 May, 14.45 – 16.15, Oral abstracts: primary care<br />
page 46<br />
Ms Elizabeth Jackson, Brighton and Sussex Medical School, Brighton<br />
A case control study of risk factors <strong>for</strong> elective hip replacement<br />
or resurfacing surgery in HIV-infected adults<br />
Poster 116, Wednesday 2 May, 10.45 – 11.45, Poster viewing<br />
Mr Amin Oomatia, University of Cambridge, Cambridge<br />
Peripheral neuropathy in systemic lupus erythematosus<br />
Poster 337, Thursday 3 May, 10.30 – 11.30, Poster viewing<br />
Innovations Award 2012 Supported by Abbott<br />
<strong>The</strong> awards will recognise innovation in rheumatology:<br />
a project, initiative or pioneering new strategy that has<br />
been utilised in practice to improve patient care.<br />
Dr Giuseppina Abignano, Leeds Institute of Molecular Medicine, Leeds<br />
Optical coherence tomography validation: a new quantitative<br />
imaging biomarker <strong>for</strong> affected skin in scleroderma<br />
Wednesday 2 May, 11.45 – 13.15, Oral abstracts: connective<br />
tissue diseases, page 42<br />
‘<strong>The</strong> award has given me the opportunity to<br />
be here that I might have missed otherwise.<br />
Listening to others starting out in research<br />
has inspired and enthused me’ Prize winner 2011
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 11<br />
IN RA, WHEN COMBINATION WITH MTX IS NOT AN OPTION,<br />
Think<br />
THINK BIOLOGIC<br />
MONOTHERAPY<br />
®<br />
PRESCRIBING INFORMATION ROACTEMRA ® (tocilizumab):<br />
Please refer to RoActemra SPC <strong>for</strong> full prescribing<br />
in<strong>for</strong>mation.<br />
Indication: RoActemra, in combination with methotrexate (MTX),<br />
is indicated <strong>for</strong> the treatment of adult patients with moderate to<br />
severe active rheumatoid arthritis who have had an inadequate<br />
response or intolerance to previous DMARDs or TNF antagonists.<br />
RoActemra can be given as monotherapy if continued treatment<br />
with MTX is inappropriate. RoActemra has been shown to reduce<br />
the rate of progression of joint damage as measured by X-ray and<br />
to improve physical function when given in combination with MTX.<br />
Dosage and Administration: Recommended posology is 8mg/<br />
kg iv infusion given over one hour diluted to a volume of 100ml<br />
and given once every 4 weeks. For patients with body weight over<br />
100kg, doses exceeding 800mg per infusion are not recommended.<br />
Doses above 1.2g have not been evaluated. Treatment should be<br />
initiated by an appropriately experienced healthcare professional<br />
and patients should be given the Patient Alert Card. Dose<br />
adjustments: No dose adjustment is required in elderly patients,<br />
or in patients with mild renal impairment. Dose adjustments to<br />
4mg/kg, or interruptions, are recommended in the event of raised<br />
liver enzymes, low absolute neutrophil count or low platelet count<br />
(see SPC <strong>for</strong> details). RoActemra should not be initiated in patients<br />
with absolute neutrophil count below 2x10 9 /l. Contraindications:<br />
Hypersensitivity to any component of the product; active, severe<br />
infections. Precautions: Infections: Serious and sometimes fatal<br />
infections have been reported with RoActemra. In cases of serious<br />
infection interrupt therapy until controlled. Caution in patients<br />
with recurring/chronic infections, or other conditions which may<br />
predispose to infection. Severe neutropenia may be associated<br />
with an increased risk of serious infections. Tuberculosis: Screen<br />
<strong>for</strong> and treat latent TB prior to starting therapy. Viral reactivation:<br />
Viral reactivation (e.g. hepatitis B virus) has been reported with<br />
biologic therapies <strong>for</strong> RA. Diverticulitis: Caution in patients with<br />
a history of intestinal ulceration or diverticulitis. Patients with<br />
symptoms of complicated diverticulitis should be evaluated<br />
promptly. Hypersensitivity reactions: Fatal anaphylaxis may occur<br />
in patients who have experienced hypersensitivity reactions during<br />
previous infusions even if they have received premedication<br />
with steroids and antihistamines. Appropriate treatment should<br />
be available <strong>for</strong> immediate use in the event of an anaphylactic<br />
reaction. If serious hypersensitivity/serious infusion related<br />
reactions occur stop RoActemra treatment and permanently<br />
discontinue. Active hepatic disease/impairment: Use with caution<br />
in patients with active hepatic disease/impairment. Hepatic<br />
transaminase elevations: Not recommended in patients with<br />
baseline ALT or AST >5xULN; caution in patients with ALT or AST<br />
>1.5xULN. Monitor ALT/AST levels according to SPC. Consider<br />
other liver function tests including bilirubin if clinically indicated.<br />
Haematological abnormalities: Caution in patients with platelet<br />
count
12 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
Keynote speakers<br />
Tuesday 1 May, 14.00 – 16.00<br />
Keynote: Jewels in the Crown<br />
Sir Philip Craven, President, International<br />
Paralympic Committee<br />
Sir Philip Craven is a five time<br />
Paralympian in Wheelchair Basketball<br />
(1972-1988) and Swimming (1972).<br />
His international achievements in<br />
Wheelchair Basketball include World<br />
championship/Gold Cup (1973), Gold<br />
medal – European Championship (1991<br />
and 1994) and Bronze medal – World<br />
Championship/Gold Cup (1975). Sir Philip has also received a<br />
number of prestigious awards including Knight Bachelor by HM<br />
Queen Elizabeth II <strong>for</strong> services to Paralympic Sport (2005) and<br />
Member of the Order of the <strong>British</strong> Empire (MBE) by HM Queen<br />
Elizabeth II <strong>for</strong> services to Wheelchair Basketball (1991).<br />
Sir Philip is the current President of the International<br />
Paralympic Committee. His major contributions to Paralympic<br />
sport include Member of the International Olympic Committee<br />
(IOC) (since 2003), Member of the Executive Board, <strong>British</strong><br />
Olympic Association (since 2003), Board Member of the London<br />
2012 Organizing Committee <strong>for</strong> the Olympic and Paralympic<br />
Games (since 2005) and Member of the IOC Commission <strong>for</strong><br />
Culture and Olympic Education (since 2005). Sir Philip Craven’s<br />
professional career has included Per<strong>for</strong>mance Director, GBWBA<br />
Men’s Wheelchair Basketball Team (1998-2002), Chief<br />
Executive Officer, International Wheelchair Basketball Federation<br />
(1994-1998) and Company Secretary, <strong>British</strong> Coal Corporation<br />
(Western Area) (1986-1991).<br />
Tuesday 1 May, 11.30 – 13.00<br />
Droitwich Lecture<br />
Dr Jackie Hill, Senior Lecturer in <strong>Rheumatology</strong>,<br />
University of Leeds, Leeds<br />
Jackie has worked in rheumatology <strong>for</strong><br />
over 30 years as a practitioner, a<br />
senior lecturer and a researcher. She<br />
was one of the first rheumatology nurses<br />
in the UK to hold nurse led clinics and<br />
undertook the seminal research into<br />
outcomes from these clinics. She<br />
obtained her Masters Degree in 1991,<br />
her PhD in 2000 and in 1990 was honoured with Fellowship of<br />
the Royal College of Nursing <strong>for</strong> an outstanding contribution to<br />
the science and art of rheumatology nursing. Jackie is a <strong>for</strong>mer<br />
Chair of the RCN <strong>Rheumatology</strong> Nursing Forum, President of<br />
BHPR and has sat on several EULAR committees. More recently<br />
she was co-convenor of the EULAR Nursing Task Force which<br />
published Recommendations <strong>for</strong> the Basic and Advanced Role of<br />
the Nurse in the Management of Chronic Inflammatory Arthritis.<br />
Be<strong>for</strong>e her retirement in July 2011 she was co-director of the<br />
Academic and Clinical Unit <strong>for</strong> Musculoskeletal Nursing, a reviewer<br />
<strong>for</strong> ten journals and a grant application reviewer <strong>for</strong> six national<br />
bodies including NIHR. Jackie was the Associate Editor of<br />
Musculoskeletal Care and editor/author of three books and ten<br />
book chapters. She has published over 130 papers and has given<br />
numerous presentations and keynote lectures at national and<br />
international <strong>conference</strong>s.
1-3 May| SECC, Glasgow, UK | <strong>Rheumatology</strong> 2012 13<br />
Tuesday 1 May, 16.30 – 17.30<br />
Heberden Round<br />
Prof Philip Conaghan, Professor of Musculoskeletal<br />
Medicine, University of Leeds, Leeds<br />
Professor Conaghan’s major research<br />
interests are in understanding pathogenesis<br />
and therapeutic response in osteoarthritis<br />
and rheumatoid arthritis, with a special<br />
focus on the role of imaging. His research<br />
incorporates a spectrum from translational<br />
and proof-of-concept work through to large<br />
clinical trials. He is Professor of<br />
Musculoskeletal Medicine at the University of Leeds, and Chairs the<br />
NICE OA Guidelines Development Group and Arthritis Research UK’s<br />
OA Clinical Studies Group. He previously chaired the Assessment of<br />
Structural Change Working Group of the OARSI-FDA OA Initiative.<br />
He recently completed his term as inaugural Chair of the EULAR<br />
Standing Committee on Imaging, is leader <strong>for</strong> the OMERACT<br />
Imaging & Biomarkers workstream and is President of the<br />
International <strong>Society</strong> <strong>for</strong> Musculoskeletal Imaging in <strong>Rheumatology</strong>.<br />
He has authored over 250 papers, book chapters and books.<br />
Wednesday 2 May 16.45 – 17.45<br />
Heberden Oration<br />
Prof Paul Wordsworth, Professor of <strong>Rheumatology</strong> and<br />
Consultant Rheumatologist, Nuffield Department of<br />
Orthopaedics, <strong>Rheumatology</strong> and Musculoskeletal<br />
Sciences, Ox<strong>for</strong>d<br />
Professor Wordsworth works in the NIHR<br />
Ox<strong>for</strong>d Musculoskeletal Biomedical<br />
Research Unit. His clinical and research<br />
interests are particularly oriented towards<br />
understanding the genetic basis of<br />
musculoskeletal diseases. <strong>The</strong>se include<br />
monogenic disorders, such as Marfan<br />
syndrome and skeletal dysplasias, but also<br />
complex polygenic inflammatory arthropathies. He is a co-founder<br />
of the international consortium investigating the genetics of<br />
ankylosing spondylitis that identified the association with IL23R<br />
and ERAP1. His group also helped to solve the crystal structure of<br />
ERAP1 in 2011. He is co-author of Clinical and Biochemical<br />
Disorders of the Skeleton and has published over 300 original<br />
scientific papers, mainly on the genetics of rheumatic diseases.<br />
He is a Fellow of Green Templeton College.
14 <strong>Rheumatology</strong> 2012 | 1-3 May| SECC, Glasgow, UK<br />
Poster categories and tours<br />
Tuesday 1 May 2012 | 10.30 – 11.30<br />
BHPR research: qualitative 1 – 10<br />
BHPR research: quantitative 11 – 17<br />
BHPR: clinical evaluation and audit delivery 18 - 42<br />
Imaging 43 - 51<br />
Metabolic and crystal arthropathies 52 - 53<br />
Miscellaneous rheumatic diseases 54 - 59<br />
Rheumatoid arthritis: clinical features 60 - 68<br />
Rheumatoid arthritis: comorbidities 69 – 81<br />
Scleroderma and related disorders 82 - 95<br />
Spondylarthropathies (including psoriatic arthritis) 96 – 110<br />
Wednesday 2 May 2012 | 10.45 – 11.45<br />
Muscle disorders 111 - 115<br />
Orthopaedics and rehabilitation 116 - 117<br />
Osteoarthritis 118 - 135<br />
Osteoporosis and metabolic bone disease 136 - 151<br />
Paediatric and adolescent rheumatology 152 - 160<br />
Primary care 161 - 167<br />
Psychology, measurement and management of pain 168 - 173<br />
Rheumatoid arthritis: treatment 174 - 230<br />
Soft tissue and regional musculoskeletal disease, 231<br />
fibromyalgia<br />
Thursday 3 May 2012 | 10.30 – 11.30<br />
Basic science 232 - 245<br />
Biology of bone, cartilage and connective tissue disease 246<br />
Cell receptor-ligand Interaction, signalling, activation 247 - 248<br />
and apoptosis<br />
Cytokines and inflammatory mediators 249 - 253<br />
Rheumatoid arthritis: aetiopathogenesis and 254 – 257<br />
animal models<br />
Case reports 258 – 277<br />
Education research 278 - 288<br />
Epidemiology 289 - 299<br />
Genetics 300 - 303<br />
Health services research, economics and 304 - 328<br />
outcomes research<br />
Sjögren’s syndrome and other connective tissue 329 - 330<br />
disorders<br />
SLE and antiphospholipid syndrome 331 - 343<br />
Vasculitis 344 - 350<br />
A poster drop off/pick up and hanging service is available.<br />
Drop off your poster the day prior to your session and one<br />
of our poster staff will hang it <strong>for</strong> you.<br />
Poster tours 2012<br />
Our poster tours are guided by leaders in the field and will be<br />
highlighting a selection of BSR and BHPR posters helping delegates<br />
make the most of poster viewing sessions. Each tour will take<br />
approximately 45 minutes and will consist of approximately 10<br />
carefully selected high scoring abstracts.<br />
Places on the tours are limited, so please register in advance at<br />
the poster registration desk, in the poster area.<br />
Tuesday 1 May 10.40 – 11.25<br />
Tour<br />
BHPR<br />
Rheumatoid arthritis<br />
Spondyloarthropathies<br />
Wednesday 2 May 10.50 – 11.35<br />
Tour<br />
Osteoarthritis<br />
Rheumatoid arthritis: treatment<br />
Thursday 3 May 10.40 – 11.25<br />
Tour<br />
Basic science<br />
Connective tissue diseases<br />
Leader<br />
Prof Krysia Dziedzic<br />
Prof Kevin Davies<br />
Dr Karl Gaffney<br />
Leader<br />
Dr Nick Shenker<br />
Dr Chris Edwards<br />
Leader<br />
To be confirmed<br />
Dr Frances Hall
<strong>Rheumatology</strong> 2013<br />
is the UK’s leading rheumatology event and<br />
offers delegates an unparalleled opportunity to<br />
expand their knowledge and network with the whole<br />
rheumatology community.<br />
23-25 April | Birmingham, UK<br />
So join us next year in Birmingham<br />
96% of your colleagues would recommend that you do!<br />
Be a part of <strong>Rheumatology</strong> 2013<br />
You can contribute to the <strong>conference</strong> and ensure that we maintain the high quality<br />
of our <strong>programme</strong> by submitting an abstract or submitting a proposal <strong>for</strong> a<br />
<strong>conference</strong> session. Tell us what you need us to deliver at next year’s event.<br />
Full details can be found at www.rheumatology.org.uk/<strong>conference</strong><br />
Conference session proposal deadline: Friday 18 May 2012<br />
Abstract deadline: Wednesday 21 November 2012<br />
Early bird registration: Friday 1 February 2013<br />
www.rheumatology.org.uk/<strong>conference</strong>
20.00 - Late | Wednesday 2 May 2012<br />
Conference dinner and ceilidh | Òran Mór<br />
Join us <strong>for</strong> an un<strong>for</strong>gettable evening of<br />
traditional Scottish food and dancing at<br />
Òran Mór, a breathtaking converted church<br />
in the heart of Glasgow’s West End.<br />
This event will provide you with the perfect<br />
opportunity to network with collegues while<br />
experiencing real Scottish hospitality.<br />
Limited tickets are available from the<br />
registration desk £40 (inc VAT)
Meeting at a glance<br />
1-3 May 2012 | SECC, Glasgow, UK<br />
Meeting at a glance<br />
1-3 May 2012
1-3 May 2012 | Meeting at a glance 17<br />
Tuesday 1 May 2012<br />
09.00 - 10.30<br />
Reproductive issues in rheumatology | Clyde Auditorium 21<br />
Clinical trials to advance the development of 21<br />
new therapies | Hall 1<br />
Hypermobility - overmedicalised? A debate 22<br />
Lomond Auditorium<br />
BHPR: Physical activity and exercise in inflammatory 22<br />
arthritis | Forth Room<br />
Oral abstracts: Spondyloarthropathies | Alsh Room 23<br />
SIG: BHPR Connective tissue disease | Dochart Room 23<br />
SIG: Lung disease in rheumatoid arthritis | Boisdale Room 24<br />
10.30 - 11.30 | Tea and coffee<br />
Poster viewing and exhibition<br />
Poster tours: BHPR | RA | Spondyloarthropathies | Poster area<br />
Registration necessary<br />
11.30 - 13.00<br />
INBANK, BSR Registers and the new in<strong>for</strong>mation age 25<br />
Hall 1<br />
Sport and exercise medicine | Lomond Auditorium 25<br />
Sex discrimination in the autoimmune rheumatic 26<br />
diseases | Clyde Auditorium<br />
BHPR: Droitwich Lecture, lifetime achievement award 26<br />
and prizes | Forth Room<br />
Oral abstracts: Imaging | Alsh Room 27<br />
SIG: Polymyalgia rheumatica and giant cell arteritis 28<br />
Boisdale Room<br />
SIG: RA outcomes | Dochart Room 28<br />
13.00 - 14.00 | Lunch<br />
Exhibition<br />
13.00 - 14.00<br />
BHPR AGM | Forth Room 29<br />
BHPR Post graduate research student network 29<br />
Leven Room<br />
BSRBR open meeting | Hall 1 29<br />
14.00 - 16.00<br />
Jewels in the Crown | Clyde Auditorium 30<br />
16.00 - 16.30 | Tea and coffee<br />
Exhibition<br />
16.30 - 17.30<br />
Heberden Round | Clyde Auditorium 30<br />
17.30 - 17.45<br />
Industry supported symposia catering | Forth Room 30<br />
17.45 - 19.15<br />
Industry supported symposium: Pfizer Inc | Forth Room 30<br />
19.30 - 21.00<br />
Presidents’ reception | Crowne Plaza Hotel 31
18 Meeting at a glance | 1-3 May 2012<br />
Wednesday 2 May 2012<br />
07.30 - 09.00<br />
Industry supported symposia:<br />
Bristol-Myers Squibb | Alsh Room 33<br />
Cellestis GmbH | Boisdale Room 35<br />
09.15 - 10.45<br />
Essentials: Disease management | Clyde Auditorium 35<br />
Mimickers of myositis and treatment update 36<br />
Lomond Auditorium<br />
Osteoporosis: topical issues | Hall 1 36<br />
BHPR: Primary care rheumatology: leading the way 37<br />
Forth Room<br />
Oral abstracts: RA treatments and outcomes 37<br />
Dochart Room<br />
SIG: MSK health in multi ethnic minorities | Morar Room 38<br />
SIG: Genetics of inflammatory arthritis | Gala Room 38<br />
SIG: Scleroderma | Leven Room 39<br />
10.45 - 11.45 | Tea and coffee<br />
Poster viewing and exhibition<br />
Poster tours: Osteoarthritis | RA: treatment | Poster area<br />
Registration necessary<br />
11.45 - 13.15<br />
Essentials: Symptom diagnosis and management 41<br />
Clyde Auditorium<br />
ARMA: Devolution of health: what can we learn? 40<br />
Lomond Auditorium<br />
Rheumatological challenges in primary care | Boisdale Room 40<br />
BHPR plenary orals | Hall 1 41<br />
Oral abstracts: connective tissue diseases | Alsh Room 42<br />
SIG: Vasculitis | Forth Room 42<br />
SIG: Paediatric and adolescent rheumatology 43<br />
Gala Room<br />
13.15 - 14.45<br />
BSR AGM | Dochart Room 43<br />
BHPR: How to get your abstract published | Leven Room 43<br />
14.45 - 16.15<br />
Essentials: Keeping up to date, clinical 44<br />
decision making | Clyde Auditorium<br />
BHPR: Current thinking on conservative management 44<br />
of back pain | Hall 1<br />
Juvenile-onset SLE and childhood scleroderma 45<br />
Forth Room<br />
Recent advances in osteoarthritis therapy 45<br />
Lomond Auditorium<br />
Oral abstracts: Primary care | Alsh Room 46<br />
SIG: Heritable disorders of connective tissue 46<br />
Boisdale Room<br />
SIG: BHPR Rheumatoid arthritis | Gala Room 47<br />
16.15 - 16.45 | Tea and coffee<br />
Exhibition<br />
16.45 - 17.45<br />
Heberden Oration | Clyde Auditorium 47<br />
17.45 - 18.00<br />
Industry supported symposia catering 48<br />
18.00 - 19.30<br />
Industry supported symposia:<br />
Abbott | Forth Room 48<br />
Roche | Hall 1 51<br />
20.00 - Late<br />
Conference dinner and ceilidh | Òran Mór 51<br />
13.15 - 14.45 | Lunch<br />
Exhibition
1-3 May 2012 | Meeting at a glance 19<br />
Thursday 3 May 2012<br />
07.30 - 09.00<br />
Industry supported symposium: Abbott | Forth Room 53<br />
SIG: Myositis | Leven Room 53<br />
09.00 - 10.30<br />
Science: Molecular mechanisms of disease:<br />
osteoarthritis | Dochart Room 54<br />
Optimising therapy <strong>for</strong> rheumatoid arthritis<br />
Clyde Auditorium 54<br />
BHPR: Pain and motor function: mechanisms and 55<br />
treatment approaches | Lomond Auditorium<br />
Trainee: Interactive quiz and clinical teaching | Hall 1 55<br />
Oral abstracts: Epidemiology | Alsh Room 56<br />
SIG: Sjögren’s syndrome | Boisdale Room 1 56<br />
SIG: MSK ultrasound | Boisdale Room 2 57<br />
10.30 - 11.30 | Tea and coffee<br />
Poster viewing and exhibition<br />
Poster tours: Basic science/CTD | Poster area<br />
Registration necessary<br />
13.00 - 14.00 | Lunch<br />
Exhibition<br />
13.00 - 14.00<br />
Trainee: RATs AGM | Hall 1 61<br />
BHPR: NICE and NHS Evidence and the in<strong>for</strong>mation<br />
revolution | Forth Room 61<br />
14.00 - 15.30<br />
Science: Molecular mechanisms of disease: 63<br />
inflammatory arthritis II | Dochart Room<br />
Trainee: <strong>Rheumatology</strong> and the NHS | Hall 1 62<br />
BHPR: Improving work participation: new developments 62<br />
in reducing work absence <strong>for</strong> people with<br />
musculoskeletal conditions | Forth Room<br />
What’s new in ankylosing spondylitis pathogenesis, 63<br />
assessment and treatment | Clyde Auditorium<br />
Oral abstracts: Genetics | Alsh Room 64<br />
SIG: Education | Boisdale Room 1 64<br />
SIG: Osteoarthritis | Boisdale Room 2 65<br />
11.30 - 13.00<br />
Advances in psoriatic arthritis | Clyde Auditorium 58<br />
Science: Molecular mechanisms of disease: 59<br />
inflammatory arthritis I | Dochart Room<br />
Trainee: Ask the experts: myositis | Hall 1 58<br />
BHPR: <strong>The</strong> management of upper limb dysfunction 59<br />
in people with rheumatoid arthritis | Forth Room<br />
Oral abstracts: Education | Alsh Room 60<br />
SIG: Osteoporosis | Boisdale Room 1 60<br />
SIG: Foot and ankle | Boisdale Room 2 61<br />
15.30 - 17.00<br />
SIG: Spondyloarthritis | Carron Room 1 65<br />
17.00 End of meeting
20 Meeting at a glance | 1-3 May 2012<br />
Additional meetings<br />
Tuesday 1 May 2012<br />
Closed meetings (invitees only)<br />
10.30-11.30 Author clinic Carron Room 1<br />
Wednesday 2 May 2012<br />
Open meetings<br />
07.30-08.30 CMF breakfast Gala Room<br />
Closed meetings (invitees only)<br />
09.00-12.45 Glasgow Clinical Research Facility Carron Room 1<br />
09.15-10.45 CAC regional chairs Ness Room<br />
15.45-16.45 OTTER trial Morar Room<br />
Thursday 3 may 2012<br />
Open meetings<br />
13.00-14.00 BSR standards guidelines and audit Leven Room<br />
working group<br />
Closed meetings (invitees only)<br />
10.30-11.30 Musculoskeletal ultrasound SIG meeting Ness Room<br />
10.30-11.30 TRACTISS Morar Room<br />
Connect with us via Twitter, Facebook or Linkedin:<br />
@<strong>Rheumatology</strong>UK<br />
⧣Rheum2012<br />
facebook.com/rheumatologyUK<br />
Search ‘Groups’:<br />
<strong>Rheumatology</strong> 2012
Programme<br />
Tue 1 May 2012<br />
Programme:<br />
Tuesday 1 May 2012
Ankylosing Spondylitis Register<br />
Launched<br />
<strong>The</strong> BSR Biologics Registers team are pleased to announce that<br />
the Ankylosing Spondylitis (AS) register officially started in April<br />
2012. <strong>The</strong> register will build on the success of the Rheumatoid<br />
Arthritis register and will gather important data on AS patients<br />
being treated with Adalimumab and Etanercept anti-TNF therapies.<br />
<strong>The</strong> AS team is based at the University of Aberdeen and are led<br />
by Professor Gary Macfarlane, who will be presenting on the<br />
register in Hall 1 on Tuesday from 11.30 to 11.50.<br />
Straight after this session there will be a BSR Biologics<br />
Registers lunchtime open meeting from 13.00 to 14.00,<br />
where Dr Gareth Jones will provide further in<strong>for</strong>mation<br />
and be available to answer any questions on BSRBR-AS.<br />
We are keen to receive expressions of interest from any centre<br />
interested in contributing patients to this important new study<br />
please talk to us on the BSR Biologics Registers stand or<br />
email us via ELawton@rheumatology.org.uk<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong><br />
<strong>Rheumatology</strong><br />
Biologics Registers<br />
Ankylosing Spondylitis
Tuesday 1 May 2012 | Programme 21<br />
Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
09.00 - 10.30 Reproductive issues in rheumatology: do you know how to advise your patients? | Clyde Auditorium<br />
Chairs: Dr Ian Giles, UCL, London | Prof Caroline Gordon, University of Birmingham, Birmingham<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with up to date knowledge of the issues surrounding rheumatological<br />
conditions and drugs in conception, pregnancy, and lactation<br />
Delegates will be aware of the current state of knowledge amongst rheumatologists and<br />
obstetricians surrounding the safe use of rheumatological drugs in conception, pregnancy<br />
and lactation<br />
Delegates will be aware of the need <strong>for</strong> a national consensus on the use of rheumatological<br />
drugs in conception, pregnancy and lactation, and how such a consensus can be achieved<br />
Delegates will have a better understanding of the complications in pregnancy associated<br />
with rheumatological conditions<br />
09.00 Is pregnancy a stress test <strong>for</strong> subsequent development of autoimmunity?<br />
Dr David Williams, UCLH, London<br />
09.20 Drugs in conception, pregnancy, and lactation: towards a national consensus<br />
Dr Munther Khamashta, St Thomas’ Hospital, London<br />
09.40 Safety of biologics in pregnancy?<br />
Prof Monika Østensen, Sörlandet Hospital, Kristiansand, Norway<br />
10.00 Rheumatological conditions in pregnancy and the puerperium<br />
Prof Catherine Nelson-Piercy, Guy’s and St Thomas’ Foundation Trust, London<br />
10.20 Discussion<br />
09.00 - 10.30 IRS | Clinical trials to advance the development of new therapies | Hall 1<br />
Chair: Dr Duncan Porter, Gartnavel General Hospital, Glasgow<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
This session is to in<strong>for</strong>m rheumatologists about per<strong>for</strong>ming clinical trials in rheumatoid arthritis<br />
Delegates will understand how stratified medicine and biomarkers can be applied to improve<br />
therapeutic responses in patients<br />
Delegates will understand the influence of genetics on responses observed in clinical trials<br />
09.00 Conducting clinical trials in rheumatoid arthritis: practicalities and potential pitfalls<br />
Prof Paul Emery, University of Leeds, Leeds<br />
09.25 Stratified medicine and biomarkers<br />
Prof Mahesh Parmar, UCL, London<br />
09.50 Design, analysis and reporting of pharmacogenetic studies<br />
Prof Anne Barton, University of Manchester, Manchester<br />
10.20 Discussion
22 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
09.00 - 10.30 IRS | Hypermobility: overmedicalised? A debate | Lomond Auditorium<br />
Chairs: Prof Howard Bird, University of Leeds, Leeds | Prof Anthony Redmond, University of Leeds, Leeds<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To transparently debate key controversial aspects of our diagnosis and management of child and adult joint<br />
laxity/hypermobility (as currently defined); this should in<strong>for</strong>m clinical and academic future direction<br />
Delegates will gain an understanding of evidence underpinning management and learn new<br />
epidemiological data<br />
Delegates will participate in healthy discussion on pros and cons of current diagnosis and management<br />
Delegates will decide which of the opposing viewpoints is most convincing<br />
09.00 First proposition<br />
Dr Jacqui Clinch, University of Bath, Bath<br />
09.20 Second proposition<br />
Prof Alan Silman, University of Manchester, Manchester<br />
09.40 First opposition<br />
Prof Rodney Grahame, UCL, London<br />
10.00 Second opposition<br />
Dr Alan Hakim, Whipps Cross University Hospital, London<br />
09.00 - 10.30 Physical activity and exercise in inflammatory arthritis | Forth Room<br />
Chairs: Dr Fiona Cramp, University of the West of England, Bristol | Dr Claire Goodchild,<br />
King’s College London, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an overview of the role of physical activity and exercise in the management of<br />
inflammatory arthritis<br />
Attendees will understand the effects of physical activity and exercise in those with inflammatory<br />
arthritis<br />
Attendees will understand the current UK physical activity guidelines, the uptake and physical<br />
activity preferences in people with rheumatic diseases<br />
Attendees will consider the implementation of a home based physical activity <strong>programme</strong> <strong>for</strong><br />
people with inflammatory arthritis<br />
09.00 <strong>The</strong> efficacy and safety of exercise <strong>for</strong> RA patients. <strong>The</strong> case <strong>for</strong> exercise as a treatment <strong>for</strong> RA:<br />
is anyone listening?<br />
Prof Andrew Lemmey, Bangor University, Bangor<br />
09.35 Understanding physical inactivity in rheumatic diseases: the patients perspective<br />
Ms Victoria Manning, King’s College London, London<br />
10.00 Implementation of a physical activity <strong>programme</strong> <strong>for</strong> people with rheumatoid arthritis using<br />
motivational interviewing<br />
Dr Emalie Hurkmans, Leiden University Medical Centre, Leiden, <strong>The</strong> Netherlands
Tuesday 1 May 2012 | Programme 23<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
09.00 - 10.30 Oral abstracts: Spondyloarthropathies | Alsh Room<br />
Chair: Dr Paul Bowness, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d<br />
9.00 Detecting axial spondyloarthritis (ASpA) amongst primary care back pain referrals<br />
Mrs Claire Harris, Northwick Park Hospital, Harrow<br />
9.15 Validation of a screening questionnaire <strong>for</strong> axial SpA in a UK population<br />
Dr Karl Gaffney, Norfolk and Norwich University Hospital, Norwich<br />
9.30 <strong>The</strong> prevalence and burden of ankylosing spondylitis in Europe: a systematic review<br />
Ms Linda Morton, University of Aberdeen, Aberdeen<br />
9.45 Work disability in established psoriatic arthritis: a cross sectional study using the work productivity<br />
activity index (WPAI)<br />
Dr Willi Tillett, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath<br />
10.00 Influence of leflunomide on the levels of matrix metalloproteinase-3 (MMP-3) and pyridinoline (PYR) in<br />
patients with psoriatic arthritis (PsA)<br />
Dr Dmytro Fedkov, Kiev National Medical, Kyiv, Ukraine<br />
10.15 Evaluation of efficacy and safety of secukinumab in the treatment of patients with moderate-to-severe<br />
ankylosing spondylitis<br />
Prof Paul Emery, University of Leeds, Leeds<br />
09.00 - 10.30 BHPR SIG: Connective tissue disease | Dochart Room<br />
Chair: Mrs Sue Brown, Royal National Hospital <strong>for</strong> Rheumatic Diseases NHS Foundation Trust, Bath<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an overview of the complexities of disease presentations and management approaches<br />
in scleroderma, including digital ulcer disease and pulmonary hypertension<br />
To gain an understanding of the diagnostic process <strong>for</strong> those with scleroderma, including<br />
management and treatment options<br />
To become aware of the significance of digital ulcer disease in scleroderma, its impact on the<br />
patient and the supportive role of the nurse specialist<br />
To gain an understanding of the importance of a multi-disciplinary approach in effective and early<br />
diagnosis, treatment and management of scleroderma associated lung and cardiac disease<br />
09.00 Diagnosing scleroderma and treatment options, the role of the rheumatologist<br />
Dr John Pauling, Royal National Hospital <strong>for</strong> Rheumatic Diseases NHS Foundation Trust, Bath<br />
09.20 Managing digital ulcers and supporting patients with scleroderma, the role of the clinical<br />
nurse specialist<br />
Mrs Sue Brown, Royal National Hospital <strong>for</strong> Rheumatic Diseases NHS Foundation Trust, Bath<br />
09.40 Lung and pulmonary vascular disease in scleroderma, the role of the specialist pulmonary physician<br />
Dr Jay Suntharalingham, Royal United Hospital, Bath<br />
10.00 Cardiac and pulmonary vascular disease in scleroderma, the role of the specialist cardiologist<br />
Dr Gerry Coghlan, Royal Free Hospital NHS Foundation Trust, London<br />
10.20 Questions
24 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
09.00 - 10.30 SIG: Lung disease in rheumatoid arthritis | Boisdale Room<br />
Chair: Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To update on progress with the National Database of interstitial lung disease in RA, educate members on<br />
the use of novel treatments <strong>for</strong> interstitial lung disease in RA and in<strong>for</strong>m members of the latest data on<br />
serology in lung disease complicating RA<br />
To ensure that members are aware of the plans <strong>for</strong> a national database <strong>for</strong> ILD in RA and the challenges<br />
in developing this<br />
To educate members about the growing body of evidence <strong>for</strong> the use of novel therapies <strong>for</strong> the treatment<br />
of interstitial lung disease in RA<br />
To update members with the latest data on the serological associations with lung disease in patients<br />
with RA<br />
9.00 Welcome and Introduction<br />
Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead<br />
9.05 <strong>The</strong> extent of ILD assessed by high resolution CT and correlation with survival<br />
Dr Nav Sathi, St Helens Hospital, Merseyside<br />
9.25 Safety and efficacy of rituximab in patients with RA-ILD<br />
Dr Shouvik Dass, Leeds Teaching Hospitals NHS Trust, Leeds<br />
9.45 Immunosuppressives in the treatment of RA-ILD in Wales<br />
Dr Yasmeen Ahmad, Bangor University, Bangor<br />
10.05 Autoantibodies and HLA studies in RA-ILD: what should we focus on?<br />
Dr Hector Chinoy, University of Manchester, Manchester<br />
10.25 Summary of agreed actions<br />
10.30 - 11.30 Poster viewing and exhibition | Tea and coffee<br />
Categories:<br />
Poster tours:<br />
BHPR<br />
BHPR<br />
Imaging<br />
Rheumatoid arthritis<br />
Metabolic and crystal arthropathies Spondyloarthropathies<br />
Miscellaneous rheumatic diseases<br />
Rheumatoid arthritis: clinical features<br />
Rheumatoid arthritis: comorbidities<br />
Scleroderma and related disorders<br />
Spondylarthropathies (including psoriatic arthritis)
Tuesday 1 May 2012 | Programme 25<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
11.30 - 13.00 INBANK, BSR Registers and the new in<strong>for</strong>mation age | Hall 1<br />
Chairs: Prof Deborah Bax, Royal Hallamshire Hospital, Sheffield | Prof David L Scott, King’s<br />
College London, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To in<strong>for</strong>m the membership about new and emerging data resources in rheumatology, and to raise<br />
awareness of the opportunities af<strong>for</strong>ded by the establishment of INBANK as a national resource <strong>for</strong><br />
clinical data linkage to biological samples and NHS outcomes<br />
Understand the value of national data resources in rheumatology and raise awareness of datasets<br />
including the newly established ankylosing spondylitis biologics register and the national joint register<br />
Understand how INBANK will function and allow clinicians both to audit their own clinical per<strong>for</strong>mance<br />
and participate in research<br />
Allow participants to ask questions about key issues including consent, access, security and resources<br />
11.30 Advances in drug in<strong>for</strong>mation in rheumatic disease: the ankylosing spondylitis register<br />
Prof Gary Macfarlane, University of Aberdeen, Aberdeen<br />
11.50 <strong>The</strong> power of data linkage: lessons from the National Joint Register<br />
Prof Alex MacGregor, University of East Anglia, Norwich<br />
12.10 INBANK: a national musculoskeletal in<strong>for</strong>mation plat<strong>for</strong>m<br />
Prof Alan Silman, Arthritis Research UK<br />
12.30 INBANK in practice<br />
Dr William Dixon, University of Manchester, Manchester<br />
12.50 Discussion<br />
11.30 - 13.00 Sport and exercise medicine | Lomond Auditorium<br />
Chairs: Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and<br />
Dentistry, London | Dr Roger Wolman, Royal National Orthopaedic Hospital, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates an overview of the challenges faced by modern sport and exercise medicine practice<br />
Delegates will be able to identify the key issues concerning modern sport and exercise medicine<br />
practice, and discuss these in an open, interactive session<br />
Delegates will be aware of how these issues may affect rheumatology in the future<br />
Delegates will have a better understanding of how sports and exercise medicine and<br />
rheumatology will be able to interact to provide optimal medical care<br />
11.30 <strong>British</strong> sport and exercise medicine: a five minute history of a specialty<br />
Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and<br />
Dentistry, London<br />
11.35 Exercise: a unique therapeutic intervention <strong>for</strong> primary, secondary and tertiary disease prevention.<br />
Let’s all prescribe it!<br />
Dr Christopher Hughes, Queen Mary University of London, Barts and the London School of Medicine and<br />
Dentistry, London<br />
11.55 Anterior cruciate ligament reconstruction: good <strong>for</strong> your knee?<br />
Prof Anthony Bull, Imperial College London, London<br />
12.15 Platelet-rich plasma in musculoskeletal medicine: some truths<br />
Dr Umile Giuseppe Longo, University Campus Biomedico, Rome, Italy<br />
12.40 Taking care of tender tendons<br />
Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and<br />
Dentistry, London
26 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
11.30 - 13.00 Why can’t a man be more like a woman? Sex discrimination in autoimmune rheumatic<br />
diseases | Clyde Auditorium<br />
Chairs: Prof David Isenberg, University College London Hospital, London | Dr Patrick Gordon, King’s College<br />
Hospital, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide a thought provoking session on the evident disparity in the prevalence, causes and<br />
consequences of autoimmune rheumatic disease (ARDs) involvement between men and women<br />
To achieve a better understanding of the disparity and differential effects of ARDs on men and women<br />
To achieve a better understanding of the links between the immune and endocrine systems<br />
To achieve a better understanding of whether hormonal manipulation might play a part in the<br />
therapy of ARDs<br />
11.30 Sex hormones modulate autoimmunity<br />
Dr Betty Diamond, Feinstein Institute Medical Research, New York, USA<br />
11.55 Male lupus: the Loch Ness monster syndrome revisited<br />
Prof David Isenberg, University College London Hospital, London<br />
12.10 Rheumatoid arthritis in men<br />
Prof John Isaacs, University of Newcastle, Newcastle Upon Tyne<br />
12.25 Scleroderma in men<br />
Prof Christopher Denton, Royal Free Hospital, London<br />
12.40 Blocking female hormones: smart or stupid?<br />
Prof Anisur Rahman, University College London Hospital, London<br />
11.30 - 13.00 Droitwich Lecture, Lifetime achievement award and prizes | Forth Room<br />
Chair: Mrs Lindsey Hawley, President BHPR<br />
11.30 Droitwich Lecture: <strong>Rheumatology</strong> nursing: a journey of discovery<br />
Dr Jackie Hill, Senior Lecturer in <strong>Rheumatology</strong> Nursing, University of Leeds, Leeds<br />
12.15 Lifetime achievement award<br />
Dr Jackie Hill, Senior Lecturer in <strong>Rheumatology</strong> Nursing, University of Leeds, Leeds<br />
12.20 Chris Moran poster prize<br />
This prize will be awarded to a poster author at the <strong>conference</strong><br />
12.25 BHPR/Arthritis Research UK research UK silver medal research prize<br />
Physical inactivity among UK adults with rheumatic diseases: an evaluation of physical activity participation,<br />
recommendation and preferences<br />
Miss Victoria Manning, King's College London, London<br />
12.30 Arthritis Research UK physiotherapy silver medal prize<br />
Comparison of stratified primary care management <strong>for</strong> low back pain with current best practice (STarT Back):<br />
a randomised controlled trial<br />
Dr Jonathan Hill, Keele University, Keele
Tuesday 1 May 2012 | Programme 27<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
Droitwich Lecture, Lifetime achievement award and prizes | Forth Room<br />
12.35 Arthritis Research UK/PRCA podiatry silver medal prize<br />
Factors predicting the outcome of foot and ankle surgery in patients with rheumatoid arthritis<br />
Mr Michael Backhouse, University of Leeds, Leeds<br />
12.40 Arthritis Research UK occupational therapy prize<br />
Mrs Kate Hackett, Newcastle University, Newcastle<br />
Functional impairment and primary Sjögren’s syndrome: A case <strong>for</strong> occupational therapy?<br />
12.45 Arthritis Research UK nurses prize<br />
Don’t <strong>for</strong>get to clean your teeth - does in<strong>for</strong>ming patients about the link between dental hygiene and<br />
Rheumatoid Arthritis encourage better dental care?<br />
Mrs Patricia Cornell, Poole Hospital NHS Foundation Trust, Poole<br />
11.30 - 13.00 Oral abstracts: Imaging | Alsh Room<br />
Chair: Dr Helena Marzo-Ortega, Chapel Allerton Hospital, Leeds<br />
11.30 Hand osteoarthritis pain has peripheral and central components demonstrated by algometer scores<br />
and functional MRI<br />
Dr Nidhi Sofat, St George’s, University of London, London<br />
11.45 Ultrasound features of osteophytes and cartilage thickness at the knee are associated with pain<br />
and functional impairment: the Newcastle thousand families study<br />
Dr Ajay Abraham, Newcastle University, Newcastle upon Tyne<br />
12.00 <strong>The</strong> diagnostic utility of salivary gland ultrasound <strong>for</strong> the investigation of Sjögren’s syndrome<br />
Dr Andrew Carr, Newcastle Dental Hospital, Newcastle upon Tyne<br />
12.15 Long-term radiographic outcome in psoriatic arthritis patients treated with Golimumab: 104 week<br />
results from the go-reveal study<br />
Dr Chandrabhusan Chattopadhyay, Wrightington Hospital, Wigan<br />
12.30 Early effect of Secukinumab in reducing spinal inflammation as detected by magnetic resonance<br />
imaging in patients with ankylosing spondylitis<br />
Prof Jaap Van Laar, Newcastle University, Newcastle upon Tyne<br />
12.45 Tocilizumab as monotherapy or in combination with methotrexate associated with early reductions in<br />
tissue inflammation: 12 week results from a magnetic resonance imaging substudy of a randomized<br />
controlled trial<br />
Prof Philip Conaghan, University of Leeds, Leeds
28 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
11.30 - 13.00 SIG: Polymyalgia rheumatica and giant cell artertis | Boisdale Room<br />
Chair: Prof Bhaskar Dasgupta, Southend University Hospital, Southend<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To increase awareness of the attendees of advances in the diagnosis, guidelines on management,<br />
clinical trials, biomarkers and patient support in PMR and GCA<br />
Attendees will learn about the EULAR ACR Classification Criteria <strong>for</strong> PMR and the approach to<br />
differentiate PMR from other conditions that present with a polymyalgic syndrome<br />
Attendees will learn about the management of PMR and GCA in PMR and development of<br />
pathways to improve diagnosis and reduce ischemic complications<br />
Attendees will learn about the status of ongoing clinical trials in PMR, GCA and large vessel vasculitis<br />
11.30 PMR Classification Criteria<br />
Prof Bhaskar Dasgupta, Southend University Hospital, Southend<br />
11.45 Pathways and management of PMR and GCA in primary care<br />
Prof Christian Mallen, Keele University, Keele<br />
12.00 Clinical trials in PMR, GCA and large vessel vasculitis<br />
Prof Carlo Salvarani, Azienda Ospedaliera Arcispedale Santa Maria Nuova Reggio Emilia, Italy<br />
12.15 Annexin and its receptor in PMR and GCA<br />
Prof Mauro Perretti, St Barts Hospital, London<br />
12.30 Development of a patient support organisation <strong>for</strong> PMR and GCA<br />
Dr Kate Gilbert, Chair, PMRGCAUK<br />
12.45 Discussion<br />
11.30 - 13.00 SIG: RA outcomes | Dochart Room<br />
Chair: Dr Adam Young, St Albans City Hospital, St Albans<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To discuss topical and recent issues in management and outcomes of early RA by leaders in this field<br />
Understand the many facets of pain in RA<br />
Appreciate the importance of joint failure in RA as measured by orthopaedic surgery<br />
Debate the different perspectives proposed <strong>for</strong> DAS28 cut offs <strong>for</strong> biological therapy<br />
11.30 Pain in early RA: inflammatory or central sensitisation?<br />
Prof David Walsh, <strong>The</strong> University of Nottingham, Nottingham<br />
11.50 Orthopaedic interventions <strong>for</strong> RA: clinical and health economic aspects<br />
Dr Elena Nikiphorou, St Albans City Hospital and UCL, London | Prof Steve Morris, UCL, London<br />
12.10 DAS28 criteria <strong>for</strong> initiation of biologics in early RA: a clinician’s view<br />
Dr Patrick Kiely, St George’s Hospital, London<br />
12.30 DAS28 criteria <strong>for</strong> initiation of biologics in early RA: NICE perspectives<br />
Dr Chris Deighton, Derby Hospitals NHS Trust, Derby<br />
12.50 Discussion
Tuesday 1 May 2012 | Programme 29<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
13.00 - 14.00 Exhibition | Lunch<br />
13.00 - 14.00 BHPR AGM | Forth Room<br />
Join your colleagues over lunch and meet BHPR Council members to hear what they have been doing on your<br />
behalf and how they plan to meet the challenges of the year ahead. Your attendance, which is highly valued,<br />
automatically enters you into a prize draw <strong>for</strong> a chance to win free registration to the 2013 <strong>conference</strong><br />
in Birmingham. You will have the chance to network with members of the newly <strong>for</strong>med rheumatology<br />
physiotherapy SIG.<br />
13.00 - 14.00 BSRBR open meeting | Hall 1<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To in<strong>for</strong>m all those wanting to understand the implications of Register research <strong>for</strong> their practice<br />
Update the membership on the latest news about the recruitment to the BSR-Biologics Registers and<br />
the research being conducted with it<br />
Provide a <strong>for</strong>um <strong>for</strong> discussion on all aspects of the registers<br />
Open to all with an interest in the Biologics Registers, whether as a contributor of patient data or as a researcher<br />
interested in accessing the data. <strong>The</strong>re will be an update of the latest news on recruitment and research.<br />
13.00 - 14.00 BHPR Post graduate research student network: a practical guide to post-doctoral career<br />
progression | Leven Room<br />
Chairs: Dr Michael Backhouse, University of Leeds, Leeds | Ms Lindsay Hooper, University of Southampton,<br />
Southampton<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide a coordinated network <strong>for</strong> early career researchers that facilitates peer group discussion<br />
and support from a range of leading academics<br />
Attendees will be able to identify the key steps in developing post-doctoral careers<br />
Attendees will gain practical tips on developing collaborative networks, managing funding portfolios<br />
and structuring programs of research<br />
Attendees will have the opportunity to discuss the lecture content with peers and senior<br />
academics, facilitating the opportunity to develop their own collaborative links<br />
13.00 Introduction from the chair<br />
Dr Michael Backhouse, University of Leeds, Leeds<br />
13.05 Post-PhD career planning<br />
Prof Nadine Foster, Keele University, Keele<br />
13.25 Facilitated group discussion<br />
Prof Sarah Hewlett and Dr Tessa Sanderson, University of West of England, Bristol
30 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
14.00 - 16.00 Jewels in the Crown | Clyde Auditorium<br />
Chairs: Prof David L Scott, President BSR | Mrs Lindsey Hawley, President BHPR<br />
14.00 Self determination: the driving <strong>for</strong>ce of all paralympians<br />
Sir Phillip Craven MBE, President of the International Paralympic Committee (IPC)<br />
14.20 Michael Mason prize winner: Silver standard: measuring treatment effects using observational data<br />
Dr Kimme Hyrich, University of Manchester, Manchester<br />
14.40 Garrod Prize winner: <strong>The</strong> relationship between pregnancy and long-term functional disability in<br />
women with inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR)<br />
Mrs Elizabeth Camacho, University of Manchester, Manchester<br />
15.00 Epidemiology of sporting injuries on elite soccer players: a longitudinal study<br />
Mr Philip Cooper, MRC Lifecourse Epidemiology Unit, Southampton<br />
15.20 Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe<br />
systemic lupus erythematosus (SLE): results from Emblem, a phase IIB study<br />
Prof Caroline Gordon, University of Birmingham, Birmingham<br />
15:40 Will I waste your time? Delays in help-seeking <strong>for</strong> RA flares<br />
Ms Caroline Flurey, University of the West of England, Bristol<br />
16.00 - 16.30 Exhibition | Tea and coffee<br />
16.30 - 17.30 Heberden Round: <strong>The</strong> new rheumatoid arthritis | Clyde Auditorium<br />
Chair: Prof David L Scott, President BSR<br />
Prof Philip Conaghan, Chair of Musculoskeletal Medicine, University of Leeds, Leeds<br />
17.30 - 17.45 Industry supported symposium catering<br />
17.45 - 19.15 Industry supported symposium | Forth Room<br />
Pfizer Inc.<br />
Emerging treatment directions: signalling changes in rheumatoid arthritis<br />
Dr Patrick Kiely, St George's Healthcare NHS Trust, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To deliver an in<strong>for</strong>mative and interactive <strong>programme</strong> on the latest advances in rheumatoid arthritis, focusing<br />
on how signalling cascades offer opportunities <strong>for</strong> new treatment targets<br />
Understand the role of signalling pathways in the pathogenesis of rheumatoid arthritis and their potential as<br />
therapeutic targets<br />
Distinguish between differing modes of action of emerging agents targeting signalling pathways currently in<br />
development <strong>for</strong> rheumatoid arthritis<br />
Review the clinical profiles of emerging treatments based on available clinical evidence
Emerging Treatment Directions:<br />
Signalling Changes in Rheumatoid Arthritis<br />
Forth Room<br />
Tuesday 1st May 2012 | 17.45 – 19.15<br />
Agenda<br />
Chair’s introduction<br />
Intracellular signalling pathways – Exploring potential targets<br />
Targeting intracellular pathways – Examining the clinical perspective<br />
Interactive panel discussion: A scientific exchange<br />
Date of preparation: February 2012<br />
INF001<br />
This symposium is sponsored<br />
and funded by Pfizer
32 Programme | Tuesday 1 May 2012<br />
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event<br />
Award winner | IRS (interactive audience response system)<br />
Pfizer Inc.<br />
Emerging treatment directions: signalling changes in rheumatoid arthritis<br />
17.45 Welcome and Introduction<br />
Dr Patrick Kiely, St George’s Healthcare NHS Trust, London<br />
17.50 Intracellular signalling pathways: exploring potential targets<br />
Professor John D Isaacs, Institute of Cellular Medicine, Newcastle University, Newcastle<br />
18.20 Targeting intracellular pathways: examining the clinical perspective<br />
Professor Ernest Choy, Institute of Infection and Immunity, Cardiff University, Cardiff<br />
18.55 Interactive panel discussion: a scientific exchange<br />
Panel including Prof Peter Taylor, Kennedy Institute of <strong>Rheumatology</strong>, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d<br />
19.30 - 21.00 Presidents’ reception<br />
19.30 - 21.00 | Tuesday 1 May 2012<br />
Presidents’ Reception | Crowne Plaza Hotel<br />
<strong>The</strong> Presidents of BSR and BHPR invite<br />
all <strong>conference</strong> attendees to join them <strong>for</strong><br />
a champagne reception at the nearby<br />
Crowne Plaza Hotel. <strong>The</strong> perfect opportunity<br />
to meet and continue your discussions with<br />
rheumatology colleagues and industry peers<br />
in a relaxed and in<strong>for</strong>mal setting.<br />
Drinks, canapés and entertainment will be provided<br />
This event is free to attend <strong>for</strong> registered delegates.<br />
This networking event cannot be missed!
Programme<br />
Wed 2 May 2012<br />
Programme:<br />
Wednesday 2 May 2012
A Bristol-Myers Squibb satellite symposium<br />
Getting it right: optimising<br />
RA treatment strategies in<br />
the evolving NHS<br />
Wednesday 2 May 2012, 07:30–09:00<br />
Alsh Room, Level 0, SECC, Glasgow, UK<br />
RHEUMATOLOGY 2012<br />
Organised and funded by<br />
Date of preparation: February 2012 427UK12PM007<br />
Chair: Professor Philip Conaghan,<br />
University of Leeds, UK<br />
<strong>The</strong> new NHS and rheumatology:<br />
what does the future hold?<br />
Dr Mark Davies, RES Consortium, Andover, UK<br />
Is MOA of biologics important when<br />
choosing an RA treatment?<br />
Professor Paul Garside, University of Glasgow, UK<br />
Patient profiling in RA: what do we know?<br />
Where are we heading?<br />
Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge, UK<br />
Tailoring biologic treatment to patient<br />
profiles in RA<br />
Dr Rieke Alten, Schlosspark-Klinik, University Medicine Berlin,<br />
Germany<br />
Chairman’s closing remarks<br />
Q&A session<br />
Breakfast will be provided
Wednesday 2 May 2012 | Programme 33<br />
Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
07.30 - 09.00 Industry supported symposium: | Alsh Room<br />
Bristol-Myers Squibb<br />
Getting it right: optimising RA treatment strategies in the evolving NHS<br />
Chair: Prof Philip Conaghan, University of Leeds, Leeds<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To educate delegates on how they can tailor biologic treatment choices in rheumatoid arthritis (RA) to deliver<br />
value both <strong>for</strong> patients and the NHS, in context of the evolving NHS (QIPP, QoF). To deliver an update on the<br />
differing mode of actions of biologic therapy, examining whether the different MOAs available offer different<br />
outcomes <strong>for</strong> patients. <strong>The</strong> session will also explore the current theories/research into the RA patient<br />
profiling, and show how tailoring biologic therapy can offer better outcomes <strong>for</strong> the patient whilst delivering<br />
value to the NHS<br />
Delegates will have a better understanding of how the NHS changes (White Paper, QIPP agenda) could affect<br />
the role of the rheumatologist and specialist RA services. Highlighting the need <strong>for</strong> services to be able to<br />
demonstrate the best outcomes <strong>for</strong> patients, whilst driving efficiencies<br />
Delegates will have an update into the current research that is taking place into patient profiles/subtypes in<br />
RA and how these can be used to deliver better outcomes<br />
Delegates will understand how using a tailored approach to biologic therapy can improve patient<br />
outcomes/demonstrate value to the NHS, within the framework of currently available NICE guidance<br />
07.30 <strong>The</strong> new NHS and rheumatology: what does the future hold?<br />
Dr Mark Davies, RES Consortium, Andover<br />
07.50 Is the mode of action of biologics important when choosing an RA treatment?<br />
Prof Paul Garside, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow<br />
08.05 Patient profiling in RA: what do we know? Where are we heading?<br />
Dr Andrew Östör, <strong>Rheumatology</strong> Research Unit, Addenbrooke’s Hospital, Cambridge<br />
08.25 Tailoring biologic treatment to patient profiles in RA<br />
Dr Rieke Alten, Director of <strong>Rheumatology</strong> Research Center, Schlosspark-Klinik,<br />
University Medicine Berlin, Germany<br />
08.45 Conclusion: To conclude the meeting there will be closing remarks from the Chairperson, followed by a panel<br />
Q&A to draw conclusions on the session as a whole, whilst giving delegates the opportunity to ask questions of<br />
each separate session
Symposium – Cellestis GmbH<br />
Wednesday, May 2 nd , 2012<br />
Conference Room Boisdale<br />
7.30 – 9.00 am<br />
Screening of TB infection in pre TNF-alpha patients.<br />
How IGRA improves outcomes.<br />
Chair: Sue Oliver NRAS and RCN, Barnstaple<br />
Lecture 1: Background to TB incidence and prevalence in UK<br />
Prof. Peter Davies, Liverpool<br />
Lecture 2: Latent Tuberculosis Infection (LTBI) Screening in Autoimmune,<br />
Immunosuppressed Patients<br />
Prof. Stephan D. Gadola, Southampton<br />
Lecture 3: Pre-Biologic Screening <strong>for</strong> Latent Tuberculosis Infection (LTBI)<br />
in North East England – Data and Case Studies<br />
Karl Nicholl, Newcastle-Upon-Tyne
Wednesday 2 May 2012 | Programme 35<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
07.30 - 09.00 Industry supported symposium: | Boisdale Room<br />
Cellestis GmbH<br />
Screening of TB infection in pre TNF-alpha patient. How IGRA improves outcomes<br />
Chair: Sue Oliver NRAS and RCN, Barnstaple<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with an overview of the incidence and prevalence of TB and the issues surrounding<br />
misdiagnosis of latent TB infection in the pre-biologic setting.<br />
Delegates will be made aware of the incidence and prevalence of TB and LTBI in the UK<br />
Presented data will highlight the implications of misdiagnosis of LTBI, whilst suggesting some better<br />
screening practices<br />
Delegates will be made aware, by supporting data, that screening <strong>for</strong> LTBI using risk factors as a sole<br />
method has significant drawbacks<br />
07.30 Background to TB incidence and prevalence in UK<br />
Prof Peter Davies, Liverpool and Broadgreen Hospitals, Liverpool<br />
08.00 Latent tuberculosis infection (LTBI) screening in autoimmune, immune-suppressed patients<br />
Prof Stephan D Gadola, Southampton University Hospitals, Southampton<br />
08.30 Pre-biologic screening <strong>for</strong> latent tuberculosis infection (LTBI) in North East England: data and case studies<br />
Karl Nicholl, Biologics Nurse Specialist, Freeman Hospital, Newcastle-Upon-Tyne<br />
09.15 - 10.45 Essentials in rheumatology: disease management | Clyde Auditorium<br />
A comprehensive update covering everything you need to know about changes in rheumatology<br />
Chairs: Prof John Ax<strong>for</strong>d, St George’s Hospital, London | Dr Charles Mackworth-Young, Charing Cross<br />
Hospital, London<br />
Aim:<br />
Outcome:<br />
To prepare rheumatologists <strong>for</strong> revalidation and provide a valuable educational opportunity <strong>for</strong> trainees<br />
Delegates will have been brought up to date on disease management<br />
09.15 Metabolic bone diseases<br />
Prof Juliet Compston, University of Cambridge, Cambridge<br />
09.45 Psoriatic arthritis<br />
Prof Oliver Fitzgerald, St Vincent’s University Hospital, Dublin<br />
10.15 Antiphosphlipid syndrome<br />
Prof Anisur Rahman, UCL, London
36 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
09.15 - 10.45 Mimickers of myositis and treatment update: room <strong>for</strong> improvement and lessons from<br />
neurology | Lomond Auditorium<br />
Chair: Dr Robert Cooper, Hope Hospital, Manchester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with an overview of the issues surrounding misdiagnosis in myositis and an update in<br />
best practice<br />
Delegates will be able to identify the key factors in securing a diagnosis of metabolic/mitochondrial myopathy<br />
or dystrophy and excluding inflammatory myopathy<br />
Delegates will have a better understanding of the key clinical features in inclusion body myositis, how the<br />
diagnosis may be missed and current management strategies<br />
Delegates will receive an update on current best practice in the management of myositis<br />
09.15 Adult onset metabolic/mitochondrial myopathies and dystrophies: how these cases can be missed<br />
Dr Mark Roberts, Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d<br />
09.45 Inclusion body myositis and misdiagnosis of polymyositis<br />
Dr Matt Parton, National Hospital of Neurology and Neurosurgery, London<br />
10.15 Treatment update and best practice in inflammatory myopathy<br />
Prof Chester Oddis, Arthritis Institute, Pittsburgh, USA<br />
09.15 - 10.45 Osteoporosis: topical issues | Hall 1<br />
Chair: Dr Emma Clark, University of Bristol, Bristol<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide general rheumatologists and trainees with an update on topical issues in osteoporosis<br />
To understand the association between calcium/vitamin D supplementation and cardiovascular outcomes<br />
To discuss ways of maximising adherence with bisphosphonates<br />
To highlight how recent advances in genetics of High Bone Mass could impact on clinical practice<br />
09.15 Should we stop regular prescribing of calcium/vitamin D supplementation because of the risk of<br />
adverse cardiovascular outcomes?<br />
Prof Bo Abrahamsen, University of Southern Denmark, Odense, Denmark<br />
09.40 Bisphosphonates: what can we do to maximise adherence?<br />
Prof Rob Horne, University of London, London<br />
10.05 Causes of high bone mass and the clinical relevance<br />
Dr Celia Gregson, University of Bristol, Bristol<br />
10.30 Discussion
Wednesday 2 May 2012 | Programme 37<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
09.15 - 10.45 Primary care rheumatology: leading the way | Forth Room<br />
Chairs: Dr Louise Warburton, NHS Tel<strong>for</strong>d and Wrekin, Tel<strong>for</strong>d | Ms Melanie Holden, Keele University, Keele<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Delegates will gain an understanding of models of established primary care based musculoskeletal services<br />
Delegates will have an awareness of the role and contribution of allied health professionals working<br />
in primary care<br />
Delegates will explore the implications of commissioning changes <strong>for</strong> allied health professionals<br />
09.15 Primary care led rheumatology services<br />
Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham<br />
09:40 Musculoskeletal interface clinics: how physiotherapy has contributed to this model of care<br />
Mrs Kay Stevenson, Haywood Hospital, Stoke on Trent<br />
10.05 Business planning <strong>for</strong> a patient centred rheumatology service<br />
Mrs Ann Todd, Pennine Musculoskeletal Partnership, Oldham<br />
10.30 Discussion<br />
09.15 - 10.45 Oral abstracts: RA treatment and outcomes | Dochart Room<br />
Chair: Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge<br />
9.15 Validation of JADAS in all subtypes of juvenile idiopathic arthritis (JIA) in the clinical setting<br />
Dr Flora McErlane, University of Manchester, Manchester<br />
9.30 Has orthopaedic intervention <strong>for</strong> RA changed in line with combination and anti-TNF therapies?<br />
An evaluation of joint surgery rates and prognostic factors in two UK inception cohorts (1986-2011)<br />
ERAS/ERAN<br />
Dr Elena Nikiphorou, St Albans City Hospital, St Albans<br />
9.45 Predicting responses to anti-TNFα therapy in patients with rheumatoid arthritis using metabolomic<br />
analysis of urine<br />
Dr Sabrina Kapoor, University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust,<br />
Birmingham<br />
10.00 Doubleblind study of Tocilizumab + Methotrexate vs Tocilizumab + placebo in patients with active<br />
rheumatoid arthritis despite prior Methotrexate: progression of structural damage, quality of life,<br />
and physical function at 24 weeks<br />
Prof Philip Conaghen, University of Leeds, Leeds<br />
10.15 Secukinumab treatment provides sustained response over one year in patients with rheumatoid arthritis<br />
Dr Patrick Durez, Université Catholique de Louvain, Louvain, Belgium<br />
10.30 Withdrawal of Adalimumab in early rheumatoid arthritis patients who attained stable low disease activity<br />
with Adalimumab plus Methotrexate: results of a phase 4, double-blind, placebo-controlled trial<br />
Prof Paul Emery, Leeds Teaching Hospital, Leeds
38 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
09.15 - 10.45 SIG: MSK health in multi ethnic minorities | Morar Room<br />
Chair: Prof Kuntal Chakravarty, Queens Hospital, Rom<strong>for</strong>d<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To develop awareness of health issues in multi ethnic minorities with special emphasis on MSK health<br />
To understand the global issues on multi ethnic minority health issues<br />
To develop <strong>programme</strong>s of research and audit<br />
To develop strategy of improving the health care with special emphasis on MSK health<br />
09.15 Global health issues in multi ethnic minority: UK perspective<br />
Dr Sonya Fernandez, Kent University, Canterbury<br />
09.45 What research should be done in minority communities and how to publish<br />
Dr Kamran Abbasi, <strong>The</strong> Royal <strong>Society</strong> of Medicine, London<br />
10.15 Taking patient education into newer immigrant communities<br />
Ms Chandrika Gordhan, University of Birmingham, Birmingham<br />
09.15 - 10.45 SIG: Genetics of inflammatory arthritis | Gala Room<br />
Chair: Prof Anne Barton, University of Manchester, Manchester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To illustrate how advances in the understanding of the genetic basis of rheumatic diseases may<br />
impact clinically<br />
<strong>The</strong> attendees will understand the role of genetic markers in risk prediction and how this is being<br />
applied in the clinical setting<br />
Delegates will appreciate that treatment response is multi-factorial and will understand that genetics,<br />
environmental, host factors and epigenetics all play a role<br />
Novel approaches to analysis of outcome will be described with reference to juvenile idiopathic arthritis<br />
09.15 Using genetics to in<strong>for</strong>m risk prediction in RA<br />
Dr Sophia Steer, King’s College Hospital, London<br />
09.35 Predicting treatment response<br />
Prof Anne Barton, University of Manchester, Manchester<br />
09.55 <strong>The</strong> role of epigenetics in prediction of treatment response<br />
Prof Gerry Wilson, University of Sheffield, Sheffield<br />
10.15 Translation of genetic studies into prediction of outcome in JIA<br />
Prof Wendy Thomson, University of Manchester, Manchester<br />
10.35 Panel discussion
Wednesday 2 May 2012 | Programme 39<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
09.15 - 10.45 SIG: Scleroderma | Leven Room<br />
Chair: Prof Chris Denton, UCL Medical School/Royal Free Hospital<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To discuss some of the challenging areas of management of systemic sclerosis and present consensus<br />
best practice pathways that have been developed over the past 18 months by scleroderma centres in the<br />
UK. This is a major initiative of the UK scleroderma study group (UKSSG) that has developed draft<br />
consensus pathways <strong>for</strong> digital vasculopathy and <strong>for</strong> gastrointestinal complications of scleroderma<br />
(systemic sclerosis)<br />
Appreciation of multi-disciplinary definition of the domains of major clinical involvement of the<br />
gastrointestinal tract in scleroderma<br />
Understanding the interplay between upper and lower limb vasculopathy leading to complications of<br />
secondary Raynaud’s phenomenon in scleroderma<br />
Challenges in early detection of systemic sclerosis and appropriate stratification of cases <strong>for</strong> high intensity<br />
treatment such as immunosuppression with stem cell rescue<br />
09.15 Development of expert consensus best practice management <strong>for</strong> systemic sclerosis: a UK scleroderma<br />
study group (UKSSG) initiative<br />
Prof Chris Denton, UCL Medical School/Royal Free Hospital, London<br />
09.25 Gastrointestinal tract manifestations of systemic sclerosis<br />
Dr Charles Murray, Royal Free Hospital, London<br />
09.45 Complications of scleroderma vasculopathy: Raynaud’s phenomenon, digital ulcers and critical digital<br />
ischaemia<br />
Prof Ariane Herrick, Sal<strong>for</strong>d Royal Hospital and University of Manchester<br />
10.05 Early diagnosis of scleroderma: prevention rather than treatment. Secondary Raynaud’s and risk<br />
stratification by autoantibody profile<br />
Dr John Pauling, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath<br />
10.45 - 11.45 Poster viewing and exhibition | Tea and coffee<br />
Categories:<br />
Poster tours:<br />
Muscle disorders<br />
Osteoarthritis<br />
Orthopaedics and rehabilitation<br />
Rheumatoid arthritis: treatment<br />
Osteoarthritis<br />
Osteoporosis and metabolic bone disease<br />
Paediatric and adolescent rheumatology<br />
Primary care<br />
Psychology, measurement and management of pain<br />
Rheumatoid arthritis: treatment<br />
Soft tissue and regional musculoskeletal disease, fibromyalgia
40 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
11.45 - 13.15 ARMA session | Lomond Auditorium<br />
Devolution of health: what can we learn?<br />
Chair: Dr Anthony Redmond, University of Leeds, Leeds<br />
11.45 Focus on England: Taking <strong>for</strong>ward the MSK networks and an update on commissioning activity<br />
Mrs Laura Guest, CEO <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong><br />
12.15 Focus on Scotland<br />
Dr Sarah Mitchell, National Programme Manager <strong>for</strong> the Delivery Framework <strong>for</strong> Adult Rehabilitation,<br />
Scottish Government Health Department<br />
This project has three key work areas:<br />
1) Multi professional MSK care pathways<br />
2) A pilot using NHS 24 telephony to provide a national advice triage service to signpost to in<strong>for</strong>mation<br />
and local MSK services<br />
3) Embedding working health services Scotland in all MSK pathways<br />
12.45 Focus on Wales<br />
Wales project speaker to be confirmed<br />
11.45 - 13.15 Rheumatological challenges in primary care | Boisdale Room<br />
Chair: Dr Elspeth Wise, Encompass Healthcare, Washington<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Outcome 4:<br />
To provide delegates with an understanding of difficulties in diagnosing rheumatological conditions and<br />
associated problems in primary care<br />
Awareness of how frequently rheumatological problems present in primary care<br />
Understanding of how to diagnose early inflammatory arthritis in primary care<br />
Increased knowledge of co-morbidity associated with polymyalgia rheumatica<br />
Understanding of how to differentiate inflammatory back pain from other causes of low back pain in<br />
primary care<br />
11.45 What musculoskeletal problems does the average GP see?<br />
Dr Mark Porcheret, Arthritis Research UK Primary Care Centre, Keele<br />
12.00 How to better diagnose early inflammatory arthritis in primary care<br />
Dr Karim Raza, University of Birmingham, Birmingham<br />
12.25 Polymyalgia rheumatica: more than just shoulder pain<br />
Prof Christian Mallen, Arthritis Research UK Primary Care Centre, Keele<br />
12.50 Seeing the wood <strong>for</strong> the trees: diagnosing inflammatory back pain in primary care<br />
Prof Ingemar Petersson, Skane University Hospital, Lund, Sweden
Wednesday 2 May 2012 | Programme 41<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
11.45 - 13.15 Essentials in rheumatology: symptom diagnosis and management | Clyde Auditorium<br />
A comprehensive update covering everything you need to know about changes in rheumatology<br />
Chairs: Prof John Ax<strong>for</strong>d, St George’s Hospital, London | Dr Charles Mackworth-Young, Charing Cross<br />
Hospital, London<br />
Aim:<br />
Outcome:<br />
To prepare rheumatologists <strong>for</strong> revalidation and provide a valuable educational opportunity <strong>for</strong> trainees<br />
Delegates will have had the opportunity to discuss symptom diagnosis<br />
11.45 Ocular manifestations of rheumatological disorders<br />
Mr Carlos Pavesio, Moorfields Eye Hospital, London<br />
12:15 Is there infection? Arthritis, bones and prosthetics<br />
Prof Tony Berendt, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d<br />
12.45 Improving patient management: what do patients want?<br />
Prof Sir Gordon Duff, University of Sheffield, Sheffield<br />
11.45 - 13.15 BHPR plenary orals | Hall 1<br />
Chair: Dr Richard Rees, St Mary’s Hospital, London I Mr Robert Field, Dorset HealthCare University<br />
Foundation Trust, Dorset<br />
11.45 <strong>The</strong> impact of pain on successful ageing<br />
Dr Ross Wilkie, Keele University, Keele<br />
12.00 Forefoot bursae are a prognostic indicator of disabling foot complications in patients with RA: results of<br />
a prospective three-year study<br />
Ms Lindsey Hooper, University of Southhampton, Southampton<br />
12.15 <strong>The</strong> continuing professional development <strong>for</strong> health professionals working within musculoskeletal<br />
services: a national UK survey<br />
Dr Jo Adams, University of Southampton, Southampton<br />
12.30 Debridement of painful <strong>for</strong>efoot plantar callosities in rheumatoid arthritis: the CARROT randomised<br />
controlled trial<br />
Mrs Heidi Siddle, University of Leeds, Leeds<br />
12.45 Psychological well-being in early rheumatoid arthritis: findings from the early rheumatoid arthritis<br />
network (ERAN)<br />
Dr S Norton, University of Cambridge, Cambridge<br />
13.00 Health professionals’ perceptions of the effects of exercise on joint health in rheumatoid arthritis (RA)<br />
patients II: a follow-up focus group study<br />
Ms Serena Halls, Bangor University, Cardiff
42 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
11.45 - 13.15 Oral abstracts: connective tissue diseases | Alsh Room<br />
Chair: Dr Betty Diamond, Feinstein Institute Medical Research, New York, USA<br />
11.45 Variability in the phenotype of metabolic syndrome over time in a multicentre international inception cohort<br />
of patients with SLE<br />
Dr Ben Parker, University of Manchester, Manchester<br />
12.00 Nitrated nucleosome levels in patients with systemic lupus erythematosus: associations with ethnicity,<br />
autoantibody status and disease activity<br />
Dr Sara Croca, University College London, London<br />
12.15 Is there an association between Warfarin and survival in SSC-PAH patients treated with first line<br />
bosentan monotherapy?<br />
Dr Clare Warrell, Royal Free Hampstead NHS Trust, London<br />
12.30 ANTI-EIF2 is associated with interstitial lung disease in patients with systemic sclerosis<br />
Dr Zoe Betteridge, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath<br />
12.45 Optical coherence tomography validation: a new quantitative imaging biomarker <strong>for</strong> affected skin in<br />
scleroderma<br />
Dr Giuseppina Abignano, Leeds Institute of Molecular Medicine, Leeds<br />
13.00 <strong>The</strong> clinical relevance of ANTI-RO52 and ANTI-RO60 in patients in the United Kingdom primary Sjögren’s<br />
syndrome registry (UKPSSR)<br />
Dr Josephine Vila, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Sunderland<br />
11.45 - 13.15 SIG: Vasculitis | Forth Room<br />
Chairs: Prof Raashid Luqmani, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d | Dr Chetan Mukhtyar, Norfolk and Norwich University<br />
Hospitals, Norwich<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an update on current areas of research in systemic vasculitis, emphasising the potential<br />
<strong>for</strong> attendees to take an active role<br />
To gain an understanding of the diverse research projects curently conducted in systemic vasculitis<br />
To understand the evidence base <strong>for</strong> current management in systemic vasculitis (including emerging<br />
diagnostic tests and therapeutics)<br />
To enable attendees to take an active role in vasculitis studies now and in the future<br />
11.45 Quality of life in ANCA associated vasculitis (VASQoL study findings)<br />
Dr Neil Basu, University of Aberdeen, Aberdeen<br />
12.00 Update on developing diagnostic and classification criteria in systemic vasculitis (DCVAS)/<br />
Update on the temporal artery biopsy vs ultrasound study (TABUL)<br />
Dr Joanna Robson and Prof Raashid Luqmani, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d<br />
12.15 Use of the General Practice Research database in vasculitis: focus on aortic aneurysm risk in GCA<br />
Prof Nigel Arden, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d<br />
12.30 European Vasculitis Study Group (EUVAS) therapeutic trials in vasculitis where have we got to and where<br />
are we going?<br />
Dr David Jayne, Addenbrooke’s Hospital, Cambridge,<br />
12.45 Genome wide association studies in ANCA associated vasculitis<br />
Dr Richard Watts, University of East Anglia, Ipswich<br />
13.00 Panel discussion
Wednesday 2 May 2012 | Programme 43<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
11.45 - 13.15 SIG: Paediatric and adolescent rheumatology | Gala Room<br />
Chairs: Dr Clare Pain, Alder Hey Hospital, Liverpool I Dr Alison Jordan, University Hopsitals<br />
Birmingham, Birmingham<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To focus on the changing role of paediatric and adult rheumatologists in the care of young people,<br />
including discussion of the drivers and barriers <strong>for</strong> change and consumer involvement<br />
Delegates will have discussed how we ensure adult services provide rheumatologists with appropriate<br />
skills and experience to take on the care of young people<br />
Delegates will have addressed how we engage young people / consumers in their care and<br />
involving them in research<br />
Delegates will have fedback on what they would like the paediatric and adolescent SIG to achieve in the future<br />
11.45 Standards of care <strong>for</strong> children and young people with JIA<br />
Dr Eileen Baildam, Alder Hey Hospital, Liverpool<br />
12.10 Adolescent training Issues and RCP involvement<br />
Dr Rachel Tatterall, Sheffield Teaching Hospitals NHS Trust, Sheffield<br />
12.35 Involving young people in rheumatology research<br />
Dr Janet McDonagh, Birmingham Children’s Hospital, Birmingham<br />
13.00 Discussion<br />
13.15 - 14.45 Exhibition | Lunch<br />
13.15 - 14.45 BSR AGM | Dochart Room<br />
Join your colleagues over lunch and meet the Trustees and committee members of your society. Hear what they<br />
have been doing on your behalf and how they plan to meet the challenges of the year ahead. Your attendance<br />
is highly valued and lunch will be provided<br />
13.15 - 14.45 How to get your abstract published | Leven Room<br />
Chair: Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with the tools to submit a quality abstract submission<br />
Delegates will understand the key issues surrounding a quality abstract submission<br />
Delegates will be able to critically analyse an abstract submission with a view to improving the quality<br />
Delegates will be able to re-<strong>for</strong>mulate an abstract to make a quality submission<br />
13.15 Abstract review: what the reviewers are looking <strong>for</strong> in a quality abstract submission<br />
Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole<br />
13.30 Group work: critically analyzing 2-3 abstracts<br />
Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole | Ms Diana Finney, Sussex Community<br />
NHS Trust, Brighton | Dr Sarah Ryan, Haywood Hospital, Stoke on Trent
44 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
14.45 - 16.15 Current thinking on conservative management of back pain | Hall 1<br />
Chairs: Mrs Sue Gurden, Aneurin Bevan Health Board, Abergavenny | Prof Nadine Foster, Keele<br />
University, Keele<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To update delegates on current thinking on low back pain management<br />
Delegates will have an increased knowledge of tools available to aid treatment selection in low back pain<br />
in the clinic<br />
Delegates will have an increased knowledge of health economics and it’s clinical application in treatment<br />
selection and service delivery in low back pain<br />
Delegates will have an increased knowledge of the influence of patient’s and practitioner’s health beliefs<br />
on rehabilitation in low back pain<br />
14.45 Can we choose the best treatment <strong>for</strong> back pain patients?<br />
Dr Jonathan Hill, Keele University, Keele<br />
15.05 Are back pain treatments cost-effective? What clinicians need to know about health economics<br />
Dr Duncan Critchley, King’s College London, London<br />
15.25 Low back pain in primary care<br />
Prof Martin Underwood, University of Warwick, Coventry<br />
15:45 <strong>The</strong> direct and indirect impact of health beliefs in low back pain on outcomes<br />
Dr Tamar Pincus, University of London, Egham<br />
14.45 - 16.15 IRS | Essentials in rheumatology: Keeping up to date, clinical decision making - what is the<br />
evidence? | Clyde Auditorium<br />
A comprehensive update covering everything you need to know about changes in rheumatology<br />
Chairs: Prof John Ax<strong>for</strong>d, St George’s Hospital, London | Dr Charles Mackworth-Young, Charing Cross<br />
Hospital, London<br />
Put your clinical decision making to the test using interactive voting keypads<br />
Aim:<br />
Outcome:<br />
To prepare rheumatologists <strong>for</strong> revalidation and provide a valuable educational opportunity <strong>for</strong> trainees<br />
Delegates will have had their clinical decision making skills tested<br />
14.45 Ankylosing spondylitis<br />
Prof Roger Sturrock, Glasgow Royal Infirmary, Glasgow<br />
15.30 Vasculitis<br />
Dr David Jayne, Addenbrookes Hospital, Cambridge
Wednesday 2 May 2012 | Programme 45<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
14.45 - 16.15 Juvenile-onset SLE and childhood scleroderma: new insights into pathology, treatment and<br />
outcomes | Forth Room<br />
Chairs: Dr Jacqui Clinch, University of Bath, Bath | Prof David Isenberg, UCL, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Gain insight into recent developments in the diagnosis, treatment and research domains in childhood SLE<br />
and scleroderma<br />
Improved knowledge concerning SLE in the developing child/adolescent<br />
Understand importance of optimal control of childhood lupus, particularly in relation to long term outcome<br />
as adults<br />
Improved understanding of childhood scleroderma, and impact of this disease in adult rheumatology<br />
practice<br />
14.45 What is the natural history of scleroderma with its onset in childhood?<br />
Dr Eileen Baildam, Alder Hey Children’s NHS Foundation Trust, Liverpool<br />
15.10 Why is it important to know about lupus in children?<br />
Prof Michael Beres<strong>for</strong>d, University of Liverpool, Liverpool<br />
15.35 Improving and optimising long term outcomes of patients with juvenile-onset SLE<br />
Dr Clarissa Pilkington, Great Ormond Street Hospital, London<br />
16.00 Panel discussion<br />
14.45 - 16.15 Recent advances in osteoarthritis therapy | Lomond Auditorium<br />
Chairs: Prof Philip Conaghan, University of Leeds, Leeds | Dr George Peat, Keele University, Keele<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with a state of the art update on the clinical management and structural<br />
modification of OA<br />
Understand the varying effectiveness of mechanical interventions in the clinical management and<br />
structural modification of lower limb OA<br />
Understand the therapeutic role and effectiveness of structural modifying drugs in OA<br />
Gain understanding of joint distraction as a method of tissue modification in OA<br />
14.45 Mechanical effectiveness of foot orthoses in foot osteoarthritis<br />
Mrs Jill Halstead, University of Leeds, Leeds<br />
15.05 Varying effectiveness of mechanical interventions in knee OA<br />
Dr Richard Jones, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d<br />
15.25 Tissue structure modification in late stage osteoarthritis is feasible<br />
Prof Floris Lafeber, University Medical Center Utrecht, Utrecht, <strong>The</strong> Netherlands<br />
15.45 <strong>The</strong> role of strontium ranelate in the treatment of osteoarthritis<br />
Prof Cyrus Cooper, Southampton General Hospital, Southampton
46 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
14.45 - 16.15 Oral abstracts: Primary Care | Alsh Room<br />
Chair: Dr Louise Warburton, NHS Tel<strong>for</strong>d and Wrekin, Tel<strong>for</strong>d<br />
14.45 Audit to assess GP awareness and documentation of biologic and DMARD drugs in primary care patient<br />
records<br />
Dr Charlotte Goodhead, Queen Elizabeth Hospital Gateshead, Gateshead<br />
15.00 <strong>The</strong> MRC physiodirect trial: a pragmatic randomised controlled trial of ‘physiodirect’ telephone<br />
assessment and advice services versus usual care <strong>for</strong> musculoskeletal problems<br />
Dr Annette Bishop, Keele University, Keele<br />
15.15 Frequency of musculoskeletal symptoms and presenting complaints in video observed primary care<br />
consultations with patients aged 45 and over<br />
Dr Zoe Paskins, Arthritis Research UK Primary Care Centre, Keele<br />
15.30 Deciding to consult the general practitioner <strong>for</strong> symptomatic osteoarthritis: a choice-based conjoint<br />
analysis study<br />
Ms Domenica Coxon, Keele University, Keele<br />
15.45 Are rheumatoid arthritis patients screened <strong>for</strong> cardiovascular disease in primary care?<br />
Ms Helen Monk, Keele University, Keele<br />
16.00 Gout, allopurinol and erectile dysfunction: an epidemiological study in a primary care<br />
consultation database<br />
Dr Edward Roddy, Arthritis Research UK Primary Care Centre, Stoke on Trent<br />
14.45 - 16.15 SIG: Heritable disorders of connective tissue | Boisdale Room<br />
Chair: Prof Howard Bird, University of Leeds, Leeds<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To equip rheumatology clinicians with knowledge and understanding of the impact of chronic pain in<br />
EDS/JHS and the evidence base <strong>for</strong> its alleviation by physical and cognitive interventions<br />
Delegates will acquire a greater appreciation of the multi-systemic nature of EDS/JHS, including chronic<br />
pain, dysautonomia and gastrointestinal dysmotility<br />
Delegates will be able to offer a multidisciplinary strategy <strong>for</strong> the rehabilitation of patients with severe<br />
deconditioning, reduced mobility and independence<br />
Delegates will acquire a greater familiarity with new developments in relevant therapeutic modalities in<br />
the published literature<br />
14.45 Hypermobility, fibromyalgia and chronic pain<br />
Dr Alan Hakim, Whipps Cross Hospital, London<br />
15.05 Medical rehabilitation and pain control<br />
Dr Helen Cohen, Royal National Orthopaedic Hospital, Stanmore<br />
15.25 Physical rehabilitation: role of physiotherapy/OT<br />
Rosemary Keer, Hospital of St John and St Elizabeth’s, London<br />
15.45 Cognitive interventions in EDS/JHS and chronic pain<br />
Dr Clare Daniel, UCLH, London<br />
16.05 Panel discussion
Wednesday 2 May 2012 | Programme 47<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
14.45 - 16.15 BHPR SIG: Rheumatoid arthritis | Gala Room<br />
Chair: Ms Janet Cushnaghan, Southampton General Hospital, Southampton<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To hold a session on rheumatoid arthritis of interest to BHPR and BSR members. Topics to be covered are<br />
tocilizumab therapy and early arthritis<br />
Delegates will learn new in<strong>for</strong>mation on tocilizumab therapy<br />
Delegates will learn about the delays to presentation and treatment in RA<br />
Delegates will have an opportunity to ask questions and participate in discussion on the topics presented<br />
14.45 Tocilizumab: all you need to know<br />
Sandra Robinson, Senior Research Nurse, Newcastle Upon Tyne<br />
15.15 Early management: are we meeting NICE guidelines?<br />
Dr Peter Prouse, Basingstoke and North Hampshire Hospital<br />
15.45 Delay in presenting as a patient: the reasons why<br />
Dr Rebecca Stack, Sandwell and West Birmingham Hospitals NHS Trust<br />
16.15 - 16.45 Exhibition | Tea and coffee<br />
16.45 - 17.45 Heberden Oration | Clyde Auditorium<br />
Lessons in rheumatology from extreme phenotypes and subtle genotypes<br />
Chair: Prof David L Scott, President BSR<br />
Prof Paul Wordsworth, Professor of <strong>Rheumatology</strong> and Consultant Rheumatologist, Nuffield Department<br />
of Orthopaedics, <strong>Rheumatology</strong> and Musculoskeletal Sciences<br />
‘A highly professional event, made me proud to<br />
be part of this speciality’ Delegate 2011
48 Programme | Wednesday 2 May 2012<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
17.45 - 18.00 Industry supported symposium catering<br />
18.00 - 19.30 Industry supported symposium: | Forth Room<br />
Abbott<br />
<strong>The</strong> patient at the heart of Treat to Target<br />
New practical tools to optimise the consultation process<br />
Chair: Prof Paul Emery, Chapel Allerton Hospital, Leeds<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with the latest advances in T2T and practical guidance on how best to engage patents<br />
in T2T to optimise outcomes<br />
Delegates will be given access to latest advances in T2T, including initiatives that incorporate ultrasound<br />
and patient audit<br />
Delegates will better understand the ‘ideal’ target and ‘ideal’ outcomes that are practical to achieve <strong>for</strong><br />
different patients<br />
Delegates will be provided with a new tool that assists with patient involvement in T2T in the consultation<br />
process<br />
18.00 Welcome and introduction<br />
Prof Paul Emery, Chapel Allerton Hospital, Leeds<br />
18.05 New initiatives to drive Treat to Target<br />
Prof Paul Emery, Chapel Allerton Hospital, Leeds<br />
18.20 Translating clinical targets into realistic personalised goals<br />
Prof Peter Taylor, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d<br />
18.50 TRACK to optimise the consultation process<br />
Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge and Kate Gadsby, <strong>Rheumatology</strong> Nurse Specialist,<br />
Derbyshire Royal Infirmary, Derby<br />
19.15 Question and answer session<br />
All speakers (facilitated by Prof Paul Emery)<br />
19.25 Thank you and close<br />
Prof Paul Emery, Chapel Allerton Hospital, Leeds
CPD accredited<br />
Treat To Target<br />
Symposium<br />
THE PATIENT AT<br />
THE HEART OF<br />
TREAT TO TARGET<br />
New practical tools to optimise<br />
the consultation process<br />
Wednesday 2 May 2012<br />
18.00-19.30<br />
(Light refreshments served from 17.45)<br />
Forth Room<br />
Chair: Prof. Paul Emery<br />
Speakers: Prof. Peter Taylor, Dr Andrew Östör and Kate Gadsby<br />
This Treat to Target initiative is led by the UK Treat to Target Steering<br />
Committee and funded by Abbott Laboratories<br />
Date of Preparation: February 2012 AXHUR120178a
ASSESSING THE EVIDENCE:<br />
the benefits of IL-6R<br />
inhibition in RA<br />
Wednesday 2nd May 2012<br />
Canapés 17.45<br />
Symposium 18.00–19.30<br />
Venue Hall 1<br />
CHAIR:<br />
Professor Ernest Choy Cardiff University School of Medicine<br />
SPEAKERS:<br />
Professor John Isaacs Newcastle University<br />
Professor Naveed Sattar University of Glasgow<br />
Professor George Kitas Russell’s Hall Hospital, Dudley<br />
Professor David Linch University College London<br />
This symposium is sponsored by Roche Products Ltd<br />
and Chugai Pharma UK Ltd.<br />
RCUKACTE00445 February 2012
Wednesday 2 May 2012 | Programme 51<br />
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event<br />
Industry supported symposium |<br />
Award winner | IRS (interactive audience response system)<br />
18.00 - 19.30 Industry supported symposium: | Hall 1<br />
Roche<br />
Assessing the evidence: the benefits of IL-6R inhibition in RA<br />
Chair: Prof Ernest Choy, Cardiff University School of Medicine, Cardiff<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with an overview of the use of IL-6R inhibition in patients with rheumatoid arthritis<br />
Delegates will be updated on the latest data on the use of IL-6R inhibition in rheumatoid arthritis<br />
Delegates will learn about infections and CV risks and their impact on daily practice, and how these risks<br />
can be managed<br />
Delegates will have a good understanding of the haematological manifestations relating to rheumatoid<br />
arthritis and IL-6R inhibition<br />
18.00 <strong>The</strong> use of IL-6R inhibition in rheumatoid arthritis<br />
Prof Ernest Choy, Cardiff University School of Medicine, Cardiff<br />
18.15 <strong>The</strong> significance of infection risk and relevant patient management<br />
Prof John Isaacs, Newcastle University, Newcastle<br />
18.30 Cardiovascular risk and the role of IL-6<br />
Prof Naveed Sattar, University of Glasgow, Glasgow<br />
18.45 Practical management of CV risk in patients with RA<br />
Professor George Kitas, Russell’s Hall Hospital, Dudley<br />
19.00 <strong>The</strong> effects of IL-6 on neutrophils, platelets and anaemia<br />
Professor David Linch, University College London, London<br />
19.15 Question and answer session, followed by summary and close<br />
20.00 - Late Conference dinner and ceilidh<br />
Join us <strong>for</strong> our networking dinner. Enjoy an un<strong>for</strong>gettable evening of traditional Scottish food, drink and<br />
entertainment at Òran Mór, which appropriately means the ‘great melody of life’<br />
<strong>The</strong> evening will begin at 20.00 and tickets are only £40 (inc VAT).
We encourage your use of social media<br />
in and around <strong>Rheumatology</strong> 2012<br />
@<strong>Rheumatology</strong>UK<br />
⧣Rheum2012<br />
Search on Twitter <strong>for</strong> the hashtag #Rheum2012 to<br />
follow the feed of tweets related to the <strong>conference</strong><br />
and include #Rheum2012 in any tweets<br />
that you send out.<br />
• Converse with other attendees<br />
• Suggest sessions to attend and posters to visit<br />
• Plan to meet up in the Exhibition or at the<br />
social events<br />
• Provide helpful feedback to BSR staff and make<br />
suggestions <strong>for</strong> next year’s meeting<br />
facebook.com/rheumatologyUK<br />
Search ‘Groups’:<br />
<strong>Rheumatology</strong> 2012
Programme:<br />
Thursday 3 May 2012<br />
Programme<br />
Thu 3 May 2012
New developments<br />
in spondyloarthritis<br />
Diagnosis, management and<br />
clinical advances in axial SpA<br />
Thursday 3rd May 2012,<br />
7:30 – 9:00am<br />
Forth Room<br />
<strong>Rheumatology</strong> 2012,<br />
SECC, Glasgow<br />
Chair<br />
Prof Paul Wordsworth<br />
Speakers<br />
Dr Helena Marzo-Ortega<br />
Dr Alex Bennett<br />
Prof Désirée van der Heijde<br />
This symposium is organised and funded by Abbott Laboratories.<br />
Date of preparation: February 2012. AXHUR120167p
Thursday 3 May 2012 | Programme 53<br />
Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
07.30 - 09.00 Industry supported symposium: | Forth Room<br />
Abbott<br />
Abbott Axial SpA symposium<br />
New developments in spondyloarthritis: diagnosis, management and clinical advances in axial SpA<br />
Prof Paul Wordsworth, Botnar Research Centre, Ox<strong>for</strong>d<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide diagnosis, management, and treatment guidance <strong>for</strong> axial spondyloarthritis (SpA)<br />
Delegates should be able to recognise distinguishing factors and classification criteria attributed to axial SpA<br />
Delegates should be able to recognise the assessment capabilities of using whole spine MRI and the<br />
advantages of adding this to classification process<br />
Delegates should be aware of new research advances relating to the management of axial SpA<br />
07.30 Welcome and introduction<br />
Prof Paul Wordsworth, Botnar Research Centre, Ox<strong>for</strong>d<br />
07.40 <strong>The</strong> concept of axial SpA<br />
Dr Helena Marzo Ortega, Leeds Musculoskeletal Biomedical Research Unit, Leeds<br />
08.00 MRI <strong>for</strong> diagnosis and prognosis of SpA<br />
Dr Alex Bennett, Defence Medical Rehabilitation Centre, Epsom<br />
08.20 New evidence <strong>for</strong> anti-TNF treatment in patients with axial SpA<br />
Prof Désirée van der Heidje, Leiden University Medical Centre, <strong>The</strong> Netherlands<br />
08.40 Question and answer<br />
Panel<br />
08.55 Summary and close<br />
Prof Paul Wordsworth, Botnar Research Centre, Ox<strong>for</strong>d<br />
07.30 - 09.00 SIG: Myositis | Leven Room<br />
Chair: Dr Hector Chinoy, Dr Hector Chinoy, University of Manchester, Manchester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an update on pertinent issues in myositis and upcoming research/clinical activities<br />
To discuss the latest investigations used in the diagnosis and differential diagnosis of myositis<br />
To discuss current controversies in the management of inflammatory myositis<br />
To gain an understanding of the research topics undertaken through UKMYONET<br />
07.30 Update on Arthritis Research UK Clinical Studies Group involvement in CTDs<br />
Professor David Isenberg, UCL, London<br />
07.45 Update on antibody testing in inflammatory myopathy<br />
Prof Neil McHugh, Royal National Hospital <strong>for</strong> Rheumatic Disease, Bath | Dr Harsha Gunawardena,<br />
North Bristol NHS Trust, Bristol<br />
08.00 Standardisation of histopathological testing in myositis<br />
Dr Patrick Gordon, King’s College Hospital, London
54 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
SIG: Myositis (cont) | Leven Room<br />
08.15 Treatment issues in myositis: case presentations and discussion<br />
Dr Chris Edwards, Southampton University Hospitals NHS Trust, Southampton<br />
08.30 Genome wide association studies in inflammatory myopathy and UK MYONET genetic study<br />
Prof Robert Cooper, Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d<br />
08.45 Discussion<br />
09.00 - 10.30 Molecular mechanisms of disease: osteoarthritis | Dochart Room<br />
Chair: Dr Tonia Vincent, Imperial College London, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To give attendees an overview and understanding of key issues in the molecular mechanisms of osteoarthritis<br />
Delegates will be aware of current dogma of molecular pathogenesis in osteoarthritis<br />
Delegates will be aware of novel laboratory research in osteoarthritis<br />
09.00 Keynote talk on osteoarthritis<br />
Dr Tonia Vincent, Imperial College London, London<br />
09.10 Identification of novel osteoarthritis genes using Zebrafish<br />
Dr Chrissy Hammond, University of Bristol, Bristol<br />
09.30 Is adrenomedullin a potential therapeutic <strong>for</strong> osteoarthritis while its truncated peptide 22-52 acts as a<br />
pro degenerative factor?<br />
Dr Frédéric Velard, Lariboisière Hospital, Paris, France<br />
09.50 Investigation of the role of UFM1 specific peptidase 2 in Beukes hip dysplasia<br />
Mr Michal Dudek, University of Manchester, Manchester<br />
10.10 Cannabidiol blocks the inhibitory effects of the GPR55 agonist L-alpha-lysophosphatidylinositol on<br />
mechanosensitive knee joint afferents<br />
Mr Kenneth Paton, University of Nottingham, Nottingham<br />
09.00 - 10.30 Optimising therapy <strong>for</strong> rheumatoid arthritis | Clyde Auditorium<br />
Chairs: Dr Maya Buch, University of Leeds, Leeds | Prof Michael Ehrenstein, UCL, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Provide an update on new therapies in RA and how to more effectively use existing therapies to<br />
achieve remission<br />
Understand the principles of treat to target in RA<br />
Appreciate how new therapies will fit into the current treatment pathway <strong>for</strong> RA<br />
Update on the challenges and treatment of extrarticular manifestations of RA<br />
09.00 Achieving tight control in RA<br />
Prof Ronald Van Vollenhoven, Karolinska University Hospital, Stockholm, Sweden<br />
09.25 New therapies <strong>for</strong> RA: is there room?<br />
Dr Maya Buch, University of Leeds, Leeds<br />
09.50 Extra-articular complications in RA: impact of biologic therapies and unmet patient need<br />
Prof Ian Bruce, University of Manchester, Manchester<br />
10.15 Panel discussion
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
Thursday 3 May 2012 | Programme 55<br />
09.00 - 10.30 Pain and motor function: mechanisms and treatment approaches | Lomond Auditorium<br />
Chairs: Prof Mike Hurley, St George’s University of London, London | Prof Jackie Campbell, University of<br />
Northampton, Northampton<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To explain how pain interacts at the cortical and peripheral level with the sensorimotor system and<br />
how therapies can be targeted to improve musculoskeletal pain using osteoarthritis as a model<br />
Delegates will have a greater understanding of how chronic musculoskeletal pain interacts and<br />
changes peripheral and central motor control systems<br />
<strong>The</strong>y will understand how these changes in function can be identified and explored in the clinical<br />
research setting<br />
Delegates will have a greater understanding of how therapies can be designed to reduce pain and<br />
improve function in the community setting<br />
09.00 Keeping control of function in the presence of pain: how does the brain cope?<br />
Prof Candy McCabe, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath and University of the West<br />
of England, Bath<br />
09.25 Changes in sensorimotor behavior with pain and how to monitor these in a movement analysis laboratory<br />
Prof Charlotte Häger, Umeå University, Umeå, Sweden<br />
09.50 Developing effective and af<strong>for</strong>dable community based interventions to improve osteoarthritic pain<br />
Dr Nicola Walsh, University of the West of England, Bristol<br />
10.15 Discussion<br />
09.00 - 10.30 IRS |Interactive quiz and clinical teaching | Hall 1<br />
Chairs: Dr Ben Parker, University of Manchester, Manchester | Dr Sonia Panchal, University Hospital of<br />
Leicester NHS Trust, Leicester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To review and update clinical teaching of spondyloarthropathies using interactive voting pads to<br />
encourage participation<br />
To review the spondyloarthropathies<br />
To update clinical teaching<br />
09.00 Psoriatic arthritis<br />
Dr Philip Helliwell, University of Leeds, Leeds<br />
09:45 Ankylosing spondylitis<br />
Dr Andrew Keat, Northwick Park Hospital, Harrow
56 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
09.00 - 10.30 Oral abstracts: Epidemiology and outcomes | Alsh Room<br />
Prof Gary Macfarlane, University of Aberdeen, Aberdeen I Dr Hoda Mijafari, University of Manchester,<br />
Manchester<br />
9.00 <strong>The</strong> risk of solid cancer in patients receiving anti-tumour necrosis factor therapy <strong>for</strong> rheumatoid arthritis:<br />
results from the <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> Biologics Register<br />
Dr Louise Mercer, University of Manchester, Manchester<br />
9.15 Systemic rheumatoid vasculitis in the biologic era<br />
Dr Eleana Ntatsaki, Norfolk and Norwich University Hospital, Norwich<br />
9.30 Incidence of rheumatoid arthritis in the UK using the 2010 ACR/EULAR classification criteria; and<br />
comparison with estimates using the 1987 ACR criteria<br />
Dr Jennifer Humphreys, University of Manchester, Manchester<br />
9.45 Smoking and rheumatoid factor status in predicting responses to biologics<br />
Dr Abdul Khan, King’s College Hospital, London<br />
10.00 Breast is best. Lifecourse influences on the development of knee osteophytes: the Newcastle thousand<br />
families study<br />
Dr Ajay Abraham, Newcastle University, Newcastle upon Tyne<br />
10.15 Association of systemic sclerosis with different autoantibody subgroups and malignancies: a retrospective<br />
registry-based UK cohort study<br />
Dr Pia Moinzadeh, Royal Free Hospital, London<br />
09.00 - 10.30 SIG: Sjögren’s syndrome | Boisdale Room 1<br />
Chair: Dr Simon Bowman, University Hospitals Birmingham, Birmingham | Dr Elisabeth Price, Great Western<br />
Hospital, Marlborough Road, Swindon<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To review recent advances in oral diagnosis and ocular diagnosis, treatment and research in Sjögren’s<br />
syndrome. To review current ongoing clinical research in Sjögren’s syndrome and discuss new initiatives<br />
Participants will have updated their knowledge on the oral and ocular manifestations of Sjögren’s<br />
syndrome<br />
Participants will have been brought up to date on current research and current and future treatments<br />
Participants will have received an update on the current multicentre studies<br />
09.00 Sjögren’s: oral perspectives<br />
Dr Gill Smith, Department of Oral Medicine at the Dental Hospital, Glasgow<br />
09.20 Sjögren’s: the ophthalmology perspective<br />
Mr Sanjay Mantry and Dr Ramesh Arora, General Hospital, Glasgow<br />
09.40 Update on TRACTISS<br />
Dr Simon Bowman, Queen Elizabeth Medical Centre, Birmingham<br />
10.00 Update on UKPSSRS and future directions <strong>for</strong> Sjögren’s research<br />
Dr Fai Ng, Newcastle University, Newcastle upon Tyne<br />
10.20 Panel discussion
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
Thursday 3 May 2012 | Programme 57<br />
09.00 - 10.30 SIG: MSK ultrasound | Boisdale Room 2<br />
Chair: Dr Cristina Estrach, Aintree Hospital, Liverpool<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide a plat<strong>for</strong>m to discuss and share research and training topics to further advance and promote<br />
musculoskeletal ultrasound in rheumatology<br />
Attendees will learn about new training developments<br />
Attendees will be updated in the latest research and direction of ultrasound in rheumatology<br />
Attendees will have the opportunity to discuss and share local and national initiatives and projects<br />
09.00 SIG update<br />
Dr Cristina Estrach, Aintree University Hospitals NHS Foundation Trust, Liverpool<br />
Training developments:<br />
09.15 Update Anatomy course<br />
Dr David Wright, City Hospital Sunderland, Sunderland<br />
09.25 West Midlands training project<br />
Dr Rainer Klocke, Dudley Hospitals, Dudley<br />
09.35 <strong>The</strong> Scottish training <strong>programme</strong><br />
Dr Anna Ciechomska, Inverclyde Royal Hospital, Greenock<br />
09.45 <strong>The</strong> Yorkshire training <strong>programme</strong><br />
Dr Zunaid Karim, Pinderfields General Hospital, Wakefield<br />
10.00 Where are we going with ultrasound?<br />
Prof Peter Taylor, Kennedy Institute, Ox<strong>for</strong>d<br />
10.20 Questions and discussion<br />
10.30 - 11.30 Poster viewing and exhibition | Tea and coffee<br />
Categories:<br />
Poster tours:<br />
Basic science<br />
Basic science<br />
Biology of bone, cartilage and connective tissue disease Connective tissue diseases<br />
Case reports<br />
Cell receptor-ligand interaction, signalling, activation and apoptosis<br />
Cytokines and inflammatory mediators<br />
Education research<br />
Epidemiology<br />
Genetics<br />
Health services research, economics and outcomes research<br />
Rheumatoid arthritis: aetiopathogenesis and animal models<br />
Sjögren’s syndrome and other connective tissue disorders<br />
SLE and antiphospholipid syndrome<br />
Vasculitis
58 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
11.30 - 13.00 Advances in psoriatic arthritis | Clyde Auditorium<br />
Chairs: Prof Costantino Pitzalis, Barts and <strong>The</strong> London School of Medicine, London | Prof Roger Sturrock,<br />
University of Glasgow, Glasgow<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To learn about psoriatic arthritis, from pathogenesis to novel therapies<br />
Gain insights on how pathogenesis may contribute to diverse subset evolution both from the joint<br />
and skin prospective<br />
Understand the issues relating to establishing and running a specialist PsA clinic<br />
Be in<strong>for</strong>med on the latest therapeutic strategies to treat PsA<br />
11.30 Advances in pathogenesis: the rheumatology view - what biological processes drive different<br />
disease expressions in PsA?<br />
Prof Costantino Pitzalis, Barts and <strong>The</strong> London School of Medicine, London<br />
11.50 Advances in pathogenesis: the dermatology view<br />
Prof Frank Nestle, St John’s Institute of Dermatology, London<br />
12.10 Establishing a specialist PsA clinic: pitfalls and opportunities to improve patient care<br />
Prof Neil McHugh, University of Bath, Bath<br />
12.30 Advances in the treatment of PsA<br />
Dr Philip Helliwell, University of Leeds, Leeds<br />
11.30 - 13.00 Ask the experts: myositis | Hall 1<br />
Chairs: Dr Ben Parker, University of Manchester, Manchester | Dr Sonia Panchal, University Hospital of<br />
Leicester NHS Trust, Leicester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To discuss the evidence-based approach to myopathies<br />
To evaluate complex cases of myopathy with specific reference to the current evidence<br />
To discuss complex cases of myopathy<br />
11.30 Trainees will present three cases to the experts and experts will present two to three slides<br />
demonstrating the evidence to support the advice on best practice<br />
Dr Hector Chinoy, University of Manchester, Manchester | Prof David Isenberg, UCL, London
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
Thursday 3 May 2012 | Programme 59<br />
11.30 - 13.00 Molecular mechanisms of disease: inflammatory arthritis I | Dochart Room<br />
Chair: Prof Michael Ehrenstein, UCL, London<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To give attendees an overview and understanding of key issues in the molecular mechanisms<br />
of inflammatory arthritis<br />
Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis<br />
Delegates will be aware of novel laboratory research in inflammatory arthritis<br />
11.30 Keynote talk on inflammatory arthritis<br />
Prof Michael Ehrenstein, UCL, London<br />
11.40 ANTI-VCA and EBNA1 antibodies are produced in the rheumatoid synovium in the presence of ectopic<br />
lymphoid structures and correlates with ACPA production<br />
Ms Cristina Croia, Queen Mary University of London, London<br />
12.00 TLR9 induces tolerance to apoptotic cells and is responsible <strong>for</strong> inducing regulatory B cells<br />
Dr Mohini Gray, University of Edinburgh, Edinburgh<br />
12.20 Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with<br />
heightened T and B cell responses<br />
Dr Gareth Jones, Cardiff University, Cardiff<br />
12.40 Anti-TNF antibody therapy, but not TNF receptor blockade, induces IL-17 suppressing regulatory T cells<br />
Ms Jenny McGovern, University College London, London<br />
11.30 - 13.00 <strong>The</strong> management of upper limb dysfunction in people with rheumatoid arthritis | Forth Room<br />
Chairs: Ms Jenny Ratcliffe, Macclesfield District General Hospital, Macclesfield | Prof Krysia Dziedzic, Keele<br />
University, Keele<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an update on the evidence based rehabilitation of upper limb dysfunction in people with<br />
rheumatoid arthritis (RA)<br />
Attendees will gain an understanding of recent advances in the rehabilitation of upper limb dysfunction<br />
in RA<br />
Attendees will gain an insight into the current surgical management of upper limb dysfunction in RA<br />
Attendees will gain an understanding of functional outcome measurement of upper limb dysfunction in RA<br />
11.30 Current surgical management of the rheumatoid hand and wrist: indications and outcomes<br />
Prof Jagdeep Nanchahal, Imperial College London, London<br />
11.50 Hand and upper limb function assessment in rheumatoid arthritis<br />
Mrs Catherine Ball, Imperial College London, London<br />
12.10 Exercise therapy in the management of upper limb dysfunction in rheumatoid arthritis<br />
Dr Lindsay Bearne, King’s College London, London<br />
12:30 <strong>The</strong> role of upper limb splinting in the management of people with rheumatoid arthritis<br />
Dr Jo Adams, University of Southampton, Southampton
60 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
11.30 - 13.00 Oral abstracts: Education | Alsh Room<br />
Chair: Dr Lesley Kay, Freeman Hospital, Newcastle upon Tyne<br />
11.30 NRAS workwise workshops online resources: tools <strong>for</strong> people with RA to help them remain in the<br />
workplace/get back to work<br />
Mrs Clare Jacklin, National Rheumatoid Arthritis <strong>Society</strong>, Maidenhead<br />
11.45 Designing virtual patients <strong>for</strong> musculoskeletal education: a grounded theory qualitative study<br />
Dr Jes Bateman, University Hospitals Coventry and Warwickshire NHS Trust, Coventry<br />
12.00 Have you been to Capri? www.capri.scot.nhs.uk early results of a clinic <strong>for</strong> arthritis patients in remission<br />
on the internet<br />
Dr Helen Harris, NHS Fife, Kirkcaldy<br />
12.15 <strong>The</strong> evaluation of an arthritis education outreach <strong>programme</strong> to black and minority ethnic communities<br />
Mrs Chandrika Gordhan, University of Birmingham, Birmingham<br />
12.30 Patient experiences, attitudes and expectations towards receiving in<strong>for</strong>mation about anti-TNF: a<br />
qualitative study<br />
Dr Paul Arkell, Keele University, Keele<br />
12.45 National Rheumatoid Arthritis <strong>Society</strong> survey: impact of RA on the family<br />
Mrs Clare Jacklin, National Rheumatoid Arthritis <strong>Society</strong>, Maidenhead<br />
11.30 - 13.00 SIG: Osteoporosis | Boisdale Room 1<br />
Chair: Dr Emma Clarke, University of Bristol, Bristol<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To discuss the management of acute and chronic vertebral fractures <strong>for</strong> allied health professionals<br />
To increase knowledge <strong>for</strong> allied health care professionals, especially nurses, physiotherapist and<br />
occupational therapists of acute vertebral fracture management. Focusing on pain relief and<br />
conservative methods of pain relief<br />
To increase knowledge and awareness of management of chronic vertebral fracture and further<br />
fracture prevention. Suitable <strong>for</strong> all allied health professionals including dietician, pharmacists and<br />
podiatrists<br />
To discuss the role of allied health care professionals within various fracture liason service models,<br />
vertebral pain mangement and prevention of further fracture<br />
11.30 <strong>The</strong> management of pain and chronic vertebral fracture and role within fracture liaison service<br />
Cathy Churchman, Weston General Hospital, Weston-super-Mare | Rachel Lewis MCSP, North Bristol NHS<br />
Trust, Bristol
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
Thursday 3 May 2012 | Programme 61<br />
11.30 - 13.00 SIG: Foot and ankle | Boisdale Room 2<br />
Chair: Dr Anthony Redmond, University of Leeds, Leeds<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an update on current developments in the foot and ankle with an emphasis on<br />
degenerative disorders<br />
To set out the current areas of research activity in foot and ankle research relating to OA<br />
To provide a state of the art review of current knowledge<br />
To provide a <strong>for</strong>um to identify future research directions and explore collaborations<br />
11.30 Researching foot osteoarthritis in primary care<br />
Dr Edward Roddy, Keele University, Keele<br />
11.45 Foot outcomes from the Ching<strong>for</strong>d cohort study of 1,000 women over 22 years<br />
Dr Catherine Bowen, University of Southampton, Southampton<br />
12.00 Foot modeling in degenerative disease and its effect on biomechanical response to interventions<br />
Dr Richard Jones, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d<br />
12.15 Modeling function in barefoot and shod conditions<br />
Dr Jill Halstead, University of Leeds, Leeds<br />
12.30 Clinical and biomechanical foot assessments and knee OA in the COASt (Clinical Outcomes in<br />
knee arthroplasty) study<br />
Ms Lucy Gates, University of Southampton, Southampton<br />
12.45 Discussion<br />
13.00 - 14.00 Exhibition | Lunch<br />
13.00 - 14.00 RATS AGM | Hall 1<br />
Lunch will be provided<br />
13.00 - 14.00 NICE and NHS Evidence and the in<strong>for</strong>mation revolution | Forth Room<br />
Chairs: Dr Michael Backhouse, University of Leeds, Leeds | Prof Martijn Steuitjens, Glasgow Caledonian<br />
University, Glasgow<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Outcome 4:<br />
To demonstrate the key features of NHS Evidence and lead a discussion around further development<br />
opportunities <strong>for</strong> the service<br />
Delegates will be able to see how features of the site work and identify what will be useful to them<br />
Delegates will be able to discuss any future ideas/developments that could be made around their needs<br />
Delegates will learn about the practical QIPP examples that are available and learn how to submit<br />
their own case studies<br />
Delegates will have more confidence in using the resource in their work around decision-making<br />
processes<br />
13.00 Presentation and discussion facilitation<br />
Dr Gillian Leng, Deputy Chief Executive, NICE
62 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
14.00 - 15.30 <strong>Rheumatology</strong> and the NHS | Hall 1<br />
Chairs: Dr Ben Parker, University of Manchester, Manchester | Dr Sonia Panchal, University Hospital of<br />
Leicester NHS Trust, Leicester<br />
Aim:<br />
Outcome 1:<br />
To update trainees on political changes in the NHS<br />
To review the NHS changes as they affect rheumatology and trainees, from both primary and secondary<br />
care perspectives<br />
14.00 A year in politics: an update on political influences on rheumatology and its trainees<br />
Dr Chris Deighton, Derbyshire Royal Infirmary, Derby<br />
14.45 Changes in the NHS: a rheumatology provider’s perspective<br />
Dr Alan Nye, Pennine MSK Partnership, Manchester<br />
14.00 - 15.30 Improving work participation: new developments in reducing work absence <strong>for</strong> people with<br />
musculoskeletal conditions | Forth Room<br />
Chairs: Dr Ross Wilkie, Keele University, Keele | Mrs Victoria Chamberlain, Traf<strong>for</strong>d Hospital Centre<br />
Manchester Foundation NHS Trust, Manchester<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide delegates with an overview of recent advances in approaches and future plans to reduce<br />
work absence <strong>for</strong> people with musculoskeletal conditions<br />
Attendees have a clear understanding of the importance of supporting people with arthritis / MSDs<br />
in remaining and returning to work, and of the role of health professionals in this<br />
Attendees learn about practical tools (e.g. the fit-note) and examples of best practice in supporting<br />
people with arthritis / MSDs in remaining and returning to work<br />
Attendees are aware of further developments in policy and practice to reduce work absence<br />
14.00 What is next <strong>for</strong> musculoskeletal conditions and work?<br />
Prof Dame Carol Black, Department <strong>for</strong> Work and Pensions, London<br />
14.20 What has the “fit-note” done <strong>for</strong> us? Reflections on the impact on work absence and disability<br />
Dr Bill Gunneyon, Department <strong>for</strong> Work and Pensions, London<br />
14.40 <strong>Rheumatology</strong> and work: evolving practice<br />
Dr David Walker, Freeman Hospital, Newcastle upon Tyne<br />
15.00 <strong>The</strong> barriers <strong>for</strong> returning to work<br />
Ms Adele Higginbottom, Arthritis Research UK Primary Care Centre, Keele
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
Thursday 3 May 2012 | Programme 63<br />
14.00 - 15.30 Molecular mechanisms of disease: inflammatory arthritis II | Dochart Room<br />
Chair: to be confirmed<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
To give attendees an overview and understanding of key issues in the molecular mechanisms<br />
of inflammatory arthritis<br />
Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis<br />
Delegates will be aware of novel laboratory research in inflammatory arthritis<br />
14.00 Inhibition of NAMPT (PBEF/Visfatin) decreases the ability of human neutrophils to generate reactive<br />
oxidants, but does not impair bacterial killing<br />
Ms Kate Roberts, University of Liverpool, Liverpool<br />
14.15 Neutrophil microparticles as potential novel effectors of joint disease<br />
Ms Sarah Headland, Barts and the London School of Medicine and Dentistry, London<br />
14.30 Resolvin D1 limits PMN recruitment to inflammatory loci: receptor dependent bioactions<br />
Dr Lucy Norling, Barts and <strong>The</strong> London Medical School, London<br />
14.45 <strong>The</strong> mesenchymal stromal cell marker CD248 regulates inflammatory arthritis and bone <strong>for</strong>mation<br />
Dr Amy Naylor, University of Birmingham, Birmingham<br />
15.00 <strong>The</strong> regulation of arthritic bone erosions by IL-10<br />
Dr Claire Greenhill, Cardiff University, Cardiff<br />
15.15 Dual specificity phosphatase 1 is a crucial negative regulator of inflammatory osteolysis and a<br />
mediator of therapeutic effects of dexamethasone in collagen-induced arthritis<br />
Ms Youridies Vattakuzhi, Kennedy Institute of <strong>Rheumatology</strong>, London<br />
14.00 - 15.30 What’s new in ankylosing spondylitis pathogenesis, assessment and treatment | Clyde Auditorium<br />
Chairs: Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Ox<strong>for</strong>d | Dr Jonathan Packham, University<br />
Hospital of North Staf<strong>for</strong>dshire, Stoke on Trent<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To give attendees an overview of new developments in the genetics, pathogenesis and treatment<br />
of ankylosing spondylitis<br />
Delegates will be aware the genetic contribution and pathogenic theories of ankylosing spondylitis<br />
pathogenesis<br />
Delegates will be able to describe the new ASA criteria <strong>for</strong> Axial SpA and the ASDAS<br />
Delegates will be able to describe the critically evaluate the efficacies of new treatments <strong>for</strong><br />
ankylosing spondylitis<br />
14.00 Overview of ankylosing spondylitis genetics and pathogenesis<br />
Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Ox<strong>for</strong>d<br />
14.30 What’s new in the clinical assessment of AS?<br />
Prof Désirée van der Heijde, Leiden University Medical Center, Leiden, <strong>The</strong> Netherlands<br />
15.00 New therapies <strong>for</strong> ankylosing spondylitis, targeting the Th17 pathway?<br />
Prof Dominique Baeten, University of Amsterdam, Amsterdam, <strong>The</strong> Netherlands
64 Programme | Thursday 3 May 2012<br />
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group<br />
Award winner | IRS (interactive audience response system)<br />
14.00 - 15.30 Oral abstracts: Genetics | Alsh Room<br />
Chair: Prof Anne Barton, University of Manchester, Manchester<br />
14.00 Global gene expression analysis of dedifferentiated chondrocytes<br />
Mr Alan Mueller, University of Liverpool, Liverpool<br />
14.15 Largest UK rheumatoid arthritis genome wide association study to date of 8,300 samples strengthens<br />
confirmed loci and highlights more potential RA genetic risk factors<br />
Dr Gisela Orozco, University of Manchester, Manchester<br />
14.30 Fine mapping in over 14,000 rheumatoid arthritis cases and 18,500 controls refine associations to<br />
known loci, indicate multiple independent affects and reveal novel associations<br />
Dr Stephen Eyre, <strong>The</strong> University of Manchester, Manchester<br />
14.45 Investigation of idiopathic inflammatory myopathy <strong>for</strong> shared genetic risk factors with other autoimmune<br />
disorders<br />
Dr Meghna Jani, Sal<strong>for</strong>d Royal NHS Foundation Trust, Manchester<br />
15.00 Analysis of the immunochip in a large cohort of oligo- and polyarthritis juvenile idiopathic arthritis<br />
cases confirms previous and identifies novel associations<br />
Dr Joanna Cobb, University of Manchester, Manchester<br />
15.15 Genome-wide association study of methotrexate response identifies novel genes in a large cohort of<br />
European juvenile idiopathic arthritis cases<br />
Dr Joanna Cobb, University of Manchester, Manchester<br />
14.00 - 15.30 SIG: Education | Boisdale Room 1<br />
Chair: Dr Lesley Kay, Newcastle University, Newcastle Upon Tyne I Prof Andrew Hassell, Keele University School<br />
of Medicine and Haywood Hospital, Keele<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To provide an update on Arthritis Research UK educational developments over the last 12 months<br />
Participants will understand (and participate in) the Arthritis Research UK tool <strong>for</strong> evalution of online<br />
learning resources<br />
Participants will be in<strong>for</strong>med of the results of a study of CPD activities among rheumatology nurses<br />
and allied health professionals<br />
<strong>The</strong> opportunity <strong>for</strong> participants to discuss work in progress: educational developments or research<br />
14.00 Development of a tool to evaluate online learning resources in rheumatology<br />
Dr David Walker, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne | Dr Tom Margham,<br />
Arthritis Research UK<br />
14.40 In<strong>for</strong>ming the educational needs of rheumatology nurses and AHPs: the experiences of people with<br />
osteoarthritis and rheumatoid arthritis<br />
Dr Sarah Ryan, Haywood Hospital, Stoke-on-Trent<br />
15.00 Open <strong>for</strong>um of educational developments<br />
Prof Andrew Hassell, Keele University School of Medicine and Haywood Hospital, Keele
Thursday 3 May 2012 | Programme 65<br />
14.00 - 15.30 SIG: Osteoarthritis | Boisdale Room 2<br />
Chair: Dr Fraser Birrell, Newcastle University, Newcastle I Ms Anne Smith, North Tyneside General Hospital,<br />
North Shields<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
To reflect on achievements of the OA CSG over the first four years and learn from other CSGs in shaping<br />
future strategy<br />
Know the strategy, submission and review processes of the Arthritis Research UK OA Clinical Studies Group<br />
Learn how to become involved in ongoing studies<br />
Have had the opportunity to network with other researchers and discuss research ideas<br />
14.00 Introduction and welcome<br />
Dr Fraser Birrell, Newcastle University, Newcastle upon Tyne<br />
14.05 Progress of the Inflammatory Arthritis CSG<br />
Prof John Isaacs, Newcastle University, Newcastle upon Tyne<br />
14.20 Clinical Studies Group <strong>for</strong> OA and Related Disorders strategy<br />
Prof Philip Conaghan, University of Leeds, Leeds<br />
14.40 Translating ideas into action and results: group work<br />
Hand OA<br />
Facilitator: Dr Krysia Dziedzic, Keele University, Keele<br />
Knee OA<br />
Facilitator: Dr George Peat, Keele University, Keele<br />
Hip OA<br />
Facilitator: Dr Ish Atchia, Northumbria Healthcare, Newcastle upon Tyne<br />
15.20 Question and answer session<br />
15.30 - 17.00 SIG: Spondyloarthritis | Carron Room 1<br />
Chairs: Prof Dennis McGonagle, University of Leeds, Leeds I Dr Raj Sengupta, <strong>The</strong> Royal National Hospital<br />
<strong>for</strong> Rheumatic Diseases, Bath<br />
Aim:<br />
Outcome 1:<br />
Outcome 2:<br />
Outcome 3:<br />
Outcome 4:<br />
To update delegates on the recent advances in the diagnosis and management of spondyloarthritis<br />
Delegates will participate in a discussion to <strong>for</strong>mulate the key Quality indicators <strong>for</strong> spondyloarthritis<br />
Attendees will be able to appreciate the benefits and limitations of using MRI imaging in the diagnosis<br />
of SpA<br />
To better understand emergent imaging markers of PsA disease evolution<br />
To understand the post TNF therapy landscape in PsA<br />
15.30 Welcome and Introduction<br />
Prof Dennis McGonagle, University of Leeds, Leeds | Dr Raj Sengupta, <strong>The</strong> Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath<br />
15.40 Quality indicators <strong>for</strong> SpA in the UK<br />
Dr Jon Packham, Keele University, Keele<br />
16.00 Pitfalls with diagnosis in spinal MRI scans<br />
Dr Alex Bennett, Guys and St Thomas’ Teaching Hospitals, London<br />
16.20 Emerging cytokines and cytokine signalling molecules as therapeutic targets in psoriasis<br />
Dr Miriam Witttmann, University of Leeds, Leeds<br />
16.40 <strong>The</strong> transition between psoriasis and arthritis: an imaging perspective<br />
Dr Zoe Ash, University of Leeds, Leeds<br />
17.00 End of meeting
66 Programme | Thursday 3 May 2012
Oral presentation<br />
of abstacts<br />
Oral presentation<br />
of abstracts
BSR and BHPR oral presentation of abstracts<br />
Tuesday 1 May 2012<br />
1-3 May 2012 | Oral presentation of abtracts 67<br />
09.00 – 10.30<br />
Spondyloarthropathies<br />
1.<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, United Kingdom; 2. Pharmacy and<br />
Pharmacology, University of Bath, Bath, United Kingdom<br />
O1<br />
O2<br />
O3<br />
O4<br />
DETECTING AXIAL SPONDYLOARTHRITIS AMONGST<br />
PRIMARY CARE BACK PAIN REFERRALS<br />
Claire Harris 1 , Denis Remedios 2 , Tanya Aptowitzer 3 , Andrew<br />
Keat 1 ;<br />
1.<br />
<strong>Rheumatology</strong> Department, Northwick Park Hospital, Harrow,<br />
United Kingdom; 2. Radiology Department, Northwick Park<br />
Hospital, Harrow, United Kingdom; 3. Physiotherapy<br />
department, Northwick Park Hospital, Harrow, United Kingdom<br />
VALIDATION OF A SCREENING QUESTIONNAIRE FOR AXIAL<br />
SPONDYLOARTHRITIS IN A UK POPULATION<br />
Louise Hamilton 1 , Geoffrey Guile 3 , Abdelghani Belkhiri 2 ,<br />
David Newman 2 , Andoni Toms 2 , Alex Macgregor 1,3 ,<br />
Karl Gaffney 1 ;<br />
1.<br />
<strong>Rheumatology</strong> Department, Norfolk and Norwich University<br />
Hospital, Norwich, United Kingdom; 2. Radiology Department,<br />
Norfolk and Norwich University Hospital, Norwich, United<br />
Kingdom; 3. Norwich Medical School, University of East Anglia,<br />
Norwich, United Kingdom<br />
THE PREVALENCE AND BURDEN OF ANKYLOSING<br />
SPONDYLITIS IN EUROPE: A SYSTEMATIC REVIEW<br />
Linda Morton 1 , Gareth T. Jones 1 , Alan G. MacDonald 2 ,<br />
Christina Downham 1 , Gary J. Macfarlane 1 ;<br />
1.<br />
Aberdeen Musculoskeletal Research Group (Epidemiology),<br />
University of Aberdeen, Aberdeen, United Kingdom;<br />
2.<br />
Department of <strong>Rheumatology</strong>, Aberdeen Royal Infirmary,<br />
Aberdeen, United Kingdom<br />
WORK DISABILITY IN ESTABLISHED PSORIATIC ARTHRITIS:<br />
A CROSS-SECTIONAL STUDY USING THE WORK<br />
PRODUCTIVITY ACTIVITY INDEX<br />
William Tillett 1 , Deepak Jadon 1 , Dinny Wallis 1 , Luisa Costa 1 ,<br />
Nicola Waldron 1 , Nina Griffith 1 , Charlotte Cavill 2 ,<br />
Eleanor Korendowych 1 , Corinne de Vries 2 , Neil McHugh 1,2 ;<br />
O5<br />
O6<br />
INFLUENCE OF LEFLUNOMIDE ON THE LEVELS OF MATRIX<br />
METALLOPROTEINASE-3 AND PYRIDINOLINE IN PATIENTS<br />
WITH PSORIATIC ARTHRITIS<br />
Oleg Iaremenko, Dmytro Fedkov;<br />
Department of Internal Medicine, National Medical University<br />
O.O.Bogomolets, Kyiv, Ukraine<br />
EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB<br />
IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-<br />
SEVERE ANKYLOSING SPONDYLITIS<br />
Paul Emery 1 , Dominique Baeten 2 , Joachim Sieper 3 , Jurgen<br />
Braun 4 , D. van der Heijde 5 , Iain McInnes 6 , Jaap Van Laar 7 ,<br />
R. Landewe 8 , Bryan P. Wordsworth 9 , Jurgen Wollenhaupt 10 ,<br />
Herbert Kellner 11 , I. Paramarta 2 , Arthur Bertolino 12<br />
Andrew M. Wright 13 , Wolfgang Hueber 12 ;<br />
1.<br />
Department of Medicine, University of Leeds, Leeds, United<br />
Kingdom; 2. Academic Medical Center, University of<br />
Amsterdam, Amsterdam, Netherlands; 3. Department of<br />
Gastroenterology, Charite Campus Benjamin Franklin, Berlin,<br />
Germany; 4. Department of Medicine, Rheumazentrum<br />
Ruhrgebiet, Herne, Germany; 5. Department of <strong>Rheumatology</strong>,<br />
Leiden University Medical Center, Leiden, Netherlands;<br />
6.<br />
Glasgow Biomedical Research Centre, University of Glasgow,<br />
Glasgow, United Kingdom; 7. Department of Medicine,<br />
Newcastle University, Newcastle upon Tyne, United Kingdom;<br />
8.<br />
Department of Medicine, Maastricht University Medical<br />
Center, Maastricht, Netherlands; 9. Department of Medicine,<br />
Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom;<br />
10.<br />
Klinik für Rheumatologie, Eilbeck Hospital, Hamburg,<br />
Germany; 11. Department of Medicine, Center <strong>for</strong> Inflammatory<br />
Joint Diseases, Munich, Germany; 12. TM Dermatology, Novartis<br />
Institutes <strong>for</strong> BioMedical Research, Basel, Switzerland;<br />
13.<br />
M&S Statistics, Novartis Pharma AG, Basel, Switzerland
68 Oral presentation of abtracts | 1-3 May 2012<br />
O7<br />
O8<br />
O9<br />
11.30 – 13.00<br />
Imaging<br />
HAND OSTEOARTHRITIS PAIN HAS PERIPHERAL AND<br />
CENTRAL COMPONENTS DEMONSTRATED BY ALGOMETER<br />
SCORES AND FUNCTIONAL MRI<br />
Nidhi Sofat 1,2 , Cori Smee 2 , Monika Hermansson 2 ,<br />
Julekha Wajed 1 , Kaushik Sanyal 1 , Patrick Kiely 1 ,<br />
Matthew Howard 3 , Franklyn A. Howe 4 , Thomas R. Barrick 4 ;<br />
1.<br />
<strong>Rheumatology</strong>, St George’s, University of London, London,<br />
United Kingdom; 2. Biomedical Sciences, St George’s,<br />
University of London, London, United Kingdom; 3. Institute of<br />
Psychiatry, King’s College London, London, United Kingdom;<br />
4.<br />
Clinical Sciences, St George’s, University of London, London,<br />
United Kingdom<br />
ULTRASOUND FEATURES OF OSTEOPHYTES AND CARTILAGE<br />
THICKNESS AT THE KNEE ARE ASSOCIATED WITH PAIN AND<br />
FUNCTIONAL IMPAIRMENT: THE NEWCASTLE THOUSAND<br />
FAMILIES STUDY<br />
Ajay M. Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 ,<br />
Roger M. Francis 3 , Fraser Birrell 2 ;<br />
1.<br />
Institute of Health and <strong>Society</strong>, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom; 2. Musculoskeletal<br />
Research Group, Institute of Cellular Medicine, Newcastle<br />
University, Newcastle upon Tyne, United Kingdom; 3. Institute<br />
<strong>for</strong> Ageing and Health, Newcastle University, Newcastle upon<br />
Tyne, United Kingdom<br />
THE DIAGNOSTIC UTILITY OF SALIVARY GLAND ULTRASOUND<br />
FOR THE INVESTIGATION OF SJÖGREN’S SYNDROME<br />
Andrew Carr 1 , Iain Macleod 1 , Wan-Fai Ng 2 ;<br />
1.<br />
Dental and Maxillofacial Radiology, Newcastle Dental<br />
Hospital, Newcastle upon Tyne, United Kingdom;<br />
2.<br />
Musculoskeletal Research Group, Institute of Cellular<br />
Medicine, Faculty of Medical Sciences, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom<br />
O10<br />
O11<br />
LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC<br />
ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: 104<br />
WEEK RESULTS FROM THE GO-REVEAL STUDY<br />
Arthur Kavanaugh 1 , Desiree Van de Heide 2 ,<br />
Chandrabhusan Chattopadhyay 3 , Dafna Gladman 4 ,<br />
Philip Mease 5 , Iain McInnes 6 , Gerald Krueger 7 , Weichun Xu 8 ,<br />
Neil Goldstein 8 , Anna Beutler 8 ;<br />
1.<br />
Immunology, University of Cali<strong>for</strong>nia, San Diego, San Diego,<br />
Cali<strong>for</strong>nia, United States of America; 2. <strong>Rheumatology</strong>, Leiden<br />
University Medical Center, Leiden, Netherlands;<br />
3.<br />
<strong>Rheumatology</strong>, Wrightington Hospital, Wigan, United<br />
Kingdom; 4. <strong>Rheumatology</strong>, Toronto Western Hospital, Toronto,<br />
Ontario, Canada; 5. <strong>Rheumatology</strong>, Swedish Medical Center/<br />
University of Washington, Seattle, Washington, United States<br />
of America; 6. <strong>Rheumatology</strong>, University of Glasgow, Glasgow,<br />
United Kingdom; 7. Dermatology, University of Utah Health<br />
Sciences Center, Salt Lake City, Utah, United States of<br />
America; 8. Immunology, Janssen Research and Development,<br />
Inc, Malvern, Pennsylvania, United States of America<br />
EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL<br />
INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE<br />
IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS<br />
Jaap Van Laar 1 , Xenofon Baraliakos 2 , Jurgen Braun 2 ,<br />
Didier D. Laurent 3 , Dominique Baeten 4 , D. van der Heijde 5 ,<br />
Joachim Sieper 6 , Paul Emery 7 , Iain McInnes 8 , R. Landewe 9 ,<br />
Bryan P. Wordsworth 10 , Jürgen Wollenhaupt 11 ,<br />
Herbert Kellner 12 , Andrew M. Wright 13 , Sandro Gsteiger 13 ,<br />
Wolfgang Hueber 3 ;<br />
1.<br />
Department of Medicine, Newcastle University, Newcastle<br />
upon Tyne, United Kingdom; 2. Department of Medicine,<br />
Rheumazentrum Ruhrgebiet, Herne, Germany; 3. Translational<br />
Medicine Dermatology, Novartis Institutes <strong>for</strong> BioMedical<br />
Research, Basel, Switzerland; 4. Academic Medical Center,<br />
University of Amsterdam, Amsterdam, Netherlands;<br />
5.<br />
Department of <strong>Rheumatology</strong>, Leiden University Medical<br />
Center, Leiden, Netherlands; 6. Department of<br />
Gastroenterology, Charitè Campus Benjamin Franklin, Berlin,<br />
Germany; 7. Department of Medicine, University of Leeds,<br />
Leeds, United Kingdom; 8. Glasgow Biomedical Research<br />
Centre, University of Glasgow, Glasgow, United Kingdom;<br />
9.<br />
Department of Medicine, Maastricht University Medical<br />
Center, Maastricht, Netherlands; 10. Department of Medicine,<br />
Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom; 11. Klinik<br />
für Rheumatologie, Eilbeck Hospital, Hamburg, Germany;<br />
12.<br />
Department of Medicine, Center <strong>for</strong> Inflammatory Joint<br />
Diseases, Munich, Germany; 13. M&S Statistics, Novartis<br />
Pharma AG, Basel, Switzerland
1-3 May 2012 | Oral presentation of abtracts 69<br />
O12<br />
TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION<br />
WITH METHOTREXATE ASSOCIATED WITH EARLY<br />
REDUCTIONS IN TISSUE INFLAMMATION: 12 WEEK<br />
RESULTS FROM A MAGNETIC RESONANCE IMAGING<br />
SUBSTUDY OF A RANDOMIZED CONTROLLED TRIAL<br />
Philip G. Conaghan 1 , Charles G. Peterfy 2 , Julie DiCarlo 2 ,<br />
Ewa Olech 3 , Alan R. Alberts 4 , Jeffrey A. Alper 5 ,<br />
Jenny Devenport 6 , Andrew M. Anisfeld 6 ,Orrin M. Troum 7<br />
1.<br />
NIHR-Leeds Biomedical Research Unit and Leeds Institute of<br />
Molecular Medicine, University of Leeds, Leeds, United<br />
Kingdom 2. Spire Sciences LLC, San Francisco, CA, USA,<br />
3.<br />
Oklahoma Medical Research Foundation, Oklahoma City, OK,<br />
USA, 4. West Broward <strong>Rheumatology</strong> Associates, Inc., Tamarac,<br />
FL, USA, 5. Jeffrey Alper MD Research, Naples, FL, USA,<br />
6.<br />
Genentech, South San Francisco, CA, 7. USC Keck School of<br />
Medicine, Santa Monica, CA, USA<br />
PA2<br />
EPRATUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL<br />
IMPROVEMENTS IN PATIENTS WITH MODERATE-TO-SEVERE<br />
SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM<br />
EMBLEM, A PHASE IIB STUDY<br />
Caroline Gordon 1 , K. Kalunian 2 , M. Petri 3 , V. Strand 4 ,<br />
B. Kilgallen 5 , A. Barry 5 , D. Wallace 6 ;<br />
1.<br />
<strong>Rheumatology</strong>, University of Birmingham, Birmingham,<br />
United Kingdom; 2. University of Cali<strong>for</strong>nia, San Diego, School<br />
of Medicine, La Jolla, Cali<strong>for</strong>nia, United States of America;<br />
3.<br />
Medicine, <strong>The</strong> John Hopkins University, Baltimore, Maryland,<br />
United States of America; 4. Division of Immunology and<br />
<strong>Rheumatology</strong>, Stan<strong>for</strong>d University, Palo Alto, Cali<strong>for</strong>nia, United<br />
States of America; 5. UCB Inc, Smyrna, Georgia, United States<br />
of America; 6. Medicine, Cedars-Sinai Medical Center and<br />
UCLA School of Medicine, Los Angeles, Cali<strong>for</strong>nia, United<br />
States of America<br />
PA1<br />
14.00 – 16.00<br />
BSR and BHPR plenary abstracts<br />
EPIDEMIOLOGY OF SPORTING INJURIES AMONG ELITE<br />
SOCCER PLAYERS: A LONGITUDINAL STUDY<br />
Philip Cooper 1 , Mo Gimpel 3 , Greg Deakin 1 , Karen Jameson 1 ,<br />
Malcolm Godtschailk 3 , Stephan Gadola 2 , Maria Stokes 2 ,<br />
Cyrus Cooper 1,2 ;<br />
PA3<br />
WILL I WASTE YOUR TIME? DELAYS IN SEEKING HELP FOR<br />
RA FLARES<br />
Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 ,<br />
Rod Hughes 3 , Pam Richards 2 , Sarah Hewlett 1 ;<br />
1.<br />
Faculty of Health and Life Sciences, University of the West of<br />
England, Bristol, United Kingdom; 2. <strong>Rheumatology</strong>, University<br />
Hospitals Bristol, Bristol, United Kingdom; 3. <strong>Rheumatology</strong>,<br />
St Peter’s Hospital, Chertsey, United Kingdom<br />
1.<br />
University of Southampton, MRC Lifecourse Epidemiology<br />
Unit, Southampton, United Kingdom; 2. NIHR Musculoskeletal<br />
BRU, University of Southampton, Southampton, United<br />
Kingdom; 3. Department of Sports Medicine, Southampton<br />
Football Club, Southampton, United Kingdom
70 Oral presentation of abtracts | 1-3 May 2012<br />
Wednesday 2 May 2012<br />
O13<br />
09.15 – 10.45<br />
RA treatment and outcomes<br />
VALIDATION OF JADAS IN ALL SUBTYPES OF JUVENILE<br />
IDIOPATHIC ARTHRITIS IN A CLINICAL SETTING<br />
Flora McErlane 1,2 , Michael W. Beres<strong>for</strong>d 1,3 ,<br />
Eileen M. Baildam 3 , Wendy Thomson 2 , Kimme Hyrich 2 ,<br />
Alice Chieng 7 , Joyce Davidson 5 , Helen E. Foster 4 ,<br />
Janet Gardner-Medwin 5 , Mark Lunt 2 , Lucy Wedderburn 6 ;<br />
1.<br />
Institute of Child Health, University of Liverpool, Liverpool,<br />
United Kingdom; 2. School of Translational Medicine, University<br />
of Manchester, Manchester, United Kingdom; 3. Paediatric<br />
<strong>Rheumatology</strong>, Alder Hey Children’s Hospital, Liverpool, United<br />
Kingdom; 4. <strong>Rheumatology</strong>, Newcastle Medical School,<br />
Newcastle upon Tyne, United Kingdom; 5. <strong>Rheumatology</strong>, Royal<br />
Hospital <strong>for</strong> Sick Children, Glasgow, United Kingdom;<br />
6.<br />
<strong>Rheumatology</strong> Unit, Institute of Child Health, London, United<br />
Kingdom; 7. <strong>Rheumatology</strong>, Royal Manchester Children’s<br />
Hospital, Manchester, United Kingdom<br />
O16<br />
1.<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham,<br />
Birmingham, United Kingdom; 2. <strong>Rheumatology</strong>, University of<br />
Birmingham & Sandwell & West Birmingham Hospitals NHS<br />
Trust, Birmingham, United Kingdom; 3. <strong>Rheumatology</strong>,<br />
University Hospitals Birmingham NHS Foundation Trust,<br />
Birmingham, United Kingdom; 4. Kennedy Institute of<br />
<strong>Rheumatology</strong>, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom;<br />
5.<br />
<strong>Rheumatology</strong>, Imperial College, London, United Kingdom;<br />
6.<br />
Institute of Infection, Immunity and Inflammation, University<br />
of Glasgow, Glasgow, United Kingdom<br />
DOUBLEBLIND STUDY OF TOCILIZUMAB + METHOTREXATE<br />
VERSUS TOCILIZUMAB + PLACEBO IN PATIENTS WITH<br />
ACTIVE RHEUMATOID ARTHRITIS DESPITE PRIOR<br />
METHOTREXATE: PROGRESSION OF STRUCTURAL DAMAGE,<br />
QUALITY OF LIFE AND PHYSICAL FUNCTION AT 24 WEEKS<br />
Maxime Dougados 1 , Karsten Kissel 2 , Howard Amital 3 ,<br />
Philip Conaghan 4 , Emilio Martin-Mola 5 , Evgeny Nasonov 6 ,<br />
Georg Schett 7 , Orrin Troum 8 , Tiina Veldi 9 , Corrado Bernasconi 2 ,<br />
Tom Huizinga 10 ;<br />
O14<br />
O15<br />
HAS ORTHOPAEDIC INTERVENTION FOR RHEUMATOID<br />
ARTHRITIS CHANGED IN LINE WITH COMBINATION AND<br />
ANTI-TNF THERAPIES? AN EVALUATION OF JOINT SURGERY<br />
RATES AND PROGNOSTIC FACTORS IN TWO UK INCEPTION<br />
COHORTS (1986-2011)<br />
Elena Nikiphorou 1 , Lewis Carpenter 2 , Patrick Kiely 3 ,<br />
David Walsh 4 , Josh Dixey 5 , Adam Young 1 ;<br />
1.<br />
<strong>Rheumatology</strong>, ERAS/ERAN, St Albans, United Kingdom;<br />
2.<br />
Centre <strong>for</strong> Lifespan & Chronic Illness Research, University of<br />
Hert<strong>for</strong>dshire, Hatfield, United Kingdom; 3. <strong>Rheumatology</strong>,<br />
St George’s Healthcare NHS Trust, London, United Kingdom;<br />
4.<br />
Academic <strong>Rheumatology</strong>, Arthritis Research UK Pain Centre,<br />
University of Nottingham, Nottingham, United Kingdom;<br />
5.<br />
<strong>Rheumatology</strong>, New Cross Hospital, Wolverhampton,<br />
United Kingdom<br />
PREDICTING RESPONSES TO ANTI-TNFα THERAPY IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS USING<br />
METABOLOMIC ANALYSIS OF URINE<br />
Sabrina R. Kapoor 1,2 , Andrew Filer 1,3 , Martin Fitzpatrick 1 ,<br />
Benjamin A. Fisher 5 , Peter C. Taylor 4 , Christopher Buckley 1,2 ,<br />
Iain McInnes 6 , Karim Raza 1,2 , Stephen P. Young 1 ;<br />
O17<br />
1.<br />
<strong>Rheumatology</strong>, Paris-Descartes University, Cochin Hospital,<br />
Paris, France; 2. Roche, F. Hoffmann-La Roche Ltd, Basel,<br />
Switzerland; 3. <strong>Rheumatology</strong>, Sheba Medical Center,<br />
Tel-hashomer, Israel; 4. NIHR-Leeds Biomedical Research Unit,<br />
University of Leeds, Leeds, United Kingdom; 5. <strong>Rheumatology</strong>,<br />
Hospital Universitario La Paz, Madrid, Spain; 6. <strong>Rheumatology</strong>,<br />
Institute of <strong>Rheumatology</strong>, Moscow, Russian Federation;<br />
7.<br />
Department of Internal Medicine, Institute <strong>for</strong> Clinical<br />
Immunology, University of Erlangen-Nuremberg, Erlangen,<br />
Germany; 8. <strong>Rheumatology</strong>, Keck School of Medicine, University<br />
of Southern Cali<strong>for</strong>nia, Santa Monica, Cali<strong>for</strong>nia, United States<br />
of America; 9. <strong>Rheumatology</strong>, East-Tallinn Central Hospital,<br />
Tallinn, Estonia; 10. <strong>Rheumatology</strong>, Leiden University Medical<br />
Center, Leiden, Netherlands<br />
SECUKINUMAB TREATMENT PROVIDES SUSTAINED RE-<br />
SPONSE OVER ONE YEAR IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS<br />
Patrick Durez 1 , Mark C. Genovese 2 , Hanno B. Richards 3 ,<br />
Jerzy Supronik 4 , Eva Dokoupilova 5 , Jacob A. Aelion 6 ,<br />
Sang-Heon Lee 7 , Christine E. Codding 8 , Herbert Kellner 9 ,<br />
Takashi Ikawa 10 , Sophie Hugot 3 , Gregory Ligozio 11 ,<br />
Shephard Mpofu 3 ;
1-3 May 2012 | Oral presentation of abtracts 71<br />
1.<br />
<strong>Rheumatology</strong>, Université Catholique de Louvain, Louvain,<br />
Belgium; 2. Immunology and <strong>Rheumatology</strong>, Stan<strong>for</strong>d University,<br />
Palo Alto, Cali<strong>for</strong>nia, United States of America; 3. Integrated<br />
Hospital Care, Novartis Pharma AG, Basel, Switzerland;<br />
4.<br />
Department of Medicine, NZOZ Centrum Medyczne Artur<br />
Racewicz, Bialystok, Poland; 5. Department of Medicine,<br />
Medical Plus, Uherske Hradiste, Czech Republic; 6. Department<br />
of Medicine, Arthritis Clinic, Jackson, Tennessee, United States<br />
of America; 7. Internal Medicine, Konkuk University Medical<br />
Center, Seoul, Republic of Korea; 8. <strong>Rheumatology</strong> & Internal<br />
Medicine, Health Research of Oklahoma, Oklahoma, United<br />
States of America; 9. <strong>Rheumatology</strong>, Centre <strong>for</strong> Inflammatory<br />
Joint Diseases, Munich, Germany; 10. Department of Medicine,<br />
Kobe-Konan Yamate Clinic, Kobe, Japan; 11. Integrated Hospital<br />
Care, Novartis Pharmaceuticals Corporation, East Hanover,<br />
New Jersey, United States of America<br />
O19<br />
O20<br />
11.45 – 13.15<br />
BHPR<br />
THE IMPACT OF PAIN ON SUCCESSFUL AGEING<br />
Ross Wilkie 1 , Abdelouahid Tajar 2 , John Mcbeth 1 ;<br />
1.<br />
Keele University, Keele, United Kingdom; 2. Centre <strong>for</strong><br />
Statistics in Medicine, Ox<strong>for</strong>d University, Ox<strong>for</strong>d, United<br />
Kingdom<br />
FOREFOOT BURSAE ARE A PROGNOSTIC INDICATOR OF<br />
DISABLING FOOT COMPLICATIONS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS: RESULTS OF A PROSPECTIVE<br />
THREE-YEAR STUDY<br />
Lindsey S. Hooper 1,2 , Catherine J. Bowen 1,2 , Lucy Gates 1,2 ,<br />
David Culli<strong>for</strong>d 1 , Christopher J. Edwards 1,2 , Nigel K. Arden 2,3 ;<br />
O18<br />
WITHDRAWAL OF ADALIMUMAB IN EARLY RHEUMATOID<br />
ARTHRITIS PATIENTS WHO ATTAINED STABLE LOW DISEASE<br />
ACTIVITY WITH ADALIMUMAB PLUS METHOTREXATE:<br />
RESULTS OF A PHASE 4, DOUBLE-BLIND,<br />
PLACEBO-CONTROLLED TRIAL<br />
Arthur Kavanaugh 1 , Paul Emery 2 , Roy Fleischmann 3 ,<br />
Ronald Van Vollenhoven 4 , Karel Pavelka 5 , Patrick Durez 6 ,<br />
Benoît Guérette 7 , Sourav Santra 8 , Laura Redden 8 ,<br />
Hartmut Kupper 9 , Josef S. Smolen 10 ;<br />
1.<br />
Division of <strong>Rheumatology</strong>, Allergy and Immunology, University<br />
of Cali<strong>for</strong>nia, San Diego, La Jolla, Cali<strong>for</strong>nia, United States of<br />
America; 2. Department of <strong>Rheumatology</strong>, Leeds Teaching<br />
Hospital, Leeds, United Kingdom; 3. Department of<br />
<strong>Rheumatology</strong>, University of Texas Southwestern, Dallas, Texas,<br />
United States of America; 4. Department of <strong>Rheumatology</strong>, <strong>The</strong><br />
Karolinska Institute, Stockholm, Sweden; 5. Department of<br />
<strong>Rheumatology</strong>, Charles University, Prague, Czech Republic;<br />
6.<br />
Department of <strong>Rheumatology</strong>, Université Catholique de<br />
Louvain, Brussels, Belgium; 7. GPRD, Abbott, Rungis, France;<br />
8.<br />
GPRD, Abbott, Abbott Park, IL; 9. GPRD, Abbott,<br />
Ludwigshafen, Germany; 10. Department of <strong>Rheumatology</strong>,<br />
Medical University of Vienna and Hietzing Hospital, Vienna,<br />
Austria<br />
O21<br />
O22<br />
1.<br />
Faculty of Health Sciences, University of Southampton,<br />
Southampton, United Kingdom; 2. <strong>Rheumatology</strong>, Southampton<br />
University Hospitals NHS Trust, Southampton, United Kingdom;<br />
3.<br />
Nuffield Department of Orthopaedics, <strong>Rheumatology</strong> and<br />
Musculoskeletal Sciences, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d,<br />
United Kingdom<br />
THE CONTINUING PROFESSIONAL DEVELOPMENT FOR<br />
HEALTH PROFESSIONALS WORKING WITHIN<br />
MUSCULOSKELETAL SERVICES: A NATIONAL UK SURVEY<br />
Jo Adams 1 , Sarah Ryan 2 , Hannah Haywood 1 , Helen Pain 1 ;<br />
1.<br />
Faculty of Health Sciences, University of Southampton,<br />
Southampton, United Kingdom; 2. Staf<strong>for</strong>dshire <strong>Rheumatology</strong><br />
Centre, Haywood Hospital, Stoke-on-Trent, United Kingdom<br />
DEBRIDEMENT OF PAINFUL FOREFOOT PLANTAR<br />
CALLOSITIES IN RHEUMATOID ARTHRITIS: THE CARROT<br />
RANDOMISED CONTROLLED TRIAL<br />
Heidi J. Siddle 1,2 , Anthony C. Redmond 1 , Robin Waxman 1 ,<br />
Abigail R. Dagg 3 , Begonya Alcacer-Pitarch 1 ,<br />
Richard A. Wilkins 1 , Philip S. Helliwell 1 ;<br />
1.<br />
Division of Musculoskeletal Disease, University of Leeds,<br />
Leeds, United Kingdom; 2. Foot Health Department, Leeds<br />
Teaching Hospitals NHS Trust, Leeds, United Kingdom;<br />
3.<br />
Podiatry Department, <strong>The</strong> Mid Yorkshire Hospitals NHS Trust,<br />
Wakefield, United Kingdom
72 Oral presentation of abtracts | 1-3 May 2012<br />
O23<br />
O24<br />
O25<br />
O26<br />
PSYCHOLOGICAL WELL-BEING IN EARLY RHEUMATOID<br />
ARTHRITIS: FINDINGS FROM THE EARLY RHEUMATOID<br />
ARTHRITIS NETWORK<br />
Sam Norton 1 , Patrick Kiely 3 , David Walsh 4 , Richard Williams 5 ,<br />
Adam Young 2 ;<br />
1.<br />
Institute of Public Health, University of Cambridge,<br />
Cambridge, United Kingdom; 2. <strong>Rheumatology</strong> Department, City<br />
Hospital, St Albans, United Kingdom; 3. Department of<br />
<strong>Rheumatology</strong>, St George’s Healthcare NHS Trust, London,<br />
United Kingdom; 4. Department of <strong>Rheumatology</strong>, Sherwood<br />
Forest Hospitals NHS Foundation Trust, Nottingham, United<br />
Kingdom; 5. Department of <strong>Rheumatology</strong>, Here<strong>for</strong>d Hospitals<br />
NHS Trust, Here<strong>for</strong>d, United Kingdom<br />
HEALTH PROFESSIONALS’ PERCEPTIONS OF THE EFFECTS<br />
OF EXERCISE ON JOINT HEALTH IN RHEUMATOID ARTHRITIS<br />
PATIENTS II: A FOLLOW-UP FOCUS GROUP STUDY<br />
Serena Halls 1 , Rebecca-Jane Law 1 , Jeremy Jones 1,2 ,<br />
David Markland 1 , Peter Maddison 1 , Jeanette Thom 1 ;<br />
1.<br />
School of Sport, Health and Exercise Sciences, Bangor<br />
University, Bangor, United Kingdom; 2. <strong>Rheumatology</strong>, Betsi<br />
Cadwaladr University Health Board, Bangor, United Kingdom<br />
Connective tissue diseases<br />
VARIABILITY IN THE PHENOTYPE OF METABOLIC SYNDROME<br />
OVER TIME IN A MULTICENTRE INTERNATIONAL INCEPTION<br />
COHORT OF PATIENTS WITH SLE<br />
Ben Parker 1 , Murray B. Urowitz 3 , Dafna D. Gladman 3 ,<br />
Ian Bruce 1,2 , On Behalf of the SLICC Registry 3 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2. Kellgren Centre<br />
<strong>for</strong> <strong>Rheumatology</strong>, Manchester Royal Infirmary, Manchester,<br />
United Kingdom; 3. Centre <strong>for</strong> Prognosis Studies, Toronto<br />
Western Hospital, Toronto, Ontario, Canada<br />
NITRATED NUCLEOSOME LEVELS IN PATIENTS WITH<br />
SYSTEMIC LUPUS ERYTHEMATOSUS – ASSOCIATIONS WITH<br />
ETHNICITY, AUTOANTIBODY STATUS AND ETHNICITY<br />
Sara C. Croca, Charis Pericleous, Harry Yong, David Isenberg,<br />
Ian Giles, Anisur Rahman, Yiannis Ioannou;<br />
O27<br />
O28<br />
O29<br />
BSR Young investigator award winner<br />
IS THERE AN ASSOCIATION BETWEEN WARFARIN AND<br />
SURVIVAL IN SSC-PAH PATIENTS TREATED WITH FIRST-LINE<br />
BOSENTAN MONOTHERAPY?<br />
Clare E. Warrell 1 , David Dobarro 1 , Clive Handler 1 ,<br />
Christopher P. Denton 2 , Benjamin E. Schreiber 1 ,<br />
John G. Coghlan 1 ;<br />
1.<br />
Pulmonary Hypertension, Royal Free Hampstead NHS Trust,<br />
London, United Kingdom; 2. <strong>Rheumatology</strong>, Royal Free<br />
Hampstead NHS Trust and UCL Medical School, London,<br />
United Kingdom<br />
ANTI-EIF2 IS ASSOCIATED WITH INTERSTITIAL LUNG<br />
DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS<br />
Zoe E. Betteridge 1,2 , Felix Woodhead 8,3 , Christopher Bunn 4 ,<br />
Christopher P. Denton 5 , David Abraham 4 , Sujal Desai 6 ,<br />
Roland du Bois 7 , Athol Wells 3 , Neil McHugh 1,2 ;<br />
1.<br />
Bath Institute <strong>for</strong> Rheumatic Diseases, University of Bath,<br />
Bath, United Kingdom; 2. <strong>Rheumatology</strong>, Royal National<br />
Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom;<br />
3.<br />
National Heart and Lung Institute, Imperial College, London,<br />
United Kingdom; 4. Department of Immunology, Royal Free<br />
Hospital, London, United Kingdom; 5. Centre <strong>for</strong> <strong>Rheumatology</strong>,<br />
Royal Free Hospital, London, United Kingdom; 6. Department of<br />
Radiology, Kings College Hospital, London, United Kingdom;<br />
7.<br />
Medicine, National Jewish Health, Denver, Colorado, United<br />
States of America; 8. Respiratory Medicine, University Hospitals<br />
Coventry and Warwickshire, Coventry, United Kingdom<br />
BSR medical student bursary winner<br />
OPTICAL COHERENCE TOMOGRAPHY VALIDATION: A NEW<br />
QUANTITATIVE IMAGING BIOMARKER FOR AFFECTED SKIN<br />
IN SCLERODERMA<br />
Giuseppina Abignano 1,2 , Sibel Aydin 1 ,<br />
Conception Castillo-Gallego 1 , Daniel Woods 3 , Adam Meekings 3 ,<br />
Dennis McGoonagle 1 , Paul Emery 1 , Francesco Del Galdo 1 ;<br />
1.<br />
Section of Musculoskeletal Diseases, Leeds Institute of<br />
Molecular Medicine, Leeds, United Kingdom; 2. <strong>Rheumatology</strong><br />
Unit, Second University of Naples, Naples, Italy; 3. Michelson,<br />
Diagnostics Ltd, Kent, United Kingdom<br />
<strong>Rheumatology</strong>, University College London, London,<br />
United Kingdom
1-3 May 2012 | Oral presentation of abtracts 73<br />
O30<br />
THE CLINICAL RELEVANCE OF ANTI-RO52 AND ANTI-RO60<br />
IN PATIENTS IN THE UNITED KINGDOM PRIMARY SJÖGREN’S<br />
SYNDROME REGISTRY (UKPSSR)<br />
Josephine Vila 2 , Sheryl Mitchell 2 , Simon Bowman 2 ,<br />
Elizabeth Price 3 , Colin T. Pease 4 , Paul Emery 4 ,<br />
Jacqueline Andrews 4 , Michele Bombardieri 5 , Nurhan Sutcliffe 5 ,<br />
Constantino Pitzalis 5 , Peter Lanyon 6 , John Hunter 7 ,<br />
Monica Gupta 7 , John McLaren 8 , Marian Regan 9 ,<br />
Annie Cooper 10 , Ian Giles 11 , David Isenberg 11 ,<br />
Saravanan Vadivelu 12 , David Coady 13 , Bridget Griffiths 2 ,<br />
Dennis Lendrem 2 , Heather Foggo 2 , Jessica Tarn 2 , Wan-Fai Ng 1 ;<br />
1.<br />
Musculoskeletal Research Group, Institute of Cellular<br />
Medicine, Newcastle University, Newcastle upon Tyne, United<br />
Kingdom; 2. <strong>Rheumatology</strong>, Newcastle upon Tyne Hospitals<br />
NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;<br />
3.<br />
<strong>Rheumatology</strong>, Great Western Hospitals NHS Foundation<br />
Trust, Swindon, United Kingdom; 4. Section of Musculoskeletal<br />
Disease, Leeds Institute of Molecular Medicine, University of<br />
Leeds, Leeds, United Kingdom; 5. <strong>Rheumatology</strong>, Barts and the<br />
London NHS Trust UK, London, United Kingdom;<br />
6.<br />
<strong>Rheumatology</strong>, Nottingham University Hospital, Nottingham,<br />
United Kingdom; 7. <strong>Rheumatology</strong>, Gartnavel Genral Hospital,<br />
Glasgow, United Kingdom; 8. <strong>Rheumatology</strong>, NHS Fife,<br />
Whiteman’s Brae Hospital, Kirkaldy, United Kingdom;<br />
9.<br />
<strong>Rheumatology</strong>, Royal Derby Hospital, Derby, United Kingdom;<br />
10.<br />
<strong>Rheumatology</strong>, Royal Hampshire County Hospital,<br />
Winchester, United Kingdom; 11. <strong>Rheumatology</strong>, University<br />
College London Hospitals NHS Foundation Trust, London,<br />
United Kingdom; 12. <strong>Rheumatology</strong>, Queen Elizabeth Hospital,<br />
Gateshead, United Kingdom; 13. <strong>Rheumatology</strong>, Sunderland<br />
Royal Hospital, Sunderland, United Kingdom<br />
O32<br />
O33<br />
O34<br />
THE MRC PHYSIODIRECT TRIAL: A PRAGMATIC<br />
RANDOMISED CONTROLLED TRIAL OF PHYSIODIRECT<br />
TELEPHONE ASSESSMENT AND ADVICE SERVICES VERSUS<br />
USUAL CARE FOR MUSCULOSKELETAL PROBLEMS<br />
Chris Salisbury 1 , Nadine E. Foster 2 , Annette Bishop 2 ,<br />
Jo Coast 3 , Angelo Franchini 1 , Jeanette Hall 4 ,<br />
Sandra Hollinghurst 1 , Cherida Hopper 1 , Sean Grove 4 ,<br />
Surinder Kaur 1 , Alan Montgomery 1 ;<br />
1.<br />
Academic Unit of Primary Health Care, University of Bristol,<br />
Bristol, United Kingdom; 2. Arthritis Research UK Primary Care<br />
Centre, Keele University, Keele, United Kingdom; 3. Department<br />
of Helath Economics, University of Birmingham, Birmingham,<br />
United Kingdom; 4. MSK Outpatients, Bristol Community<br />
Health, Bristol, United Kingdom<br />
FREQUENCY OF MUSCULOSKELETAL SYMPTOMS AND<br />
PRESENTING COMPLAINTS IN VIDEO-OBSERVED PRIMARY<br />
CARE CONSULTATIONS WITH PATIENTS AGED 45 AND OVER<br />
Zoe Paskins 1 , Tom Sanders 1 , Peter R. Croft 1 , Andy B. Hassell 1 ;<br />
1.<br />
Arthritis Research UK Primary Care Centre, Keele,<br />
United Kingdom<br />
DECIDING TO CONSULT THE GENERAL PRACTITIONER FOR<br />
SYMPTOMATIC OSTEOARTHRITIS: A CHOICE-BASED<br />
CONJOINT ANALYSIS STUDY<br />
Domenica E. Coxon 1 , Martin Frisher 2 , Kelvin P. Jordan 1 ,<br />
Clare Jinks 1 , George Peat 1 ;<br />
1.<br />
Arthritis Research UK Primary Care Centre, Keele University,<br />
Keele, United Kingdom; 2. Department of Medicines<br />
Management, Keele University, Keele, United Kingdom<br />
O31<br />
14.45 – 16.15<br />
Primary care<br />
AUDIT TO ASSESS GP AWARENESS AND DOCUMENTATION<br />
OF BIOLOGIC AND DMARDS IN PRIMARY CARE PATIENT<br />
RECORDS<br />
Charlotte Goodhead 1 , Priya Shekar 1 , Clive Kelly 1 , Gail Francis 1 ,<br />
Ann-Marie Bailey 2 , Lynsey Thompson 1 , Jennifer Hamilton 1 ;<br />
1.<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital Gateshead,<br />
Gateshead, United Kingdom; 2. South of Tyne and Wear<br />
Medicines Management, Sunderland teaching primary<br />
care trust, Sunderland, United Kingdom<br />
O35<br />
O36<br />
BSR Medical student bursary winner<br />
ARE RHEUMATOID ARTHRITIS PATIENTS SCREENED FOR<br />
CARDIOVASCULAR DISEASE IN PRIMARY CARE?<br />
Helen L. Monk 1 , Sara Muller 1 , Christian Mallen 1 ,<br />
Samantha L. Hider 1 ;<br />
1.<br />
Arthritis Research UK Primary Care Centre, Keele University,<br />
Keele, United Kingdom<br />
GOUT, ALLOPURINOL AND ERECTILE DYSFUNCTION:<br />
AN EPIDEMIOLOGICAL STUDY IN A PRIMARY CARE<br />
CONSULTATION DATABASE<br />
Edward Roddy 1 , Sara Muller 1 , Richard Hayward 1 ,<br />
Christian Mallen 1 ;<br />
1.<br />
Arthritis Research UK Primary Care Centre, Stoke-on-Trent,<br />
United Kingdom
74 Oral presentation of abtracts | 1-3 May 2012<br />
Thursday 3 May 2012<br />
09.00 – 10.30<br />
Epidemiology and outcomes<br />
S1<br />
S2<br />
Molecular mechanisms of disease: osteoarthritis<br />
IDENTIFICATION OF NOVEL OSTEOARTHRITIS GENES USING<br />
ZEBRAFISH<br />
Chrissy Hammond 1 ;<br />
1.<br />
Biochemistry, University of Bristol, Bristol, United Kingdom<br />
IS ADRENOMEDULLIN A POTENTIAL THERAPEUTIC FOR<br />
OSTEOARTHRITIS, WHILE ITS TRUNCATED PEPTIDE 22-52<br />
ACTS AS A PRO-DEGENERATIVE FACTOR?<br />
Frédéric Velard 1,2 , Marie-Dominique Ah Kioon 1,2 ,<br />
Dominique Côme 1,2 , Narjes Hafsia 1,2 , Hilène Lin 1,2 ,<br />
Hang-Korng Ea 1,2 , Frédéric Lioté 1,2 ;<br />
1.<br />
INSERM, U606, Paris, France; 2. Hôpital, Lariboisière,<br />
Paris, France<br />
O37<br />
O38<br />
THE RISK OF SOLID CANCER IN PATIENTS RECEIVING<br />
ANTI-TUMOUR NECROSIS FACTOR THERAPY FOR<br />
RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH<br />
SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER<br />
Louise Mercer 1 , James Galloway 1 , Audrey Low 1 , Kath Watson 1 ,<br />
Mark Lunt 1 , William Dixon 1 , BSRBR Control Centre<br />
Consortium 1 , Deborah Symmons 1 , Kimme Hyrich 1 ,<br />
on behalf of the BSRBR 2 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom; 2. <strong>British</strong> <strong>Society</strong><br />
<strong>for</strong> <strong>Rheumatology</strong>, London, United Kingdom<br />
SYSTEMIC RHEUMATOID VASCULITIS IN THE BIOLOGIC ERA<br />
Eleana Ntatsaki 1 , Richard A. Watts 2,3 , Janice Mooney 2 ,<br />
David G.I. Scott 1,3 ;<br />
S3<br />
INVESTIGATION OF THE ROLE OF UFM1 SPECIFIC<br />
PEPTIDASE 2 IN BEUKES HIP DYSPLASIA<br />
Michal Dudek 1 , Gillian A. Wallis 1 ;<br />
1.<br />
University of Manchester, Manchester, United Kingdom<br />
1.<br />
<strong>Rheumatology</strong>, Norfolk and Norwich University Hospital,<br />
Norwich, United Kingdom; 2. Norwich Medical School,<br />
University of East Anglia, Norwich, United Kingdom;<br />
3.<br />
<strong>Rheumatology</strong>, Ipswich Hospital NHS Trust, Ispwich,<br />
United Kingdom<br />
S4<br />
CANNABIDIOL BLOCKS THE INHIBITORY EFFECTS OF THE<br />
GPR55 AGONIST L-ALPHA-LYSOPHOSPHATIDYLINOSITOL ON<br />
MECHANOSENSITIVE KNEE JOINT AFFERENTS<br />
Kenneth Paton 1 , John Harris 1 , David A. Kendall 2 ,<br />
Sara Kelly 3,1 ;<br />
1.<br />
School of Biosciences, University of Nottingham,<br />
Nr Loughborough, United Kingdom; 2. School of Biomedical<br />
Sciences, University of Nottingham, Nottingham, United<br />
Kingdom; 3. Arthritis Research UK Pain Centre, University of<br />
Nottingham, Nottingham, United Kingdom<br />
O39<br />
BSR Young investigator award winner<br />
INCIDENCE OF RHEUMATOID ARTHRITIS IN THE UK<br />
USING THE 2010 ACR/EULAR CLASSIFICATION CRITERIA<br />
AND COMPARISON WITH ESTIMATES USING THE 1987<br />
ACR CRITERIA<br />
Jennifer Humphreys 1 , Suzanne M. Verstappen 1 ,<br />
Tarnya Marshall 2 , Mark Lunt 1 , Kimme Hyrich 1 ,<br />
Deborah P. Symmons 1 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, School of<br />
Translational Medicine, University of Manchester, Manchester,<br />
United Kingdom; 2. Department of <strong>Rheumatology</strong>, Norfolk and<br />
Norwich University Hospital, Norwich, United Kingdom<br />
O40<br />
SMOKING AND RHEUMATOID FACTOR STATUS IN<br />
PREDICTING RESPONSES TO BIOLOGICS<br />
Abdul Khan 1 , David L. Scott 1 ;<br />
1.<br />
<strong>Rheumatology</strong>, Kings College Hospital, London,<br />
United Kingdom
1-3 May 2012 | Oral presentation of abtracts 75<br />
O41<br />
O42<br />
BREAST IS BEST. LIFECOURSE INFLUENCES ON THE<br />
DEVELOPMENT OF KNEE OSTEOPHYTES: THE NEWCASTLE<br />
THOUSAND FAMILIES STUDY<br />
Ajay Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 ,<br />
Roger M. Francis 2 , Fraser Birrell 3 ;<br />
1.<br />
Institute of Health and <strong>Society</strong>, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom; 2. Institute <strong>for</strong> Ageing<br />
and Health, Newcastle University, Newcastle upon Tyne,<br />
United Kingdom; 3. Musculoskeletal Research Group, Institute<br />
of Cellular Medicine, Newcastle University, Newcastle upon<br />
Tyne, United Kingdom<br />
ASSOCIATION OF SYSTEMIC SCLEROSIS WITH DIFFERENT<br />
AUTOANTIBODY SUBGROUPS AND MALIGNANCIES: A<br />
RETROSPECTIVE REGISTRY-BASED UK COHORT STUDY<br />
Pia Moinzadeh 1,2 , Carmen Fonseca 1 , Martin Hellmich 3 ,<br />
Ami Shah 4 , Cecilia Chighizola 5 , Christopher P. Denton 1 ,<br />
Voon Ong 1 ;<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
UCL Medical School, Royal Free Hospital, London, United<br />
Kingdom; 2. Dermatology, University of Cologne, Cologne,<br />
Germany; 3. Institute of Medical Statistics, In<strong>for</strong>matics and<br />
Epidemiology, University of Cologne, Cologne, Germany;<br />
4.<br />
Division of <strong>Rheumatology</strong>, Johns Hopkins University School<br />
of Medicine, Baltimore, Maryland, United States of America;<br />
5.<br />
<strong>Rheumatology</strong> Division, Department of Internal Medicine,<br />
School of Medicine, Milan, Italy<br />
S6<br />
S7<br />
S8<br />
TLR9 INDUCES TOLERANCE TO APOPTOTIC CELLS AND IS<br />
RESPONSIBLE FOR INDUCING REGULATORY B CELLS<br />
Katherine Miles 1 , Jonathan Heaney 1 , Zaneta Sibinska 1 ,<br />
Donald Salter 1 , John Savill 1 , David Gray 2 , Mohini Gray 1 ;<br />
1.<br />
Queen’s Medical Research Institute, University of Edinburgh,<br />
Edinburgh, United Kingdom; 2. Institute of Immunology &<br />
Infection Research, University of Edinburgh, Edinburgh,<br />
United Kingdom<br />
INTERLEUKIN-27 RECEPTOR-DEFICIENT MICE DEVELOP<br />
EXACERBATED INFLAMMATORY ARTHRITIS ASSOCIATED<br />
WITH HEIGHTENED T- AND B-CELL RESPONSES<br />
Gareth W. Jones 1,2 , Claire J. Greenhill 1 , Anwen S. Williams 1 ,<br />
Mari A. Nowell 1 , Brendan J. Jenkins 2 , Simon A. Jones 1 ;<br />
1.<br />
Institute of Infection and Immunity, Cardiff University, Cardiff,<br />
United Kingdom; 2. Centre <strong>for</strong> Innate Immunity and Infectious<br />
Diseases, Monash Institute of Medical Research, Clayton,<br />
Victoria, Australia<br />
ANTI-TNF ANTIBODY THERAPY, BUT NOT TNF RECEPTOR<br />
BLOCKADE, INDUCES IL-17 SUPPRESSING REGULATORY<br />
T CELLS<br />
Jenny McGovern 1 , Dao X. Nguyen 1 , Clare A. Notley 1 ,<br />
Claudia Mauri 1 , David Isenberg 1 , Michael Ehrenstein 1 ;<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London, London,<br />
United Kingdom<br />
11.30 – 13.00<br />
Education<br />
S5<br />
Molecular mechanisms of disease: inflammatory arthritis I<br />
ANTI-VCA AND EBNA1 ANTIBODIES ARE PRODUCED IN THE<br />
RHEUMATOID SYNOVIUM IN THE PRESENCE OF ECTOPIC<br />
LYMPHOID STRUCTURES AND CORRELATES WITH ACPA<br />
PRODUCTION<br />
Cristina Croia 1 , Michele Bombardieri 1 , Aloisi Francesca 2 ,<br />
Barbara Serafini 2 , Frances Humby 1 , Stephen Kelly 1 ,<br />
Paola Migliorini 3 , Costantino Pitzalis 1 ;<br />
1.<br />
Experimental Medicine and <strong>Rheumatology</strong>, Queen Mary<br />
University of London, London, United Kingdom; 2. Cell Biology<br />
and Neuroscience, Istituto Superiore di Sanita’, Rome, Italy;<br />
3.<br />
Internal Medicine, University of Pisa, Pisa, Italy<br />
O43<br />
O44<br />
NATIONAL RHEUMATOID ARTHRITIS SOCIETY WORKWISE<br />
WORKSHOPS’ ONLINE RESOURCES: TOOLS TO HELP<br />
PEOPLE WITH RHEUMATOID ARTHRITIS REMAIN IN THE<br />
WORKPLACE OR GET BACK TO WORK<br />
Clare Jacklin 1 , Ailsa M. Bosworth 1 ;<br />
1.<br />
External Affairs, National Rheumatoid Arthritis <strong>Society</strong>,<br />
Maidenhead, United Kingdom<br />
DESIGNING VIRTUAL PATIENTS FOR MUSCULOSKELETAL<br />
EDUCATION: A GROUNDED THEORY QUALITATIVE STUDY<br />
James Bateman 1,2 , Maggie Allen 2 , Dipti Samani 2 ,<br />
David Davies 1 ;<br />
1.<br />
Institute of Clinical Education, University of Warwick,<br />
Coventry, United Kingdom; 2. Department of <strong>Rheumatology</strong>,<br />
University Hospitals Coventry and Warwickshire NHS Trust,<br />
Coventry, United Kingdom
76 Oral presentation of abtracts | 1-3 May 2012<br />
O45<br />
HAVE YOU BEEN TO CAPRI? WWW.CAPRI.SCOT.NHS.UK<br />
EARLY RESULTS OF A CLINIC FOR ARTHRITIS PATIENTS IN<br />
REMISSION ON THE INTERNET<br />
Helen E. Harris 1 , Suzanne Brannan 3 , Gavin Venters 2 ,<br />
Alan McQuillian 2 , Fiona Lovegrove 1 , Jane Gibson 1 ,<br />
David Chinn 4 , John S. Mclaren 1 ;<br />
1.<br />
Fife Rheumatic Diseases Unit, NHS Fife, Kirkcaldy, United<br />
Kingdom; 2. In<strong>for</strong>mation Technology Department, NHS<br />
Scotland, Edinburgh, United Kingdom; 3. Opthalmology<br />
Department, Queen Margaret Hospital, Dunfermline, United<br />
Kingdom; 4. Research and Development, NHS Fife,<br />
Dunfermline, United Kingdom<br />
S9<br />
14.00 – 15.30<br />
Molecular mechanisms of disease: inflammatory<br />
arthritis II<br />
INHIBITION OF NAMPT (PBEF/VISFATIN) DECREASES THE<br />
ABILITY OF HUMAN NEUTROPHILS TO GENERATE REACTIVE<br />
OXIDANTS, BUT DOES NOT IMPAIR BACTERIAL KILLING<br />
Kate J. Roberts 1 , Robert J. Moots 2 , Steven W. Edwards 1 ;<br />
1.<br />
Institute of Integrative Biology, University of Liverpool,<br />
Liverpool, United Kingdom; 2. Institute of Ageing and Chronic<br />
Disease, University Hospital Aintree, University of Liverpool,<br />
Liverpool, United Kingdom<br />
O46<br />
O47<br />
THE EVALUATION OF AN ARTHRITIS EDUCATION<br />
OUTREACH PROGRAMME FOR BLACK AND ETHNIC<br />
MINORITY COMMUNITIES<br />
Chandrika Gordhan 3,1 , Rebecca J. Stack 1,2 , Kanta Kumar 1,2 ,<br />
Ishraga Awad 4 , Karim Raza 1,2 , Paul Bacon 3,1 ;<br />
1.<br />
<strong>Rheumatology</strong> Research Group, School of Immunity and<br />
Infection, University of Birmingham, Birmingham, United<br />
Kingdom; 2. <strong>Rheumatology</strong> Department, Sandwell and West<br />
Birmingham Hospitals NHS Trust, Birmingham, United<br />
Kingdom; 3. Birmingham Arthritis Resource Centre, Birmingham<br />
Central Library, Birmingham, United Kingdom; 4. Public Health<br />
Medicine, Sandwell Primary Care Trust, West Bromwich,<br />
United Kingdom<br />
PATIENT EXPERIENCES, ATTITUDES AND EXPECTATIONS<br />
TOWARDS RECEIVING INFORMATION ABOUT ANTI-TNF:<br />
A QUALITATIVE STUDY<br />
Paul Arkell 1,2 , Sarah Ryan 2 , Ann Brownfield 2 ,<br />
Jonathan Packham 1,2 ;<br />
S10<br />
S11<br />
NEUTROPHIL MICROPARTICLES AS POTENTIAL NOVEL<br />
EFFECTORS OF JOINT DISEASE<br />
Sarah E. Headland 1 , Mauro Perretti 1 ;<br />
1.<br />
William Harvey Research Institute, Barts & the London<br />
School of Medicine & Dentistry, London, United Kingdom<br />
RESOLVIN D1 LIMITS PMN RECRUITMENT TO<br />
INFLAMMATORY LOCI: RECEPTOR DEPENDENT BIOACTIONS<br />
Lucy Norling 1 , Jesmond Dalli 2,1 , Roderick Flower 1 ,<br />
Charles Serhan 2 , Mauro Perretti 1 ;<br />
1.<br />
William Harvey Research Institute, Barts and <strong>The</strong> London<br />
Medical School, London, United Kingdom; 2. Anesthesiology,<br />
Perioperative and Pain Medicine, Brigham and Women’s<br />
Hospital and Harvard Medical School, Boston, Massachusetts,<br />
United States of America<br />
1.<br />
Primary Care and Health Sciences Department, Keele<br />
University, Keele, United Kingdom; 2. <strong>The</strong> Haywood Hospital<br />
<strong>Rheumatology</strong> Department, University Hospital of North<br />
Staf<strong>for</strong>dshire, Stoke-on-Trent, United Kingdom<br />
O48<br />
NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY:<br />
IMPACT OF RHEUMATOID ARTHRITIS ON THE FAMILY<br />
Clare Jacklin 1 , Ailsa M. Bosworth 1 , Kate Wilkinson 1 ;<br />
1.<br />
External Affairs, National Rheumatoid Arthritis <strong>Society</strong>,<br />
Maidenhead, United Kingdom
1-3 May 2012 | Oral presentation of abtracts 77<br />
S12<br />
BSR Young investigator award winner<br />
THE MESENCHYMAL STROMAL CELL MARKER CD248<br />
REGULATES INFLAMMATORY ARTHRITIS AND BONE<br />
FORMATION<br />
Amy Naylor 1 , Eman Azzam 2 , Stuart Smith 1 , Adam Croft 1 ,<br />
Jeremy Duffield 5 , David Huso 6 , Steffen Gay 3 , Caroline Ospelt 3 ,<br />
Mark Cooper 1 , Clare Isacke 4 , Simon Goodyear 2 ,<br />
Michael Rogers 2 , Chris Buckley 1 ;<br />
1.<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham,<br />
Birmingham, United Kingdom; 2. Musculoskeletal Programme,<br />
University of Aberdeen, Aberdeen, United Kingdom;<br />
3.<br />
Department of <strong>Rheumatology</strong>, University Hospital Zurich,<br />
Zurich, Switzerland; 4. Institute of Cancer Research, Royal<br />
Cancer Hospital, London, United Kingdom; 5. Institute <strong>for</strong> Stem<br />
Cell and Regenerative Medicine, University of Washington,<br />
Washington, United States of America; 6. Molecular and<br />
Comparative Pathobiology, Johns Hopkins University,<br />
Baltimore, Maryland, United States of America<br />
O49<br />
O50<br />
Genetics<br />
GLOBAL GENE EXPRESSION ANALYSIS OF<br />
DEDIFFERENTIATED CHONDROCYTES<br />
Alan J. Mueller 1 , Elizabeth G. Laird 1 , Simon R. Tew 1 ,<br />
Peter D. Clegg 1 ;<br />
1.<br />
Musculoskeletal Biology, Institute of Ageing and Chronic<br />
Disease, University of Liverpool, Neston, United Kingdom<br />
LARGEST UK RHEUMATOID ARTHRITIS GENOME WIDE<br />
ASSOCIATION STUDY TO DATE OF 8,300 SAMPLES<br />
STRENGTHENS CONFIRMED LOCI AND HIGHLIGHTS<br />
MORE POTENTIAL RA GENETIC RISK FACTORS<br />
Gisela Orozco 1 , Steve Eyre 1 , John Bowes 1 , Edward Flynn 1 ,<br />
Anne Barton 1 , Jane Worthington 1 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom<br />
S13<br />
THE REGULATION OF ARTHRITIC BONE EROSIONS BY IL-10<br />
Claire J. Greenhill 1 , Anwen S. Williams 1 , Gareth W. Jones 1 ,<br />
Mari A. Nowell 1 , Abdul N. Moideen 1 , Marcela Rosas 1 ,<br />
Phil R. Taylor 1 , Ian R. Humphreys 1 , Simon A. Jones 1 ;<br />
1.<br />
Institute of Infection and Immunity, Cardiff University, Cardiff,<br />
United Kingdom<br />
BSR Young investigator award winner<br />
O51<br />
FINE MAPPING IN OVER 14,000 RHEUMATOID ARTHRITIS<br />
CASES AND 18,500 CONTROLS REFINE ASSOCIATIONS TO<br />
KNOWN LOCI, INDICATE MULTIPLE INDEPENDENT AFFECTS<br />
AND REVEAL NOVEL ASSOCIATIONS<br />
Steve Eyre 1 , John Bowes 1 , Anne Barton 1 , Chris Amos 2 ,<br />
Dorothée Diogo 3 , Annette Lee 4 , Leonid Padyukov 5 ,<br />
Eli A. Stahl 3 , Javier Martin 5 , Solbritt Rantapaa-Dahlqvist 6 ,<br />
Soumya Raychaudhuri 3 , Robert Plenge 3 , Lars Klareskog 7 ,<br />
Peter Gregersen 4 , Jane Worthington 1 ;<br />
S14<br />
DUAL SPECIFICITY PHOSPHATASE 1 IS A CRUCIAL NEGATIVE<br />
REGULATOR OF INFLAMMATORY OSTEOLYSIS AND A<br />
MEDIATOR OF THERAPEUTIC EFFECTS OF DEXAMETHASONE<br />
IN COLLAGEN-INDUCED ARTHRITIS<br />
Youridies Vattakuzhi 1 , Nicole J. Horwood 1 , Andy R. Clark 1 ;<br />
1.<br />
Kenndy Institute of <strong>Rheumatology</strong>, London, United Kingdom<br />
1.<br />
Musculoskeletal Research Group, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom; 2. Epidemiology,<br />
University of Texas, Houston, Texas, United States of America;<br />
3.<br />
Division of Genetics, Harvard Medical School, Boston,<br />
Massachusetts, United States of America; 4. Centre <strong>for</strong><br />
Genomics and Human Genetics, Feinstein Institute <strong>for</strong> Medical<br />
Research, New York, New York, United States of America;<br />
5.<br />
Instituto de Parasitology, CSIC Granada, Granada, Spain;<br />
6.<br />
<strong>Rheumatology</strong>, Umea University, Umea, Sweden;<br />
7.<br />
<strong>Rheumatology</strong>, Karolinska University Hospital Solna,<br />
Stockholm, Sweden
78 Oral presentation of abtracts | 1-3 May 2012<br />
O52<br />
INVESTIGATION OF IDIOPATHIC INFLAMMATORY MYOPATHY<br />
FOR SHARED GENETIC RISK FACTORS WITH OTHER<br />
AUTOIMMUNE DISORDERS<br />
Meghna Jani 1 , Hector Chinoy 1,2 , Janine Lamb 2 , Platt Hazel 2 ,<br />
Lucy Wedderburn 3 , Jiri Vencovsky 4 , Katalin Danko 5 ,<br />
Ingrid Lundberg 6 , Albert Selva O’Callaghan 7 ,<br />
Timothy Radstake 8 , William E.R. Ollier 2 , Robert G. Cooper 1 ;<br />
1.<br />
Rheumatic Diseases Centre, Sal<strong>for</strong>d Royal NHS Foundation<br />
Trust, Sal<strong>for</strong>d, United Kingdom; 2. Centre <strong>for</strong> Integrated<br />
Genomic Medical Research, University of Manchester,<br />
Manchester, United Kingdom; 3. <strong>Rheumatology</strong> Unit, Institute<br />
of Child Health, University College London, London, United<br />
Kingdom; 4. <strong>Rheumatology</strong>, Institute of <strong>Rheumatology</strong>, Prague,<br />
Czech Republic; 5. Division of Clinical Immunology, Medical and<br />
Health Science Center, University of Debrecen, Debrecen,<br />
Sweden; 6. <strong>Rheumatology</strong> Unit, Karolinska Institutet,<br />
Stockholm, Sweden; 7. Internal Medicine Department, Vall<br />
d’Hebron General Hospital, Barcelona, Spain; 8. Department of<br />
<strong>Rheumatology</strong>, Radboud University, Nijmegen Medical Center,<br />
Nijmegen, Netherlands<br />
O54<br />
GENOME-WIDE ASSOCIATION STUDY OF METHOTREXATE<br />
RESPONSE IDENTIFIES NOVEL GENES IN A LARGE COHORT<br />
OF EUROPEAN JUVENILE IDIOPATHIC ARTHRITIS CASES<br />
Joanna Cobb 1 , Anne Hinks 1 , Edward Flynn 1 , Shashi Hirani 2 ,<br />
Fiona Patrick 3 , Laura Kassoumeri 3 , Simona Ursu 3 ,<br />
Halima Moncrieffe 3 , Maja Bulatovic 4 , Marek Bohm 5 ,<br />
Bertrand van Zelst 6 , Pavla Dolezalova 5 , Robert de Jonge 6 ,<br />
Nico Wulffraat 4 , Stan Newman 2 , Wendy Thomson 1 ,<br />
Lucy Wedderburn 3 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2. School of<br />
Community & Health Sciences, City University London,<br />
London, United Kingdom; 3. Institute of Child Health, University<br />
College London, London, United Kingdom; 4. Department of<br />
Paediatric Immunology, Wilhelmina Children’s Hospital,<br />
University Medical Centre Utrecht, Utrecht, Netherlands;<br />
5.<br />
First Faculty of Medicine, General Faculty Hospital, Prague,<br />
Czech Republic; 6. Department of <strong>Rheumatology</strong>, Erasmus<br />
University Medical Centre, Rotterdam, Netherlands<br />
BSR Young investigator award winner<br />
O53<br />
ANALYSIS OF THE IMMUNOCHIP IN A LARGE COHORT OF<br />
OLIGO- AND POLYARTHRITIS JUVENILE IDIOPATHIC<br />
ARTHRITIS CASES CONFIRMS PREVIOUS AND IDENTIFIES<br />
NOVEL ASSOCIATIONS<br />
Joanna Cobb 1 , Anne Hinks 1 , John Bowes 1 , Kathryn Steel 1 ,<br />
Marc Sudman 2 , Miranda C. Marion 3 , Mehdi Keddache 4 ,<br />
Lucy R. Wedderburn 5 , Johannes P. Haas 6 , David N. Glass 2 ,<br />
Carl D. Langefeld 3 , Wendy Thomson 1 , Susan D. Thompson 2 ;<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2. Cincinnati<br />
Children’s Hospital Medical Center, Cincinnati Children’s<br />
Hospital, Cincinnati, Ohio, United States of America;<br />
3.<br />
Department of Biostatistical Sciences, Wake Forest University<br />
School of Medicine, Winston-Salem, North Carolina, United<br />
States of America; 4. Division of Human Genetics, Cincinnati<br />
Children’s Hospital Medical Center, Cincinnati, Ohio, United<br />
States of America; 5. Institute of Child Health, University<br />
College London, London, United Kingdom; 6. German Centre<br />
<strong>for</strong> <strong>Rheumatology</strong> in Children and Young People,<br />
Garmische-Partenkirchen, Germany
Poster viewing:<br />
Tuesday 1 May 2012<br />
Poster viewing<br />
Tue 1 May 2012
Poster viewing: Tuesday 1 May 2012<br />
Tuesday 1 May 2012 | Poster viewing 79<br />
BHPR research: qualitative<br />
1 COMPLEX REASONING DETERMINES PATIENTS’ PERCEPTION<br />
OF OUTCOME FOLLOWING FOOT SURGERY IN RHEUMATOID<br />
ARTHRITIS<br />
Michael R. Backhouse 1,2 , Karen A. Vinall 1 ,<br />
Anthony Redmond 1,2 , Philip Helliwell 1,2 , Anne-Maree Keenan 1<br />
1.<br />
Section of Musculoskeletal Disease, University of Leeds,<br />
Leeds, United Kingdom. 2. Leeds Musculoskeletal Biomedical<br />
Research Unit, University of Leeds, Leeds, United Kingdom.<br />
2 AN EVALUATION OF PATIENTS’ PERSPECTIVES OF<br />
PARTICIPATING IN A TWO WEEK INPATIENT ANKYLOSING<br />
SPONDYLITIS (AS) REHABILITATION PROGRAMME<br />
Rebecca M. Dale 1,2 , Amanda Thomas 1 , Diane Aronson 1 ,<br />
Julie Turner-Cobb 2 , Raj Sengupta 1 , Brisa France 1 , Ingrid Hill 1<br />
1.<br />
<strong>Rheumatology</strong> Department, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom. 2. Health<br />
Psychology Department, University of Bath, Bath,<br />
United Kingdom.<br />
3 “YOU MAKE YOUR OWN LUCK”: THREE DIFFERENT<br />
PERCEPTIONS OF LIVING WITH RA: A Q-METHODOLOGICAL<br />
STUDY<br />
Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 ,<br />
Rod Hughes 3 , Pam Richards 2 , Sarah Hewlett 1<br />
1.<br />
Faculty of Health and Life Sciences, University of the West of<br />
England, Bristol, United Kingdom. 2. <strong>Rheumatology</strong>, University<br />
Hospitals Bristol, Bristol, United Kingdom. 3. <strong>Rheumatology</strong>,<br />
St Peter’s Hospital, Chertsey, United Kingdom.<br />
4 WHAT I WANT THE HEALTH PROFESSIONAL TO KNOW:<br />
THE EXPERIENCES OF PEOPLE WITH OSTEOARTHRITIS<br />
AND RHEUMATOID ARTHRITIS<br />
Sarah Ryan 1 , Kate Lille 1 , Jo Adams 2 , Inam Haq 3<br />
1.<br />
School of Nursing & Midwifery, Keele University, Stoke on<br />
Trent, United Kingdom. 2. School of Health Sciences, University<br />
of Southampton, Southampton, United Kingdom. 3. Medical<br />
Education, Arthritis Research UK, London, United Kingdom.<br />
5 EXPLORING OCCUPATIONAL GAIN IN PEOPLE WITH<br />
INFLAMMATORY ARTHRITIS RECEIVING ANTI-TNFα<br />
Margaret McArthur 1 , Lynne Goodacre 1 , Linda Birt 1<br />
1.<br />
School of Allied Health Professions, University of East Anglia,<br />
Norwich, United Kingdom.<br />
6 “JUST DO SOMETHING ABOUT MY FEET”: FOOT PROBLEMS<br />
AND ACCESS TO FOOT CARE IN PEOPLE WITH RHEUMATOID<br />
ARTHRITIS<br />
Oonagh Wilson 1 , John Kirwan 2 , Emma Dures 1 , Enid Quest 2 ,<br />
Sarah Hewlett 1<br />
1.<br />
Faculty of Health and Life Sciences, University of the West of<br />
England, Bristol, United Kingdom. 2. Academic <strong>Rheumatology</strong><br />
Unit, University of Bristol, Bristol, United Kingdom.<br />
7 OBSERVATIONAL STUDY OF EXERCISE AND RA: PATIENTS<br />
PERCEPTIONS AND EFFECT ON DISEASE ACTIVITY<br />
MEASURES<br />
Rizwan Rajak 1 , Tasmin Thomas 1 , Tom Lawson 1<br />
1.<br />
<strong>Rheumatology</strong> Dept, Princess of Wales Hospital, ABM Health<br />
Board, Bridgend, United Kingdom.<br />
8 EXPLORING THE EXPERIENCES AND NEEDS OF YOUNG<br />
ADULTS (16-25 YRS), WITH A CHRONIC INFLAMMATORY<br />
MUSCULOSKELETAL DISEASE WITHIN AN ADULT<br />
RHEUMATOLOGY SERVICE: A QUALITATIVE STUDY<br />
Sharon Pet<strong>for</strong>d 1,3 , Elizabeth Hale 1 , George D. Kitas 1 ,<br />
Sarah Ryan 2,3<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Dudley Group of Hospitals NHS<br />
Foundation Trust, Dudley, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
<strong>The</strong> Haywood Hospital, Stoke-on-Trent, United Kingdom.<br />
3.<br />
Nursing, Keele University, Newcastle-under-Lyme,<br />
United Kingdom.<br />
Don’t <strong>for</strong>get<br />
to sign up <strong>for</strong><br />
poster tours!
80 Poster viewing | Tuesday 1 May 2012<br />
9 INVOLVING SERVICE USERS IN TRIAL DESIGN: OUTCOMES,<br />
SPLINT SELECTION AND PLACEBO DESIGN IN A TRIAL OF<br />
TREATMENT FOR THUMB BASE OSTEOARTHRITIS<br />
Rachael Gooberman-Hill 1 , Clare Jinks 2 , Krysia Dziedzic 2 ,<br />
Sofia Barbosa Bouças 3 , Kelly Hislop 3 , Carol Rhodes 2 ,<br />
Jo Adams 3<br />
1.<br />
Musculoskeletal Research Unit, School of Clinical Sciences,<br />
University of Bristol, Bristol, United Kingdom. 2. Primary Care<br />
Sciences, Keele University, Keele, United Kingdom. 3. Faculty<br />
of Health Sciences, University of Southampton, Southampton,<br />
United Kingdom.<br />
10 ‘…WELL, I PUT IT DOWN TO HAVING A CLEAR CONSCIENCE;<br />
BEING POLITE TO ALL PEOPLE AND BEING A MEMBER OF<br />
THE LABOUR PARTY.’ PREVENTION OF KNEE PAIN: A<br />
QUALITATIVE STUDY IN SYMPTOMLESS OLDER ADULTS<br />
Fizzah Ali 1 , Clare Jinks 1 , Bie Nio Ong 1<br />
1.<br />
Arthritis Research UK Primary Care Centre, Primary Care<br />
Sciences, Keele University, Keele, United Kingdom.<br />
BHPR Research - quantitative<br />
11 CONCURRENT VALIDATION OF THREE NOVEL ACTIVITY<br />
MONITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Michael R. Backhouse 1, 2 , Derrick White 2 , Elizabeth Hensor 1, 2 ,<br />
Anne-Maree Keenan 2 , Philip Helliwell 1, 2 , Anthony Redmond 1, 2<br />
1.<br />
Section of Musculoskeletal Disease, University of Leeds,<br />
Leeds, United Kingdom. 2. NIHR Leeds Biomedical Research<br />
Unit, University of Leeds, Leeds, United Kingdom.<br />
12 FACTORS ASSOCIATED WITH ADHERENCE IN RHEUMATOID<br />
ARTHRITIS<br />
Anna M. Ferguson 1 , Abdel Douiri 2 , David L. Scott 1 ,<br />
Heidi Lempp 1<br />
1.<br />
Academic <strong>Rheumatology</strong>, King’s College London University,<br />
London, United Kingdom. 2. Department of Primary Care And<br />
Public Health Sciences, King’s College London, London,<br />
United Kingdom.<br />
13 HEALTH PROFESSIONALS’ PERCEPTIONS OF THE EFFECTS<br />
OF EXERCISE ON JOINT HEALTH IN RHEUMATOID ARTHRITIS<br />
(RA) PATIENTS I; A QUESTIONNAIRE STUDY<br />
Serena Halls 1 , Rebecca-Jane Law 1 , Jeremy Jones 1,2 ,<br />
David Markland 1 , Peter Maddison 1 , Jeanette Thom 1<br />
1.<br />
School of Sport, Health and Exercise Sciences, Bangor<br />
University, Bangor, United Kingdom. 2. <strong>Rheumatology</strong>, Betsi<br />
Cadwaladr University Health Board, Bangor, United Kingdom.<br />
14 CARTILAGE TURNOVER, SYSTEMIC AND SYNOVIAL<br />
INFLAMMATION; THE ACUTE RESPONSE TO HIGH-INTENSITY<br />
AEROBIC AND RESISTANCE EXERCISE<br />
Rebecca-Jane Law 1 , Jeanette M. Thom 1 , Peter Maddison 1 ,<br />
Anne Breslin 2 , Alexandra Kraus 3<br />
1.<br />
School of Sport, Health and Exercise Sciences, Bangor<br />
University, Bangor, United Kingdom. 2. <strong>Rheumatology</strong>, Betsi<br />
Cadwaladr University Health Board, Bangor, United Kingdom.<br />
3.<br />
Radiology, Betsi Cadwaladr University Health Board, Bangor,<br />
United Kingdom.<br />
15 THE CONTINUING NEED OF BME COMMUNITIES FOR<br />
ARTHRITIS EDUCATION<br />
Chandrika Gordhan 1,2 , Sean Dennis 1 , John Connor 1 , Bhavani<br />
Chowdhary 1 , Neena Lottay 1 , Parmjit Juneja 1 , Paul A. Bacon 2, 1<br />
1.<br />
Birmingham Arthritis resource Centre, Birmingham Central<br />
Library, Birmingham, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
University of Birmingham, Birmingham, United Kingdom.<br />
16 MEASURING THE RESPONSE OF EXTRA HEPATIC<br />
SYMPTOMS AND QUALITY OF LIFE TO ANTIVIRAL<br />
TREATMENT IN PATIENTS WITH HEPATITIS C<br />
David Isaacs 1 , James Jack 2 , Majella Keller 2 , Jeremy Tibble 2 ,<br />
Inam Haq 1<br />
1.<br />
Brighton & Sussex Medical School, Brighton, United<br />
Kingdom. 2. Medicine, Royal Sussex County Hospital,<br />
Brighton, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 81<br />
17 DEVELOPMENT OF THE EVALUATION OF DAILY ACTIVITY<br />
QUESTIONNAIRE (EDAQ) IN MUSCULOSKELETAL<br />
CONDITIONS: PHASE ONE<br />
Alison Hammond 1 , Rachel Gill 1 , Sarah Tyson 1 , Alan Tennant 2 ,<br />
Ulla Nordenskiold 3<br />
1.<br />
Centre <strong>for</strong> Health Sciences Research, University of Sal<strong>for</strong>d,<br />
Sal<strong>for</strong>d, United Kingdom. 2. Academic Rehabilitation,<br />
University of Leeds, Leeds, United Kingdom. 3. Rehabilitation<br />
Medicine, Sahlgrenska Academy, Goteborg, Sweden.<br />
BHPR – Clinical evaluation and audit delivery<br />
18 AUDIT: ARE POTENTIAL REACTIVE ARTHRITIS PATIENTS<br />
SCREENED FOR A SEXUAL AETIOLOGY?<br />
Emily E. Pease 1 , Colin T. Pease 1<br />
1.<br />
<strong>Rheumatology</strong>, Chapel Allerton Hospital, Leeds,<br />
United Kingdom.<br />
19 CONNECTIVE TISSUE DISEASE SERVICE IN A DISTRICT<br />
HOSPITAL - ARE WE ACHIEVING QUALITY OF CARE?<br />
Anne Trehane 1 , Fouz Rahmeh 1 , Patricia Cornell 1 ,<br />
Sarah L. Westlake 1<br />
1.<br />
<strong>Rheumatology</strong>, Poole Hospital NHS Trust, Poole,<br />
United Kingdom.<br />
20 MONITORING IGG FOLLOWING RITUXIMAB THERAPY FOR<br />
RHEUMATOID ARTHRITIS<br />
Katy Rose 1 , Catherine Fouad Alber 1 , Liam Watson 1 ,<br />
Richard Stratton 2,1 , Mark Lazarus 2<br />
1.<br />
Medical School, UCL , London, London, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, Royal Free Hospital, London, United<br />
Kingdom.<br />
21 A SERVICE EVALUATION OF A PHYSIOTHERAPY<br />
EXTENDED SCOPE PRACTITIONER COMMUNITY-LED<br />
INJECTION SERVICE<br />
Natasha E. McNeilly 1, 2 , Jackie Waterfield 2<br />
1.<br />
Musculoskeletal Service, Solihull Community Services<br />
(HEFT), Solihull, United Kingdom. 2. Physiotherapy,<br />
Keele University, Staf<strong>for</strong>dshire, United Kingdom.<br />
22 POST-OPERATIVE REHABILITATION PROVIDES UNMET NEED<br />
FOR BETTER PATIENT SUPPORT AND ADVICE FOLLOWING<br />
LUMBAR SPINAL FUSION<br />
Mike Hurley 1 , James Greenwood 2<br />
1.<br />
School of Rehabilitation Sciences, St George’s University<br />
of London, London, United Kingdom. 2. Physiotherapy<br />
Department, University College Hospital, London,<br />
United Kingdom.<br />
23 SELF REFERRAL TO RHEUMATOLOGY PHYSIOTHERAPY:<br />
A VITAL COMPONENT OF SELF MANAGEMENT<br />
Ann M. Clayton 1,2 , Michael Lynch 1 , Adrian Clewes 1 ,<br />
Julie Dawson 1 , Veronica Abernethy 1 , Ann E. Griffiths 1,2<br />
1.<br />
<strong>Rheumatology</strong>, St Helens & Knowsley Teaching Hospitals,<br />
St. Helens, United Kingdom. 2. Secondary Care <strong>The</strong>rapy<br />
Service, KIPS at 5 Boroughs Partnership, St. Helens,<br />
United Kingdom.<br />
24 DOES OUR TELEPHONE ADVICE LINE SERVICE MEET<br />
CURRENT NATIONAL GUIDANCE?<br />
Victoria A. Chamberlain 1 , YokeMei McLoughlin 1 ,<br />
Sophie Campbell 1 , Janita Hayes 1 , Claire Moffat 1 ,<br />
Frank McKenna 1 , Preeti Shah 1<br />
1.<br />
<strong>Rheumatology</strong>, Traf<strong>for</strong>d Healthcare NHS Trust, Manchester,<br />
United Kingdom.<br />
25 EVALUATION OF PREEXISTING PULMONARY DISEASE IN RA<br />
PATIENTS INITIATING ANTITNF<br />
Rizwan Rajak 1 , Ann Williams 1 , Ceril Rhys-Dillon 1 ,<br />
Rhian Goodfellow 1 , James C. Martin 1<br />
1<br />
<strong>Rheumatology</strong>, Cwm Taf Health Board, Llantrisant,<br />
United Kingdom.<br />
26 ALL WALES RE-AUDIT OF THE INITIAL MANAGEMENT OF<br />
GIANT CELL ARTERITIS (GCA)<br />
Rizwan Rajak 1 , Farhan Bari 1 , Gwenan Hughes 1 , Eleri Thomas 1<br />
1.<br />
<strong>Rheumatology</strong> Dept, Princess of Wales Hospital, ABM Health<br />
Board, Bridgend, United Kingdom.<br />
27 CHRONIC KIDNEY DISEASE MAY BE UNDERRECOGNISED IN<br />
RHEUMATOLOGY PATIENTS ON DMARDS<br />
Sarah Baker 1 , David Collins 1 , Elizabeth Price 1 , Lyn Williamson 1<br />
1.<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, Swindon,<br />
United Kingdom.
82 Poster viewing | Tuesday 1 May 2012<br />
28 AUDIT: IN A ROUTINE RHEUMATOLOGY OPD WHAT IS THE<br />
UTILITY OF WHOLE SPINE MRI IN PATIENTS WITH<br />
SUSPECTED INFLAMMATORY BACK PAIN (IBP)?<br />
Lisa Dunkley 1 , Matthew J. Youll 1<br />
1.<br />
<strong>Rheumatology</strong>, Sheffield Teaching Hospitals NHS Trust,<br />
Sheffield, South Yorkshire, United Kingdom.<br />
29 A RE-AUDIT OF SERUM 25-HYDROXY VITAMIN D IN A<br />
RHEUMATOLOGY OUTPATIENT CLINIC<br />
Mia Rodziewicz 1,2 , John A. Reynolds 2 , Jacqueline Berry 3,2 ,<br />
Chee Pavey 2 , Kimme Hyrich 2 , Rachel Gorodkin 2 ,<br />
Kate Wilkinson 2 , Ian Bruce 2 , Anne Barton 2 , Alan Silman 2 ,<br />
Pauline Ho 2<br />
1.<br />
Medical School, <strong>The</strong> University of Manchester, Manchester,<br />
United Kingdom. 2. <strong>The</strong> Kellgren Centre <strong>for</strong> <strong>Rheumatology</strong>,<br />
Manchester Royal Infirmary, Manchester, United Kingdom.<br />
3.<br />
Vitamin D Research Group, Manchester Royal Infirmary,<br />
Manchester, United Kingdom.<br />
Award winner<br />
30 DOES INFORMING PATIENTS ABOUT THE LINK BETWEEN<br />
GUM DISEASE AND RHEUMATOID ARTHRITIS (RA)<br />
ENCOURAGE BETTER DENTAL CARE?<br />
Tricia Cornell 1 , Sarah L. Westlake 1 , Selwyn Richards 1<br />
1.<br />
Poole Hospital NHS Foundation Trust, Poole,<br />
United Kingdom.<br />
31 IMPACT OF ANTI-TNF THERAPY ON BASDAI AND<br />
EMPLOYMENT IN ANKYLOSING SPONDYLITIS<br />
A. Holmes 1 , S. Parker 1 , H. Smith 1 , N. Briggs 1 , S. Arthanari 1 ,<br />
M. Nisar 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Burton Hospitals NHS<br />
Foundation Trust, Burton on Trent, United Kingdom.<br />
32 A REVIEW OF THE IMPLEMENTATION OF CURRENT<br />
GUIDELINES REGARDING TRIPLE DMARD THERAPY FOR<br />
EARLY RA: IS IT HAPPENING IN PRACTICE?<br />
Catharine Thwaites 1,2 , Sarah Ryan 2,1 , Sanjeet Kamath 2 ,<br />
Shyra Price 2<br />
33 NEGOTIATING TARGETS FOR THERAPY ACROSS THE RANGE<br />
OF FOLLOW-UP RHEUMATOLOGICAL CONDITIONS<br />
Sandra M. Robinson 1 , David Walker 1<br />
1.<br />
Musculoskeletal Directorate, Newcastle Upon Tyne Hospitals<br />
NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.<br />
34 AN AUDIT ON VACCINATIONS IN PATIENTS WITH<br />
AUTOIMMUNE RHEUMATIC DISEASES<br />
Hazel Coop 1 , Wahab Al-Allaf 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Wolverhampton NHS trust,<br />
Wolverhampton, United Kingdom.<br />
35 PERSISTENCE WITH HYDROXYCHLOROQUINE IN A<br />
RHEUMATOLOGY COHORT<br />
Sarah Baker 1 , Lyn Williamson 1 , Elizabeth Price 1 , David Collins 1<br />
1.<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United<br />
Kingdom.<br />
36 AN AUDIT OF THE EFFECTIVENESS OF SILDENAFIL IN<br />
THE MANAGEMENT OF PATIENTS WITH MULTI-TREATMENT<br />
RESISTANT RAYNAUD’S PHENOMENON<br />
Rebecca C. Charleton 1 , Bridget Griffiths 1<br />
1<br />
<strong>Rheumatology</strong> Department, Newcastle Hospitals Foundation<br />
Trust, Newcastle upon Tyne, United Kingdom.<br />
37 THE APPROPRIATENESS OF ANA REQUESTING BY GENERAL<br />
PRACTITIONERS AND THE RELEVANCE OF A POSITIVE TEST<br />
Elizabeth A. Edwards 1 , Rosamund Partlett 1 , Keith Martin 2 ,<br />
Mike Tarzi 2 , Sathianathan Panthakalam 1<br />
1.<br />
<strong>Rheumatology</strong>, East Sussex Healthcare NHS, Eastbourne,<br />
United Kingdom. 2. Immunology, East Sussex Healthcare NHS,<br />
Eastbourne, United Kingdom.<br />
38 AN AUDIT TO ASSESS THE EFFICACY OF THE OXFORD<br />
MUSCULOSKELETAL REFERRAL HUB SERVICE<br />
Tanya Freeman 1 , Louise Ainley 1 , Michael Turner 1<br />
1.<br />
Ox<strong>for</strong>d university, Ox<strong>for</strong>d, United Kingdom.<br />
1.<br />
School of Nursing and Midwifery, Keele University,<br />
Newcastle-under-Lyme, Staf<strong>for</strong>dshire, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong> Department, Haywood Hospital,<br />
Stoke-on Trent, Staf<strong>for</strong>dhsire, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 83<br />
39 DO PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WANT<br />
SMS TEXT MESSAGES TO REMIND THEM ABOUT HOSPITAL<br />
APPOINTMENTS AND DRUG ADHERENCE?<br />
Lyndsay Hughes 1 , Bridget Russell 1 , Suzanne Jenkins 2 ,<br />
John Done 1 , Adam Young 2<br />
1.<br />
Centre <strong>for</strong> Lifespan and Chronic Illness Research, University<br />
of Hert<strong>for</strong>dshire, Hatfield, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
West Herts Hospital NHS Trust, St.Albans, United Kingdom.<br />
40 THE FEASIBILITY, ACCEPTABILITY AND USEFULNESS OF<br />
EXTENDED DATA COLLECTION IN RHEUMATOID ARTHRITIS<br />
Tadeusz Jones 1 , Ian C. Gaywood 1 , Ira Pande 1 ,<br />
Marie-Josèphe Pradère 1<br />
1.<br />
<strong>Rheumatology</strong>, Nottingham University Hospitals NHS Trust,<br />
Nottingham, United Kingdom.<br />
41 AN AUDIT OF ASSESSING RISK AND TREATING<br />
MYCOBACTERIAL INFECTION IN PATIENTS WITH<br />
INFLAMMATORY ARTHRITIS PRIOR TO STARTING AN<br />
ANTI-TNF AGENT<br />
Mahua Bhaduri 1 , Angela Smith 1 , Haley Cook 1 ,<br />
Sonya Abraham 1<br />
1.<br />
Imperial College London, London, United Kingdom.<br />
42 IMPACT OF SEXUAL DYSFUNCTION AND PSYCHOLOGICAL<br />
EFFECTS IN WOMEN WITH SYSTEMIC SCLEROSIS<br />
Tanaka Ngcozana 1 , Christopher P. Denton 1 , Louise Parker 1 ,<br />
Carol M. Black 1 , Voon Ong 1<br />
1.<br />
Centre of <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
Royal Free Hampstead NHS Trust, London, United Kingdom.<br />
Imaging<br />
43 AN OBSERVATIONAL STUDY OF THE UTILITY OF CRANIAL<br />
ULTRASOUND IN SUSPECTED GIANT CELL ARTERITIS<br />
Nicola Thompson 1 , Catherine White 1 , Martin Duddy 2 ,<br />
Paresh Jobanputra 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Queen Elizabeth Hospital,<br />
Birmingham, United Kingdom. 2. Department of Radiology,<br />
Queen Elizabeth Hospital, Birmingham, United Kingdom.<br />
44 DEVELOPMENT OF AN ACCREDITED INNOVATIVE FOCUSSED<br />
ULTRASOUND TRAINING COURSE FOR REGISTERED HEALTH<br />
PROFESSIONALS<br />
Pauline Bacon 1 , Jacqueline Smith 2 , Ann Richardson 3 ,<br />
Giorgio Giancola 3 , Vicky Soh 3 , Simon Spencer 3 ,<br />
Ann Greenhalgh 3 , Mark Hanson 1 , Denise De Lord 2<br />
1.<br />
Medical Physics, EKHUFT, Canterbury, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, EKHUFT, Canterbury, United Kingdom.<br />
3.<br />
Radiology, EKHUFT, Canterbury, United Kingdom.<br />
45 THE POWER OF PET/CT<br />
Mark Lloyd 1 , Henna Wong 4 , Damian Wren 2 , Bob Grover 6 ,<br />
John Hall 7 , Cai Neville 5 , Peter Alton 3<br />
1.<br />
<strong>Rheumatology</strong>, Frimley Park Hospital, Frimley, United<br />
Kingdom. 2. Neurology, Frimley Park Hospital, Frimley,<br />
United Kingdom. 3. Haematology, Frimley Park Hospital,<br />
Frimley, United Kingdom. 4. Immunology, John Radcliffe<br />
Infirmary, Ox<strong>for</strong>d, United Kingdom. 5. <strong>Rheumatology</strong>, Royal<br />
Surrey County Hospital, Guild<strong>for</strong>d, United Kingdom.<br />
6.<br />
Gastroenterology, Hillingdon Hospital, Hillingdon,<br />
United Kingdom. 7. Radiology, Frimley Park Hospital,<br />
Frimley, United Kingdom.<br />
46 ULTRASOUND GUIDED SYNOVIAL BIOPSIES: SAFETY,<br />
TOLERABILITY, AND TISSUE QUALITY<br />
Stephen Kelly 1 , Michele Bombardieri 1 , Fran Humby 1 ,<br />
Nora Ng 1 , Maria Di Cicco 1 , Rebecca Hands 1 , Oscar Epis 5 ,<br />
Andrew Filer 2 , Christopher Buckley 2 , Iain McInnes 4 ,<br />
Peter Taylor 3 , Costantino Pitzalis 1<br />
1.<br />
Experimental Medicine and <strong>Rheumatology</strong>, Queen Marys<br />
University of London, London, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham,<br />
Birmingham, United Kingdom. 3. Nuffield Department of<br />
Orthopaedics, <strong>Rheumatology</strong> and Musculoskeletal Sciences,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom. 4. Glasgow<br />
Biomedical Research Centre, University of Glasgow, Glasgow,<br />
United Kingdom. 5. <strong>Rheumatology</strong>, A.O. Ospedale Niguarda<br />
Ca’ Granda, Milan, Italy.
84 Poster viewing | Tuesday 1 May 2012<br />
47 USEFULNESS OF NOVEL WHOLE BODY MULTIPLE JOINT<br />
MRI IMAGING IN ESTABLISHING ACCURATE AND TIMELY<br />
DIAGNOSES IN PATIENTS PRESENTING WITH<br />
INFLAMMATORY ARTHRITIS<br />
Jane Freeston 1,2 , Philip Conaghan 1,2 , Andrew Grainger 3 ,<br />
Philip J. O’Connor 3 , Rob Evans 2 , Paul Emery 1,2 ,<br />
Richard Hodgson 2<br />
1.<br />
Section of Musculoskeletal Disease, University of Leeds,<br />
Leeds, United Kingdom. 2. Leeds Musculoskeletal Biomedical<br />
Research Unit, Chapel Allerton Hospital, Leeds, United<br />
Kingdom. 3. Leeds Teaching Hospitals NHS Trust, Chapel<br />
Allerton Hospital, Leeds, United Kingdom.<br />
48 PREDICTORS OF RADIOGRAPHIC PROGRESSION IN<br />
METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID<br />
ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA<br />
FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL<br />
Paul Emery 1 , Roy Fleischmann 2 , Chenglong Han 3 , Desiree Van<br />
de Heide 4 , Philip Conaghan 1 , Weichun Xu 5 , Elizabeth Hsia 5,6<br />
1.<br />
NIHR Leeds Musculoskeletal Biomedical Research Unit,<br />
University of Leeds, Leeds, United Kingdom. 2. Metroplex<br />
Clinical Research Center, University of Texas Southwest<br />
Medical Center, Dallas, TX, United States. 3. Worldwide Market<br />
Access, Janssen Global Services, LLC, Malvern, PA, United<br />
States. 4. <strong>Rheumatology</strong>, Leiden University Medical Center,<br />
Leiden, Netherlands. 5. Immunology, Janssen Research &<br />
Development, Inc, Malvern, PA, United States.<br />
6.<br />
<strong>Rheumatology</strong>, University of Pennsylvania School of<br />
Medicine, Philadelphia, PA, United States.<br />
49 GOLIMUMAB TREATMENT INHIBITS PROGRESSION IN JOINT<br />
DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS<br />
REGARDLESS OF BASELINE DISEASE SEVERITY<br />
Arthur Kavanaugh 1 , Dafna Gladman 2 ,<br />
Chandrabhusan Chattopadhyay 3 , Anna Beutler 4 ,<br />
Chenglong Han 5<br />
1.<br />
<strong>Rheumatology</strong>, Allergy and Immunology, University of<br />
Cali<strong>for</strong>nia San Diego, San Diego, CA, United States.<br />
2.<br />
<strong>Rheumatology</strong>, University of Toronto, Toronto, ON, Canada.<br />
3.<br />
<strong>Rheumatology</strong>, Wrightington Hospital, Toronto, United<br />
Kingdom. 4. Immunology, Janssen Research & Development,<br />
Inc, Malvern, PA, United States. 5. Worldwide Market Access,<br />
Janssen Global Services, L.L.C, Malvern, PA, United States.<br />
50 ULTRASOUND DETECTED BONE EROSIONS: ARE THEY<br />
SPECIFIC FOR RHEUMATOID ARTHRITIS?<br />
Ahmed S. Zayat 1 , Philip Conaghan 1 , Jane Freeston 1 ,<br />
Elizabeth Hensor 1 , Karen Ellegard 2 , Lene Terslev 2 , Paul Emery 1 ,<br />
Richard J. Wakefield 1<br />
1.<br />
Academic Unit of Musculoskeletal Disease, University of<br />
Leeds, Leeds, United Kingdom. 2. Copenhagen University<br />
Hospital, Parker Institute, Copenhagen, Denmark.<br />
51 THE USEFULNESS OF A MUSCULOSKELETAL ULTRASOUND<br />
(MUS) SCORING SYSTEM FOR 22 HAND JOINTS<br />
EXAMINATION FOR THE DETECTION OF EARLY<br />
UNDIFFERENTIATED INFLAMMATORY ARTHRITIS AND<br />
TREATMENT DECISIONS MAKING IN ESTABLISHED<br />
INFLAMMATORY ARTHRITIS<br />
Coziana Ciurtin 1 , Maria Leandro 1 , Dzifa Dey 1 ,<br />
Anupama Nandagudi 1 , Ian Giles 1 , Mike Shipley 1 ,<br />
Vanessa Morris 1 , John Ioannou 1 , Michael Ehrenstein 1 , Debajit<br />
Sen 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, University College London<br />
Hospitals, London, United Kingdom.<br />
Metabolic and crystal arthropathies<br />
52 AUDIT OF THE ADHERENCE TO BSR GUIDELINES ON THE<br />
MANAGEMENT OF GOUT (2007), IN TWO PRIMARY CARE<br />
CENTRES WITHIN THE MERSEYSIDE REGION<br />
Marian Chan 1 , Tim M. Quinlan 2 , Richard Brophy 2 , Devesh<br />
Mewar 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Liverpool University and Broadgreen<br />
Hospital, Liverpool, United Kingdom. 2. General Practice,<br />
Mersey Deanery, Mersey, United Kingdom.<br />
53 A CASE OF SPINAL GOUT<br />
Dipti Patel 1 , M. J. Wilby 3 , Vincent Pellegrini 2 , Brian Eyes 2 ,<br />
Daniel Crooks 4 , Marina Anderson 1<br />
1.<br />
<strong>Rheumatology</strong>, Aintree University Hospital NHS Foundation<br />
Trust, Liverpool, United Kingdom. 2. Radiology, Aintree<br />
University Hospital NHS Foundation Trust, Liverpool, United<br />
Kingdom. 3. Neurosurgery, <strong>The</strong> Walton Centre NHS Foundation<br />
Trust, Liverpool, United Kingdom. 4. Histopathology, <strong>The</strong> Walton<br />
Centre NHS Foundation Trust, Liverpool, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 85<br />
Miscellaneous rheumatic diseases<br />
54 STEROID INJECTION IN PLANTAR FASCIITIS - A PLACEBO<br />
CONTROLLED TRIAL<br />
Elisabeth Ball 1 , Helen McKeeman 1 , James Burns 1 ,<br />
Wing Hoi Yau 1 , Owen Moore 1 , Joanne Foo 1 , Claire Benson 1 ,<br />
Chris Patterson 2 , Gary Wright 1 , Allister Taggart 1<br />
1.<br />
<strong>Rheumatology</strong>, Musgrave Park Hospital, Belfast, United<br />
Kingdom. 2. Medical Statistics, Queens’ University, Belfast,<br />
United Kingdom.<br />
55 HELPLINE AUDIT: DOES THE NRAS TELEPHONE HELPLINE<br />
SERVICE BENEFIT USERS WHO HAVE BEEN DIAGNOSED<br />
WITH RHEUMATOID ARTHRITIS?<br />
Sarah Drew 1 , Lorraine Tanner 2<br />
1.<br />
Fundraising Team, National Rheumatoid Arthritis <strong>Society</strong>,<br />
Maidenhead, United Kingdom. 2. Helpline Team, National<br />
Rheumatoid Arthritis <strong>Society</strong>, Maidenhead, United Kingdom.<br />
56 PRESENTATION AND CLINICAL OUTCOME OF SARCOIDOSIS<br />
PATIENTS PRESENTING TO RHEUMATOLOGY: A REGIONAL<br />
AUDIT<br />
Kaushik Sanyal 1 , Brian E. Bourke 1 , Mark Lloyd 3 , Claire Alston 2 ,<br />
Charlotte Baqai 3 , Michael Chard 6 , Virinderjit Sandhu 1 ,<br />
Cai Neville 4 , Kelsey Jordan 6 , Catherine Munns 3 , Louisa Zouita 3 ,<br />
Warren Shattles 2 , Ursula Davies 2 , Raad Makadsi 2 ,<br />
Sian Griffith 2 , Patrick D. Kiely 1<br />
1.<br />
<strong>Rheumatology</strong>, St. George’s Hospital NHS Trust, London ,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, East Surrey Hospital NHS<br />
Trust, Redhill, United Kingdom. 3. <strong>Rheumatology</strong>, Frimley Park<br />
Hospital NHS Trust, Frimley, United Kingdom. 4. <strong>Rheumatology</strong>,<br />
Royal Surrey County Hospital NHS Trust, Guild<strong>for</strong>d, United<br />
Kingdom. 5. <strong>Rheumatology</strong>, Brighton and Sussex University<br />
Hospital NHS Trust, Brighton, United Kingdom.<br />
6.<br />
<strong>Rheumatology</strong>, Worthing Hospital NHS Trust, Worthing,<br />
United Kingdom.<br />
57 SERUM LEPTIN LEVELS IN PATIENTS WITH<br />
HYPOTHYROIDISM AND SYMPTOMS OF INFLAMMATORY<br />
ARTHRITIS IS SIGNIFICANTLY INCREASED COMPARED<br />
WITH A MATCHED GROUP WITHOUT PERIPHERAL JOINTS<br />
ASSOCIATED SYMPTOMS<br />
Coziana Ciurtin 1,2 , Ionela Dimofte 2 , Mihaela Dabu 2 ,<br />
Bogdan Dabu 2<br />
1.<br />
Department of <strong>Rheumatology</strong>, UCLH, London, London,<br />
United Kingdom. 2. Department of Molecular Biology,<br />
Carol Davila University of Medicine and Pharmacy,<br />
Bucharest, Romania.<br />
58 CLINICAL EFFECTIVENESS OF PAH SPECIFIC THERAPIES IN<br />
SARCOIDOSIS-RELATED PULMONARY HYPERTENSION<br />
David Dobarro 1 , Benjamin E. Schreiber 1 , Clare Warrell 1 ,<br />
Clive Handler 1 , Gerry Coghlan 1 , Chris Denton 1<br />
1.<br />
Pulmonary Hypertension, Royal Free Hampstead Hospital<br />
NHS Trusts, London, United Kingdom.<br />
59 CLINICAL AND LABORATORY FEATURES OF PATIENTS<br />
PRESENTING TO A RHEUMATOLOGY CLINIC WITH POSITIVE<br />
ANTI-C1Q ANTIBODY SEROLOGY<br />
Jasmine Ishorari 1 , Chris Bunn 1 , Huw Beynon 1 ,<br />
Christopher P. Denton 1 , Richard Stratton 1<br />
1.<br />
<strong>Rheumatology</strong> Department, Royal Free hospital, London,<br />
United Kingdom.<br />
Rheumatoid arthritis: clinical features<br />
60 COMPARISON OF MOBILE AND FIXED BEARING TOTAL KNEE<br />
REPLACEMENTS IN RHEUMATOID ARTHRITIS<br />
Joby J. George Malal 1 , Ben Boton-Maggs 1<br />
1.<br />
Orthopaedics, St Helens & Knowsley Teaching Hospitals,<br />
Widnes, United Kingdom.<br />
61 DEFINING CRITERIA FOR RHEUMATOID ARTHRITIS<br />
PATIENT-DERIVED DISEASE ACTIVITY SCORE (PDAS) THAT<br />
CORRESPOND TO DISEASE ACTIVITY SCORE 28 (DAS28)<br />
AND CLINICAL DISEASE ACTIVITY INDEX (CDAI) BASED<br />
DISEASE STATUSES AND RESPONSE CRITERIA<br />
Alexander Leung 1 , Daniel Farewell 2 , Ernest Choy 1<br />
1.<br />
<strong>Rheumatology</strong>, Cardiff University School of Medicine, Cardiff,<br />
United Kingdom. 2. Institute of Primary Care & Public Health,<br />
Cardiff University School of Medicine, Cardiff, United Kingdom.
86 Poster viewing | Tuesday 1 May 2012<br />
62 PREDICTING ONGOING ACTIVE DISEASE IN EARLY RA USING<br />
CLINICAL MEASURES<br />
Nicola J. Gullick 1 , Adam Young 2 , Ernest H. Choy 3 ,<br />
David L. Scott1<br />
1.<br />
Academic Department of <strong>Rheumatology</strong>, King’s College<br />
London, London, United Kingdom. 2. <strong>Rheumatology</strong>, St Albans<br />
City Hospital, Cardiff, United Kingdom. 3. Section of<br />
<strong>Rheumatology</strong>, Cardiff University School of Medicine, Cardiff,<br />
United Kingdom.<br />
63 THE ROLE OF AMINO-PROPEPTIDE OF TYPE III COLLAGEN<br />
AND HYALURONIC ACID AS BIOMARKERS FOR SYNOVIAL<br />
VOLUME IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Chris Wincup 1 , Ben Fisher 1 , Peter Charles 1 , Peter Taylor 2<br />
1.<br />
Kennedy Institute of <strong>Rheumatology</strong>, Imperial College,<br />
London, United Kingdom. 2. Kennedy Institute of<br />
<strong>Rheumatology</strong>, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom.<br />
64 TEMPORAL IMPROVEMENTS IN DISEASE ACTIVITY IN<br />
OUTPATIENTS WITH RHEUMATOID ARTHRITIS<br />
Nicola J. Gullick 1,2 , Louise C. Pollard 1 , Bruce W. Kirkham 2 ,<br />
David L. Scott 1<br />
1.<br />
Academic Department of <strong>Rheumatology</strong>, King’s College,<br />
London, London, United Kingdom. 2. <strong>Rheumatology</strong>, Guy’s &<br />
St Thomas’ NHS Foundation Trust, London, United Kingdom.<br />
65 BIOMAKER SIGNATURE IN RHEUMATOID ARTHRITIS<br />
PATIENTS WITH LOW DISEASE ACTIVITY: THE<br />
REMIRA STUDY<br />
Margaret H. Ma 1 , Saroja Ramanujan 2 , Guy Cavet 2 ,<br />
Doug Haney 2 , Gabrielle H. Kingsley 1 , David Scott 1 ,<br />
Andrew Cope 1<br />
1.<br />
<strong>Rheumatology</strong>, King’s College London, London, United<br />
Kingdom. 2. In<strong>for</strong>matics, Crescendo Bioscience, South<br />
San Francisco, CA, United States.<br />
67 LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID<br />
ARTHRITIS CLINICAL TRIALS<br />
Mark C. Genovese 1 , Anthony Sebba 2 , Andrea Rubbert-Roth 3 ,<br />
Juan Scali 4 , Moshe Zilberstein 5 , Liz Thompson 6 , Ronald Van<br />
Vollenhoven 7<br />
1.<br />
<strong>Rheumatology</strong> , Stan<strong>for</strong>d University Medical Center, Palo<br />
Alto, CA, United States. 2. <strong>Rheumatology</strong>, University of South<br />
Florida, Palm Harbor, FL, United States. 3. <strong>Rheumatology</strong>,<br />
University of Cologne, Cologne, Germany. 4. <strong>Rheumatology</strong>,<br />
Durand University Hospital, Buenos Aires, Argentina. 5. Roche,<br />
Roche Nutley, Nutley, NJ, United States. 6. Roche, Roche UK,<br />
Welwyn, United Kingdom. 7. <strong>Rheumatology</strong>, Karolinska<br />
University Hospital, Stockholm, Sweden.<br />
68 THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH<br />
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WK DATA<br />
FROM A PHASE 3 CLINICAL TRIAL<br />
Fabrizio De Benedetti 1 , Hermine Brunner 2 , Roger Allen 3 ,<br />
Diane Brown 2 , Jeffrey Chaitow 3 , Manuela Pardeo 3 ,<br />
Graciela Espada 3 , Berit Flato 3 , Gerd Horneff 3 , Clare Devlin 4 ,<br />
Andrew Kenwright 4 , Rayfel Schneider 5 , Patricia Woo 6 ,<br />
Alberto Martini 3 , Daniel Lovell 2 , Nicola Ruperto 3<br />
1.<br />
<strong>Rheumatology</strong>, IRCCS Ospedale Pediatrico Bambino Gesù,<br />
Rome, Italy. 2. Pediatric <strong>Rheumatology</strong> Collaborative Study<br />
Group [PRCSG], Pediatric <strong>Rheumatology</strong> Collaborative Study<br />
Group [PRCSG], Cincinnati, OH, United States. 3. Paediatric<br />
<strong>Rheumatology</strong> International Trials Organisation – IRCCS<br />
[PRINTO], Paediatric <strong>Rheumatology</strong> International Trials<br />
Organisation – IRCCS [PRINTO] , Genova, Italy. 4. Roche,<br />
Roche, Welwyn, United Kingdom. 5. Hospital <strong>for</strong> Sick Children,<br />
University of Toronto, Toronto, ON, Canada. 6. University<br />
College London Medical School, University College London<br />
Medical School, London, United Kingdom.<br />
66 SENSITIVITY AND SPECIFICITY OF ANTIBODIES TO<br />
CITRULLINATED VIMENTIN IN RHEUMATOID ARTHRITIS:<br />
EXPERIENCE FROM A LARGE SECONDARY CARE CENTRE<br />
Animesh Singh 1 , Jo Wilson 2 , Anthony Isaacs 1 , Charlotte Wing 1 ,<br />
Maeve McLaughlin 1 , Henry Penn 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Northwick Park Hospital,<br />
London, United Kingdom. 2. Department of Immunology,<br />
Northwick Park Hospital, London, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 87<br />
Rheumatoid arthritis: comorbidities<br />
69 A RANDOMISED CONTROLLED TRIAL OF A COGNITIVE BE-<br />
HAVIOURAL PATIENT EDUCATION INTERVENTION VERSUS A<br />
TRADITIONAL INFORMATION LEAFLET TO ADDRESS THE<br />
CARDIOVASCULAR ASPECTS OF RHEUMATOID DISEASE<br />
Holly John 1,2 , Elizabeth D. Hale 1,2 , Gareth J. Treharne 3 ,<br />
George D. Kitas 1,4 , Douglas Carroll 2<br />
1.<br />
Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals<br />
NHS Trust, Dudley, United Kingdom. 2. Department of Sport<br />
and Exercise Sciences, University of Birmingham, Birmingham,<br />
United Kingdom. 3. Department of Psychology, University of<br />
Otago, Dunedin, New Zealand. 4. AR-UK Epidemiology Unit,<br />
University of Manchester, Manchester, United Kingdom.<br />
70 OUTCOME OF WOMEN WITH PREVIOUS CARCINOMA IN<br />
SITU OF THE CERVIX WITH RESPECT TO FEMALE GENITAL<br />
CANCER, FOLLOWING TREATMENT WITH NON-BIOLOGIC<br />
DMARD OR ANTI-TNF FOR RHEUMATOID ARTHRITIS:<br />
RESULTS FROM THE BSRBR<br />
Louise Mercer 1 , Audrey Low 1 , James Galloway 1 , Kath Watson 1 ,<br />
Mark Lunt 1 , BSRBR Control Centre Consortium 1 ,<br />
Deborah Symmons 1 , Kimme Hyrich 1 , On Behalf of the BSRBR 2<br />
1.<br />
Arthritis Research UK Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. <strong>British</strong> <strong>Society</strong><br />
<strong>for</strong> <strong>Rheumatology</strong>, London, United Kingdom.<br />
71 CARDIOVASCULAR MORTALITY RATES (SMR) ARE ELEVATED<br />
IN A NATIONAL COHORT OF SUBJECTS WITH RHEUMATOID<br />
ARTHRITIS COMPARED TO THE UK GENERAL POPULATION<br />
WHETHER OR NOT THEY WERE TREATED WITH BIOLOGIC<br />
DRUGS: RESULTS FROM THE BSRBR<br />
Audrey Low 1 , Louise Mercer 1 , James Galloway 1 ,<br />
Rebecca Davies 1 , Kath Watson 1 , Mark Lunt 1 , BSRBR Control<br />
Centre Consortium 2 , William Dixon 1 , Kimme Hyrich 1 ,<br />
Deborah Symmons 1,2<br />
1.<br />
Arthritis Research UK Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. <strong>British</strong> <strong>Society</strong><br />
<strong>for</strong> <strong>Rheumatology</strong>, Bride House, London, United Kingdom.<br />
72 AN AUDIT OF INVESTIGATION OF ANAEMIA IN RHEUMATOID<br />
ARTHRITIS<br />
Sharmili Balarajah 1 , Amrita Sandhu 1 , Mercy Ariyo 1 ,<br />
Elizabeth Rankin 1<br />
1.<br />
University Hospitals Birmingham NHS Foundation Trust,<br />
Birmingham, United Kingdom.<br />
73 ANTI-TNFα THERAPY TRANSIENTLY IMPROVES HIGH<br />
DENSITY LIPOPROTEIN LEVELS AND MICROVASCULAR<br />
ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS: A LONGITUDINAL STUDY<br />
Aamer Sandoo 1,2 , Jet J. Veldhuijzen van Zanten 2,1 ,<br />
Tracey E. Toms 1,3 , Douglas Carroll 2 , George D. Kitas 1,3<br />
1.<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals, Dudley, United<br />
Kingdom. 2. School of Sport and Exercise Sciences, University<br />
of Birmingham, Birmingham, United Kingdom. 3. Arthritis<br />
Research UK Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom.<br />
74 PREDICTORS OF SUBENDOCARDIAL VIABILITY RATIO IN<br />
PATIENTS WITH RA: THE ROLE OF INFLAMMATION AND<br />
CLASSICAL CARDIOVASCULAR DISEASE RISK FACTORS<br />
Aamer Sandoo 1,2 , Jacqueline P. Smith 1 , George D. Kitas 1,3<br />
1.<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals, Dudley, United<br />
Kingdom. 2. School of Sport and Exercise Sciences, University<br />
of Birmingham, Birmingham, United Kingdom. 3. Arthritis<br />
Research UK Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom.<br />
75 IS THE NATURAL HISTORY OF INTERSTITIAL LUNG DISEASE<br />
IN RHEUMATOID ARTHRITIS CHANGING?<br />
Saadia Malik 1,2 , Elizabeth Toberty 1 , Nishanthi Thalayasingam 1 ,<br />
Jennifer Hamilton 1 , Clive Kelly 1,2<br />
1.<br />
QEH <strong>Rheumatology</strong>, Gateshead, United Kingdom.<br />
2.<br />
Medicine, University of Newcastle upon Tyne, Newcastle,<br />
United Kingdom.<br />
76 SEVERE URINARY TRACT INFECTIONS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS<br />
Daniel Puntis 1 , Saadia Malik 1 , Jennifer Hamilton 1 ,<br />
Vadivelu Saravanan 1 , Martin Rynne 1 , Carol Heycock 1 ,<br />
Clive Kelly 1<br />
1.<br />
QEH <strong>Rheumatology</strong>, Gateshead, United Kingdom.
88 Poster viewing | Tuesday 1 May 2012<br />
77 THORACIC HRCT STUDY TO ASSESS FOR PREEXISTING<br />
LUNG DISEASE IN RA PATIENTS DUE TO START ANTI-TNF<br />
THERAPY<br />
Rizwan Rajak 1 , Rhian Goodfellow 1 , Ceril Rhys-Dillon 1 ,<br />
Richard Winter 1 , Phil Wardle 1 , James C. Martin 1<br />
1.<br />
<strong>Rheumatology</strong>, Cwm Taf Health Board, Llantrisant,<br />
United Kingdom.<br />
78 THE EFFECT OF ANTI-INFLAMMATORY THERAPY ON LIPID<br />
SUB-FRACTIONS AND VASCULAR FUNCTION IN<br />
RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY<br />
Tracey Toms 1 , Aamer Sandoo 1 , Jacqueline Smith 1 ,<br />
Susan Cadman 1 , Peter Nightingale 3 , George Kitas 1,2<br />
1.<br />
<strong>Rheumatology</strong>, Dudley group of hospitals NHS trust, Dudley,<br />
United Kingdom. 2. Arthritis Research UK epidemiology unit,<br />
Manchester University, Manchester, United Kingdom.<br />
3.<br />
Wolfson computer laboratory, Birmingham University,<br />
Birmingham, United Kingdom.<br />
79 HIGH CRP IS THE BEST MARKER OF DYSLIPIDEMIA IN<br />
PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS (IP):<br />
RESULTS FROM THE NORFOLK ARTHRITIS REGISTRY (NOAR)<br />
Awal Z. Alhusain 1 , Suzanne M. Verstappen 1 , Hoda Mirjafari 1 ,<br />
Mark Lunt 1 , Valentine Charlton-Menys 2 , Diane Bunn 3 ,<br />
Deborah Symmons 1 , Paul Durrington 2 , Ian Bruce 1<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom. 2. Cardiovascular<br />
Research Group, University of Manchester, Manchester, United<br />
Kingdom. 3. Norfolk Arthritis Register, University of East Anglia,<br />
Norwich, United Kingdom.<br />
80 RHEUMATOID ARTHRITIS PATIENTS ARE TOO FAT AND UNFIT<br />
Jennifer K. Cooney 1 , Jeanette M. Thom 1 , Jonathan P. Moore 1 ,<br />
Andrew Lemmey 1 , Jeremy G. Jones 2 , Peter J. Maddison 1 ,<br />
Yasmeen A. Ahmad 2<br />
1.<br />
School of Sport Health and Exercise Science, Bangor<br />
University, Bangor, United Kingdom. 2. <strong>The</strong> Department of<br />
<strong>Rheumatology</strong>, Betsi Cadwaladr University Health Board<br />
(West), Llandudno, United Kingdom.<br />
81 DEPRESSION AND RHEUMATOID ARTHRITIS: THE<br />
PREVALENCE AND PREDICTORS OF DEPRESSION IN A<br />
RHEUMATOID ARTHRITIS POPULATION<br />
Tazeen J. Ahmed 1 , Francesca Leone 1 , Patrick D. Kiely 1<br />
1.<br />
St Georges Healthcare NHS Trust, London, United Kingdom.<br />
Scleroderma and related disorders<br />
82 AN AUDIT OF THE TREATMENT OF RAYNAUD’S<br />
PHENOMENON SECONDARY TO CONNECTIVE TISSUE<br />
DISEASE AND A COST-EFFECTIVENESS STUDY OF THESE<br />
TREATMENTS<br />
Hannah K. Browne 1 , Ceril Rhys-Dillon 1<br />
1.<br />
<strong>Rheumatology</strong> Dept, Royal Glamorgan Hospital, Llantrisant,<br />
United Kingdom.<br />
83 ANTI-CENTROMERE ANTIBODY PREDICTS FALL IN ANKLE<br />
BRACHIAL PRESSURE INDEX (ABPI)IN PATIENTS WITH<br />
SYSTEMIC SCLEROSIS<br />
Surabhi Wig 1 , Aurelie Chevance 2 , Tonia Moore 1 ,<br />
Joanne Manning 1 , Andy Vail 2 , Ariane L. Herrick 1<br />
1.<br />
Musculoskeletal Research Group, School of Translational<br />
Medicine, Manchester Academic Health Science Centre,<br />
Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d, Sal<strong>for</strong>d, United<br />
Kingdom. 2. School of Community Based Medicine, University<br />
of Manchester, Manchester Academic Health Science Centre,<br />
Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d, Sal<strong>for</strong>d, United<br />
Kingdom.<br />
84 EXPRESSION PROFILING OF SKIN AND LUNG TISSUE AND<br />
EXPLANTED FIBROBLASTS IN THE TβRIIΔK-FIB TRANSGENIC<br />
MOUSE MODEL OF SCLERODERMA<br />
Emma Derrett-Smith 1 , Rachel Hoyles 1 , Pia Moinzadeh 1 ,<br />
Cecilia Chighizola 1 , Korsa Khan 1 , Voon Ong 1 , David Abraham 1 ,<br />
Christopher P. Denton 1<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
UCL Medical School, London, United Kingdom.<br />
85 BIG IS BEAUTIFUL: BODY SIZE AND SURVIVAL IN<br />
CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY<br />
ARTERIAL HYPERTENSION<br />
Benjamin E. Schreiber 1 , David Dobarro 1 , Clare E. Warrell 1 ,<br />
Clive Handler 1 , Christopher P. Denton 1 , Gerry Coghlan 1<br />
1.<br />
Royal Free Hampstead NHS Trust, London, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 89<br />
86 SURGICAL PROCEDURES ON THE FINGERS IN PATIENTS<br />
WITH SYSTEMIC SCLEROSIS<br />
Rebecca Sykes 1 , Lindsay Muir 2 , Holly Ennis 1 , Ariane L. Herrick 1<br />
1.<br />
Musculoskeletal Research Group, School of Translational<br />
Medicine, Manchester Academic Health Science Centre,<br />
University of Manchester, Manchester, United Kingdom.<br />
2.<br />
Department of Hand Surgery, Sal<strong>for</strong>d Royal NHS Foundation<br />
Trust, Sal<strong>for</strong>d, United Kingdom.<br />
87 FAK/SRC INHIBITION ALLEVIATES THE PERSISTENT FIBROTIC<br />
PHENOTYPE OF LESIONAL SCLERODERMA FIBROBLASTS<br />
Xu Shiwen 1 , Katherine Thompson 2 , Korsa Khan 1 ,<br />
Shangxi Liu 2 , Christopher P. Denton 1 , Andrew Leask 2 ,<br />
David J. Abraham 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Free Hospital, London, United Kingdom.<br />
2.<br />
Dentistry and Physiology and Pharmacology, University of<br />
Western Ontario, London ON, ON, Canada.<br />
88 AUTOANTIBODY PROFILE AND CLINICAL ASSOCIATIONS IN A<br />
BRITISH COHORT WITH SCLERODERMA<br />
Gemma Strickland 1 , John Pauling 1 , Zoe Betteridge 2 ,<br />
Juliet Dunphy 2 , Pat Owen 2 , Neil McHugh 2,3<br />
1.<br />
<strong>Rheumatology</strong>, RNHRD, Bath, United Kingdom. 2. Research,<br />
Bath Institute <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom.<br />
3.<br />
Pharmacy and Pharmacology, University of Bath, Bath,<br />
United Kingdom.<br />
89 ELF SCORE: A VALIDATED SERUM TEST STRONGLY<br />
PREDICTIVE OF FIBROSIS IN SYSTEMIC SCLEROSIS<br />
Giuseppina Abignano 1,2 , Giovanna Cuomo 2 , Maya H. Buch 1 ,<br />
William M. Rosenberg 3 , Gabriele Valentini 2 , Paul Emery 1 ,<br />
Francesco Del Galdo 1<br />
1.<br />
Section of Musculoskeletal Diseases, Leeds Institute of<br />
Molecular Medicine, Leeds, United Kingdom. 2. <strong>Rheumatology</strong><br />
Unit, Second University of Naples, Naples, Italy. 3. Centre <strong>for</strong><br />
Hepatology, University College of London, London, United<br />
Kingdom.<br />
90 PULMONARY FUNCTION TEST ABNORMALITIES IN PATIENTS<br />
WITH SYSTEMIC SCLEROSIS AND ANTICENTROMERE<br />
AUTOANTIBODIES WITHOUT ESTABLISHED<br />
CARDIOPULMONARY DISEASE<br />
Jessica Jenkins 1 , John D. Pauling 1 , Neil McHugh 1,2<br />
1.<br />
Department of <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom. 2. Department of<br />
Pharmacy and Pharmacology, University of Bath, Bath, United<br />
Kingdom.<br />
91 IMPACT OF IL-6 TRANS-SIGNALLING IN DRIVING FIBROSIS<br />
VIA JAK2/STAT3 SIGNALLING PATHWAYS IN EARLY DCSSC<br />
Korsa Khan 1 , Xu Shiwen 1 , David Abraham 1 ,<br />
Christopher P. Denton 1 , Voon Ong 1<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
UCL Medical School, London, United Kingdom.<br />
92 IMPACT OF ANA SUBTYPE ON PROGRESSION FROM<br />
ISOLATED RP TO SSC: IMPLICATIONS FOR CLASSIFICATION<br />
AND EARLY DIAGNOSIS<br />
Pia Moinzadeh 1,2 , Kevin Howell 1 , Voon Ong 1 ,<br />
Svetlana Nihtyanova 1 , Christopher P. Denton 1<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
UCL Medical School, Royal Free Hospital, London, United<br />
Kingdom. 2. Dermatology, University of Cologne, Cologne,<br />
Germany.<br />
93 IL7 AXIS IN SSC: ANALYSIS OF LIGAND AND RECEPTOR SNP<br />
POLYMORPHISMS AND SERUM IL7 LEVELS<br />
Pia Moinzadeh 1,2 , Carmen Fonseca 1 , Korsa Khan 1 ,<br />
David Abraham 1 , Voon Ong 1 , Christopher P. Denton 1<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases,<br />
UCL Medical School, Royal Free Hospital, London,<br />
United Kingdom. 2. Dermatology, University of Cologne,<br />
Cologne, Germany.
90 Poster viewing | Tuesday 1 May 2012<br />
94 THE HAND ISCHAEMIA SCORE: A NOVEL HAND ISCHAEMIA<br />
OUTCOME MEASURE IN SYSTEMIC SCLEROSIS<br />
Anshuman P. Malaviya 1 , Andreas V. Hadjinicolaou 2 ,<br />
Muhammad K. Nisar 1 , Michael Ruddlesden 3 , Anita Furlong 1 ,<br />
Sharon Baker 4 , France C. Hall 2,1<br />
1.<br />
<strong>Rheumatology</strong>, Cambridge Uviversiy Hospitals NHS<br />
Foundation Trust, Cambridge, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, University of Cambridge School of Clinical<br />
Medicine, Cambridge, United Kingdom. 3. None, Abbey<br />
College, Ramsey, Cambridgeshire, United Kingdom.<br />
4.<br />
Cambridge Research Facility, Addenbrooke’s Hospital,<br />
Cambridge, United Kingdom.<br />
95 REGIONAL OXYGEN SATURATION AS A NOVEL OUTCOME<br />
MEASURE IN SYSTEMIC SCLEROSIS-ASSOCIATED HAND<br />
ISCHAEMIA<br />
Andreas V. Hadjinicolaou 1 , Anshuman P. Malaviya 2 ,<br />
Muhammad K. Nisar 2 , Michael Ruddlesden 3 ,<br />
Dominique Raut-Roy 2 , Anita Furlong 2 , Sharon Baker 4 ,<br />
Frances C. Hall 1,2<br />
1.<br />
None, University of Cambridge School of Clinical Medicine,<br />
Cambridge, United Kingdom. 2. <strong>Rheumatology</strong>, Cambridge<br />
University Hospitals NHS Foundation Trust, Cambridge, United<br />
Kingdom. 3. None, Abbey College, Ramsey, United Kingdom.<br />
4.<br />
ACCI, Cambridge Research Facility, Cambridge, United<br />
Kingdom.<br />
Spondylarthropathies (including psoriatic arthritis)<br />
96 DISCOVERTEBRAL EROSION IN PATIENTS WITH<br />
ENTEROPATHIC ARTHRITIS DETECTED BY MRI<br />
Rosario Peluso 1 , Di Minno M. N Dario 1 , Iervolino Salvatore 1 ,<br />
Luisa Costa 1 , Atteno Mariangela 1 , Lofrano Mariana 1 ,<br />
Soscia Ernesto 2 , Castiglione Fabiana 1 , Foglia Francesca 1 ,<br />
Scarpa Raffaele 1<br />
1.<br />
Clinical and Experimental Medicine, University Federico II,<br />
Naples, Italy. 2. Biostructures and Bioimaging Institute,<br />
National Council of Research, Naples, Italy.<br />
97 USE OF THE WORLD HEALTH ORGANISATION FRACTURE<br />
RISK ASSESSMENT TOOL (FRAX) IN ANKYLOSING<br />
SPONDYLITIS<br />
Dinny Wallis 1 , Amanda Thomas 1 , Ingrid Hill 1 , Brisa France 1 ,<br />
Raj Sengupta 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, Bath, United Kingdom.<br />
98 PREDICTING JOINT AND SKIN REMISSION AT 24 WEEKS IN<br />
PATIENTS WITH PSORIATIC ARTHRITIS<br />
Maxime Dougados 1 , Edward Keystone 3 , Michele Heckaman 4 ,<br />
Philip Mease 2<br />
1.<br />
Department of <strong>Rheumatology</strong>, University of Paris V, Cochin<br />
Hospital, Paris, France. 2. Department of <strong>Rheumatology</strong>,<br />
Swedish Medical Center and University of Washington, Seattle,<br />
WA, United States. 3. Mount Sinai Hospital, University of<br />
Toronto, Toronto, ON, Canada. 4. GPRD, Abbott, Abbott Park,<br />
IL, United States.<br />
99 SEVERITY OF BASELINE SKIN DISEASE DOES NOT<br />
CORRELATE WITH CLINICAL, PATIENT-REPORTED, OR<br />
RADIOGRAPHIC RESPONSES IN PATIENTS WITH PSORIATIC<br />
ARTHRITIS TREATED WITH ADALIMUMAB<br />
Robert Landewé 1 , Dianne Nguyen 2 , Michele Heckaman 3 ,<br />
Philip Mease 4<br />
1.<br />
Department of <strong>Rheumatology</strong>, Maastricht University Medical<br />
Center, Maastricht, Netherlands. 2. GPRD, Abbott, Singapore,<br />
Singapore, Singapore. 3. GPRD, Abbott, Abbott Park, IL, United<br />
States. 4. Department of <strong>Rheumatology</strong>, Swedish Medical<br />
Center and University of Washington, Seattle, WA, United<br />
States.<br />
100 BASDAI: IT IS EASIER AND QUICKER TO USE NUMERIC<br />
RATING SCALES (NRS) RATHER THAN VISUAL ANALOGUE<br />
SCALES<br />
Rachel A. Winfield 1 , Claire Dyke 1 , Mark Clemence 1 ,<br />
Kirsten Mackay 1<br />
1.<br />
<strong>Rheumatology</strong>, South Devon Healthcare NHS Foundation<br />
Trust, Torbay, United Kingdom.<br />
101 ASSESSING FATIGUE IN ANKYLOSING SPONDYLITIS:<br />
THE IMPORTANCE OF FREQUENCY AND SEVERITY<br />
Kirstie L. Haywood 1 , Jon Packham 2,3 , Kelvin P. Jordan 2<br />
1.<br />
Royal College of Nursing Research Institute, School of Health<br />
and Social Studies, University of Warwick, Coventry, United<br />
Kingdom. 2. Arthritis Research UK Primary Care Centre,<br />
Primary Care Sciences, Keele University, Stoke-on-Trent,<br />
United Kingdom. 3. Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre,<br />
Haywood Hospital, Stoke-on-Trent, United Kingdom.
Tuesday 1 May 2012 | Poster viewing 91<br />
102 SELF-MANAGING FATIGUE IN ANKYLOSING SPONDYLITIS<br />
AND POTENTIAL INTERVENTIONS: A QUALITATIVE STUDY OF<br />
PATIENT’S PERSPECTIVES<br />
Helen Davies 1 , Sinead Brophy 1 , Elizabeth Irvine 1 , Roxanne<br />
Cooksey 1 , Michael S. Dennis 1 , Stefan Siebert 1<br />
1.<br />
College of Medicine, Swansea University, Swansea,<br />
United Kingdom.<br />
103 QUALITY OF LIFE IN PSORIATIC ARTHRITIS: COMPARATIVE<br />
RESULTS TO RHEUMATOID ARTHRITIS USING SF36 IN<br />
TRIALS USING METHOTREXATE<br />
Gabrielle H. Kingsley 1 , Fowzia Ibrahim 1 , David L. Scott 1<br />
1<br />
<strong>Rheumatology</strong>, King’s College London, London, United<br />
Kingdom.<br />
104 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH<br />
NORMALIZED PHYSICAL FUNCTION, HEALTH-RELATED<br />
QUALITY OF LIFE & SIGNIFICANTLY IMPROVED<br />
PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC<br />
ARTHRITIS TREATED WITH GOLIMUMAB: 2-YEAR DATA<br />
FROM PHASE III GO-REVEAL TRIAL<br />
Arthur Kavanaugh 1 , Iain McInnes 2 , Chandrabhusan<br />
Chattopadhyay 3 , Gerald Krueger 4 , Dafna Gladman 5 , Anna<br />
Beutler 6 , Tim Gathany 7 , Surekha Mudivarthy 6 , Michael Mack 6 ,<br />
Neeta Tandon 8 , Chenglong Han 7 , Philip Mease 9<br />
1.<br />
Division of <strong>Rheumatology</strong>, Allergy and Immunology, UCSD,<br />
San Diego, CA, United States. 2. Division Immunology,<br />
Infection and Inflammation, University of Glasgow, Glasgow,<br />
United Kingdom. 3. <strong>Rheumatology</strong>, Wrightington Hospital,<br />
Wigan, United Kingdom. 4. Division of Dermatology, U of Utah<br />
Health Sciences Center, Salt Lake City, UT, United States.<br />
5.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Toronto Western Hospital, Toronto, ON,<br />
Canada. 6. Immunology, Janssen Research and Development,<br />
Inc, Malvern, PA, United States. 7. Worldwide Market Access,<br />
Janssen Global Services LLC, Malvern, PA, United States.<br />
8.<br />
Health Economics & Outcomes Research, Janssen Scientific<br />
Affairs, LLC, Horsham, PA, United States. 9. <strong>Rheumatology</strong>,<br />
Swedish Med Ctr/U of Washington, Seattle, WA, United States.<br />
105 EFFECT OF SECUKINUMAB ON SIGNS AND SYMPTOMS OF<br />
PSORIATIC ARTHRITIS (PsA): RESULTS OF A 24-WEEK<br />
MULTICENTER, DOUBLE-BLIND, RANDOMIZED,<br />
PLACEBO-CONTROLLED TRIAL<br />
Iain McInnes 1 , Joachim Sieper 2 , Jürgen Braun 3 , Paul Emery 4 ,<br />
Désirée van der Heijde 5 , John Isaacs 6 , Georg Dahmen 7 ,<br />
Jürgen Wollenhaupt 8 , Hendrik Schulze-Koops 9 ,<br />
Sandro Gsteiger 10 , Arthur Bertolino 11 , Wolfgang Hueber 12 ,<br />
Paul P. Tak 13<br />
1.<br />
Glasgow Biomedical Research Centre, University of Glasgow,<br />
Glasgow, United Kingdom. 2. Department of Gastroenterology,<br />
Charitè Campus Benjamin Franklin, Berlin, Germany.<br />
3.<br />
Department of Medicine, Rheumazentrum Ruhrgebiet,<br />
Herne, Germany. 4. Leeds Institute of Molecular Medicine,<br />
University of Leeds, Leeds, United Kingdom. 5. Department of<br />
<strong>Rheumatology</strong>, Leiden University Medical Center, Leiden,<br />
Netherlands. 6. Newcastle University, and the Freeman<br />
Hospital, Newcastle-upon-Tyne, United Kingdom.<br />
7.<br />
Department of Medicine, Praxis fuer klinische Studien,<br />
Hamburg, Germany. 8. Klinik für Rheumatologie, Eilbeck<br />
Hospital, Hamburg, Germany. 9. Klinikum Innenstadt der<br />
Ludwig-Maximilians-Universität, Rheumatologie, Munich,<br />
Germany. 10. Modelling & Simulation Statistics, Novartis<br />
Pharma AG, Basel, Switzerland. 11. Translational Medicine<br />
Dermatology, Novartis Institutes <strong>for</strong> BioMedical Research,<br />
Basel, Switzerland. 12. Translational Medicine Autoimmunity,<br />
Novartis Institutes <strong>for</strong> BioMedical Research, Basel,<br />
Switzerland. 13. Division of Clinical Immunology and<br />
<strong>Rheumatology</strong>, University of Amsterdam, Amsterdam,<br />
Netherlands.<br />
106 A CCR6 VARIANT STRONGLY ASSOCIATED WITH<br />
RHEUMATOID ARTHRITIS IN TWO POPULATIONS IS NOT<br />
ASSOCIATED WITH ANKYLOSING SPONDYLITIS<br />
Carla J. Cohen 2 , Tugce Karaderi 2 , Jennifer J. Pointon 1,2 ,<br />
Bryan P. Wordsworth 1,2<br />
1.<br />
NIHR Ox<strong>for</strong>d Comprehensive Biomedical Research Centre,<br />
Botnar Research Centre, Ox<strong>for</strong>d, United Kingdom. 2. NIHR<br />
Ox<strong>for</strong>d Musculoskeletal Biomedical Research Unit, Botnar<br />
Research Centre, Ox<strong>for</strong>d, United Kingdom.
92 Poster viewing | Tuesday 1 May 2012<br />
107 THE EFFECT OF PHYSICAL ACTIVITY AND MOTIVATION ON<br />
FUNCTION IN ANKYLOSING SPONDYLITIS<br />
Roxanne Cooksey 1 , Helen Davies 1 , Michael S. Dennis 1 ,<br />
Stefan Siebert 1 , Sinead Brophy 1<br />
1.<br />
College of Medicine, Swansea University, Swansea, United<br />
Kingdom.<br />
108 A RAPID SINGLE TUBE METHOD FOR TYPING rs4349859,<br />
THE SNP THAT TAGS HLA-B27<br />
Sarah Keidel 1,2 , Jennifer J. Pointon 1,2 , Claire Farrar 3 ,<br />
Tugce Karaderi 2 , Louise H. Appleton 1,2 , Bryan P. Wordsworth 1,2<br />
1.<br />
NIHR Ox<strong>for</strong>d Comprehensive Biomedical Research Centre,<br />
Botnar Research Centre, Ox<strong>for</strong>d, United Kingdom. 2. NIHR<br />
Ox<strong>for</strong>d Musculoskeletal Biomedical Research Unit, Botnar<br />
Research Centre, Ox<strong>for</strong>d, United Kingdom. 3. NIHR Thames<br />
Valley CLRN, Botnar Research Centre, Ox<strong>for</strong>d, United Kingdom.<br />
109 REFERRAL RECOMMENDATIONS FOR AN EARLY<br />
INFLAMMATORY BACK PAIN SERVICE<br />
Rebecca Adshead 1 , Hasan Tahir 1 , Mandy Greenwood 1 ,<br />
Simon P. Donnelly 1<br />
1.<br />
<strong>Rheumatology</strong>, Whipps Cross University Hospital Trust,<br />
London, United Kingdom.<br />
110 ASSESSING PSORIATIC ARTHRITIS: A MODULAR APPROACH<br />
Julekha Wajed 1 , Bruce Kirkham 1<br />
1.<br />
<strong>Rheumatology</strong>, Guy’s & St.Thomas’ Hospital, London,<br />
United Kingdom
Poster viewing:<br />
Wednesday 2 May 2012<br />
Poster viewing<br />
Wed 2 May 2012
Poster viewing: Wednesday 2 May 2012<br />
Wednesday 2 May 2012 | Poster viewing 93<br />
Muscle Disorders<br />
111 THE IMPACT OF FATIGUE IN PATIENTS WITH IDIOPATHIC<br />
INFLAMMATORY MYOPATHY: A MIXED METHOD STUDY<br />
Richard Campbell 2,1 , Darija Hofmann 1 , Stephani Hatch 3 ,<br />
Patrick Gordon 2,1 , Heidi Lempp 1<br />
1.<br />
Academic <strong>Rheumatology</strong>, Kings College , London, United<br />
Kingdom. 2. <strong>Rheumatology</strong>, King’s College Hospital NHS<br />
Foundation Trust, London, United Kingdom. 3. Psychological<br />
Medicine, Institute of Psychiatry, King’s College, London,<br />
United Kingdom.<br />
112 IMMUNOHISTOCHEMICAL MAJOR HISTOCOMPATIBILITY<br />
COMPLEX CLASS I AND II EXPRESSION IN IDIOPATHIC<br />
INFLAMMATORY MYOPATHIES<br />
Leena Das 1 , Peter Blumbergs 2 , Vidya Limaye 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Adelaide Hospital, Adelaide, SA,<br />
Australia. 2. Hanson Institute, Centre <strong>for</strong> Neurological<br />
Diseases,University of Adelaide, Adelaide, SA, Australia.<br />
113 EVIDENCE FOR IMMUNOTHERAPY IN DERMATOMYOSITIS<br />
AND POLYMYOSITIS: A SYSTEMATIC REVIEW<br />
Erin Vermaak 1 , Neil McHugh 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom.<br />
114 MUSCLE SIZE AND STRENGTH AS PREDICTORS OF BONE<br />
STRUCTURE, FALLS AND FRACTURES IN THE<br />
HERTFORDSHIRE COHORT STUDY<br />
Mark H. Edwards 1 , Karen Jameson 1 , Avan Aihie Sayer 1 ,<br />
Elaine Dennison 1 , Cyrus Cooper 1<br />
1.<br />
MRC Lifecourse Epidemiology Unit, University of<br />
Southampton, Southampton, Hampshire, United Kingdom.<br />
115 MUSCLE OUTCOME IN PATIENTS WITH IDIOPATHIC<br />
INFLAMMATORY MYOPATHIES<br />
Fernando B. Salvador 1,3 , Carolina Huertas 2,3 , David Isenberg 3<br />
1.<br />
Internal Medicine, Centro Hospitalar de Trás-os-Montes e<br />
Alto Douro, Vila Real, Portugal. 2. <strong>Rheumatology</strong>, Hospital<br />
General Universitario Gregorio Marañón, Madrid, Spain.<br />
3.<br />
<strong>Rheumatology</strong>, University College London Hospital,<br />
London, United Kingdom.<br />
Orthopaedics and rehabilitation<br />
Medical student bursary winner<br />
116 A CASE CONTROL STUDY OF RISK FACTORS FOR ELECTIVE<br />
HIP REPLACEMENT OR RESURFACING SURGERY IN<br />
HIV-INFECTED ADULTS<br />
Elizabeth J. Jackson 1 , Annie Middleton 1 , Duncan Churchill 2 ,<br />
Karen Walker-Bone 1,2<br />
1.<br />
<strong>Rheumatology</strong>, Brighton & Sussex Medical School, Brighton,<br />
United Kingdom. 2. HIV and GU Medicine, Brighton & Sussex<br />
University Hospitals NHS Trust, Brighton, United Kingdom.<br />
117 CLINICAL OUTCOMES FOLLOWING MOTOR CONTROL<br />
REHABILITATION FOR SHOULDER IMPINGEMENT<br />
Peter R. Worsley 1 , Sarah Mottram 1 , Martin Warner 1 ,<br />
Dylan Morrissey 2 , Stephan Gadola 3 , Andrew Carr 4 ,<br />
Cyrus Cooper 5 , Maria Stokes 1<br />
1.<br />
Faculty of Health Sciences, University of Southampton,<br />
Southampton, Hampshire, United Kingdom. 2. Centre <strong>for</strong><br />
Sports and Exercise Medicine, Queen Mary University of<br />
London, London, United Kingdom. 3. Faculty of Medicine,<br />
University of Southampton, Southampton, Hampshire, United<br />
Kingdom. 4. Ox<strong>for</strong>d NIHR Musculoskeletal Biomedical<br />
Research Unit, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom.<br />
5.<br />
MRC Lifecourse Epidemiology Unit, Southampton University<br />
Health Trust, Southampton, United Kingdom.<br />
Osteoarthritis<br />
118 WHICH RADIOLOGICAL FEATURE IS A TRUE PREDICTOR OF<br />
CLINICAL SEVERITY IN KNEE OSTEOARTHRITIS?<br />
Rajeshwar N. Srivastava 1 , Divya Sanghi 1<br />
1.<br />
Orthopaedic Surgery, KG Medical College, CSM Medical<br />
University, Lucknow, UP, India.<br />
Don’t <strong>for</strong>get<br />
to sign up <strong>for</strong><br />
poster tours!
94 Poster viewing | Wednesday 2 May 2012<br />
119 INFLUENCE OF DIETARY NUTRIENTS IN PREVALENCE OF<br />
OSTEOARTHRITIS (OA) KNEE<br />
Rajeshwar N. Srivastava 1 , Divya Sanghi 1<br />
1.<br />
Orthopaedic Surgery, KG Medical College, CSM Medical<br />
University, Lucknow, UP, India.<br />
120 A NEW NON-INVASIVE BIOMECHANICAL THERAPY FOR<br />
KNEE OSTEOARTHRITIS IMPROVES CLINICAL SYMPTOMS<br />
AND GAIT PATTERNS<br />
Avi Elbaz 1 , Amit Mor 1 , Ganit Segal 1 , Michael Drexler 2 ,<br />
Doron Norman 3 , Eli Peled 3 , Nimrod Rozen 4<br />
1.<br />
Apos<strong>The</strong>rapy research group, Apos Medical and Sports<br />
Technologies, Herzliya, Israel. 2. Department of Orthopedic<br />
Surgery, Sourasky Medical Center, Tel Aviv, Israel.<br />
3.<br />
Department of Orthopedic Surgery, Rambam Medical Center,<br />
Haifa, Israel. 4. Department of Orthopedic Surgery, HaEmek<br />
Medical Center, Afula, Israel.<br />
121 FOOT CENTER OF PRESSURE MANIPULATION AND GAIT<br />
THERAPY INFLUENCE LOWER LIMB MUSCLE ACTIVATION IN<br />
PATIENTS WITH OSTEOARTHRITIS OF THE KNEE<br />
Yulia Goryachev 1 , Eytan M. Debbi 1 , Amir Haim 1,2 ,<br />
Nimrod Rozen 3 , Alon Wolf 1<br />
1.<br />
Biorobotics and Biomechanics Lab, Faculty of Mechanical<br />
Engineering, Technion-Israel Institute of Technology, Haifa,<br />
Israel. 2. Department of Orthopedic Surgery, Sourasky Medical<br />
Center, Tel Aviv, Israel. 3. Department of Orthopedic Surgery,<br />
Ha’Emek Medical Center, Afula, Israel.<br />
122 DIFFERENCES IN GAIT BETWEEN MADIAL AND FRONTAL<br />
KNEE PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE<br />
KNEE<br />
Ronen Debi 1 , Amit Mor 2 , Ganit Segal 2 , Eytan M. Debbi 2 ,<br />
Marc S. Cohen 2 , Ilya Igolnikov 2 , Yaron Bar Ziv 3 , Vadim<br />
Benkovich 4 , Benjamin Bernfeld 5 , Nimrod Rozen 6 , Avi Elbaz 2<br />
1.<br />
Department of orthopedic surgery, Barzilay Medical Center,<br />
Ashkelon, Israel. 2. Apos<strong>The</strong>rapy research group, Apos,<br />
Herzliya, Israel. 3. Department of orthopedic surgery, Assaf<br />
Harofeh Medical Center, Zerifin, Israel. 4. Department of<br />
orthopedic surgery, Soroka University Medical Center, Beer<br />
Sheva, Israel. 5. Department of orthopedic surgery, Carmel<br />
Medical Center, Haifa, Israel. 6. Department of orthopedic<br />
surgery, HaEmek Medical Center, Afula, Israel.<br />
123 EFFECT OF OXYGEN TENSION AND PH ON MITOCHONDRIAL<br />
FUNCTION IN HUMAN OSTEOARTHRITIC ARTICULAR<br />
CHONDROCYTES (HOAC)<br />
John Collins 1 , Robert Moots 2 , Peter D. Clegg 1 , Peter I. Milner 1<br />
1.<br />
Institute of aging and chronic disease, University of Liverpool,<br />
Leahurst campus, Neston, United Kingdom. 2. Institute of<br />
aging and chronic disease, University of Liverpool, University<br />
Hospital Aintree, Aintree, United Kingdom.<br />
124 STUDY SHOWS THAT ENDOGENOUS RETROVIRUS ERV-3 IS<br />
NOT IMPLICATED IN RHEUMATOID ARTHRITIS BUT MAY<br />
PROVIDE A BIOMARKER OF OSTEOARTHRITIS<br />
Hora D. Ejtehadi 1 , Paul N. Nelson 2<br />
1.<br />
Health Sciences, Birmingham City University, Birmingham,<br />
West Midland, United Kingdom. 2. Research Institute in<br />
Healthcare Sciences, University of Wolverhampton,<br />
Wolverhampton, United Kingdom.<br />
125 DYNAMIC, CONTRAST-ENHANCED MAGNETIC RESONANCE<br />
IMAGING OF THE OSTEOARTHRITIC KNEE IN ASSESSMENT<br />
OF RESPONSE TO INTRA-ARTICULAR (IA) CORTICOSTEROID<br />
Claire Wenham 1,2 , Sharon Balamoody 1,3 , Richard Hodgson 1,3 ,<br />
Philip Conaghan 1,2<br />
1.<br />
NIHR Leeds Musculoskeletal Biomedical Research Unit,<br />
University of Leeds, Leeds, United Kingdom. 2. Section of<br />
Musculoskeletal Disease, Chapel Allerton Hospital, Leeds,<br />
United Kingdom. 3. Department of Musculoskeletal Radiology,<br />
Leeds Teaching Hospitals Trust, Leeds, United Kingdom.<br />
126 IDENTIFYING THE KEY TARGETS TO IMPROVE PARTICIPATION<br />
IN OLDER ADULTS WITH LOWER LIMB OSTEOARTHRITIS:<br />
PROSPECTIVE COHORT STUDY<br />
Ross Wilkie 1 , Milisa Blagojevic 1 , Kelvin P. Jordan 1 ,<br />
John Mcbeth 1<br />
1.<br />
Keele University, Keele, United Kingdom.<br />
127 ABSOLUTE QUANTIFICATION OF CARTILAGE MATRIX<br />
PROTEINS<br />
Mandy J. Peffers 1 , Robert J. Beynon 2 , David J. Thornton 3 ,<br />
Peter D. Clegg 1<br />
1.<br />
Institute of Ageing and Chronic Disease, University of<br />
Liverpool, Neston, United Kingdom. 2. Proteomics and<br />
Functional Genomics Group, University of Liverpool, Liverpool,<br />
United Kingdom. 3. Wellcome Trust Centre <strong>for</strong> Cell-Matrix<br />
Research, University of Manchester, Manchester, United<br />
Kingdom.
Wednesday 2 May 2012 | Poster viewing 95<br />
128 ACTIVATION OF PERIPHERAL TRPV1 RECEPTORS INDUCES<br />
SENSITIZATION OF KNEE JOINT NOCICEPTORS<br />
Rebecca Chapman 1,2 , Victoria Chapman 1 , David Walsh 1 ,<br />
Sara Kelly 1,2<br />
1.<br />
Arthritis Research UK Pain Centre, University of Nottingham,<br />
Nottingham, United Kingdom. 2. Biosciences, University of<br />
Nottingham, Sutton Bonington, United Kingdom.<br />
129 PATTERNS OF HIP MIGRATION IN OSTEOARTHRITIS OF<br />
THE HIP<br />
Michelle Hui 1 , Weiya Zhang 1 , Sally Doherty 1 , Frances Rees 1 ,<br />
Kenneth Muir 1 , Rose Maciewicz 2 , Michael Doherty 1<br />
1.<br />
Academic <strong>Rheumatology</strong>, University of Nottingham,<br />
Nottingham, United Kingdom. 2. AstraZeneca, AstraZeneca,<br />
Macclesfield, United Kingdom.<br />
130 DKK3 CAN PREVENT CARTILAGE DEGRADATION AND<br />
REGULATE CHONDROCYTE CELL SIGNALLING<br />
Sarah Snelling 1,2 , Rose K. Davidson 1 , Tracey Swingler 1 ,<br />
Andrew Price 2 , Ian Clark 1<br />
1.<br />
BMRC, <strong>The</strong> University of East Anglia, Norwich, United<br />
Kingdom. 2. NDORMS, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United<br />
Kingdom.<br />
131 SUPRASPINAL CHANGES IN NEURONAL AND GLIAL CELLS<br />
IN ANIMAL MODELS OF OSTEOARTHRITIC PAIN<br />
Elizabeth Stockley 1 , Gareth Hathway 1 , Henryk Faas 2 ,<br />
Dorothee Auer 2 , Victoria Chapman 1<br />
1.<br />
School of Biomedical Science, University of Nottingham,<br />
Nottingham , United Kingdom. 2. Academic Radiology,<br />
University of Nottingham, Nottingham, United Kingdom.<br />
132 PSYCHOLOGICAL FACTORS INCLUDING ILLNESS<br />
PERCEPTIONS MAY PREDICT RESPONSE TO<br />
CORTICOSTEROID INJECTION IN OSTEOARTHRITIS<br />
George Hirsch 1,2 , Elizabeth Hale 1 , George Kitas 1,2 ,<br />
Rainer Klocke 1,2<br />
1.<br />
Clinical Research Unit, Dudley Group NHS FT, Dudley, West<br />
midlands, United Kingdom. 2. Arthritis Research UK Clinical<br />
Epidemiology Unit, University of Manchester, Manchester,<br />
United Kingdom.<br />
133 LIFECOURSE PREDICTORS OF ULTRASOUND FEATURES<br />
OF HIP OSTEOARTHRITIS: THE NEWCASTLE THOUSAND<br />
FAMILIES STUDY<br />
Ajay Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 , Roger M.<br />
Francis 2 , Fraser Birrell 3<br />
1.<br />
Institute of Health and <strong>Society</strong>, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom. 2. Institute <strong>for</strong> Ageing<br />
and Health, Newcastle University, Newcastle upon Tyne,<br />
United Kingdom. 3. Musculoskeletal Research Group, Institute<br />
of Cellular Medicine, Newcastle University, Newcastle upon<br />
Tyne, United Kingdom.<br />
134 PILOT STUDY TO ASSESS THE VALIDITY OF A SIMPLE<br />
ACCELEROMETRIC METHOD TO ASSESS HEEL STRIKE<br />
TRANSIENTS IN PATIENTS WITH MEDIAL KNEE JOINT<br />
OSTEOARTHRITIS<br />
Marian Tucker 1 , Stephen J. Mellon 1 , Luke Jones 1 ,<br />
Andrew J. Price 1 , Paul A. Dieppe 2 , Harinderjit S. Gill 1<br />
1.<br />
NDORMS, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom.<br />
2.<br />
Peninsula College of Medicine & Dentistry, Universities of<br />
Exeter & Plymouth, Exeter, United Kingdom.<br />
135 INCREASED SENSITIVITY TO NERVE GROWTH FACTOR<br />
IN THE MONOSODIUM-IODOACETATE MODEL OF<br />
OSTEOARTHRITIS<br />
Sadaf Ashraf 1 , Victoria Chapman 1 , David A. Walsh 1<br />
1.<br />
Arthritis Research UK Pain Centre, University of Nottingham,<br />
Nottingham, United Kingdom.<br />
Osteoporosis and metabolic bone disease<br />
136 THE IMPACT OF COMPLEX REGIONAL PAIN SYNDROME TYPE<br />
1 ON BONE MINERAL DENSITY<br />
David McCollum 1 , Candy McCabe 2,3 , Sharon Grieve 3 ,<br />
Jacqueline Shipley 4 , Rachel Gorodkin 5<br />
1.<br />
Undergraduate Medicine, University of Manchester,<br />
Manchester, United Kingdom. 2. Faculty of Health and Life<br />
Sciences, University of the West of England, Bristol, United<br />
Kingdom. 3. Bath Centre <strong>for</strong> Pain Services, Royal National<br />
Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom.<br />
4.<br />
Clinical Measurement, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, United Kingdom. 5. Kellgren Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, Manchester Royal Infirmary, Manchester,<br />
United Kingdom.
96 Poster viewing | Wednesday 2 May 2012<br />
137 INCREASING AGE IS ASSOCIATED WITH DECREASED<br />
FEMORAL NECK CROSS-SECTIONAL MOMENT OF INERTIA<br />
IN FEMALES ONLY: A POSSIBLE FACTOR IN AGE AND<br />
SEX-RELATED FRACTURE RISK<br />
Alexander G. Oldroyd 1,2 , Bronwen Evans 2 , Cathi Greenbank 2 ,<br />
Marwan Bukhari 2,3<br />
1.<br />
School of Health and Medicine, Lancaster University,<br />
Lancaster, United Kingdom. 2. <strong>Rheumatology</strong>, Royal Lancaster<br />
Infirmary, Lancaster, United Kingdom. 3. School of Clinical<br />
Sciences, University of Liverpool, Liverpool, United Kingdom.<br />
138 OSTEOPOROSIS SCREENING & MANAGEMENT IN PATIENTS<br />
COMMENCING AROMATASE INHIBITORS FOR BREAST<br />
CANCER<br />
Rizwan Rajak 1 , Cheryl Bennett 1 , Ann Williams 1 ,<br />
James C. Martin 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Glamorgan Hospital, Llantrisant,<br />
United Kingdom.<br />
139 IMPROVING REFERRAL RATE OF VERTEBRAL FRACTURES TO<br />
FRACTURE LIAISON SERVICE: A SERVICE EVALUATION<br />
Rita Abdulkader 1 , Carolyn MacNicol 1 , Karen Brixey 1 ,<br />
Sonya Stephenson 1 , Gavin Clunie 1<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Ipswich Hospital NHS Trust, Ipswich,<br />
United Kingdom.<br />
140 THE ASSOCIATION BETWEEN BREAST CANCER, AROMATASE<br />
INHIBITION THERAPY AND OSTEOPOROSIS<br />
Rebecca N. Andrews 1,2 , Alexander G. Oldroyd 1,2 ,<br />
Bronwen Evans 2 , Cathi Greenbank 2 , Marwan Bukhari 2,3<br />
1.<br />
School of Health and Medicine, Lancaster University,<br />
Lancaster, United Kingdom. 2. <strong>Rheumatology</strong>, Royal Lancaster<br />
Infirmary, Lancaster, United Kingdom. 3. School of Clinical<br />
Sciences, University of Liverpool, Liverpool, United Kingdom.<br />
141 LATERAL DXA SCANNING FOR VERTEBRAL FRACTURE<br />
ASSESSMENT IS MORE USEFUL IN POPULATION-BASED<br />
SETTINGS THAN AS PART OF FRACTURE LIAISON<br />
SERVICES (FLS)<br />
Emma M. Clark 1 , Virginia C. Gould 1 , Louise Carter 2 ,<br />
Leigh Morrison 1 , Jon H. Tobias 1<br />
1.<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United<br />
Kingdom. 2. <strong>Rheumatology</strong>, North Bristol NHS Trust, Bristol,<br />
United Kingdom.<br />
142 ACTIVE VITAMIN D (1,25-DIHYDROXYVITAMIN D) AND BONE<br />
HEALTH IN MIDDLE AGED AND ELDERLY MEN: RESULTS<br />
FROM THE EUROPEAN MALE AGEING STUDY<br />
Stephen R. Pye 1 , Dirk Vanderschueren 2,3 Terence W. O’Neill1,<br />
David M. Lee1, Ivo Jans 3 , Jaak Billen 3 , Evelien Gielen 4 ,<br />
Michael Laurent 4,5 , Frank Claessens 5 , Judith E. Adams 6 ,<br />
Kate A. Ward 7 , Gyorgy Bartfai 8 , Felipe Casanueva 9 ,<br />
Joseph D. Finn 10 , Gianni Forti 11 , Aleksander Giwercman 12 ,<br />
Thang S. Han 13 , Ilpo Huhtaniemi 14 , Krzysztof Kula 15 ,<br />
Michael E. Lean 16 , Neil Pendleton 17 , Margus Punab 18 ,<br />
Frederick C. Wu 10 , Steven Boonen 4<br />
1.<br />
Arthritis Research UK Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. Department of<br />
Andrology and Endocrinology, Katholieke Universiteit Leuven,<br />
Leuven, Belgium. 3. Department of Laboratory Medicine,<br />
Katholieke Universiteit Leuven, Leuven, Belgium. 4. Leuven<br />
University Division of Geriatric Medicine and Centre <strong>for</strong><br />
Metabolic Bone Diseases, Katholieke Universiteit Leuven,<br />
Leuven, Belgium. 5. Department of Molecular Cell Biology,<br />
Katholieke Universiteit Leuven, Leuven, Belgium. 6. Clinical<br />
Radiology, Imaging Science and Biomedical Engineering,<br />
<strong>The</strong> University of Manchester, Manchester, United Kingdom.<br />
7.<br />
MRC Human Nutrition Research, Elsie Widdowson<br />
Laboratory, Cambridge, United Kingdom. 8. Department of<br />
Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy<br />
Medical University, Szeged, Hungary. 9. Department of<br />
Medicine, Santiago de Compostela University, Santiago de<br />
Compostela, Spain. 10. Andrology Research Unit, <strong>The</strong> University<br />
of Manchester, Manchester, United Kingdom. 11. Department<br />
of Clinical Physiopathology, University of Florence, Florence,<br />
Italy. 12. Department of Urology, University of Lund, Malmo,<br />
Sweden. 13. Department of Endocrinology, Royal Free and<br />
University College Hospital Medical School, London, United<br />
Kingdom. 14. Department of Surgery and Cancer, Imperial<br />
College London, London, United Kingdom. 15. Department of<br />
Andrology and Reproductive Endocrinology, Medical University<br />
of Lodz, Lodz, Poland. 16. Department of Human Nutrition,<br />
University of Glasgow, Glasgow, United Kingdom. 17. School of<br />
Community Based Medicine, <strong>The</strong> University of Manchester,<br />
Manchester, United Kingdom. 18. Andrology Unit, United<br />
Laboratories of Tartu University Clinics, Tartu, Estonia.
Wednesday 2 May 2012 | Poster viewing 97<br />
143 MANAGEMENT OF GLUCOCORTICOID INDUCED<br />
OSTEOPOROSIS<br />
Cecilia Mercieca 1 , Jackie Webb 2 , Jacqueline Shipley 2 ,<br />
Ashok Bhalla 2<br />
1.<br />
Academic <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary, Bristol,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom.<br />
144 IS THERE AN ASSOCIATION BETWEEN ADOLESCENT<br />
FEMALES’ SKIN TONE AND BEHAVIOUR WITH RESPECT<br />
TO SUN EXPOSURE?<br />
Sue Fairbanks 1 , Katie E. Moss 2 , Catherine Collins 3 ,<br />
Philip Sedgwick 4<br />
1.<br />
Undergraduate, St George’s Hospital, University of London,<br />
London, United Kingdom. 2. <strong>Rheumatology</strong>, St George’s<br />
Hospital, University of London, London, United Kingdom.<br />
3.<br />
Dietetics, St George’s Hospital, University of London,<br />
London, United Kingdom. 4. Education, St George’s Hospital,<br />
University of London, London, United Kingdom.<br />
145 NHS RADIOGRAPH REPORTS OF VERTEBRAL FRACTURE<br />
COMPARE FAVOURABLY WITH FORMAL STANDARDISED<br />
REPORTING METHODS, BUT SOME NHS REPORTS ARE<br />
UNCLEAR<br />
Emma M. Clark 1 , Virginia C. Gould 1 , Leigh Morrison 1 ,<br />
Jon H. Tobias 1<br />
1.<br />
University of Bristol, Bristol, United Kingdom.<br />
146 INFLUENCE OF ANTI-EPILEPTIC DRUGS ON BONE MIENRAL<br />
DENSITY<br />
Joshua Parker 1 , Cathy Greenbank 1 , Bronwen Evans 1 ,<br />
Alexander G. Oldroyd 1 , Marwan Bukhari 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster, United<br />
Kingdom.<br />
147 FETAL AND INFANT GROWTH PREDICT HIP GEOMETRY AT<br />
SIX YEARS OLD: FINDINGS FROM THE SOUTHAMPTON<br />
WOMEN’S SURVEY<br />
Nicholas C. Harvey 1 , Zoe A. Cole 1 , Sarah R. Crozier 1 , Georgia<br />
Ntani 1 , Pam A. Mahon 1 , Sian M. Robinson 1 , Hazel M. Inskip 1 ,<br />
Keith M. Godfrey 1,2 , Elaine M. Dennison 1 , Cyrus Cooper 1<br />
1.<br />
MRC Lifecourse Epidemiology Unit, University of<br />
Southampton, Southampton, United Kingdom.<br />
2.<br />
Southampton NIHR Nutrition, Diet and Lifestyle Biomedical<br />
Research Unit, University of Southampton, Southampton,<br />
United Kingdom.<br />
148 FRAX/NOGG HAS LOW SENSITIVITY IN PREDICTING WRIST<br />
FRACTURES IN POST-MENOPAUSAL WOMEN<br />
Matthew Bridges 1 , Sheila Ruddick 1<br />
1.<br />
<strong>Rheumatology</strong>, Darlington Memorial Hospital, Darlington,<br />
United Kingdom.<br />
149 PLACENTAL SIZE PREDICTS OFFSPRING BONE MASS:<br />
FINDINGS FROM THE SOUTHAMPTON WOMEN’S SURVEY<br />
Christopher R. Holroyd 1 , Pam Mahon 1 , Sarah R. Crozier 1 ,<br />
Keith Godfrey 1 , Hazel M. Inskip 1 , Cyrus Cooper 1,2 ,<br />
Nicholas C. Harvey 1<br />
1.<br />
MRC Lifecourse Epidemiology Unit, University of<br />
Southampton, Southampton, Hampshire, United Kingdom.<br />
2.<br />
NIHR Musculoskeletal Biomedical Research unit, Institute of<br />
Musculoskeletal Sciences, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>dshire, United Kingdom.<br />
150 MODIFYING FRAX / NOGG GUIDELINES IN RHEUMATOLOGY<br />
PATIENTS RECIEVING CORTICOSTEROIDS: DOES IT MAKE<br />
ANY DIFFERENCE?<br />
Matthew Bridges 1 , Sheila Ruddick 1<br />
1.<br />
<strong>Rheumatology</strong>, Darlington Memorial Hospital, Darlington,<br />
United Kingdom.<br />
151 TERIPARATIDE IN DAILY PRACTICE: THE BELFAST<br />
EXPERIENCE<br />
Thomas McNeilly 1 , Collette McNally 1 , Tim Beringer 2 ,<br />
Michael Finch 1<br />
1.<br />
Musgrave Park Hospital, Belfast HSCT, Belfast, Northern<br />
Ireland, United Kingdom. 2. Royal Victoria Hospital, Belfast<br />
HSCT, Belfast, Northern Ireland, United Kingdom.<br />
Paediatric and adolescent rheumatology<br />
152 PRE-FORMED ORTHOSES IN JUVENILE IDIOPATHIC<br />
ARTHRITIS: RESULTS FROM AN RCT<br />
Andrea Coda 1 , Joyce Davidson 2 , Jo Walsh 2 , Peter Fowlie 3 ,<br />
Tom Carline 1 , Derek Santos 1<br />
1.<br />
Podiatry, Queen Margaret University, Edinburgh, United<br />
Kingdom. 2. Paediatric <strong>Rheumatology</strong>, Royal Hospital <strong>for</strong> Sick<br />
Children, Edinburgh, United Kingdom. 3. Paediatric<br />
<strong>Rheumatology</strong>, Ninewells Hospital, Edinburgh, United Kingdom.
98 Poster viewing | Wednesday 2 May 2012<br />
153 COMPARISON OF METHOTREXATE INDUCED NAUSEA AND<br />
VOMITING BETWEEN ADOLESCENT AND ADULT PATIENTS<br />
WITH INFLAMMATORY ARTHRITIS<br />
Pravin Patil 1 , Christine Rawcliffe 2 , Abigail Olaleye 2 ,<br />
Samantha Moore 2 , Amy Fox 2 , Debajit Sen 2 , Yiannis Ioannou 2<br />
1.<br />
<strong>Rheumatology</strong>, Southend University Hospital, Southend,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, University College London<br />
Hospital, London, United Kingdom.<br />
154 OSTEOSARCOMA CELL CULTURE ON COLLAGEN SURFACES<br />
AND IN HYPOXIA ALTERS MMP EXPRESSION<br />
Sohail Nisar 1 , Kenneth Rankin 1 , Mark Birch 1<br />
1.<br />
University of Newcastle upon Tyne, Musculoskeletal Research<br />
Group, Institute of Cellular Medicine, Newcastle upon Tyne,<br />
United Kingdom.<br />
155 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN<br />
JUVENILE IDIOPATHIC ARTHRITIS<br />
Sorcha Finnegan 1 , Madeleine Rooney 1 , David S. Gibson 1<br />
1.<br />
Centre <strong>for</strong> Infection and Immunity, Queen’s University,<br />
Belfast, Belfast, United Kingdom.<br />
156 EXPLORING THE RELATIONSHIPS BETWEEN ADULT JUVENILE<br />
IDIOPATHIC ARTHRITIS AND EMPLOYMENT<br />
Ajay Malviya 1 , Calum M. Ferris 2 , Stephen P. Rushton 3 ,<br />
Helen E. Foster 4 , Helen Hanson 4 , Karthik Muthumayandi 4 ,<br />
David J. Deehan 4<br />
1.<br />
Wansbeck General Hospital, Northumbria Healthcare NHS<br />
Foundation Trust, Ashington, United Kingdom. 2. Medical<br />
School, Newcastle University, Newcastle upon Tyne, United<br />
Kingdom. 3. School of Biology, Newcastle University, Newcastle<br />
upon Tyne, United Kingdom. 4. Freeman Hospital, <strong>The</strong><br />
Newcastle upon Tyne Hospitals NHS Foundation Trust,<br />
Newcastle upon Tyne, United Kingdom.<br />
157 UNDERSTANDING THE CHILD AND PARENT’S PERSPECTIVES<br />
ON MULTIDISCIPLINARY INTERVENTIONS FOR BENIGN JOINT<br />
HYPERMOBILITY SYNDROME<br />
Linda Birt 1 , Fiona Poland 1 , Alexander MacGregor 3 ,<br />
Kate Armon 3 , Michael Pfeil 2<br />
1.<br />
School of Allied Health Professions, University of East Anglia,<br />
Norwich, United Kingdom. 2. School of Nursing Sciences,<br />
University of East Anglia, Norwich, United Kingdom.<br />
3.<br />
Department of <strong>Rheumatology</strong> , Norfolk and Norwich<br />
University Hospitals NHS Foundation Trust, Norwich, United<br />
Kingdom.<br />
158 DOES EXCLUSION OF THE ESR FROM JADAS AFFECT<br />
VALIDITY IN THE ROUTINE CLINICAL SETTING?<br />
Flora McErlane 1,2 , Michael W. Beres<strong>for</strong>d 2,3 ,<br />
Eileen M. Baildam 3 , Wendy Thomson 1 , Kimme Hyrich 1 ,<br />
Alice Chieng 7 , Joyce Davidson 6 , Helen E. Foster 5 ,<br />
Janet Gardner-Medwin 6 , Mark Lunt 1 , Lucy Wedderburn 4<br />
1.<br />
School of Translational Medicine, University of Manchester,<br />
Manchester, United Kingdom. 2. Institute of Child Health,<br />
University of Liverpool, Liverpool, United Kingdom. 3. Paediatric<br />
<strong>Rheumatology</strong>, Alder Hey Children’s Hospital, Liverpool, United<br />
Kingdom. 4. <strong>Rheumatology</strong> Unit, Institute of Child Health,<br />
London, United Kingdom. 5. <strong>Rheumatology</strong>, Newcastle Medical<br />
School, Newcastle, United Kingdom. 6. <strong>Rheumatology</strong>, Royal<br />
Hospital <strong>for</strong> Sick Children, Glasgow, United Kingdom.<br />
7.<br />
<strong>Rheumatology</strong>, Royal Manchester Children’s Hospital,<br />
Manchester, United Kingdom.<br />
159 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED<br />
IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK OF<br />
DISEASE EXTENSION<br />
David S. Gibson 1,2 , Sorcha Finnegan 1 , Keri Newell 2 ,<br />
Alexandra Evans 2 , Gwen Manning 3 , Caitriona Scaife 3 ,<br />
Catherine McAllister 1 , Stephen R. Pennington3,<br />
Mark Duncan 2,4 , Terry Moore 5 , Madeleine Rooney 1<br />
1.<br />
Arthritis Research Group, Queen’s University Belfast, Belfast,<br />
County Anrtim, United Kingdom. 2. Division of Endocrinology,<br />
Metabolism and Diabetes, University of Colorado, Denver, CO,<br />
United States. 3. Proteome Research Centre, University<br />
College Dublin, Dublin, Ireland. 4. Obesity Research Center,<br />
King Saud University, Riyadh, Saudi Arabia. 5. Division of Adult<br />
and Pediatric <strong>Rheumatology</strong>, Saint Louis University, St. Louis,<br />
MO, United States.<br />
160 A NOVEL ASSAY FOR DETECTING NITRATED NUCLEOSOMES:<br />
A POTENTIAL SURROGATE BIOMARKER FOR JUVENILE<br />
ONSET SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Charis Pericleous 1,3 , Sara C. Croca 1 , Ian Giles 1 , Karim Alber 1 ,<br />
Harry Yong 1 , David Isenberg 1 , Angela Midgely 2 ,<br />
Michael W. Beres<strong>for</strong>d 2 , Anisur Rahman 1 , Yiannis Ioannou 1,3<br />
1.<br />
Adolescent <strong>Rheumatology</strong>, UCL, London, United Kingdom.<br />
2.<br />
Paediatric <strong>Rheumatology</strong>, Alder Hey Children’s NHS<br />
Foundation Trust Hospital, Liverpool, United Kingdom.<br />
3.<br />
Paediatric <strong>Rheumatology</strong>, Institute of Child Health, London,<br />
United Kingdom.
Wednesday 2 May 2012 | Poster viewing 99<br />
Primary Care<br />
161 THE COURSE OF COMORBID ANXIETY SYMPTOMS IN<br />
PATIENTS PRESENTING TO GENERAL PRACTICE WITH<br />
SYMPTOMATIC OSTEOARTHRITIS (OA): LATENT CLASS<br />
GROWTH ANALYSIS<br />
Magdalena Rzewuska 1 , Christian Mallen 1 , Vicky Y. Strauss 1 ,<br />
John Belcher 1 , George Peat 1<br />
1.<br />
Arthritis Research UK Primary Care Centre, Primary Care<br />
Sciences, Keele University, Keele, United Kingdom.<br />
162 PRIMARY CARE ATTITUDES TO METHOTREXATE MONITORING<br />
Rachel Byng-Maddick 1 , Madhavi Wijendra 1 , Henry Penn 1<br />
1.<br />
<strong>Rheumatology</strong>, Northwick Park Hospital, London,<br />
United Kingdom.<br />
163 THE ASSOCIATION OF GOUT WITH SLEEP DISORDERS AND<br />
SLEEP APNOEA: A CROSS-SECTIONAL EPIDEMIOLOGICAL<br />
STUDY IN PRIMARY CARE<br />
Edward Roddy 1 , Sara Muller 1 , Richard Hayward 1 ,<br />
Christian Mallen 1<br />
1.<br />
Arthritis Research UK Primary Care Centre, Keele University,<br />
Stoke-on-Trent, United Kingdom.<br />
164 ABSTRACT WITHDRAWN<br />
165 MANAGEMENT OF GOUT IN A PRIMARY CARE PRACTICE<br />
Fawzi Kamlow 1 , Angela Pakozdi 2 , Ali Jawad 2<br />
1.<br />
General Practice, <strong>The</strong> Burnham Surgery,<br />
Burnham-on-Crouch, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
Barts and the London NHS Trust, London, United Kingdom.<br />
166 FATIGUE AS A PRECURSOR TO POLYMYALGIA RHEUMATICA<br />
(PMR): A RETROSPECTIVE COHORT STUDY<br />
Daniel J. Green 1 , Sara Muller 1 , Christian Mallen 1 ,<br />
Sam L. Hider 1<br />
1.<br />
Primary Care Sciences, Arthritis Research UK Primary Care<br />
Centre, Keele University, Staf<strong>for</strong>dshire, United Kingdom.<br />
Psychology, measurement and management of pain<br />
168 DEVELOPMENT AND EVALUATION OF A COMPUTER<br />
GRAPHICS APPLICATION FOR COMMUNICATING BODY<br />
PERCEPTION IN PATIENTS WITH COMPLEX REGIONAL<br />
PAIN SYNDROME<br />
Ailie Turton 1 , Mark Palmer 2 , Sharon Grieve 3 , Jenny Lewis 3 ,<br />
Tim Moss 1 , Candy McCabe 1,3<br />
1.<br />
Faculty of Health and Life Sciences, University of the West<br />
of England, Bristol, Bristol, United Kingdom. 2. Faculty of<br />
Environment and Technology, University of the West of<br />
England, Bristol, United Kingdom. 3. Bath Centre <strong>for</strong> Pain<br />
Services, Royal National Hospital <strong>for</strong> Rheumatic Diseases,<br />
Bath, United Kingdom.<br />
169 AN INVESTIGATION OF PSYCHOLOGICAL CHARACTERISTICS<br />
LINKED TO PHYSICAL ACTIVITY AND SLEEP IN RHEUMATOID<br />
ARTHRITIS<br />
Claire E. Goodchild 1 , Nicole Tang 2,1 , David Scott 3 ,<br />
Paul Salkovskis 4,1<br />
1.<br />
Psychology, Institute of Psychiatry, King’s College London,<br />
London, United Kingdom. 2. Arthritis Research UK Primary<br />
Care Centre, Keele University, Keele , United Kingdom.<br />
3.<br />
Academic Department of <strong>Rheumatology</strong>, <strong>The</strong> medical School,<br />
King’s College London, London, United Kingdom.<br />
4.<br />
Psychology, University of Bath, Bath, United Kingdom.<br />
170 GOOD SLEEP HYGIENE MAY IMPROVE PAIN IN<br />
INFLAMMATORY ARTHRITIS<br />
Shilpa Selvan 1 , Lyn Williamson 1<br />
1.<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon,<br />
United Kingdom.<br />
171 A MIND MAP FOR SLEEP FOR ARTHRITIS PATIENTS<br />
Shilpa Selvan 1 , Lyn Williamson 1<br />
1.<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon,<br />
United Kingdom.<br />
167 COMMUNITY-BASED JOINT INJECTION CLINIC<br />
Sarabjit Singh Bawa 2 , Sandeep Bawa 1<br />
1.<br />
Dept of <strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow,<br />
United Kingdom. 2. Surgery, Glenboig, Lanarkshire, Scotland,<br />
United Kingdom.
100 Poster viewing | Wednesday 2 May 2012<br />
172 THE EFFECT OF VITAMIN D LEVELS ON THE ASSESSMENT<br />
OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND THE<br />
COMPONENTS OF THE DISEASE ACTIVITY SCORE<br />
Nishanthi Thalayasingam 1,2 , Matthew Higgins 3,2 ,<br />
Vadivelu Saravanan 2 , Martin Rynne 2 , Jennifer D. Hamilton 2 ,<br />
Carol Heycock 2 , Clive Kelly 2<br />
1.<br />
Northern Deanery, Newcastle, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead, United<br />
Kingdom. 3. Medical School, Newcastle University, Newcastle<br />
upon Tyne, United Kingdom.<br />
173 THE SYNCHRONOUS RELATIONSHIP BETWEEN SOMATIC<br />
SYMPTOMS AND PSYCHOLOGICAL DISTRESS IN EARLY<br />
RHEUMATOID ARTHRITIS: FINDINGS FROM A PROSPECTIVE<br />
OBSERVATIONAL STUDY<br />
Sam Norton 1 , Amanda Sacker 4 , John Done 2 , Adam Young 3<br />
1.<br />
Institute of Public Health, University of Cambridge,<br />
Cambridge, United Kingdom. 2. School of Psychology,<br />
University of Hert<strong>for</strong>dshire, Hatfield, United Kingdom.<br />
3.<br />
<strong>Rheumatology</strong> Department, City Hospital, St Albans, United<br />
Kingdom. 4. Institute <strong>for</strong> Social & Economic Research,<br />
University of Essex, Colchester, United Kingdom.<br />
Rheumatoid arthritis: treatment<br />
174 TREATING RHEUMATOID ARTHRITIS TO TARGET: OUTCOMES<br />
AND PREDICTORS IN EARLY RHEUMATOID ARTHRITIS<br />
PATIENTS TREATED WITH ADALIMUMAB PLUS<br />
METHOTREXATE, METHOTREXATE ALONE, OR<br />
METHOTREXATE PLUS SUBSEQUENT ADALIMUMAB<br />
Josef S. Smolen 1 , Roy M. Fleischmann 2 , Paul Emery 3 ,<br />
Ronald F. van Vollenhoven 4 , Benoît Guérette 5 ,<br />
Sourav Santra 6 , Hartmut Kupper 7 , Laura Redden 6 ,<br />
Arthur Kavanaugh 8<br />
1.<br />
Department of <strong>Rheumatology</strong>, Medical University of Vienna<br />
and Hietzing Hospital, Vienna, Austria. 2. Department of<br />
Medicine, University of Texas-Southwestern, Dallas, TX, United<br />
States. 3. Department of <strong>Rheumatology</strong>, Leeds Teaching<br />
Hospital, Leeds, United Kingdom. 4. Department of<br />
<strong>Rheumatology</strong>, <strong>The</strong> Karolinska Institute, Stockholm, Sweden.<br />
5.<br />
GPRD, Abbott, Rungis, France. 6. GPRD, Abbott, Abbott Park,<br />
IL, United States. 7. GPRD, Abbott GmbH & Co, Ludwigshafen,<br />
Germany. 8. Department of <strong>Rheumatology</strong>, University of<br />
Cali<strong>for</strong>nia at San Diego, La Jolla, CA, United States.<br />
175 INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS<br />
METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES<br />
IN PATIENTS WITH ADVANCED RHEUMATOID ARTHRITIS:<br />
ANALYSIS OF THE FINAL 10-YEAR RESULTS OF AN<br />
OPEN-LABEL EXTENSION OF A PHASE 3 TRAIL<br />
Edward C. Keystone 1 , Desiree Van de Heide 2 ,<br />
Michael E. Weinblatt 3 , Neelufar Mozaffarian 4 ,<br />
Benoît Guérette 5 , Hartmut Kupper 6 , Shufang Liu 4 ,<br />
Arthur Kavanaugh 7<br />
1.<br />
Department of Medicine, University of Toronto, Toronto, ON,<br />
Canada. 2. Department of <strong>Rheumatology</strong>, Leiden University<br />
Medical Center, Leiden, Netherlands. 3. Division of<br />
<strong>Rheumatology</strong>, Immunology and Allergy , Brigham and<br />
Women’s Hospital, Boston, MA, United States. 4. GPRD,<br />
Abbott, Abbott Park, IL, United States. 5. GPRD, Abbott,<br />
Rungis, France. 6. GPRD, Abbott GmbH & Co KG,<br />
Ludwigshafen, Germany. 7. Department of <strong>Rheumatology</strong>,<br />
University of Cali<strong>for</strong>nia at San Diego, La Jolla, CA, United<br />
States.<br />
176 DOES METHOTREXATE INCREASE THE RISK OF VARICELLA<br />
OR HERPES ZOSTER INFECTION IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS? A SYSTEMATIC LITERATURE<br />
REVIEW<br />
Natalie Zhang 2 , Sarah Wilkinson 2 , Mehmmod Riaz 2 ,<br />
Andrew J. Ostor 1 , Muhammad K. Nisar 1<br />
1.<br />
<strong>Rheumatology</strong>, Addenbrookes Hospital, Cambridge,<br />
United Kingdom. 2. School of Clinical Medicine, University<br />
of Cambridge, Cambridge, United Kingdom.<br />
177 SAFETY AND EFFECTIVENESS OF ADALIMUMAB IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS DURING MORE THAN 5<br />
YEARS OF THERAPY OBSERVED IN A PHASE 3B AND<br />
POST-MARKETING OBSERVATIONAL STUDY<br />
G. Burmester 1 , X. Mariette 2 , F. Navarro-Blasco 3 , U. Oezer 4 ,<br />
S. Kary 4 , K. Unnebrink 4 , H. Kupper 4<br />
1.<br />
<strong>Rheumatology</strong> and Clinical Immunology, Charité - University<br />
Medicine, Berlin, Germany. 2. Department of <strong>Rheumatology</strong>,<br />
Université Paris-Sud Hôpital Bicêtre, Le Kremlin Bicêtre,<br />
France. 3. Department of <strong>Rheumatology</strong>, Hospital General,<br />
Universitario de Elche, Alicante, Spain. 4. GPRD, Abbott GmbH<br />
& Co KG, Ludwigshafen, Germany.
Wednesday 2 May 2012 | Poster viewing 101<br />
178 RANDOMISED EFFICACY AND DISCONTINUATION STUDY OF<br />
ETANERCEPT VS ADALIMUMAB (RED SEA): A PRAGMATIC,<br />
OPEN-LABEL, NON-INFERIORITY STUDY OF FIRST TNF<br />
INHIBITOR USE IN RHEUMATOID ARTHRITIS: 1-YEAR DATA<br />
Paresh Jobanputra 1,2 , Fiona Maggs 1 , Alison Deeming 3 ,<br />
David Carruthers 3 , Elizabeth Rankin 1,2 , Alison Jordan 1,2 ,<br />
Abdul Faizal 4 , Carolyn Goddard 5 , Mark Pugh 5 ,<br />
Simon Bowman 1,2 , Sue Brails<strong>for</strong>d 1 , Peter Nightingale 6<br />
1.<br />
Department of <strong>Rheumatology</strong>, Queen Elizabeth Hospital<br />
Birmingham, Birmingham, West Midlands, United Kingdom.<br />
2.<br />
Infection & Immunity, University of Birmingham, Birmingham,<br />
West Midlands, United Kingdom. 3. Department of<br />
<strong>Rheumatology</strong>, City Hospital, Sandwell and West Birmingham<br />
Hospitals NHS Trust, Birmingham, West Midlands, United<br />
Kingdom. 4. Department of <strong>Rheumatology</strong>, Solihull Hospital,<br />
Heart of England NHS Foundation Trust, Solihull, West<br />
Midlands, United Kingdom. 5. Department of <strong>Rheumatology</strong>,<br />
St Mary’s Hospital, Newport, Isle of Wight, United Kingdom.<br />
6.<br />
Wellcome Trust Clinical Research Facility, Queen Elizabeth<br />
Hospital Birmingham, Birmingham, West Midlands, United<br />
Kingdom.<br />
179 METHOTREXATE THERAPY, RHEUMATOID ARTHRITIS AND<br />
LIFE-THREATENING LIVER COMPLICATIONS: SHOULD WE BE<br />
MONITORING MORE CLOSELY?<br />
Nicola Tugnet 1 , Sheldon C. Cooper 2 , Karen M. Douglas 3<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Royal Wolverhampton Hospitals NHS<br />
Trust, Wolverhampton, United Kingdom. 2. Gastroenterology,<br />
Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom.<br />
3.<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley,<br />
United Kingdom.<br />
180 LEFLUNOMIDE-ASSOCIATED SEVERE DYSLIPIDAEMIA IN A<br />
RHEUMATOID ARTHRITIS PATIENT<br />
Chong Seng Edwin Lim 1 , Samantha Bee Lian Low 2 ,<br />
Clayton Joy 1 , Lynne Hill 1 , Paul Davies 1<br />
1.<br />
<strong>Rheumatology</strong>, Broomfield Hospital, MEHT, Chelms<strong>for</strong>d,<br />
Essex , United Kingdom. 2. General Medicine, Queens<br />
Hospital, BHRUT, Rom<strong>for</strong>d, Essex, United Kingdom.<br />
181 TIGHT CONTROL OF RHEUMATOID ARTHRITIS (RA) IN<br />
PRACTICE AT A DISTRICT GENERAL HOSPITAL (DGH)<br />
THROUGH MONTHLY REVIEW AT NO ADDITIONAL COST<br />
Sandeep Mukherjee 1 , Patricia Cornell 1 , Sarah L. Westlake 1 ,<br />
Selwyn Richards 1 , Fouz Rahmeh 1 , Paul W. Thompson 1<br />
1.<br />
<strong>Rheumatology</strong>, Poole Hospital NHS Foundation Trust,<br />
Poole, Dorset, United Kingdom.<br />
182 INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS<br />
METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES<br />
THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH<br />
EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN<br />
OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL<br />
Ferdinand Breedveld 1 , Edward Keystone 2 ,<br />
Desiree Van de Heide 1 , Robert Landewé 3 , Josef S. Smolen 4 ,<br />
Benoît Guérette 5 , Melissa McIlraith 5 , Hartmut Kupper 6 ,<br />
Shufang Liu 7 , Arthur Kavanaugh 8<br />
1.<br />
Department of <strong>Rheumatology</strong>, Leiden University Medical<br />
Center, Leiden, Netherlands. 2. Department of <strong>Rheumatology</strong>,<br />
University of Toronto, Toronto, ON, Canada. 3. Department of<br />
<strong>Rheumatology</strong>, Academic Medical Center, Amsterdam,<br />
Netherlands. 4. Department of <strong>Rheumatology</strong>, Medical<br />
University of Vienna, Vienna, Austria. 5. GPRD, Abbott, Rungis,<br />
France. 6. GPRD, Abbott GmbH & Co KG, Ludwigshafen,<br />
Germany. 7. Abbott, Abbott Park, IL, United States.<br />
8.<br />
Department of <strong>Rheumatology</strong>, University of Cali<strong>for</strong>nia at<br />
San Diego, La Jolla, CA, United States.<br />
183 CASE SERIES OF TUBERCULOSIS IN ANTI-TNF THERAPY<br />
Rachel Byng-Maddick 1 , Henry Penn 1<br />
1.<br />
<strong>Rheumatology</strong>, Northwick Park Hospital, Harrow, United<br />
Kingdom.<br />
184 LATE ONSET NEUTROPAENIA IN RHEUMATOID ARTHRITIS<br />
TREATED WITH B-CELL DEPLETION<br />
Rita Abdulkader 1 , Chethana Dharmapalaiah 1 , L. Shand 1 ,<br />
Ginny Rose 1 , Gavin Clunie 1 , Richard Watts 1<br />
1.<br />
<strong>Rheumatology</strong> Department, <strong>The</strong> Ipswich hospital NHS Trust,<br />
Ipswich, United Kingdom.<br />
185 ARE PATIENTS WITH LONG-STANDING RHEUMATOID<br />
ARTHRITIS TREATED-TO-TARGET? AN AUDIT OF FOLLOW-UP<br />
PATIENTS IN RHEUMATOLOGY CLINIC<br />
Amr Eldashan 1 , Bhaskar Dasgupta 1 , Frances A. Borg 1<br />
1.<br />
<strong>Rheumatology</strong>, Southend Hospital, Westcliff-on-Sea, Essex,<br />
United Kingdom.
102 Poster viewing | Wednesday 2 May 2012<br />
186 AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS IN<br />
RHEUMATOID ARTHRITIS<br />
Gillian M. Bell 1,2 , Amy E. Anderson 1 , Rachel A. Harry 1 ,<br />
Jeroen N. Stoop 1 , Catharien M. Hilkens 1 , John Isaacs 1,2 ,<br />
Anne Dickinson 3 , Elaine McColl 4<br />
1.<br />
Musculoskeletal Research Group, Newcastle University,<br />
Newcastle upon Tyne, Tyne and Wear, United Kingdom.<br />
2.<br />
Musculoskeletal Unit, Freeman Hospital, Newcastle upon<br />
Tyne, Tyne and Wear, United Kingdom. 3. Haematological<br />
Sciences, Newcastle University, Newcastle upon Tyne, Tyne<br />
and Wear, United Kingdom. 4. Clinical Trials Unit, Newcastle<br />
University, Newcastle upon Tyne, Tyne and Wear, United<br />
Kingdom.<br />
187 TUBERCULOSIS PROPHYLAXIS BEFORE ANTI-TNF-α:<br />
BTS V T SPOT<br />
Snehashish Banik 1 , Lorna Smith 2 , Janice France 1 ,<br />
Sandeep Bawa 1<br />
1.<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United<br />
Kingdom. 2. School of Medicine, Glasgow University, Glasgow,<br />
United Kingdom.<br />
188 THE EVALUATION OF MUSCULOSKELETAL ULTRASOUND IN<br />
THE MANAGEMENT OF INFLAMMATORY ARTHRITIS<br />
Andrew Ruther<strong>for</strong>d 1 , Ann Scott Russell 3 , Jacqueline Smith 4 ,<br />
Imad Jassim 1 , Robin Withrington 4 , Pauline Bacon 2 ,<br />
Denise De Lord 1<br />
1.<br />
<strong>Rheumatology</strong>, QEQM Hospital, EKHUFT, Margate, United<br />
Kingdom. 2. Medical Physics, EKHUFT, Canterbury, United<br />
Kingdom. 3. <strong>Rheumatology</strong>, William Harvey Hospital, EKHUFT,<br />
Ash<strong>for</strong>d, United Kingdom. 4. <strong>Rheumatology</strong>, Kent & Canterbury<br />
hospital, EKHUFT, Canterbury, United Kingdom.<br />
189 TRIPLE THERAPY IN EARLY ACTIVE RHEUMATOID ARTHRITIS:<br />
5 YEAR FOLLOW UP<br />
Laura McGregor 1 , Islay Morrison 1 , Anne Stirling 2 ,<br />
Duncan R. Porter 2 , Sarah A. Saunders 1<br />
1.<br />
Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary,<br />
Glasgow, United Kingdom. 2. <strong>Rheumatology</strong> Department,<br />
Gartnavel General Hospital, Glasgow, United Kingdom.<br />
190 AUDIT OF SAFETY AND EFFICACY OF COMBINATION<br />
METHOTREXATE AND LEFLUNOMIDE IN EARLY ARTHRITIS<br />
USING AN ESCALATION STRATEGY<br />
Sara Else 1 , Olga Semenova 1 , Helen Thompson 1 ,<br />
Olabambo Ogunbambi 1 , Sathish Kallankara 1 , Elaine Baguley 1 ,<br />
Yusuf Patel 1,2<br />
1.<br />
<strong>Rheumatology</strong>, Hull Royal Infirmary, Hull, United Kingdom.<br />
2.<br />
Senior Lecturer, Hull York Medical School, Hull, United<br />
Kingdom.<br />
191 INCOMPLETE RESPONSE OF INFLAMMATORY ARTHRITIS TO<br />
TNFα BLOCKADE IS ASSOCIATED WITH THE TH17 PATHWAY<br />
Saba Alzabin 1 , Sonya Abraham 2 , Taher E. Taher 3 ,<br />
Andrew Palfeeman 1 , Dobrina Hull 1 , Kay McNamee 1 ,<br />
Ali Jawad 3 , Ejaz Pathan 1 , Anne Kinderlerer 4 , Peter Taylor 1 ,<br />
Richard O. Williams 1 , Rizgar A. Mageed 3<br />
1.<br />
Kennedy Institute of <strong>Rheumatology</strong>, University of Ox<strong>for</strong>d,<br />
London, United Kingdom. 2. Division of Immunology and<br />
Inflammation, Imperial College London, London, United<br />
Kingdom. 3. William Harvey Research Institute, Queen Mary<br />
University of London, London, United Kingdom. 4. St Mary’s<br />
Hospital, Imperial College NHS trust, London, United Kingdom.<br />
192 EFFECTS OF DIFFERENT NONBIOLOGICAL<br />
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)<br />
ON RADIOGRAPHIC PROGRESSION OF RHEUMATOID<br />
ARTHRITIS (RA) DEPENDING ON DISEASE DURATION<br />
(RESULTS OF 2 YEARS OF MONITORING)<br />
Oleg Iaremenko 1 , Ganna Mikitenko 1<br />
1.<br />
Department of Internal Medicine, National Medical University<br />
named O.O.Bogomolets, Kyiv, Ukraine.<br />
193 DEVELOPMENT OF A NOVEL RECOMBINANT<br />
BIOTHERAPEUTIC WITH APPLICATIONS IN TARGETED<br />
THERAPY OF HUMAN ARTHRITIS<br />
Mathieu Ferrari 1 , Tahereh Kamalati 1 , Costantino Pitzalis 1<br />
1.<br />
Experimental Medicine and <strong>Rheumatology</strong>, Queen Mary<br />
University of London, London, United Kingdom.
Wednesday 2 May 2012 | Poster viewing 103<br />
194 TO WHAT EXTENT IS THE NICE GUIDANCE ON THE<br />
MANAGEMENT OF RHEUMATOID ARTHRITIS IN ADULTS<br />
BEING IMPLEMENTED? - REGIONAL AUDIT OF THE<br />
MIDLANDS<br />
Nicola Tugnet 1 , Fiona Pearce 2 , Sofia Tosounidou 3 ,<br />
Karen Obrenovic 4 , Nicola Erb 4 , Jonathan Packham 5 ,<br />
Ravinder Sandhu 4<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Royal Wolverhampton Hospitals NHS<br />
Trust, Wolverhampton, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
Nottingham University Hospitals NHS Trust, Nottingham,<br />
United Kingdom. 3. <strong>Rheumatology</strong>, Sandwell and West<br />
Birmingham Hospitals NHS Trust, Birmingham, United<br />
Kingdom. 4. <strong>Rheumatology</strong>, Dudley Group NHS Foundation<br />
Trust, Dudley, United Kingdom. 5. <strong>Rheumatology</strong>, University<br />
Hospital of North Staf<strong>for</strong>dshire NHS Trust, Stoke, United<br />
Kingdom.<br />
195 IMMUNOGLOBULIN MONITORING IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB<br />
Catherine White 1 , Caroline M. Cardy 1 , Elizabeth Justice 1 ,<br />
Madeline Frank 1 , Lisa Li 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Queen Elizabeth Hospital<br />
Birmingham, Birmingham, United Kingdom.<br />
196 METHOTREXATE MONITORING - INITIAL EXPERIENCE WITH<br />
TRANSIENT ELASTOGRAPHY (FIBROSCAN)<br />
Mark Lloyd 1 , Ayesha Ahmed 2 , Samantha Readhead 2 ,<br />
Aftab Ala 2<br />
1.<br />
<strong>Rheumatology</strong>, Frimley Park Hospital, Frimley, United<br />
Kingdom. 2. Hepatology, Frimley Park Hospital, Frimley,<br />
United Kingdom.<br />
197 AN AUDIT OF HEPATITIS B SEROLOGY IN PATIENTS<br />
RECEIVING TNF-α BLOCKADE AND THE UNCERTAIN ROLE OF<br />
PROPHYLACTIC THERAPY IN THOSE WITH EVIDENCE OF<br />
PAST INFECTION<br />
Matthew Fittall 1 , Jessica Manson 1 , Yiannis Ioannou 1<br />
1.<br />
<strong>Rheumatology</strong>, UCLH, London, none, United Kingdom.<br />
198 ABATACEPT CONFERS CLINICAL EFFICACY REGARDLESS OF<br />
BASELINE CRP STATUS IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE<br />
IN THE AIM TRIAL<br />
Jean Sibilia 1 , René Marc Flipo 2 , Bernard Combe 3 ,<br />
Corine Gaillez 4 , Manuela Le Bars 4 , Coralie Poncet 5 ,<br />
Ayanbola Elegbe 6 , Rene Westhovens 7<br />
1.<br />
Department of <strong>Rheumatology</strong>, Louis Pasteur University,<br />
Strasbourg, France. 2. Department of <strong>Rheumatology</strong>, Centre<br />
Hospitalier Universitaire de France, Lille, France.<br />
3.<br />
Immuno-<strong>Rheumatology</strong>, Hôpital Lapeyronie, Montpellier,<br />
France. 4. Medical Affairs, Bristol-Myers Squibb,<br />
Rueil-Malmaison, France. 5. Department of Biostatistics, Docs<br />
International, Sèvres, France. 6. Global Biometric Sciences,<br />
Bristol-Myers Squibb, Princeton, NJ, United States.<br />
7.<br />
Department of <strong>Rheumatology</strong>, UZ Gasthuisberg, Leuven,<br />
Belgium.<br />
199 WHAT IS THE ROLE OF SUBCUTANEOUS METHOTREXATE IN<br />
THE TREATMENT OF RHEUMATOID ARTHRITIS?<br />
Roya Hassanzadeh 2 , Clodagh Mangan 2 , Janice France 1 ,<br />
Sandeep Bawa 1<br />
1.<br />
Dept of <strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow,<br />
United Kingdom. 2. School of Medicine, Glasgow University,<br />
Glasgow, United Kingdom.<br />
200 CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE<br />
RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE<br />
FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE<br />
REALISTIC PHASE IIIB RANDOMISED CONTROLLED STUDY<br />
M. E. Weinblatt 1 , R. Fleischmann 2 , R. van Vollenhoven 3 ,<br />
P. Emery 4 , T. W. J.Huizinga 5 , R. Goldermann 6 , B. Duncan 7 ,<br />
J. Timoshanko 8 , K. Luijtens 9 , O. Davies 9 , M. Dougados 10<br />
1.<br />
Brigham and Women’s Hospital, Boston, MA, United States.<br />
2.<br />
MCRC, University of Texas, Dallas, TX, United States.<br />
3.<br />
Karolinska Institute, Stockholm, Sweden. 4. University of<br />
Leeds, Leeds, United Kingdom. 5. Leiden University Medical<br />
Centre, Leiden, Netherlands. 6. UCB Pharma, Monheim,<br />
Germany. 7. UCB Pharma, Raleigh, NC, United States. 8. UCB<br />
Pharma, Slough, United Kingdom. 9. UCB Pharma, Brussels,<br />
Belgium. 10. René Descartes University, Paris, France.
104 Poster viewing | Wednesday 2 May 2012<br />
201 RHEUMATOID ARTHRITIS AND PHYSIOTHERAPY: A NATIONAL<br />
SURVEY CONDUCTED BY THE NATIONAL RHEUMATOID<br />
ARTHRITIS SOCIETY AND THE CHARTERED SOCIETY OF<br />
PHYSIOTHERAPY<br />
Jamie Hewitt 1<br />
1.<br />
National Rheumatoid Arthritis <strong>Society</strong>, Maidenhead,<br />
Berkshire, United Kingdom.<br />
202 BED-TIME SINGLE DOSE PREDNISOLONE IN CLINICALLY<br />
STABLE RHEUMATOID ARTHRITIS PATIENTS<br />
Mohammadbagher Owlia 1<br />
1.<br />
Medicine, Shahid Sadoughi University of Medical Sciences,<br />
Yazd, Iran, Islamic Republic of.<br />
203 CLINICAL EFFICACY OF ABATACEPT AND INFLIXIMAB IN<br />
COMBINATION WITH METHOTREXATE ACCORDING TO<br />
BASELINE RHEUMATOID FACTOR STATUS IN THE<br />
ATTEST TRIAL<br />
Maxime Dougados 1 , Corine Gaillez 2 , Manuela Le Bars 2 ,<br />
Coralie Poncet 3 , Ayanbola Elegbe 4 , Michael Schiff 5<br />
1.<br />
Department of <strong>Rheumatology</strong>, Hôpital Cochin, Descartes<br />
University, Paris, France. 2. Medical Affairs, Bristol-Myers<br />
Squibb, Rueil-Malmaison, France. 3. Department of<br />
Biostatistics, Docs International, Sèvres, France. 4. Global<br />
Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ,<br />
United States. 5. Department of <strong>Rheumatology</strong>, University of<br />
Colorado, Denver, CO, United States.<br />
204 SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT<br />
FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF<br />
EXPOSURE<br />
Rieke Alten 1 , Jeffrey L. Kaine 2 , Edward Keystone 3 ,<br />
Peter T. Nash 4 , Ingrid Delaet 5 , Keqin Qi 6 , Mark C. Genovese 7<br />
1.<br />
<strong>Rheumatology</strong> Department, Schlossparkklinik, Berlin, Germany.<br />
2. <strong>Rheumatology</strong>, Sarasota Arthritis Center, Sarasota,<br />
FL, United States. 3. Rebecca MacDonald Centre <strong>for</strong> Arthritis<br />
and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON,<br />
Canada. 4. <strong>Rheumatology</strong> Research Unit, University of<br />
Queensland, Brisbane, QLD, Australia. 5. Global Clinical<br />
Research Immunology, Bristol-Myers Squibb, Princeton, NJ,<br />
United States. 6. Global Biometric Sciences, Bristol-Myers<br />
Squibb, Princeton, NJ, United States. 7. Division of<br />
Immunology and <strong>Rheumatology</strong>, Stan<strong>for</strong>d University Medical<br />
Center, Palo Alto, CA, United States.<br />
205 DISEASE ACTIVITY SCORE (DAS) RESPONSE TO ANTI-TNF IN<br />
RA PATIENTS<br />
Judith Clark 1 , Sally Kardash 1 , Ernest Wong 1 , Richard Hull 1 ,<br />
Fiona McCrae 1 , Ragai Shaban 1 , Lynn Thomas 1 ,<br />
Steven Young-Min 1 , Joanna Ledingham 1<br />
1.<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital,<br />
Portsmouth, United Kingdom.<br />
206 SUBCUTANEOUS ABATACEPT (ABA) VERSUS INTRAVENOUS<br />
ABA IN PATIENTS (PTS) WITH RA: LONG-TERM DATA FROM<br />
THE ACQUIRE TRIAL<br />
Mark C. Genovese 1 , Arturo Covarrubias Cobos 2 ,<br />
Gustavo Leon 3 , Eduardo F. Mysler 4 , Mauro W. Keiserman 5 ,<br />
Robert M. Valente 6 , Peter T. Nash 7 ,<br />
J. Abraham Simon Campos 8 , Wieslawa Porawska 9 ,<br />
Jane H. Box 10 , Clarence W. Legerton III 11 ,<br />
Evgeny L. Nasonov 12 , Patrick Durez 13 , Ramesh Pappu 14 ,<br />
Ingrid Delaet 14 , Julie Teng 14 , Rieke Alten 15<br />
1.<br />
Division of Immunology and <strong>Rheumatology</strong>, Stan<strong>for</strong>d<br />
University Medical Center, Palo Alto, CA, United States.<br />
2.<br />
<strong>Rheumatology</strong>, Medical Center of the Americas, Mérida,<br />
Mexico. 3. <strong>Rheumatology</strong>, Instituto De Ginecologia Y Reproduccion,<br />
Lima, Peru. 4. Department of <strong>Rheumatology</strong>,<br />
Organizacion Medica de Investigación, Buenos Aires,<br />
Argentina. 5. Internal Medicine Department - <strong>Rheumatology</strong><br />
Section, Pontiphycial Catholic University, Porto Alegre, Brazil.<br />
6.<br />
<strong>Rheumatology</strong>, Arthritis Center of Nebraska, Lincoln, NE,<br />
United States. 7. <strong>Rheumatology</strong> Research Unit, University of<br />
Queensland, Brisbane, QLD, Australia. 8. <strong>Rheumatology</strong>,<br />
Centro De Especialidades Médicas, Mérida, Mexico.<br />
9.<br />
Novamed, Poznañski Ooerodek Medyczny, Poznan, Poland.<br />
10.<br />
Box Arthritis & <strong>Rheumatology</strong> of the Carolinas, Dark Road,<br />
Charlotte, NC, United States. 11. Low Country <strong>Rheumatology</strong>,<br />
2860 Tricom St, Charleston, SC, United States. 12. Institute of<br />
<strong>Rheumatology</strong>, Russian Academy of Medical Sciences,<br />
Moscow, Russian Federation. 13. Department of <strong>Rheumatology</strong><br />
Saint-Luc, Université Catholique de Louvain, Brussels,<br />
Belgium. 14. Global Clinical Research Immunology,<br />
Bristol-Myers Squibb, Princeton, NJ, United States.<br />
15.<br />
<strong>Rheumatology</strong> Department, Schlossparkklinik, Berlin,<br />
Germany.
Wednesday 2 May 2012 | Poster viewing 105<br />
207 REGIONAL DIFFERENCES IN THE TREATMENT OF<br />
RHEUMATOID ARTHRITIS IN THE UK<br />
Christopher J. Edwards 1 , Nigel Arden 2,3 , Jennifer Campbell 4 ,<br />
Tjeerd van Staa 4 , Claire Housden 5 , Ify Sargeant 6<br />
1.<br />
Department of <strong>Rheumatology</strong>, University Hospital<br />
Southampton NHS Foundation Trust, Southampton, United<br />
Kingdom. 2. Nuffield Department of Orthopaedics,<br />
<strong>Rheumatology</strong> and Musculoskeletal Sciences, University of<br />
Ox<strong>for</strong>d , Ox<strong>for</strong>d, United Kingdom. 3. University of Southampton,<br />
University Hospital Southampton NHS Foundation Trust,<br />
Southampton, United Kingdom. 4. <strong>The</strong> General Practice<br />
Research Database, Medicines and Healthcare Products<br />
Regulatory Agency, London, United Kingdom. 5. NHS Life<br />
Sciences Innovation Delivery Unit and NHS National<br />
Programmes, Roche Products Ltd, Welwyn Garden City,<br />
United Kingdom. 6. Communications, ismedica Ltd, Wrinehill,<br />
United Kingdom.<br />
208 TEMPORAL TRENDS IN THE TREATMENT OF RHEUMATOID<br />
ARTHRITIS IN THE UK WITH REFERENCE TO BEST PRACTICE<br />
Christopher J. Edwards 1 , Nigel Arden 2,3 , Jennifer Campbell 4 ,<br />
Tjeerd van Staa 4 , Claire Housden 5 , Ify Sargeant 6<br />
1.<br />
Department of <strong>Rheumatology</strong>, University Hospital<br />
Southampton NHS Foundation Trust, Southampton, United<br />
Kingdom. 2. Nuffield Department of Orthopaedics,<br />
<strong>Rheumatology</strong> and Musculoskeletal Sciences, University of<br />
Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom. 3. University of Southampton,<br />
University Hospital Southampton NHS Foundation Trust,<br />
Southampton, United Kingdom. 4. <strong>The</strong> General Practice<br />
Research Database, Medicines and Healthcare Products<br />
Regulatory Agency, London, United Kingdom. 5. NHS Life<br />
Sciences Innovation Delivery Unit and NHS National<br />
Programmes, Roche Products Ltd, Welwyn Garden City,<br />
United Kingdom. 6. Communications, ismedica Ltd, Wrinehill,<br />
United Kingdom.<br />
209 VARIATION IN THE USE OF BIOLOGICS IN THE MANAGEMENT<br />
OF RHEUMATOID ARTHRITIS (RA) ACROSS THE UNITED<br />
KINGDOM<br />
Ernest Choy 1 , Sandra McAuliffe 2 , Kirsty Roberts 3 , Ify Sargeant 4<br />
1.<br />
Section of <strong>Rheumatology</strong>, Department of Medicine, Cardiff<br />
University School of Medicine , Cardiff, United Kingdom.<br />
2.<br />
Consultancy, McAuliffe Interim Options Ltd, Ox<strong>for</strong>dshire,<br />
United Kingdom. 3. Market Insight and Analysis Group, Roche<br />
Products Ltd, Welwyn Garden City, United Kingdom.<br />
4.<br />
Communications, ismedica Ltd, Wrinehill, United Kingdom.<br />
210 RELATIVE EFFICACY OF RITUXIMAB VERSUS AN<br />
ALTERNATIVE TNF INHIBITOR IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE<br />
TO A SINGLE PREVIOUS TNF INHIBITOR: INTERIM RESULTS<br />
FROM SWITCH-RA, A GLOBAL, COMPARATIVE-<br />
EFFECTIVENESS, OBSERVATIONAL STUDY<br />
Paul Emery 1,2 , Piercarlo Sarzi-Puttini 3 , Robert J. Moots 4 ,<br />
Alexandros Andrianakos 5 , Thomas P. Sheeran 6 ,<br />
Denis Choquette 7 , Axel Finckh 8 , Marie-Laetitia Desjuzeur 9 ,<br />
Eric K. Gemmen 10 , Chiedzo Mpofu 9 , Jacques-Eric Gottenberg 11<br />
1.<br />
Division of Musculoskeletal Disease, Leeds Institute of<br />
Molecular Medicine, University of Leeds, Leeds, United<br />
Kingdom. 2. NIHR Leeds Musculoskeletal Biomedical<br />
Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds,<br />
United Kingdom. 3. <strong>Rheumatology</strong> Unit, L Sacco University<br />
Hospital, Milano, Italy. 4. Clinical Sciences Centre, University of<br />
Liverpool, Liverpool, United Kingdom. 5. Hellenic Foundation<br />
<strong>for</strong> Rheumatological Research, Athens, Greece.<br />
6.<br />
<strong>Rheumatology</strong> Department, Cannock Chase Hospital,<br />
Cannock, United Kingdom. 7. <strong>Rheumatology</strong> Department,<br />
University of Montreal, Notre-dame Hospital, Montreal, QC,<br />
Canada. 8. Department of Medical Specialties (DSM), Division<br />
of <strong>Rheumatology</strong>, University Hospital of Geneva, Geneva,<br />
Switzerland. 9. F Hoffmann-La Roche Ltd, Basel, Switzerland.<br />
10.<br />
Quintiles Inc, Rockville, MD, United States. 11. Department<br />
of <strong>Rheumatology</strong>, CHU Strasbourg, Strasbourg, France.<br />
211 COMMISSIONER QUALITY METRICS IN RHEUMATOID<br />
ARTHRITIS: IMPACT ON CLINICAL PRACTICE AND QUALITY<br />
OF CARE<br />
Marwan Bukhari 1,2 , Preeti Shah 5 , George Kitas 4 , Maureen<br />
Cox 7 , Alan Nye 6 , Anne O’Brien 8 , Peter Jones 3 , Ify Sargeant 9<br />
1.<br />
<strong>Rheumatology</strong> Department, University Hospitals of<br />
Morecambe Bay NHS Foundation Trust, Royal Lancaster<br />
Infirmary, Lancaster, United Kingdom. 2. Clinical Sciences,<br />
University of Liverpool, Liverpool, United Kingdom. 3. Statistics,<br />
Keele University, Keele, United Kingdom. 4. <strong>Rheumatology</strong>,<br />
Dudley group of hospitals NHS trust, Dudley, United Kingdom.<br />
5.<br />
<strong>Rheumatology</strong>, Traf<strong>for</strong>d General Hospital, Traf<strong>for</strong>d, United<br />
Kingdom. 6. <strong>Rheumatology</strong>, Pennine MSK partnership,<br />
Oldham, United Kingdom. 7. <strong>Rheumatology</strong>, Nuffield<br />
Orthopaedic centre, Ox<strong>for</strong>d, United Kingdom. 8. School of<br />
Health and Rehabilitation, Keele University, Keele, United<br />
Kingdom. 9. Communications, ismedica Ltd, Wrinehill,<br />
United Kingdom.
106 Poster viewing | Wednesday 2 May 2012<br />
212 THE EFFECTIVENESS OF PRACTITIONER-BASED<br />
COMPLEMENTARY AND ALTERNATIVE THERAPIES IN THE<br />
MANAGEMENT OF RHEUMATOID ARTHRITIS<br />
Gareth T. Jones 1 , Priya Paudyal 1,2 , Hugh MacPherson 3 ,<br />
Julius Sim 4 , Mike Doherty 5 , Edzard Ernst 2 , Margaret Fisken 1 ,<br />
George Lewith 6 , Jane Tadman 7 , Gary J. Macfarlane 1<br />
1.<br />
Aberdeen Musculoskeletal Research Group (Epidemiology),<br />
University of Aberdeen, Aberdeen, United Kingdom.<br />
2.<br />
Peninsula College of Medicine & Dentistry, Universities of<br />
Exeter and Plymouth, Plymouth, United Kingdom.<br />
3.<br />
Department of Health Sciences, University of York, York,<br />
United Kingdom. 4. School of Health and Rehabilitation, Keele<br />
University, Keele, United Kingdom. 5. Arthritis Research UK<br />
Pain Centre, University of Nottingham, Nottingham, United<br />
Kingdom. 6. Community Clinical Sciences, University of<br />
Southampton, Southampton, United Kingdom. 7. Press Office,<br />
Arthritis Research UK, Chesterfield, United Kingdom.<br />
213 POOLED ANALYSIS OF THE RISK OF SERIOUS INFECTIONS<br />
AND OPPORTUNISTIC INFECTIONS IN CLINICAL TRIALS OF<br />
CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS<br />
X. Mariette 1 , P. Bertin 2 , C. Arendt 3 , I. Terpstra 4 , B. VanLunen 5 ,<br />
M. de Longueville 6<br />
1.<br />
Service de Rhumatologie, Université Paris-Sud, Hôpital<br />
Bicêtre, Le Kremlin-Bicêtre Paris, France. 2. Service de<br />
Rhumatologie, C.H.U. Dupuytren, Limoges, France. 3. Clinical<br />
Development, UCB Pharma, Brussels, Belgium. 4. GCSP Drug<br />
Safety, UCB Pharma, Brussels, Belgium. 5. Global Biostatistics,<br />
UCB BioSciences Inc, Research Triangle Par, NC, United<br />
States. 6. Global Medical Affairs, UCB Pharma, Brussels,<br />
Belgium.<br />
214 KEY PHARMACOLOGICAL PARAMETERS SUPPORT MONTHLY<br />
DOSING FOR GOLIMUMAB<br />
Honghui Zhou 1 , Ann Cai 1 , Eilyn Lacy 1 , Jonathan Kay 2 ,<br />
Ed Keystone 3 , Eric Matteson 4 , Chuanpu Hu 1 , Elizabeth Hsia 1,5 ,<br />
Mittie Doyle 1,5 , Mahboob Rahman 1 , David Shealy 1<br />
1.<br />
Immunology, Janssen Research & Development, Inc,<br />
Malvern, PA, United States. 2. <strong>Rheumatology</strong> Center, UMass<br />
Memorial Medical Center, Worcester, MA, United States.<br />
3.<br />
<strong>Rheumatology</strong>, University of Toronto, Toronto, ON, Canada.<br />
4.<br />
<strong>Rheumatology</strong>, Mayo Clinic, Rochester, ON, Canada.<br />
5.<br />
<strong>Rheumatology</strong>, University of Pennsylvania School of<br />
Medicine, Philadelphia, PA, United States.<br />
215 COMBINATION ANTI-RHEUMATIC DRUGS IN EARLY<br />
RHEUMATOID ARTHRITIS: COMPARISON OF FINDINGS IN<br />
TWO RANDOMISED CONTROLLED TRIALS<br />
David L. Scott 1 , Fowzia Ibrahim 1 , Hanan Abozaid 1 ,<br />
Ernest Choy 1 , Andrew Hassell 2 , Michael Plant 3 ,<br />
Selwyn Richards 4 , David Walker 5 , Gemma Simpson 1 ,<br />
Anna Kowalczyk 1<br />
1.<br />
<strong>Rheumatology</strong>, King’s College London, London, United<br />
Kingdom. 2. <strong>Rheumatology</strong>, Haywood Hospital, Stoke On Trent,<br />
United Kingdom. 3. <strong>Rheumatology</strong>, James Cook University<br />
Hospital, Middlesbrough, United Kingdom. 4. <strong>Rheumatology</strong>,<br />
Poole Hospital, Poole, United Kingdom. 5. <strong>Rheumatology</strong>,<br />
Freeman Hospital, Newcastle Upon Tyne, United Kingdom.<br />
216 COMPLIANCE WITH NICE CLINICAL GUIDELINE 79 IN THE<br />
MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS<br />
IN 5 NHS TRUSTS IN ENGLAND<br />
Peter Prouse 1 , Andrew Brown 2 , Mano George 3 ,<br />
Namita Kumar 4 , Kirsten Mackay 5 , Samantha Marshall 6<br />
1.<br />
Department of <strong>Rheumatology</strong>, Basingstoke and North<br />
Hampshire NHS Foundation Trust, Basingstoke, United<br />
Kingdom. 2. Department of <strong>Rheumatology</strong>, York Teaching<br />
Hospital NHS Foundation Trust, York, United Kingdom.<br />
3.<br />
Department of <strong>Rheumatology</strong>, Wirral University Teaching<br />
Hospital NHS Foundation Trust, Wirral, United Kingdom.<br />
4.<br />
Department of <strong>Rheumatology</strong>, County Durham and<br />
Darlington NHS Foundation Trust , Durham, United Kingdom.<br />
5.<br />
Department of <strong>Rheumatology</strong>, South Devon Healthcare NHS<br />
Foundation Trust, Torbay, United Kingdom. 6. pH Associates,<br />
Marlow, United Kingdom.<br />
217 EFFICACY, SAFETY AND PHARMACOKINETICS OF<br />
SUBCUTANEOUS ABATACEPT IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS, WITH OR WITHOUT AN<br />
INTRAVENOUS (IV) LOADING DOSE<br />
Peter T. Nash 1 , Charles L. Ludivico 2 , Ingrid Delaet 3 , Keqin Qi 4 ,<br />
Bindu Murthy 3 , Michael Corbo 5 , Jeffrey L. Kaine 6<br />
1.<br />
<strong>Rheumatology</strong> Research Unit, University of Queensland,<br />
Brisbane, QLD, Australia. 2. <strong>Rheumatology</strong>, East Penn<br />
<strong>Rheumatology</strong> Associates, Bethlehem, PA, United States.<br />
3.<br />
Global Clinical Research Immunology, Bristol-Myers Squibb,<br />
Princeton, NJ, United States. 4. Global Biometric Sciences,<br />
Bristol-Myers Squibb, Princeton, NJ, United States. 5. Global<br />
Clinical Research, Bristol-Myers Squibb (at time of study),<br />
Princeton, NJ, United States. 6. <strong>Rheumatology</strong>, Sarasota<br />
Arthritis Center, Sarasota, FL, United States.
Wednesday 2 May 2012 | Poster viewing 107<br />
218 EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL AFTER<br />
INCOMPLETE RESPONSE TO DMARDS IN RHEUMATOID<br />
ARTHRITIS PATIENTS WITH LOW MODERATE DISEASE<br />
ACTIVITY: RESULTS FROM CERTAIN, A PHASE IIIB STUDY<br />
Paul Emery 1 , Josef S. Smolen 2 , W. Samborski 3 ,<br />
F. Berenbaum 4 , Owen Davies 5 , J. Ambrugeat 5 , B. Bennett 6 ,<br />
H. Burkhardt 7<br />
1.<br />
Academic Unit of Musculoskeletal Disease, University of<br />
Leeds, Leeds, United Kingdom. 2. Divisions of <strong>Rheumatology</strong><br />
and Medicine , Medical University of Vienna and Hietzing<br />
Hospital, Vienna, Austria. 3. Department of <strong>Rheumatology</strong>, K.<br />
Marcinkowski University of Medical Sciences, Poznan, Poland.<br />
4.<br />
Department of <strong>Rheumatology</strong>, AP-HP St -Antoine Hospital,<br />
Paris, France. 5. UCB, UCB Pharma, Brussels, Belgium.<br />
6.<br />
UCB, UCB Pharma, Smyrna, GA, United States. 7. Division of<br />
<strong>Rheumatology</strong>, Johan Wolfgang Goethe University, Frankfurt<br />
am Main, Germany.<br />
219 COMPLIANCE WITH NICE TECHNOLOGY APPRAISALS TA130<br />
AND TA186 IN THE USE OF TNF-α INHIBITOR THERAPY IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS IN 5 NHS TRUSTS<br />
IN ENGLAND<br />
Peter Prouse 1 , Andrew Brown 2 , Mano George 3 ,<br />
Namita Kumar 4 , Kirsten Mackay 5 , Samantha Marshall 6<br />
1.<br />
Department of <strong>Rheumatology</strong>, Basingstoke and North<br />
Hampshire NHS Foundation Trust, Basingstoke, United<br />
Kingdom. 2. Department of <strong>Rheumatology</strong>, York Teaching<br />
Hospital NHS Foundation Trust , York, United Kingdom.<br />
3.<br />
Department of <strong>Rheumatology</strong>, Wirral University Teaching<br />
Hospital NHS Foundation Trust, Wirral, United Kingdom.<br />
4.<br />
Department of <strong>Rheumatology</strong>, County Durham and<br />
Darlington NHS Foundation Trust , Durham, United Kingdom.<br />
5.<br />
Department of <strong>Rheumatology</strong>, South Devon Healthcare NHS<br />
Foundation Trust, Torbay, United Kingdom. 6. pH Associates,<br />
Marlow, United Kingdom.<br />
220 TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON<br />
DISEASE-MODIFYING DRUGS IN RHEUMATOID ARTHRITIS<br />
PATIENTS WITH INADEQUATE RESPONSE TO PREVIOUS<br />
TREATMENTS<br />
Vivian Bykerk 1 , Andrew J. Ostor 2 , José Román Ivorra 3 ,<br />
Jurgen Wollenhaupt 4 , Andrea Stancati 5 , Corrado Bernasconi 5 ,<br />
Jean Sibilia 6<br />
1.<br />
<strong>Rheumatology</strong>, Brigham & Women’s Hospital, Boston, MA,<br />
United States. 2. <strong>Rheumatology</strong>, University of Cambridge,<br />
Cambridge, United Kingdom. 3. <strong>Rheumatology</strong>, Hospital<br />
Universitario La Fe, Valencia, Spain. 4. <strong>Rheumatology</strong>, Schön<br />
Klinik, Hamburg, Germany. 5. Roche, Roche, Basel,<br />
Switzerland. 6. <strong>Rheumatology</strong>, CHU Hautepierre, Strasbourg,<br />
France.<br />
221 A RETROSPECTIVE STUDY OF THE EFFECTS OF SWITCHING<br />
FROM ORAL TO SUBCUTANEOUS (SC) METHOTREXATE<br />
(MTX): THE METHOTREXATE EVALUATION OF NORWICH<br />
TREATMENT OUTCOMES IN RA (MENTOR) STUDY<br />
David G I. Scott 1 , Pearl Claydon 1 , Corrinne Ellis 1 , Scot Buchan 2<br />
1.<br />
<strong>Rheumatology</strong>, Norfolk and Norwich University Hospital,<br />
Norwich, Norfolk, United Kingdom. 2. Strategen Ltd,<br />
Basingstoke, Hampshire, United Kingdom.<br />
222 RAPID REDUCTIONS IN FATIGUE AND SLEEP PROBLEMS<br />
AND CORRELATION WITH IMPROVEMENTS IN PATIENT-<br />
REPORTED OUTCOMES IN PATIENTS WITH ACTIVE RA<br />
TREATED WITH CERTOLIZUMAB PEGOL IN THE REALISTIC<br />
12-WEEK PHASE IIIB RANDOMISED CONTROLLED STUDY<br />
Janet Pope 1 , Roy Fleischmann 2 , Maxime Dougados 3 ,<br />
Clifton O. Bingham 4 , Elena M. Massarotti 5 , J. Wollenhaupt 6 ,<br />
B. Duncan 7 , Geoffroy Coteur 8 , Michael Weinblatt 5<br />
1.<br />
Division of <strong>Rheumatology</strong>, University of Western Ontario,<br />
London, ON, Canada. 2. MCRC, University of Texas, Dallas, TX,<br />
United States. 3. Department of <strong>Rheumatology</strong>, René<br />
Descartes University, Paris, France. 4. Divisions of<br />
<strong>Rheumatology</strong> and Allergy, Johns Hopkins University,<br />
Baltimore, MD, United States. 5. Division of <strong>Rheumatology</strong>,<br />
Brigham and Women’s Hospital, Boston, MA, United States.<br />
6.<br />
Department of <strong>Rheumatology</strong>, Klinikum Eilbek, Hamburg,<br />
Germany. 7. UCB, UCB Pharma, Raleigh, NC, United States.<br />
8. UCB, UCB Pharma, Brussels, Belgium.<br />
223 ANTI-TNF THERAPY IMPROVES HAND FUNCTION IN<br />
RHEUMATOID ARTHRITIS WITHIN 3 MONTHS<br />
Dobrina Hull 1 , Catherine Ball 1 , Sonya Abraham 2<br />
1.<br />
Kennedy Institute of <strong>Rheumatology</strong>, University of Ox<strong>for</strong>d,<br />
London, United Kingdom. 2. Department of Medicine, Imperial<br />
College, London, United Kingdom.
108 Poster viewing | Wednesday 2 May 2012<br />
224 A NEW APPROACH WITHIN PERSUASIVE DESIGN THEORY<br />
TO IMPROVE PATIENT ENGAGEMENT WITH EXERCISE<br />
THERAPIES<br />
Tom Ainsworth 1 , Jyri Kermik 1 , Jonathan Woodham 1 , Inam Haq 2<br />
1.<br />
Faculty of Arts and Architecture, University of Brighton,<br />
Brighton, Sussex, United Kingdom. 2. Brighton and Sussex<br />
Medical School, Falmer, Sussex, United Kingdom.<br />
225 EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE: TWO<br />
YEARS’ EXPERIENCE<br />
Estefania Quesada-Masachs 1 , Ana Carolina Diaz 1 ,<br />
Gabriela Avila 1 , Isabel Acosta 1 , Xavier Sans 1 , Cayetano Alegre 1 ,<br />
Sara Marsal 1<br />
1.<br />
<strong>Rheumatology</strong>, Hospital Universitari Vall d’Hebron,<br />
Barcelona, Spain.<br />
226 PREDICTING WHICH PATIENTS WITH EARLY RA WILL CHANGE<br />
DMARD DURING THE FIRST 2 YEARS: THE ERAN COHORT<br />
Dan McWilliams 1 , Patrick D. Kiely 3 , Adam Young 2 ,<br />
David A. Walsh 1,4<br />
1.<br />
Arthritis UK Pain Centre, University of Nottingham,<br />
Nottingham, United Kingdom. 2. <strong>Rheumatology</strong>, West<br />
Hert<strong>for</strong>dshire Hospitals NHS Trust, St Albans, United Kingdom.<br />
3.<br />
<strong>Rheumatology</strong>, St Georges Healthcare NHS Trust, London,<br />
United Kingdom. 4. <strong>Rheumatology</strong>, Sherwood Forest Hospitals<br />
NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom.<br />
227 IMPROVED QUALITY OF LIFE AND PRODUCTIVITY IN<br />
PATIENTS WITH MODERATE OR SEVERE RHEUMATOID<br />
ARTHRITIS ACTIVELY SWITCHED TO TREATMENT WITH<br />
INFLIXIMAB FROM ADALIMUMAB OR ETANERCEPT THERAPY<br />
Roy Fleischmann 1 , Rebecca Bolce 2 , Jianping Wang 3 ,<br />
Mike Ingham 2 , Ralph Dehoratius 2 , Dennis Decktor 2<br />
1.<br />
Metroplex Clinical Research Center, University of<br />
Texas/Southwestern Medical Center, Dallas, TX, United States.<br />
2.<br />
Medical Affairs, Janssen Services, LLC, Dallas, TX, United<br />
States. 3. Bio Programming , Johnson & Johnson<br />
Pharmaceutical Research and Development, LLC, Belle Mead,<br />
NJ, United States.<br />
228 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR<br />
(CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA)<br />
PATIENTS (PTS) TREATED WITH TOCILIZUMAB (TCZ)<br />
Vijay Rao 1,2 , Andrey Pavlov 3 , Micki Klearman 1 ,<br />
Dave Musselman 4 , Jon Giles 5 , Joan Bathon 5 , Naveed Sattar 6 ,<br />
Janet Lee 4<br />
1.<br />
Genentech, Genentech, South San Francisco, CA, United<br />
States. 2. Division of Cardiology, UCSF, San Francisco, CA,<br />
United States. 3. Everest, Everest, Toronto, ON, Canada.<br />
4.<br />
Roche, Roche, Nutley, NJ, United States. 5. Division of<br />
<strong>Rheumatology</strong>, Columbia University, New York, NY, United<br />
States. 6. <strong>Rheumatology</strong>, University of Glasgow, Glasgow,<br />
United Kingdom.<br />
229 A PROSPECTIVE SURVEY OF TOCILIZUMAB USE IN<br />
SCOTLAND; IMPLICATIONS FOR DAILY PRACTICE<br />
Derek Baxter 1 , John S. McLaren 2 , Margaret-Mary Gordon 3 ,<br />
Kyaw Z. Thant 4<br />
1.<br />
Department of <strong>Rheumatology</strong>, Southern General Hospital ,<br />
Glasgow, United Kingdom. 2. Fife Rheumatic Diseases Unit,<br />
Whyteman’s Brae Hospital , Kirkcaldy, United Kingdom.<br />
3.<br />
Department of <strong>Rheumatology</strong>, Gartnavel General Hospital ,<br />
United Kingdom. 4. Department of Medicine, Wishaw General<br />
Hospital, 5. Netherton Street, Glasgow, United Kingdom.<br />
230 USE OF INTRAMUSCULAR DEPOMEDRONE IN<br />
INFLAMMATORY ARTHRITIS-DOES OBESITY INFLUENCE<br />
RESPONSE TO INJECTION?<br />
Emma L. Williams 1 , Susannah Earl 3 , Paula White 2 ,<br />
Julie Williams 2 , Sarah L. Westlake 4 , Joanna Ledingham 2<br />
1.<br />
Bone & Joint Research Group, University of Southampton<br />
Medical School, Southampton, Hampshire, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital,<br />
Portsmouth, Hampshire, United Kingdom. 3. <strong>Rheumatology</strong><br />
Department, Royal Devon & Exeter NHS Foundation Trust,<br />
Won<strong>for</strong>d, Devon, United Kingdom. 4. <strong>Rheumatology</strong> Department,<br />
Poole Hospital NHS Foundation Trust, Poole, Dorset,<br />
United Kingdom.<br />
Soft tissue and regional musculoskeletal disease,<br />
fibromyalgia<br />
231 SERUM 25-HYDROXY VITAMIN D LEVELS IN PATIENTS WITH<br />
FIBROMYALGIA<br />
Adnan K. Jan 1 , Azher I. Bhatti 1 , Catriona Staf<strong>for</strong>d 1 ,<br />
Martina Carolan 1 , Sekharipuram A. Ramakrishnan 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Our Lady’s Hospital, Navan,<br />
Co. Meath, Ireland.
Poster viewing:<br />
Thursday 3 May 2012<br />
Poster viewing<br />
Thu 3 May 2012
Poster viewing: Thursday 3 May 2012<br />
Thursday 3 May 2012 | Poster viewing 109<br />
Basic Science<br />
232 CERTOLIZUMAB PEGOL PREVENTS PRO-INFLAMMATORY<br />
ALTERATIONS IN ENDOTHELIAL CELL FUNCTION<br />
Sarah Heathfield 1,2 , Ben Parker 1,2 , Leo Zeef 3 , Ian Bruce 2 ,<br />
Yvonne Alexander 1<br />
1.<br />
Cardiovascular Research Group, University of Manchester,<br />
Manchester, United Kingdom. 2. Arthritis Research UK<br />
Epidemiology Unit, University of Manchester, Manchester,<br />
United Kingdom. 3. Wellcome Trust Centre <strong>for</strong> Cell-Matrix<br />
Research, University of Manchester, Manchester, United<br />
Kingdom.<br />
233 DEATH RECEPTOR 3 AND TL1A: A DRIVING FORCE IN<br />
OSTEOCLAST DIFFERENTIATION AND POTENTIAL TARGET<br />
FOR RHEUMATOID ARTHRITIS THERAPY<br />
Fraser Collins 1 , Michael Stone 2 , Edward Wang 1 ,<br />
Anwen S. Williams 1<br />
1.<br />
Institute of Infection and Immunity, School of Medicine,<br />
Cardiff University, Cardiff, United Kingdom. 2. Geriatric<br />
Medicine Department, Llandough Hospital, Cardiff, United<br />
Kingdom.<br />
234 DISCOVERING CYTOKINE-SPECIFIC GENE EXPRESSION<br />
PROFILES IN INFLAMMATORY NEUTROPHILS USING<br />
WHOLE TRANSCRIPTOME SEQUENCING<br />
Helen L. Wright 1 , Huw B. Thomas 1 , Robert J. Moots 2 ,<br />
Steven W. Edwards 1<br />
1.<br />
Institute of Integrative Biology, University of Liverpool,<br />
Liverpool, United Kingdom. 2. Institute of Ageing and Chronic<br />
Disease, University of Liverpool, Liverpool, United Kingdom.<br />
Don’t <strong>for</strong>get<br />
to sign up <strong>for</strong><br />
poster tours!<br />
235 BLOCKADE OF CALCITONIN GENE-RELATED PEPTIDE<br />
RECEPTORS BY CGRP27-37 INHIBITS RESPONSES OF<br />
KNEE JOINT PRIMARY AFFERENTS IN THE MIA MODEL OF<br />
OSTEOARTHRITIS<br />
Craig Bullock 1,2 , Victoria Chapman 1,3 , David A. Walsh 1,4 ,<br />
Ali Mobasheri 5 , David Kendall 3 , Sara Kelly 1,2<br />
1.<br />
Arthritis Research UK Pain Centre, University of Nottingham,<br />
Nottingham, United Kingdom. 2. School of Biosciences,<br />
University of Nottingham, Nottingham, United Kingdom.<br />
3.<br />
School of Biomedical Sciences, University of Nottingham,<br />
Nottingham, United Kingdom. 4. School of Clinical Sciences,<br />
University of Nottingham, Nottingham, United Kingdom.<br />
5.<br />
School of Veterinary Medicine and Science, University of<br />
Nottingham, Nottingham, United Kingdom.<br />
236 THE EFFECTS OF ACUTE EXPOSURE TO CIGARETTE SMOKE<br />
EXTRACT ON T CELL RECEPTOR SIGNALLING<br />
Rachel Bayley 1 , Chris D. Buckley 1 , Stephen P. Young 1<br />
1.<br />
School of Immunity and Infection, University Of Birmingham,<br />
Birmingham, United Kingdom.<br />
237 AN ASSESSMENT OF CC CHEMOKINES PRESENT ON THE<br />
MICROVASCULATURE OF SYNOVIAL TISSUE IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS<br />
Lisa Rump-Goodrich 1 , Jim Middleton 2<br />
1.<br />
ARC, Keele University, Oswestry, Shropshire, United<br />
Kingdom. 2. Faculty of Medicine and Dentistry, Bristol<br />
University, Bristol, United Kingdom.<br />
238 INVESTIGATING THE ROLE OF ENDOPLASMIC RETICULUM<br />
AMINOPEPTIDASE-1 IN ANKYLSOING SPONDYLITIS<br />
Liye Chen 1 , Roman Fisher 2 , Simon Kollnberger 1 ,<br />
Nilabh Shastri 3 , Benedikt M. Kessler 2 , Paul Bowness 1<br />
1.<br />
MRC Human Immunology Unit, Weatherall Institute of<br />
Molecular Medicine, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United<br />
Kingdom. 2. Centre <strong>for</strong> Clinical and Molecular Medicine,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom. 3. Division of<br />
Immunology and Pathogenesis, Department of Molecular and<br />
Cell Biology, University of Cali<strong>for</strong>nia, Berkeley, CA, United<br />
States.
110 Poster viewing | Thursday 3 May 2012<br />
239 NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+)<br />
BIOSYNTHESIS ENZYMES IN RHEUMATOID ARTHRITIS<br />
Abdul Nazeer Moideen 1,2 , Laura Evans 2 , Louise Osgood 2 ,<br />
Anwen S. Williams 2 , Simon A. Jones 2 , Mari A. Nowell 2<br />
1.<br />
Trauma & Orthopaedics, University Hospital of Wales, Cardiff,<br />
United Kingdom. 2. Institute of Infection & Immunity, Cardiff<br />
University, Cardiff, United Kingdom.<br />
240 CHARACTERISATION OF A PATIENT’S ANTIBODIES TO THE<br />
ANTI-CD20 THERAPEUTIC RITUXIMAB<br />
Younis Mahadik 1 , Stephen Young 1 , Matthew Morgan 2 ,<br />
Caroline Gordon 1 , Lorraine Harper 2<br />
1.<br />
<strong>Rheumatology</strong> Research Group, School of Immunity &<br />
Infection, College of Medical and Dental Sciences,<br />
Birmingham, United Kingdom. 2. Renal Immunobiology Group,<br />
School of Immunity & Infection, College of Medical and Dental<br />
Sciences, Birmingham, United Kingdom.<br />
241 FUNCTIONAL AND EXPRESSION ANALYSIS OF COMPLEMENT<br />
C5 POLYMORPHISMS ASSOCIATED WITH RHEUMATOID<br />
ARTHRITIS<br />
Joanna L. Giles 1 , B.Paul Morgan 1 , Claire L. Harris 1<br />
1.<br />
Institute of Infection and Immunity, Cardiff University,<br />
Cardiff, United Kingdom.<br />
242 HLA-B27 HEAVY CHAIN DIMER EXPRESSION IN<br />
SPONDYLOARTHRITIS<br />
Oliwia J. Rysnik 1 , Kirsty McHugh 1 , Simon Kollnberger 1 ,<br />
Sravan Payeli 3 , Osiris Marroquin 3 , Jacqueline Shaw 1 ,<br />
Christoph Renner 3,4 , Paul Bowness 1,2<br />
1.<br />
MRC Human Immunology Unit, Weatherall Institute of<br />
Molecular Medicine, Nuffield Department of Clinical Medicine,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom. 2. NDORMS,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom. 3. Department<br />
of Oncology, University of Zurich, Zurich, Switzerland.<br />
4.<br />
Department of Oncology, University Hospital Zurich,<br />
Zurich, Switzerland.<br />
243 ECTOPIC LYMPHONEOGENESIS IN A NOVEL MURINE MODEL<br />
OF SALIVARY GLANDS SIALOADENITIS IS CHARACTERIZED<br />
BY ASYNCHRONY IN THE LYMPHANGIOGENETIC AND<br />
ANGIOGENETIC PROGRAM<br />
Saba Nayar 1 , Tom Cloake 1 , Michele Bombardieri 2 ,<br />
Costantino Pitzalis 2 , Chris Buckley 1 , Francesca Barone 1<br />
1.<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham,<br />
Edgbaston, United Kingdom. 2. Experiemental <strong>Rheumatology</strong>,<br />
Queen Mary University, London, United Kingdom.<br />
244 COOPERATION OF INNATE AND ACQUIRED IMMUNE SYSTEM<br />
DERIVED SIGNALS INDUCES STROMAL CELL ACTIVATION<br />
DURING CHRONIC INFLAMMATION AND ECTOPIC<br />
LYMPHONEOGENESIS<br />
Francesca Barone 1 , Saba Nayar 1 , Tom Cloake 1 , Peter Lane 2 ,<br />
Mark Coles 3 , Chris Buckley 1<br />
1.<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham,<br />
Edgbaston , United Kingdom. 2. Infection and Immunity,<br />
Birmingham University , Edgbaston , United Kingdom.<br />
3.<br />
Centre <strong>for</strong> Immunology and Infection, University of York,<br />
York, United Kingdom.<br />
245 INFLAMMATORY CYTOKINES AND BIOENGINEERING<br />
STRATEGIES FOR ARTHRITIS: FRIEND OR FOE?<br />
Emma L. Williams 1,2 , Christopher J. Edwards 2,1 ,<br />
Cyrus Cooper 3,2 , Richard O. Oreffo 1<br />
1.<br />
Bone & Joint Research Group, University of Southampton<br />
Medical School, Southampton, Hampshire, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong> Department, University Hospital Southampton<br />
NHS Foundation Trust, Southampton, Hampshire, United<br />
Kingdom. 3. MRC Lifecourse Epidemiology Unit, University<br />
Hospital Southampton NHS Foundation Trust, Southampton,<br />
Hampshire, United Kingdom.<br />
Biology of bone, cartilage and connective tissue disease<br />
246 THE EFFECTS OF CANNABINOIDS ON IL-1 INDUCED MATRIX<br />
METALLOPROTEINASE EXPRESSION<br />
Sara Dunn 1 , Aileen Craw<strong>for</strong>d 2 , Mark Wilkinson 3 ,<br />
Christine Le Maitre 1 , Rowena Bunning 1<br />
1.<br />
Biomedical Research Centre, Sheffield Hallam University,<br />
Sheffield, United Kingdom. 2. Restorative Dentistry, University<br />
of Sheffield, Sheffield, United Kingdom. 3. Bone Biomedical<br />
Research Unit, Centre <strong>for</strong> Biomedical Research Northern<br />
General Hospital, Sheffield, United Kingdom.
Thursday 3 May 2012 | Poster viewing 111<br />
Cell receptor-ligand interaction, signalling, activation<br />
and apoptosis<br />
247 INTRACELLULAR SIGNALLING MECHANISMS INDUCED BY<br />
IL-1 IN HUMAN NUCLEUS PULPOSUS CELLS<br />
Jodie Daniels 1 , Kate L E. Phillips 1 , Neil Chiverton 2 ,<br />
Christine L. Le Maitre 1<br />
1.<br />
Biomedical Research Centre, Sheffield Hallam University,<br />
Sheffield, United Kingdom. 2. Spinal Surgery, Sheffield<br />
Teachning Hospitals, Sheffield, South Yorkshire,<br />
United Kingdom.<br />
248 THE ROLE OF HLA-B27 KIR3DL2 INTERACTIONS IN THE<br />
PATHOGENESIS OF SPONDYLOARTHRITIS<br />
Simon Kollnberger 1 , Jackie Shaw 1 , Anna Ridley 1 ,<br />
Isabel Wong-Baeza 1 , Kirsty McHugh 1 , Sarah Keidel 1 ,<br />
Antoni Chan 2 , Paul Bowness 1<br />
1.<br />
NDORMS, Botnar Research Centre, Ox<strong>for</strong>d, United Kingdom.<br />
2.<br />
Dept of <strong>Rheumatology</strong>, Royal Berkshire Hospital, Reading,<br />
Berkshire, United Kingdom.<br />
Cytokines and inflammatory mediators<br />
249 CONVENTIONAL THERAPY FOR EARLY INFLAMMATORY<br />
ARTHRITIS DOES NOT MODIFY PERIPHERAL BLOOD<br />
CYTOKINE PROFILES<br />
Nicola J. Gullick 1,3 , Hanan S. Abozaid 1,4 , David M. Jayaraj 2, 3 ,<br />
Hayley G. Evans 2,3 , David L. Scott 1,3 , Ernest H. Choy 3,5 ,<br />
Leonie S. Taams 2,3<br />
1.<br />
Academic Department of <strong>Rheumatology</strong>, King’s College,<br />
London, London, United Kingdom. 2. Centre <strong>for</strong> Molecular and<br />
Cellular Biology of Inflammation, King’s College London,<br />
London, United Kingdom. 3. NIHR comprehensive Biomedical<br />
Research Centre, Guy’s and St. Thomas’ Hospital and King’s<br />
College London, London, United Kingdom. 4. <strong>Rheumatology</strong><br />
Department, Sohag Faculty of Medicine, Sohag, Egypt.<br />
5.<br />
Section of <strong>Rheumatology</strong>, Cardiff University School of<br />
Medicine, Cardiff, United Kingdom.<br />
250 SAFETY AND PHARMACOKINETICS OF CDP6038, AN<br />
ANTI-IL-6 MONOCLONAL ANTIBODY, ADMINISTERED BY<br />
SUBCUTANEOUS INJECTION AND INTRAVENOUS INFUSION<br />
TO HEALTHY MALE VOLUNTEERS: A PHASE 1 STUDY<br />
M. Hickling 1 , G. Golor 2 , A. Jullion 3 , S. Shaw 1 , K. Kretsos 1<br />
1.<br />
UCB, Celltech, Slough, United Kingdom. 2. PAREXEL,<br />
International GmBH, Berlin, Germany. 3. Arlenda, Liege,<br />
Belgium.<br />
251 DEVELOPMENT OF A HIGH FIDELITY SIMULATION FOR THE<br />
TRAINING & TEACHING OF THE IDENTIFICATION AND<br />
MANAGEMENT OF INFUSION REACTIONS TO BIOLOGIC<br />
AGENTS<br />
Syed F. Bari 1 , Brian Rhys-Dillon 1 , Nicholson Amos 2 ,<br />
Stefan Siebert 3<br />
1.<br />
<strong>Rheumatology</strong>, Princess of Wales Hospital , Bridgend, United<br />
Kingdom. 2. MPEC, Princess of Wales Hospital, Bridgend,<br />
United Kingdom. 3. <strong>Rheumatology</strong>, Swansea University,<br />
Swansea, United Kingdom.<br />
252 CYTOKINE AND CHEMOKINE EXPRESSION PROFILE IN<br />
HUMAN INTERVERTEBRAL DISC DEGENERATION<br />
Kate L E. Phillips 1 , Neil Chiverton 2 , Rowena D. Bunning 1 ,<br />
Gail Haddock 1 , Alison K. Cross 1 , Christine L. Le Maitre 1<br />
1.<br />
Biomedical Research Centre, Sheffield Hallam University,<br />
Sheffield, United Kingdom. 2. Spinal Surgery, Sheffield<br />
Teaching Hospitals, Sheffield, United Kingdom.<br />
253 THE ROLE OF CYTOKINES AND CHEMOKINES IN HUMAN<br />
INTERVERTEBRAL DISC DEGENERATION<br />
Kate L E. Phillips 1 , Alison Cross 1 , Neil Chiverton 2 ,<br />
Gail Haddock 1 , Rowena A D. Bunning 1 , Christine L. Le Maitre 1<br />
1.<br />
Biomedical Reserach Centre, Sheffield Hallam University,<br />
Sheffield, United Kingdom. 2. Spinal Surgery, Sheffield<br />
Teachning Hospitals, Sheffield, United Kingdom.
112 Poster viewing | Thursday 3 May 2012<br />
Rheumatoid arthritis: aetiopathogenesis and<br />
animal models<br />
254 DEFECTIVE CD8+CD28- REGULATORY T CELL SUPPRESSOR<br />
FUNCTION IN RHEUMATOID ARTHRITIS IS DUE TO SOLUBLE<br />
MEDIATORS AND REDUCED SENSITIVITY OF RESPONDER<br />
CELLS.<br />
Sabrina Ceeraz 1 , Jo Spencer 2 , Ernest Choy 3 , Valerie Corrigall 1<br />
1.<br />
Academic Department of <strong>Rheumatology</strong>, Centre <strong>for</strong><br />
Molecular and Cellular Biology of Inflammation , Kings College<br />
London, London, United Kingdom. 2. Peter Gorer Department<br />
of Immunobiology, Division of Immunology, Infection and<br />
Inflammatory Disease, Kings College London, London,<br />
United Kingdom. 3. Section of <strong>Rheumatology</strong>, Cardiff University<br />
School of Medicine, Cardiff University School of Medicine,<br />
Cardiff, United Kingdom.<br />
255 PROTEINASE-ACTIVATED RECEPTOR-2 MODULATES IL-17<br />
GENERATION IN COLLAGEN INDUCED ARTHRITIS<br />
Anne Crilly 1 , Helen Palmer 1 , John Lockhart 1 , Robin Plevin 2 ,<br />
William R. Ferrell 3 , Iain McInnes 3<br />
1.<br />
School of Science, University of the West of Scotland,<br />
Paisley, Scotland, United Kingdom. 2. Strathclyde Institute of<br />
Pharmacy and Biomedical Sciences, University of Strathclyde,<br />
Glasgow, Scotland, United Kingdom. 3. Institute of Infection,<br />
Immunity & Inflammation, University of Glasgow, Glasgow,<br />
Scotland, United Kingdom.<br />
256 CIGARETTE SMOKING HISTORY IS MORE STRONGLY<br />
ASSOCIATED WITH VERY STRONGLY POSITIVE RHEUMATOID<br />
FACTOR RATHER THAN VERY STRONGLY POSITIVE<br />
ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVITY<br />
WITHOUT VERY STRONGLY POSITIVE RHEUMATOID FACTOR<br />
IN RHEUMATOID ARTHRITIS.<br />
David Hutchinson 1 , Liz Perry 1<br />
1.<br />
<strong>Rheumatology</strong> Department, Royal Cornwall Hospital,<br />
Cornwall, United Kingdom.<br />
257 THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (PEAC):<br />
A PRELIMINARY ANALYSIS CORRELATING<br />
HISTOMORPHOLOGY AND DISEASE ACTIVITY<br />
Maria DiCicco 1 , Frances Humby 2,1 , Stephen Kelly 1 ,<br />
Rebecca Hands 2 , Chris Buckley 5 , Ian McInnes 3 , Peter Taylor 4 ,<br />
Michele Bombardieri 2,1 , Costantino Pitzalis 2,1<br />
1.<br />
<strong>Rheumatology</strong>, Barts and the London NHST Trust, London,<br />
United Kingdom. 2. William Harvery research Institute, Barts<br />
and the London School of Medicine, London, United Kingdom.<br />
3.<br />
Glasgow Biomedical Research Centre, University of Glasgow,<br />
Glasgow, United Kingdom. 4. Kennedy Institute of<br />
<strong>Rheumatology</strong>, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom.<br />
5.<br />
School of Immunity and Infection, University of Birmingham,<br />
Birmingham, United Kingdom.<br />
Case reports<br />
258 HYPOPHOSPHATAEMIC RICKETS AND ANKYLOSING<br />
SPONDYLITIS-LIKE FEATURES ASSOCIATED WITH AN<br />
INACTIVATING ENPP1 MUTATION, A NOVEL<br />
PATHOGENETIC LINK<br />
Puja Mehta 1 , Adam Mitchell 2 , Carolyn Tysoe 3 ,<br />
Richard Caswell 4 , Martina Owens 3 , Tonia Vincent 1<br />
1.<br />
<strong>Rheumatology</strong>, Charing Cross Hospital, London, United<br />
Kingdom. 2. Radiology, Chelsea and Westminster Hospital,<br />
London, United Kingdom. 3. Molecular Genetics, Royal Devon<br />
& Exeter NHS Foundation Trust, Exeter, United Kingdom.<br />
4.<br />
Institute of Biomedical and Clinical Science, Peninsula<br />
Medical School, Exeter, United Kingdom.<br />
259 REACTIVE ARTHRITS(ReA) AND TRISMUS POST<br />
INTRAVESICAL BCG IMMUNOTHERAPY FOR BLADDER<br />
CARCINOMA<br />
Tahir M. HASHMI 1 , Alec Price-Forbes 1<br />
1.<br />
<strong>Rheumatology</strong>, University Hospitals of Coventry &<br />
Warwickshire, Coventry, England, United Kingdom.<br />
260 IT REALLY CAN’T BE GOUT-WHAT IS IT? CRYOPYRIN-<br />
ASSOCIATED PERIODIC FEVERS: A DELAYED DIAGNOSIS<br />
Charlotte A. Sharp 1 , Helen Murphy 2 , Elizabeth F. Wood 1<br />
1.<br />
<strong>Rheumatology</strong>, Furness General Hospital, Barrow in Furness,<br />
United Kingdom. 2. Clinical Genetics, St Mary’s Hospital,<br />
Manchester, United Kingdom.
Thursday 3 May 2012 | Poster viewing 113<br />
261 SYSTEMATIC LUPUS ERYTHEMATOSUS, MOLLUSCUM<br />
CONTAGIOSUM (MC) AND HUMAN IMMUNODEFICIENCY<br />
VIRUS (HIV)<br />
Teresa Doherty 1 , Jo Sheldon 2 , Nidhi Sofat 1<br />
1.<br />
St Georges Hospital, London, United Kingdom.<br />
2.<br />
Immunology, St Georges, London, United Kingdom.<br />
262 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME<br />
(PRES) ASSOCIATED WITH TOCILIZUMAB<br />
Iain Goff 1,2 , Philip N. Platt 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Newcastle Upon Tyne<br />
Hospitals NHS Foundation Trust, Newcastle, United Kingdom.<br />
2.<br />
School of Medical Sciences, Newcastle University, Newcastle<br />
upon Tyne, United Kingdom.<br />
263 DIFFUSE OSTEONECROSIS IN ANTI-PHOSPHOLIPID<br />
SYNDROME (APLS) MANIFESTING WITH HIGH BONE<br />
MINERAL DENSITY<br />
Rita Abdulkader 1 , Gavin Clunie 1<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Ipswich hospital NHS trust, Ipswich,<br />
United Kingdom.<br />
264 AN UNUSUAL CASE OF CHILDHOOD DERMATOMYOSITIS<br />
RECURRING HALF A CENTURY LATER<br />
Mediola Ismajli 1 , Elena Nikiphorou 1 , Adam Young 1<br />
1.<br />
<strong>Rheumatology</strong>, St Albans City Hospital, St Albans,<br />
Hert<strong>for</strong>dshire, United Kingdom.<br />
265 INEXPLICABLE IMMUNOLOGY?: NEW-ONSET RHEUMATOID<br />
ARTHRITIS IN A RENAL TRANSPLANT PATIENT ON TRIPLE<br />
IMMUNOSUPPRESSIVE THERAPY<br />
Nicola Tugnet 1 , Josh Dixey 1<br />
1.<br />
<strong>Rheumatology</strong>, <strong>The</strong> Royal Wolverhampton Hospitals NHS<br />
Trust, Wolverhampton, United Kingdom.<br />
266 DOES RHEUMATOLOGY HAVE A ROLE IN IDIOPATHIC<br />
RETROPERITONEAL FIBROSIS (RPF)?<br />
Snehashish Banik 1 , Desmond Alcorn 2 , John Hunter 1<br />
1.<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United<br />
Kingdom. 2. Radiology, Gartnavel General Hospital, Glasgow,<br />
United Kingdom.<br />
267 TADALAFIL: A NOVEL TREATMENT FOR VASCULAR<br />
MANIFESTATIONS OF SYSTEMIC SCLEROSIS AND OTHER<br />
CONNECTIVE TISSUE DISEASES<br />
Win Win Maw 1 , Pravin Patil 1 , Fiona Hayes 1 , Way Main Wong 1 ,<br />
Frances A. Borg 1 , Bhaskar Dasgupta 1<br />
1.<br />
Rheumatolgy Department, Southend University Hospital,<br />
Southend-On-sea, United Kingdom.<br />
268 HARLEQUIN SYNDROME: A CASE REPORT AND REVIEW OF<br />
LITERATURE<br />
Anshuman P. Malaviya 1 , Andrew J. Ostor 1<br />
1.<br />
<strong>Rheumatology</strong>, Cambridge University Hospitals NHS<br />
Foundation Trust, Cambridge, United Kingdom.<br />
269 SUCCESSFUL USE OF TOCILIZUMAB IN A CAUCASIAN<br />
PATIENT WITH RELAPSING POLYCHONDRITIS COMPLICATED<br />
BY SWEETS SYNDROME<br />
Jasroop K. Chana 1 , Azeem A. Ahmed 1 , Sally Edmonds 1<br />
1.<br />
<strong>Rheumatology</strong>, Stoke Mandeville Hospital, Aylesbury,<br />
United Kingdom.<br />
270 A PRECIOUS METAL: COPPER DEFICIENCY PRESENTING<br />
AS MYELONEUROPATHY<br />
Fiona Hayes 1 , Lucy Coward 2 , Frances Borg 1<br />
1.<br />
<strong>Rheumatology</strong>, Southend General Hospital, Southend,<br />
United Kingdom. 2. Neurology, Southend General Hospital,<br />
Southend, United Kingdom.<br />
271 REMISSION OF RESISTANT LIFE-THREATENING NON-RENAL<br />
WEGENER’S GRANULOMATOSIS WITH RITUXIMAB AND<br />
MYCOPHENOLATE MOFITIL<br />
Jonathan Heaney 1 , Nicole Amft 1 , John Simpson 2 ,<br />
Veena Dhillon 1<br />
1.<br />
<strong>Rheumatology</strong>, Western General Hospital, Edinburgh, United<br />
Kingdom. 2. Respiratory medicine, Freeman Hospital,<br />
Newcastle-Upon-Tyne, United Kingdom.<br />
272 ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENTING AS<br />
HEMI-CHOREA IN SECOND TRIMESTER PREGNANCY<br />
Yezenash Ayalew 1 , Fazlihakim Khattak 1 , Mary Gayed 1<br />
1.<br />
<strong>Rheumatology</strong>, Sandwell General Hospital, West Bromwich,<br />
United Kingdom.
114 Poster viewing | Thursday 3 May 2012<br />
273 CASE PRESENTATION OF INFLAMMATORY MONO-ARTHRITIS<br />
TREATED WITH INTRA-ARTICULAR INFLIXIMAB<br />
Roshan I. Amarasena 1 , Frank McKenna 1<br />
1.<br />
<strong>Rheumatology</strong>, Traf<strong>for</strong>d NHS Trust, Traf<strong>for</strong>d, United Kingdom.<br />
274 A CASE OF ANTI-SYNTHETASE SYNDROME THAT<br />
RESPONDED TO RITUXIMAB TREATMENT<br />
Roshan I. Amarasena 1 , Frank McKenna 1<br />
1.<br />
<strong>Rheumatology</strong>, Traf<strong>for</strong>d NHS Trust, Traf<strong>for</strong>d, United Kingdom.<br />
275 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT<br />
WITH WEGENER’S GRANULOMATOSIS<br />
Maeve Mc Laughlin 1 , Krishnan Baburaj 1<br />
1.<br />
<strong>Rheumatology</strong>, Wat<strong>for</strong>d General Hospital, Wat<strong>for</strong>d, United<br />
Kingdom.<br />
276 ANTI TA/MA2 ANTIBODIES IN BRAINSTEM VASCULITIS<br />
WITHOUT MALIGNANCY<br />
Zozik Fattah 1 , Nora Ng 1 , Wilson Jo 1 , Bernard Colaco 1<br />
1.<br />
Central Middlesex Hospital, London, United Kingdom.<br />
277 USE OF RITUXIMAB TO TREAT RHEUMATOID ARTHRITIS<br />
AND FOCAL SEGMENTAL GLOMERULAR SCLEROSIS<br />
Mark R. Williams 1 , Tochukwu Adizie 1 , Bhaskar Dasgupta 1<br />
1.<br />
Southend Hospital, Westcliff-on-sea, United Kingdom.<br />
Education research<br />
Medical student bursary winner<br />
278 CAN PEER ASSISTED LEARNING DELIVERED BY MEDICAL<br />
STUDENTS BE USEFUL IN TRAINING SENIOR COLLEAGUES<br />
IN USE OF REMS TECHNIQUE FOR MSS EXAMINATION?<br />
A PILOT STUDY<br />
Matthew Casey 1 , Stefanie Lip 1 , Shaun Tan 1 , David Anderson 1 ,<br />
Calum Robertson 1 , Ian Devanny 1 , Max Field 1<br />
1.<br />
Wolfson Medical School Building, University of Glasgow,<br />
Glasgow, United Kingdom.<br />
279 DRUG KNOWLEDGE IN PATIENTS ESTABLISHED ON<br />
LONG-TERM TREATMENT WITH METHOTREXATE<br />
David Walker 1 , Sandra Robinson 1 , Sarah Ryan 2 ,<br />
Andrew Hassell 2<br />
1.<br />
<strong>Rheumatology</strong>, Freeman Hospital, Newcastle on Tyne,<br />
United Kingdom. 2. <strong>Rheumatology</strong> , Stoke PCT, Stoke on Trent,<br />
United Kingdom.<br />
280 OPEN ACCESS MUSCULOSKELETAL ONLINE<br />
EDUCATION- VIRTUAL PATIENTS LEADING THE WAY<br />
James Bateman 1,2 , Maggie Allen 2 , David Davies 1<br />
1.<br />
Institute of Clinical Education, University of Warwick,<br />
Coventry, United Kingdom. 2. Department of <strong>Rheumatology</strong>,<br />
University Hospitals Coventry and Warwickshire NHS Trust,<br />
Coventry, United Kingdom.<br />
281 CHOOSING A CAREER IN A MUSCULOSKELETAL SPECIALTY:<br />
HOW POPULAR ARE RHEUMATOLOGY AND ORTHOPAEDICS<br />
AMONG MEDICAL STUDENTS AND WHAT FACTORS ARE<br />
RELEVANT IN THE CHOICE?<br />
Carina Crouch 1 , Karen Walker-Bone 1 , Nicola Gainsborough 2<br />
1.<br />
<strong>Rheumatology</strong>, Brighton & Sussex Medical School, Brighton,<br />
United Kingdom. 2. Stroke Medicine, Brighton and Sussex<br />
University Hospitals NHS Trust, Brighton, United Kingdom.<br />
282 DELIVERING THE RHEUMATOLOGY CURRICULUM: A REVIEW<br />
FROM THE TRAINEE AND TRAINER PERSPECTIVE<br />
Nicola J. Gullick 1 , Pamela M. Lutalo 2 , Ursula M. Davies 2,3 ,<br />
Karen Walker-Bone 3,4<br />
1.<br />
<strong>Rheumatology</strong>, Brighton & Sussex University Hospitals,<br />
Brighton, United Kingdom. 2. <strong>Rheumatology</strong>, East Surrey<br />
Hospital, Redhill, United Kingdom. 3. <strong>Rheumatology</strong>, Kent,<br />
Surrey & Sussex Deanery, Brighton, United Kingdom.<br />
4.<br />
<strong>Rheumatology</strong>, Brighton & Sussex Medical School,<br />
Brighton, United Kingdom.<br />
283 BENEFICIAL EFFECTS OF OMEGA-3-POLYUNSATURATED<br />
FATTY ACIDS ON SF-36 SCORES IN SYSTEMIC LUPUS<br />
ERYTHEMATOSUS<br />
Jennifer R. Mckew 1 , Auleen M. Millar 1 , Stephen A. Wright 1 ,<br />
Aubrey L. Bell 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Musgrave Park Hospital,<br />
Belfast, United Kingdom.<br />
284 MEDICAL STUDENTS PERCEPTION OF RHEUMATOLOGY AS<br />
AN OPTION DURING FOUNDATION TRAINING: RESULTS<br />
FROM OPEN RESPONSES OF A NATIONAL SURVEY<br />
Muryum Thapper 1 , Thalia Roussou 2,1<br />
1.<br />
Queen Mary’s, Barts and <strong>The</strong> London School of Medicine<br />
and Dentistry, London, E1 2AD, United Kingdom. 2. <strong>Rheumatology</strong><br />
& Rehabilitation, King George Hospital Barking Havering<br />
and Redbridge University NHS TRUST, London, IG3 8YB, United<br />
Kingdom.
Thursday 3 May 2012 | Poster viewing 115<br />
285 THE INFORMATION AND SUPPORT NEEDS OF PEOPLE<br />
LIVING WITH RHEUMATOID ARTHRITIS<br />
Jo Cumming 1 , Richard G. Hull 2<br />
1.<br />
Helplines, Arthritis Care, London, United Kingdom.<br />
2.<br />
Trustee, Arthritis Care, London, United Kingdom.<br />
286 ARE MEDICAL STUDENTS INTERESTED IN SELECTING<br />
MUSCULOSKLEETAL MEDICINE (RHEUMATOLOGY &<br />
ORTHOPAEDICS COMBINED} AS A FOUNDATION YEAR<br />
TRAINING ROTATION?<br />
Muryum Thapper 1 , Thalia Roussou 2,1<br />
1.<br />
Queen Marys University, Barts and the London, School of<br />
Medicine and Denitstry, London, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong> & Rehabilitation, King George Hospital<br />
Barking Havering and Redbridge University NHS TRUST,<br />
London, United Kingdom.<br />
287 SUN EXPOSURE AND THE USE OF SUNSCREEN AMONG<br />
INFLAMMATORY ARTHROPATHY PATIENTS RECEIVING<br />
ANTI-TNF THERAPY<br />
John McKeogh 1 , Mortimer B. O’Connor 2 , Ahmed I. Hassan 2 ,<br />
Ursula Bond 2 , Joan Swan 2 , Mark J. Phelan 2<br />
1.<br />
Medicine, South Infirmary Victoria University Hospital, Cork,<br />
Ireland. 2. <strong>Rheumatology</strong>, South Infirmary Victoria University<br />
Hospital, Cork, Ireland.<br />
288 EVALUATION OF THE FIRST BSR TEACHING THE TEACHERS<br />
COURSE<br />
David Coady 1 , Namita Kumar 2<br />
1.<br />
City Hospitals Sunderland, Sunderland, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, University Hospital of North Durham, Durham,<br />
United Kingdom.<br />
Epidemiology<br />
289 PREDICTORS OF LOW BONE MINERAL DENSITY IN MEN &<br />
WOMEN UNDER 50 YEARS OF AGE<br />
Luke Farrow 2 , Marwan Bukhari 1 , Alexander G. Oldroyd 2 ,<br />
Cathi Greenbank 1<br />
1.<br />
<strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster,<br />
United Kingdom. 2. Centre <strong>for</strong> Medical Education, Lancaster<br />
University, Lancaster, United Kingdom.<br />
290 CHRONIC WIDESPREAD PAIN, CO-MORBID DEPRESSION<br />
AND FATIGUE IN OLDER PEOPLE<br />
John McBeth 1 , Rosie Duncan 1 , Deborah Brown 1 ,<br />
Michael Horan 2 , Neil Pendleton 2 , Alison Littlewood 1 ,<br />
Lis Cordingley 2 , Matthew Mulvey 1<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom. 2. School of<br />
Medicine, University of Manchester, Manchester, United<br />
Kingdom.<br />
291 LEAN MASS IS POSITIVELY ASSOCIATED WITH HIP<br />
STRENGTH AND GEOMETRY IN CHILDHOOD: FINDINGS<br />
FROM THE SOUTHAMPTON WOMEN’S SURVEY<br />
Elizabeth M. Curtis 1 , Zoe A. Cole 1 , Sarah R. Crozier 1 ,<br />
Ntani Georgia 1 , Siân M. Robinson 1 , Keith M. Godfrey 1,2 ,<br />
Avan A. Sayer 1 , Hazel M. Inskip 1 , Cyrus Cooper 1<br />
1.<br />
MRC Lifecourse Epidemiology Unit, University of<br />
Southampton, Southampton, United Kingdom. 2. NIHR<br />
Nutrition, Diet and Lifestyle Biomedical Research Unit,<br />
University of Southampton, Southampton, United Kingdom.<br />
292 DOES DEPRESSION AFFECT RESPONSE TO ANTI-TUMOUR<br />
NECROSIS FACTOR THERAPY IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS? RESULTS FROM THE BRITISH<br />
SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER<br />
Rebecca Davies 1 , Louise Mercer 1 , James Galloway 1 ,<br />
Audrey Low 1 , Kath Watson 1 , Mark Lunt 1 , BSRBR Control<br />
Centre Consortium 2 , Deborah Symmons 1 , Kimme Hyrich 1 ,<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom. 2. <strong>British</strong> <strong>Society</strong><br />
<strong>for</strong> <strong>Rheumatology</strong>, London, United Kingdom<br />
293 INITIAL TRIPLE DMARD THERAPY PREDICTS ACR EULAR<br />
REMISSION IN AN EARLY RHEUMATOID ARTHRITIS<br />
INCEPTION COHORT.<br />
Sarang Chitale 1 , Cristina Estrach 1 , Robert J. Moots 1 ,<br />
Nicola J. Goodson 1<br />
1.<br />
Department of rheumatology, Aintree University Hospital,<br />
University of Liverpool, Liverpool, United Kingdom.
116 Poster viewing | Thursday 3 May 2012<br />
294 ASSOCIATION BETWEEN PERIODONTAL DISEASE AND<br />
RHEUMATOID ARTHRITIS IN A LARGE CHINESE COHORT:<br />
FINDINGS FROM THE GUANGZHOU BIOBANK<br />
COHORT STUDY<br />
Elizabeth Rankin 1 , C. Q. Jiang 3 , K. K. Cheng 2 , T. H. Lam 4 ,<br />
Peymané Adab 2<br />
1.<br />
<strong>Rheumatology</strong>, University Hospitals Birmingham,<br />
Birmingham, United Kingdom. 2. Department of Public Health<br />
and Epidemiology, University of Birmingham, Birmingham,<br />
United Kingdom. 3. Guangzhou Occupational Health,<br />
Guangzhou no 12 Hospital, Ghangzhou, China.<br />
4.<br />
Department of Community Medicine, University of Hong<br />
Kong, Hong Kong, China.<br />
295 OBESE EARLY RHEUMATOID ARTHRITIS PATIENTS HAVE A<br />
REDUCED RESPONSE TO DMARD THERAPY DURING THEIR<br />
FIRST YEAR OF TREATMENT<br />
Stephanie Ling 1,2 , Sarang Chitale 1,2 , Robert J. Moots 1,2 ,<br />
Cristina Estrach 2 , Nicola J. Goodson 1,2<br />
1.<br />
Institute of Ageing and Chronic Disease, University of<br />
Liverpool, Liverpool, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
University Hospital Aintree, Liverpool, United Kingdom.<br />
296 OBESITY IS ASSOCIATED WITH HIGHER HAQ SCORES IN<br />
PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS:<br />
RESULTS FROM THE NORFOLK ARTHRITIS REGISTER<br />
Jennifer Humphreys 1 , Corrinne Ellis 2 , Diane Bunn 2 ,<br />
Suzanne M. Verstappen 1 , Deborah Symmons 1<br />
1.<br />
Arthritis Research UK Epidemiology Unit, School of<br />
Translational Medicine, University of Manchester, Manchester,<br />
United Kingdom. 2. Department of <strong>Rheumatology</strong>, Norfolk and<br />
Norwich University Hospital, Norwich, United Kingdom.<br />
297 DO ELECTRONIC AND PAPER QUESTIONNAIRES PRODUCE<br />
EQUIVALENT RESULTS? A SYSTEMATIC REVIEW<br />
Elisa Fluess 1 , Gary J. Macfarlane 1 , Christine Bond 2 ,<br />
Gareth T. Jones 1<br />
1.<br />
Aberdeen Pain Research Collaboration (Epidemiology Group),<br />
University of Aberdeen, Aberdeen, United Kingdom.<br />
2.<br />
Aberdeen Pain Research Collaboration (Primary Care),<br />
University of Aberdeen, Aberdeen, United Kingdom.<br />
298 A SYSTEMATIC REVIEW AND META-ANALYSIS OF<br />
ALCOHOL AS A PROTECTIVE FACTOR AGAINST RHEUMATOID<br />
ARTHRITIS<br />
Ian C. Scott 1,2 , Sophia Steer 3 , Cathryn M. Lewis 1 ,<br />
Andrew Cope 2<br />
1.<br />
Department of Medical and Molecular Genetics, King’s<br />
College London, London, United Kingdom. 2. Department of<br />
Academic <strong>Rheumatology</strong>, King’s College London, London,<br />
United Kingdom. 3. Department of <strong>Rheumatology</strong>, King’s<br />
College Hospital, London, United Kingdom.<br />
299 JOINT HYPERMOBILITY PREDICTS DISABLING AND LIMITING<br />
MUSCULOSKELETAL PAIN: RESULTS FROM THE MUSICIAN<br />
SURVEY<br />
Matthew R. Mulvey 1 , Gary J. Macfarlane 2 ,<br />
Deborah Symmons 1 , Karina Lovell 3 , Philip Keeley 3 ,<br />
Steve Woby 4 , Marcus Beasley 2 , John McBeth 1<br />
1.<br />
Arthritis Research UK, Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. Aberdeen Pain<br />
Research Collaboration, University of Aberdeen, Aberdeen,<br />
United Kingdom. 3. School of Nursing, Midwifery & Social<br />
Work, <strong>The</strong> University of Manchester, Manchester, United<br />
Kingdom. 4. <strong>The</strong> Pennine Acute Hosiptals NHS Trust, North<br />
Manchester NSH Trust, Manchester, United Kingdom.<br />
Genetics<br />
300 FURTHER REPLICATION OF THE TRAF1/C5 GENETIC<br />
ASSOCIATION WITH RADIOLOGICAL DAMAGE IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS<br />
Sebastien Viatte 1,4 , Darren Plant 1,4 , Mark Lunt 1 , Bo Fu 1 ,<br />
Ben Parker 1 , James Galloway 1 , Csilla Solymossy 2 ,<br />
Jane Worthington 1 , Deborah Symmons 1 , Josh Dixey<br />
1.<br />
Arthritis Research UK Epidemiology Unit, Manchester<br />
Academic Health Science Center, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. <strong>Rheumatology</strong><br />
Department, St Albans City Hospital, St Albans, United<br />
Kingdom. 3. Department of <strong>Rheumatology</strong>, New Cross<br />
Hospital, Wolverhampton, United Kingdom.<br />
4.<br />
Equal, contribution, Manchester, United Kingdom.
Thursday 3 May 2012 | Poster viewing 117<br />
301 SPINE CURVATURE IS HERITABLE AND ASSOCIATED WITH<br />
DISC DEGENERATION<br />
Frances M. Williams 1 , Daniel-Clement Osei-Bordom 1 ,<br />
Maria Popham 1 , Alex MacGregor 1,2 , Tim Spector 1<br />
1.<br />
Dept of Twin Research and Genetic Epidemiology, King’s<br />
College London, London, United Kingdom. 2. Dept of Medicine,<br />
University of East Anglia, Norwich, United Kingdom.<br />
302 A SYNONYMOUS VARIANT IN TREX1 IS ASSOCIATED WITH<br />
AN INCREASED RISK OF SYSTEMIC SCLEROSIS<br />
Jayne Little 1 , Ariane Herrick 3 , S. Pushpakom 2 , H. Ennis 3 ,<br />
H. McBurney 2 , J. Worthington 3 , W. Newman 2<br />
1.<br />
School of Translational Medicine, Manchester University,<br />
Manchester, Greater Manchester, United Kingdom. 2. NIHR<br />
Biomedical Research Centre, Royal Liverpool Hospital,<br />
Liverpool, Mersyside, United Kingdom. 3. Department of<br />
<strong>Rheumatology</strong>, Sal<strong>for</strong>d Royal Hospital, Sal<strong>for</strong>d, Greater<br />
Manchester, United Kingdom.<br />
303 CORRELATION OF CRP HAPLOTYPES WITH RESPONSE TO<br />
ANTI-TNF THERAPY IN UK PATIENTS: RESULTS FROM THE<br />
BRAGGSS COHORT<br />
Ibrahim Ibrahim 1 , Darren Plant 1 , Kimme Hyrich 1 ,<br />
Anne Morgan 3 , Anthony Wilson 4 , John Isaacs 2 , Anne Barton 1<br />
1.<br />
ARC-EU, University of Manchester, Manchester, United<br />
Kingdom. 2. Musculoskeletal Research Group, Newcastle<br />
University, Newcastle, United Kingdom. 3. NIHR-Leeds<br />
Musculoskeletal Biomedical Research Unit, University of<br />
Leeds, Leeds, United Kingdom. 4. Section of Musculoskeletal<br />
Sciences, University of Sheffield, Sheffield, United Kingdom.<br />
Health services research, economics and outcomes<br />
research<br />
304 DO PATIENTS’ TREATMENT PRIORITIES VARY ACCORDING<br />
TO ETHNICITY AND CULTURE? A UK COMPARISON OF<br />
WHITE BRITISH AND PUNJABI RHEUMATOID ARTHRITIS<br />
PATIENTS<br />
Tessa Sanderson 1 , Sarah Hewlett 1,2 , Michael Calnan 3 ,<br />
Marianne Morris 1 , Karim Raza 4,5 , Kanta Kumar 4,5<br />
1.<br />
School of Health and Social Care, University of West of<br />
England, Bristol, United Kingdom. 2. Department of<br />
<strong>Rheumatology</strong>, University Hospitals Bristol NHS Foundation<br />
Trust, Bristol, United Kingdom. 3. School of Social Policy,<br />
Sociology and Social Research, University of Kent, Canterbury,<br />
United Kingdom. 4. College of Medical and Dental Sciences,<br />
University of Birmingham, Birmingham, United Kingdom.<br />
5.<br />
Department of <strong>Rheumatology</strong>, Sandwell and West Birmingham<br />
Hospitals NHS Trust, Birmingham, United Kingdom.<br />
305 LITIGATION RELATED TO RHEUMATOLOGY: AN ANALYSIS OF<br />
CLAIMS AGAINST THE NHS 2000 TO 2010<br />
Caroline M. Cardy 1<br />
1.<br />
<strong>Rheumatology</strong>, University Hospitals Birmingham,<br />
Birmingham, United Kingdom.<br />
306 IMPACT OF A RHEUMATOLOGY BASED ECHOCARDIOGRAPHY<br />
AND DEDICATED OUTPATIENT CLINIC SERVICE ON<br />
CARDIOPULMONARY SCREENING IN SYSTEMIC SCLEROSIS<br />
John D. Pauling 1 , Jessica Jenkins 1 , Sue J. Brown 1 ,<br />
Neil McHugh 1,2<br />
1.<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, United Kingdom. 2. Department of Pharmacy<br />
and Pharmacology, University of Bath, Bath, United Kingdom.<br />
307 BIOLOGIC DRUGS ACCOUNT FOR A MAJOR PART OF THE<br />
COST BURDEN UP TO 15 YEARS AFTER DISEASE ONSET IN<br />
INFLAMMATORY POLYARTHRITIS<br />
Elena Nikiphorou 1,2 , Miranda Mug<strong>for</strong>d 3 , Charlotte Davies 3 ,<br />
Nicola Cooper 4 , Alan Brooksby 5 , Diane Bunn 6 ,<br />
Deborah Symmons 6 , Alex MacGregor 3<br />
1.<br />
Research Department of Epidemiology & Public Health,<br />
University College London, London, United Kingdom.<br />
2.<br />
Department of <strong>Rheumatology</strong>, St Albans City Hospital,<br />
St Albans, United Kingdom. 3. Norwich Medical School,<br />
University of East Anglia, Norwich, United Kingdom.<br />
4.<br />
Department of Epidemiology & Public Health, University of<br />
Leicester, Leicester, United Kingdom. 5. Clinical Effectiveness<br />
& Audit Department, Norfolk & Norwich University Hospital,<br />
Norwich, United Kingdom. 6. Arthritis Research UK<br />
Epidemiology Unit, University of Manchester, Manchester,<br />
United Kingdom.
118 Poster viewing | Thursday 3 May 2012<br />
308 WHY DO WE NEED TO PILOT INTERVENTIONS? ESSENTIAL<br />
REFINEMENTS IDENTIFIED DURING PILOTS OF A FATIGUE<br />
INTERVENTION<br />
Emma Dures 1 , Nick Ambler 2 , Debbie Fletcher 3 , Denise Pope 3 ,<br />
Frances Robinson 4 , Royston Rooke 4 , Sarah Hewlett 1<br />
1.<br />
Faculty of Health and Life Sciences, University of the West<br />
of England, Bristol, United Kingdom. 2. Pain Management,<br />
Frenchay Hospital, Bristol, United Kingdom. 3. <strong>Rheumatology</strong><br />
Department, University Hospitals Bristol, Bristol, United<br />
Kingdom. 4. Academic <strong>Rheumatology</strong>, University of Bristol,<br />
Bristol, United Kingdom.<br />
309 RHEUMATOLOGY EMAIL ADVICE AND LIAISON: A NEW<br />
SERVICE<br />
Claire L. Gorman 1 , Piero Reynolds 1<br />
1.<br />
<strong>Rheumatology</strong>, Homerton University Hospital NHS Trust,<br />
London, United Kingdom.<br />
310 PAN-LONDON STANDARDS OF CARE FOR INFLAMMATORY<br />
ARTHRITIS & INFLAMMATORY BACK PAIN<br />
Alan J. Hakim 1 , Ailsa Bosworth 2 , Dan Weaver 3 ,<br />
Patrick D. Kiely 4<br />
1.<br />
Trust HQ, Whipps Cross University Hospital NHS Trust,<br />
London, United Kingdom. 2. Head Office, NRAS, Maidenhead,<br />
United Kingdom. 3. General Practice, NHS Havering,<br />
Hornchurch, United Kingdom. 4. Dept of <strong>Rheumatology</strong>,<br />
St Georges Hospital, London, United Kingdom.<br />
311 NORTH WEST REGIONAL AUDIT OF THE DIAGNOSIS AND<br />
MANAGEMENT OF RHEUMATOID ARTHRITIS<br />
Sarah Skeoch 1 , Meghna Jani 5 , Roshan Amarasena 6 ,<br />
Chandini Rao 4 , Elizabeth Macphie 3 , Yokemei McLoughlin 2 ,<br />
Preeti Shah 2<br />
1.<br />
<strong>Rheumatology</strong>, Pennine Acute NHS Trust, Manchester, United<br />
Kingdom. 2. <strong>Rheumatology</strong>, Traf<strong>for</strong>d Healthcare NHS Trust,<br />
Manchester, United Kingdom. 3. <strong>Rheumatology</strong>, Lancashire<br />
Care NHS Foundation Trust, Preston, United Kingdom.<br />
4.<br />
<strong>Rheumatology</strong>, Blackpool Hospitals NHS Foundation Trust,<br />
Blackpool, United Kingdom. 5. <strong>Rheumatology</strong>, University<br />
Hospitals of Morcambe Bay NHS Foundation Trust, Lancaster,<br />
United Kingdom. 6. <strong>Rheumatology</strong>, Stockport NHS Foundation<br />
Trust, Stockport, United Kingdom.<br />
312 HOW MANY EXTRA PATIENTS COULD BE ELIGIBLE FOR<br />
BIOLOGICS IF WE ADOPTED BSR GUIDELINES IN AN EARLY<br />
ARTHRITIS POPULATION?<br />
Sara Else 1 , Olga Semenova 1 , Helen Thompson 1 ,<br />
Olabambo Ogunbambi 1 , Sathish Kallankara 1 , Yusuf Patel 1,2 ,<br />
Elaine Baguley 1<br />
1.<br />
<strong>Rheumatology</strong>, Hull Royal Infirmary, Hull, United Kingdom.<br />
2.<br />
Senior Lecturer, Hull York Medical School, Hull, United<br />
Kingdom.<br />
313 STRATEGY TO REDUCE RHEUMATOLOGY AND PAIN CLINIC<br />
REFERRALS VIA MONTHLY MULTIDISCIPLINARY TEAM<br />
MEETINGS<br />
Meghna Jani 1 , John Halsey 2 , Andrew Severn 3 ,<br />
Marwan Bukhari 2<br />
1.<br />
Department of rheumatology, Sal<strong>for</strong>d Royal NHS foundation<br />
trust, Sal<strong>for</strong>d, United Kingdom. 2. Department of<br />
<strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster, United<br />
Kingdom. 3. Department of Anaesthesia and Chronic Pain,<br />
Royal Lancaster Infirmary, Lancaster, United Kingdom.<br />
314 REQUESTING IMMUNOLOGICAL TESTS; THE IMPORTANCE<br />
OF RATIONALIZING REQUESTS<br />
Shilpa Selvan 1 , Elizabeth Price 1<br />
1.<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United<br />
Kingdom.<br />
315 IMPACT OF ANKYLOSING SPONDYLITIS ON WORK AND<br />
PRODUCTIVITY<br />
Muhammad J. Husain 1 , Sinead Brophy 2 , Ceri J. Phillips 3 ,<br />
Roxanne Cooksey 2 , Elizabeth Irvine 2 , Stefan Siebert 2<br />
1.<br />
Keele Managment School (Economics), Keele University,<br />
Newcastle-under-Lyme, Staf<strong>for</strong>dshire, United Kingdom.<br />
2.<br />
College of Medicine, Swansea University, Swansea,<br />
Swansea, United Kingdom. 3. College of Human and Health<br />
Sciences, Swansea University, Swansea, United Kingdom.
Thursday 3 May 2012 | Poster viewing 119<br />
316 EVALUATING HEALTH STATUS OF 620 PATIENTS WITH<br />
PRIMARY SJÖGREN’S SYNDROME USING EQ-5D<br />
Dennis Lendrem 1 , Sheryl Mitchell 1 , Simon Bowman 2 ,<br />
Elizabeth Price 3 , Colin T. Pease 4 , Paul Emery 4 ,<br />
Jacqueline Andrews 4 , Michele Bombardieri 5 , Nurhan Sutcliffe 5<br />
1.<br />
<strong>Rheumatology</strong>, Newcastle Hospitals NHS Foundation Trust,<br />
Newcastle upon Tyne, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
University Hospital Birmingham, Birmingham, United Kingdom.<br />
3.<br />
<strong>Rheumatology</strong>, Great Western Hospitals NHS Foundation<br />
Trust, Swindon, United Kingdom. 4. NIHR Leeds<br />
Musculoskeletal Biomedical Research Unit, Leeds Teaching<br />
Hospitals Trust, Leeds, United Kingdom. 5. <strong>Rheumatology</strong>,<br />
Barts and the London School of Medicine and Dentistry,<br />
London, United Kingdom. 6. <strong>Rheumatology</strong>, Nottingham<br />
University Hospital, Nottingham, United Kingdom.<br />
7.<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United<br />
Kingdom. 8. <strong>Rheumatology</strong>, NHS Fife, Whyteman’s Brae<br />
Hospital, Kirkcaldy, United Kingdom. 9. <strong>Rheumatology</strong>, Royal<br />
Derby Hospital, Derby, United Kingdom. 10. <strong>Rheumatology</strong>,<br />
Royal Hampshire County Hospital, Winchester, United Kingdom.<br />
11. <strong>Rheumatology</strong>, University College London Hospitals<br />
NHS Foundation Trust, London, United Kingdom. 12. Newcastle<br />
University, Newcastle upon Tyne, United Kingdom.<br />
13.<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead,<br />
United Kingdom. 14. <strong>Rheumatology</strong>, Sunderland Royal Hospital,<br />
Sunderland, United Kingdom. 15. <strong>Rheumatology</strong>, Royal<br />
National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United<br />
Kingdom.<br />
317 ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED WITH<br />
DIFFERENT DURATIONS OF MORNING STIFFNESS IN<br />
RHEUMATOID ARTHRITIS<br />
Bhaskar Dasgupta 1 , Peter Taylor 2 , Itrat Iqbal 3 , Louise Heron 4 ,<br />
Claire Pilling 4<br />
1.<br />
Department of <strong>Rheumatology</strong>, Southend Hospital NHS Trust,<br />
Westcliff-on-Sea, Essex, United Kingdom. 2. Kennedy Institute<br />
of <strong>Rheumatology</strong>, Nuffield Department of Orthopaedics,<br />
<strong>Rheumatology</strong> and Musculoskeletal Sciences, Ox<strong>for</strong>d University<br />
(Botnar Research Centre), Headington, Ox<strong>for</strong>d, United<br />
Kingdom. 3. Health Economics, Mundipharma International<br />
Limited, Cambridge Science Park, Milton Road, Cambridge,<br />
United Kingdom. 4. Value Insight and Communication, Mapi<br />
Values UK, Bollington, Cheshire, United Kingdom.<br />
318 HAS NICE GUIDANCE AFFECTED NON-STEROIDAL<br />
ANTI-INFLAMMATORY DRUG (NSAID) USE FOR<br />
OSTEOARTHRITIS? 10 YEARS OF CROSS-SECTIONAL<br />
DATA FROM A LARGE DISTRICT GENERAL HOSPITAL<br />
Jonathan Marks 1 , Richard Hull 1 , Jo Ledingham 1<br />
1.<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital,<br />
Portsmouth, United Kingdom.<br />
319 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS<br />
METHOTREXATE OR METHOTREXATE ALONE<br />
Chenglong Han 1 , Tim Gathany 1 , Neeta Tandon 2 , Elizabeth Hsia 3<br />
1.<br />
Worldwide Market Access, Janssen Global Services, LLC,<br />
Malvern, PA, United States. 2. Health Economics & Outcomes<br />
Research, Janssen Scientific Affairs, LLC, Horsham, PA, United<br />
States. 3. Immunology, Janssen Research & Development, Inc,<br />
Malvern, PA, United States.<br />
320 PATIENT EXPECTATIONS OF TREATMENT GOALS AND<br />
GOAL-SETTING PRACTICES IN RHEUMATOID ARTHRITIS IN<br />
THE UNITED KINGDOM<br />
P. Taylor 1 , V. Strand 2 , T. Sensky 3 , N. Harta 4 , S. Fleming 5<br />
1.<br />
NDORMS, Ox<strong>for</strong>d University, Ox<strong>for</strong>d, United Kingdom.<br />
2.<br />
Stan<strong>for</strong>d University, Palo Alto, CA, United States. 3. Imperial<br />
College, London, United Kingdom. 4. Opinion Matters, London,<br />
United Kingdom. 5. UCB Pharma, Slough, United Kingdom.<br />
321 PREVIOUS EXPOSURE TO VARICELLA ZOSTER INFECTION IS<br />
THE NORM IN ADULT PATIENTS STARTING BIOLOGIC DRUG<br />
THERAPY FOR INFLAMMATORY ARTHRITIS<br />
Lesley Kay 1 , Michelle Ruther<strong>for</strong>d 1 , Karl Nicholl 1<br />
1.<br />
Newcastle upon Tyne Hospitals NHS Foundation Trust,<br />
Newcastle upon Tyne, United Kingdom.<br />
322 AN ELECTRONIC ALERT SYSTEM TO NOTIFY THE<br />
RHEUMATOLOGY TEAM OF HOSPITAL ADMISSION,<br />
TRANSFER OR DISCHARGE OF RHEUMATOLOGY PATIENTS<br />
TAKING BIOLOGIC DRUGS<br />
Lesley Kay 1 , Michelle Ruther<strong>for</strong>d 1 , Karl Nicholl 1 , Tracey Eyre 1 ,<br />
Gillian Wilson 1 , Phil Johnson 1<br />
1.<br />
Newcastle upon Tyne Hospitals NHS Foundation Trust,<br />
Newcastle upon Tyne, United Kingdom.
120 Poster viewing | Thursday 3 May 2012<br />
323 OBSERVATION OF PERSISTENCE RATES AND COSTS<br />
SAVINGS ASSOCIATED WITH CERTOLIZUMAB PEGOL<br />
TREATMENT FOR RA IN ENGLAND, WALES AND NORTHERN<br />
IRELAND CLINICAL PRACTICE<br />
M. Russell 1 , J. Timoshanko 1 , G. Duncan 2 , A. Spandley 1 ,<br />
S. Roskell 3<br />
1.<br />
UCB Pharma, Slough, United Kingdom. 2. Healthcare at<br />
Home Ltd, Burton on Trent, United Kingdom. 3. <strong>Rheumatology</strong>,<br />
Cannock Chase Hospital , Cannock, United Kingdom.<br />
324 DEVELOPING A PATIENT VISION: GIVING PATIENTS A VOICE<br />
David Coady 1 , Louise West 1<br />
1.<br />
City Hospitals Sunderland, Sunderland, United Kingdom.<br />
325 EARLY INFLAMMATORY BACK PAIN SERVICE (EIBPS) TO<br />
PROVIDE ASSESSMENT, DIAGNOSIS AND PROMPT<br />
TREATMENT FOR PATIENTS WITH AXIAL<br />
SPONDYLOARTHROPATHIES<br />
Rebecca Adshead 1 , Simon P. Donnelly 1 , Simon Ashton 1 ,<br />
Hasan Tahir 1<br />
1.<br />
<strong>Rheumatology</strong>, Whipps Cross University Hospital Trust,<br />
London, United Kingdom.<br />
326 SCREENING FOR LATENT TUBERCUIOSIS IN PATIENTS<br />
STARTING ANTI TNF THERAPY<br />
Dipti Patel 1 , James Darroch 2 , Nicola J. Goodson 1<br />
1.<br />
<strong>Rheumatology</strong>, Aintree University Hospital NHS Foundation<br />
Trust, Liverpool, United Kingdom. 2. Immunology, Royal<br />
Liverpool University Hospital, Liverpool, United Kingdom.<br />
327 CAPACITY AND DEMAND IN RHEUMATOLOGY: A SYSTEM<br />
DYNAMICS APPROACH<br />
John Boulton 1<br />
1.<br />
Department of <strong>Rheumatology</strong>, Sheffield Teaching Hospitals<br />
NHS Foundation Trust, Sheffield, United Kingdom.<br />
328 ATTITUDES TOWARDS PERSONAL HEALTH BUDGETS OF<br />
PEOPLE WITH MUSCULOSKELETAL AND<br />
RHEUMATOLOGICAL CONDITIONS<br />
Benjamin Ellis 1,2 , Ron Finlay 2<br />
1.<br />
Kings Collge Hospital, London, United Kingdom. 2. Policy<br />
and Public Affairs Unit, Arthritis Research UK, London,<br />
United Kingdom.<br />
Sjögren’s syndrome and other connective tissue<br />
disorders<br />
329 HOW GOOD ARE THE EULAR SJÖGREN’S SYNDROME<br />
DISEASE ACTIVITY INDEX (ESSDAI), AND EULAR SJÖGREN’S<br />
SYNDROME PATIENTS REPORTED INDEX (ESSPRI) IN<br />
PREDICTING HEALTH STATUS IN PRIMARY SJÖGREN’S<br />
SYNDROME?<br />
Dennis Lendrem 1 , Sheryl Mitchell 1 , Simon Bowman 3 ,<br />
Elizabeth Price 4 , Colin T. Pease 5 , Paul Emery 5 ,<br />
Jacqueline Andrews 5 , Michele Bombardieri 7 , Nurhan Sutcliffe 7<br />
1.<br />
<strong>Rheumatology</strong>, Newcastle Hospitals NHS Foundation Trust,<br />
Newcastle upon Tyne, United Kingdom. 2. Newcastle<br />
University, Newcastle upon Tyne, United Kingdom.<br />
3.<br />
<strong>Rheumatology</strong>, University Hospital Birmingham, Birmingham,<br />
United Kingdom. 4. <strong>Rheumatology</strong>, Great Western Hospitals<br />
NHS Foundation Trust, Swindon, United Kingdom. 5. NIHR<br />
Leeds Musculoskeletal Biomedical Research Unit, Leeds<br />
Teaching Hospitals Trust, Leeds, United Kingdom.<br />
6.<br />
<strong>Rheumatology</strong>, Nottingham University Hospital, Nottingham,<br />
United Kingdom. 7. <strong>Rheumatology</strong>, Barts and the London<br />
School of Medicine and Dentistry, London, United Kingdom.<br />
8.<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United<br />
Kingdom. 9. <strong>Rheumatology</strong>, NHS Fife, Whyteman’s Brae<br />
Hospital, Kirkcaldy, United Kingdom. 10. <strong>Rheumatology</strong>,<br />
Royal Derby Hospital, Derby, United Kingdom.<br />
11.<br />
<strong>Rheumatology</strong>, Royal Hampshire County Hospital,<br />
Winchester, United Kingdom. 12. <strong>Rheumatology</strong>, University<br />
College London Hospitals NHS Foundation Trust, London,<br />
United Kingdom. 13. <strong>Rheumatology</strong>, Queen Elizabeth Hospital,<br />
Gateshead, United Kingdom. 14. <strong>Rheumatology</strong>, Sunderland<br />
Royal Hospital, Sunderland, United Kingdom.<br />
15.<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, United Kingdom.<br />
330 MONOCYTE-DERIVED IL-32 EXPRESSION CORRELATES WITH<br />
THE LEVEL OF INFLAMMATION IN SALIVARY GLANDS OF<br />
SJÖGREN’S SYNDROME<br />
William Murray-Brown 1 , R. Priori 2 , T. Tappuni 3 , S. Vartoukian 3 ,<br />
N. Seoudi 3 , G. Picarelli 2 , F. Fortune 3 , G. Valesini 2 , C. Pitzalis 1 ,<br />
M. Bombardieri 1<br />
1.<br />
Centre <strong>for</strong> Experimental Medicine & <strong>Rheumatology</strong>, Queen<br />
Mary University of London, London, United Kingdom.<br />
2.<br />
<strong>Rheumatology</strong>, University of Rome, La Sapienza, Italy.<br />
3.<br />
Oral Medicine, Queen Mary University of London, London,<br />
United Kingdom.
Thursday 3 May 2012 | Poster viewing 121<br />
SLE and antiphospholipid syndrome<br />
331 ULTRASOUND ASSESSMENT OF EROSIVE HAND DISEASE IN<br />
SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Elisabeth Ball 1 , Madeleine Rooney 1 , Aubrey Bell 1<br />
1.<br />
<strong>Rheumatology</strong>, Musgrave Park Hospital/Queens’ University,<br />
Belfast, Belfast, United Kingdom.<br />
332 ANTINUCLEAR AUTOANTIBODIES SEROCONVERSION IN 100<br />
PATIENTS WITH LUPUS<br />
Angeles Acosta Mérida 1 , David Isenberg 2<br />
1.<br />
Hospital Universitario de Gran Canaria Dr. Negrín, Servicio<br />
Reumatología, Las Palmas de Gran Canaria, Canary Islands,<br />
Spain. 2. University College London, Centre <strong>for</strong> <strong>Rheumatology</strong><br />
Research, London, United Kingdom.<br />
333 PATTERNS OF IMMUNOGLOBULIN-G GLYCOSYLATION<br />
DISTINGUISH DIFFERENT CLINICAL PHENOTYPES OF<br />
ANTIPHOSPHOLIPID ANTIBODY POSITIVITY<br />
Edward Tarelli 1 , John Ax<strong>for</strong>d 1 , Ian Giles 2 , Charis Pericleous 2 ,<br />
Silvia S. Pierangeli 3 , John Ioannou 2 , Anisur Rahman 2 ,<br />
Azita Alavi 1<br />
1.<br />
Division of Clinical Sciences, St. George’s University of<br />
London, London, United Kingdom. 2. Division of Medicine/<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> Research, University College London,<br />
London, United Kingdom. 3. <strong>Rheumatology</strong>/Internal Medicine,<br />
University of Texas Medical Branch, Galveston, TX, United<br />
States.<br />
334 A CASE CONTROL STUDY OF OSTEOPOROSIS IN SYSTEMIC<br />
LUPUS ERYTHEMATOSUS<br />
Michael Hughes 1 , Bronwen Evans 1 , Marwan Bukhari 1,2<br />
1.<br />
<strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, University of Liverpool,<br />
Liverpool, United Kingdom.<br />
335 A COMPARISON OF PULSE AMPLITUDE TONOMETRY (PAT)<br />
AND FLOW-MEDIATED DILATATION (FMD) OF THE BRACHIAL<br />
ARTERY AS MEASURES OF ENDOTHELIAL FUNCTION IN<br />
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)<br />
Ben Parker 1,2 , Awal Zaki 1 , Yvonne Alexander 2 , Ian Bruce 1,3<br />
1.<br />
Arthritis Research UK Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom. 2. Cardiovascular<br />
Research Group, University of Manchester, Manchester, United<br />
Kingdom. 3. Kellgren Centre <strong>for</strong> <strong>Rheumatology</strong>, Manchester<br />
Royal Infirmary, Manchester, United Kingdom.<br />
336 LONG-TERM OUTCOMES IN LUPUS NEPHRITIS: A<br />
THREE-CENTRE AUDIT<br />
Michelle Hui 1,2 , Rozeena Garner 1 , Frances Rees 2 ,<br />
Riaz Bavakunji 4 , Priya Daniel 3 , Sneha Varughese 3 ,<br />
Asha Srikanth 1 , Mariano Andres 1 , Fiona Pearce 1 , Jansen L<br />
1.<br />
<strong>Rheumatology</strong>, Nottingham University Hospitals, Nottingham,<br />
United Kingdom. 2. <strong>Rheumatology</strong> , Royal Derby Hospital,<br />
Derby, United Kingdom. 3. <strong>Rheumatology</strong>, Kings Mill Hospital,<br />
Sutton-in-Ashfield, United Kingdom. 4. Nephrology, Nottingham<br />
University Hospitals, Nottingham, United Kingdom.<br />
5.<br />
Nephrology, Royal Derby Hospital, Derby, United Kingdom.<br />
Medical Student bursary winner<br />
337 PERIPHERAL NEUROPATHY IN SYSTEMIC LUPUS<br />
ERYTHEMATOSUS<br />
Amin Oomatia 1 , Michelle Petri 2 , Hong Fang 2 , Julius Birnbaum 2<br />
1.<br />
University of Cambridge School of Clinical Medicine,<br />
University of Cambridge, Cambridge, United Kingdom.<br />
2.<br />
Department of <strong>Rheumatology</strong>, Johns Hopkins Medical<br />
Institute, Baltimore, MD, United States.<br />
338 MEASUREMENT OF ARTERIAL STIFFNESS IN A<br />
CROSS-SECTION OF SLE PATIENTS AND RELATIONSHIP TO<br />
TREATMENT WITH INTRAVENOUS METHLYPREDNISOLONE:<br />
A PILOT STUDY<br />
Maame Amissah-Arthur 1 , Mary Gayed 2 , Kirsty Stewart 2 ,<br />
Hannah Jennens 2 , Simon Braude 2 , Caroline Gordon 1,2<br />
1.<br />
<strong>Rheumatology</strong>, University Hospital Birmingham, Birmingham,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, Sandwell & West<br />
Birmingham Hospitals, Birmingham, United Kingdom.
122 Poster viewing | Thursday 3 May 2012<br />
339 BILAG BIOLOGICS PROSPECTIVE COHORT: THE USE OF<br />
NOVEL BIOLOGICAL THERAPIES IN THE TREATMENT OF<br />
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE UK<br />
Emily J. Sutton 1 , Kath D. Watson 1 , Caroline Gordon 2 ,<br />
Chee-Seng Yee 2 , Peter Lanyon 3 , David Jayne 4 ,<br />
David Isenberg 5 , Anisur Rahman 5 , Mohammed Akil 6 , McHugh 7 ,<br />
Yasmeen Ahmad 8 , Nicole Amft 9 , David D’Cruz 10 ,<br />
Christopher J. Edwards 11 , Bridget Griffiths 12 , Munther<br />
Khamashta 10 , Lee-Suan Teh 13 , Asad Zoma 14 , Ian Bruce 1<br />
1.<br />
Arthritis Research UK Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom. 2. <strong>Rheumatology</strong><br />
Research Group, University of Birmingham, Birmingham,<br />
United Kingdom. 3. <strong>Rheumatology</strong>, Nottingham University<br />
Hospital, Nottingham, United Kingdom. 4. Department of<br />
Nephrology, Addenbrooke’s Hospital, Cambridge, United<br />
Kingdom. 5. Centre <strong>for</strong> <strong>Rheumatology</strong>, University College<br />
London, London, United Kingdom. 6. Department of<br />
<strong>Rheumatology</strong>, Sheffield Teaching Hospitals NHS Trust,<br />
Sheffield, United Kingdom. 7. Department of <strong>Rheumatology</strong>,<br />
Royal National Hospital <strong>for</strong> Rheumatic Diseases NHS Trust,<br />
Bath, United Kingdom. 8. Department of <strong>Rheumatology</strong>, North<br />
West Wales NHS Trust, Bangor, United Kingdom. 9. Rheumatic<br />
Diseases Unit, Western General Hospital, Edinburgh, United<br />
Kingdom. 10. Lupus Research Unit, St Thomas’ Hospital,<br />
London, United Kingdom. 11. Department of <strong>Rheumatology</strong>,<br />
University of Southampton, Southampton, United Kingdom.<br />
12.<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital,<br />
Newcastle-upon-Tyne, United Kingdom. 13. Department of<br />
<strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United<br />
Kingdom. 14. Department of <strong>Rheumatology</strong>, Hairmyres<br />
Hospital, Lanarkshire, United Kingdom<br />
340 A NESTED CASE CONTROL STUDY OF THE ASSOCIATION<br />
BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS AND<br />
CANCER<br />
Ida D. Dey 1,2 , Ernest Kenu 2 , David Isenberg 1<br />
1.<br />
Department of rheumatology, University College London<br />
Hospitals, London, United Kingdom. 2. Department of<br />
Medicine and <strong>The</strong>rapeutics, Korlebu Teaching Hospital,<br />
Accra, Ghana.<br />
341 PROFILING SUB-TYPES OF ANTI-Β2 GLYCOPROTEIN I AND<br />
ANTI-DOMAIN I ANTIBODIES MAY DISTINGUISH BETWEEN<br />
DIFFERENT CLINICAL PHENOTYPES OF THE<br />
ANTIPHOSPHOLIPID SYNDROME<br />
Charis Pericleous 1 , Acely Garza-Garcia 2 , Lucy Murfitt 2 ,<br />
Paul C. Driscoll 2 , David Isenberg 1 , Silvia Pierangeli 3 , Ian Giles 1 ,<br />
Yiannis Ioannou 1 , Anisur Rahman 1<br />
1.<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, Division of Medicine, University<br />
College London, London, United Kingdom. 2. Structural<br />
Biology, MRC National Institute of Medical Research, London,<br />
United Kingdom. 3. Division of <strong>Rheumatology</strong>, Department<br />
of Internal Medicine , University of Texas Medical Branch,<br />
Galveston, TX, United States.<br />
342 INTERFERON-MEDIATED VASCULAR DAMAGE IN SLE:<br />
FAILURE OF ENDOTHELIAL REPAIR RATHER THAN DIRECT<br />
ENDOTHELIAL TOXICITY?<br />
John A. Reynolds 1 , David W. Ray 2 , Terence O’Neill 1 ,<br />
Yvonne Alexander 3 , Ian Bruce 1<br />
1.<br />
Arthritis Research UK Epidemiology Unit, School of<br />
Translational Medicine, <strong>The</strong> University of Manchester,<br />
Manchester, United Kingdom. 2. Endocrine Sciences Research<br />
Group, <strong>The</strong> University of Manchester, Manchester, United<br />
Kingdom. 3. Cardiovascular Research Group, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom.<br />
343 SOLUBLE VASCULAR CELL ADHESION MOLECULE-1<br />
(SVCAM-1) LEVEL IN PATIENTS WITH ANTHIPHOSPOLIPID<br />
SYNDROME (APS), ITS ASSOCIATION WITH DISEASE<br />
ACTIVITY AND ENDOTHELIUM DYSFUNCTION<br />
Iuliia Segeda 1 , Sergii Shevchuk 1 , Inna Kuvikova 1<br />
1.<br />
Institute of Invalid Reabilitation, Vinnitsa, Ukraine.<br />
Vasculitis<br />
344 PREVENTION OF TREATMENT RELATED MORBIDITY IN<br />
ANCA- ASSOCIATED VASCULITIS: THE PATIENT’S<br />
PERSPECTIVE<br />
Nina Brown 1 , Ian Bruce 3,2 , Michael Venning 1<br />
1.<br />
Renal, Central Manchester Foundation Trust, Manchester,<br />
United Kingdom. 2. <strong>Rheumatology</strong>, Central Manchester<br />
Foundation Trust, Manchester, United Kingdom. 3. Arthritis<br />
Research Council Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom.
Thursday 3 May 2012 | Poster viewing 123<br />
345 TAKAYASU’S ARTERITIS IN PREGNANCY: A BRITISH CASE<br />
SERIES<br />
Puja Mehta 1 , Mandish Dhanjal 2 , Justin Mason 1 ,<br />
Catherine Nelson-Piercy 2<br />
1.<br />
Department of <strong>Rheumatology</strong>, Imperial College Healthcare<br />
NHS Trust, London, United Kingdom. 2. Department of<br />
Obstetric Medicine, Queen Charlotte’s and Chelsea Hospital,<br />
Imperial College Healthcare NHS Trust, London, United<br />
Kingdom.<br />
346 MULTI-DISCIPLINARY MANAGEMENT OF FATIGUE IN ANCA<br />
ASSOCIATED VASCULITIS: A PILOT STUDY<br />
Neil Basu 1 , Priya Paudyal 1 , Marie Stockton 3 , Sally Lawton 3 ,<br />
Caroline Dent 3 , Kathy Kindness 3 , Gillian Meldrum 3 ,<br />
Elizabeth John 3 , Catherine Arthur 3 , Lucy West<br />
1.<br />
Institute of Applied Health Sciences (Epidemiology Group),<br />
University of Aberdeen, Aberdeen, United Kingdom. 2. Division<br />
of Applied Medicine, University of Aberdeen, Aberdeen, United<br />
Kingdom. 3. Roxburghe House, NHS Grampian, Aberdeen,<br />
United Kingdom.<br />
349 DEVELOPMENT OF AN INDEX TO ASSESS DISEASE-RELATED<br />
DAMAGE IN TAKAYASU ARTERITIS AND USE IN OUTCOME OF<br />
VASCULAR INTERVENTIONS<br />
Rajappa Sivakumar 1 , Ramnath Misra 2 , Debashish Danda 3 ,<br />
Km Mahendranath 4 , Paul A. Bacon 5<br />
1.<br />
Cerebrovascular Centre, Cerebrovascular and Vasculitis<br />
Research Foundation, Chennai, United Kingdom. 2. Clinical<br />
Immunology, Sanjay Gandhi Post Graduate Institute of Medical<br />
Sciences, Lucknow, India. 3. <strong>Rheumatology</strong>, Christian Medical<br />
College, Vellore, India. 4. <strong>Rheumatology</strong>, Samarpan Medical<br />
Centre, Bangalore, India. 5. <strong>Rheumatology</strong>, University of<br />
Birmingham, Birmingham, United Kingdom.<br />
350 ARE THERE SUFFICIENT DATA TO JUSTIFY CHANGING THE<br />
BSR GUIDELINES FOR ANEURYSM SCREENING IN GIANT<br />
CELL ARTERITIS? A SYSTEMATIC LITERATURE REVIEW<br />
Sarah L. Mackie 1,2 , Colin T. Pease 2<br />
1.<br />
NIHR-Leeds Musculoskeletal Biomedical Research Unit,<br />
University of Leeds, Leeds, United Kingdom. 2. <strong>Rheumatology</strong>,<br />
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.<br />
347 SYSTEMATIC REVIEW OF STEROID TRIALS IN GIANT CELL<br />
ARTERITIS<br />
Max Yates 1 , Yoon Loke 2 , Richard Watts 2,3 , Alex MacGregor 1,2<br />
1.<br />
Department of <strong>Rheumatology</strong>, NNUH, Norwich, United<br />
Kingdom. 2. Norwich Medical School, UEA, Norwich, United<br />
Kingdom. 3. Department of <strong>Rheumatology</strong>, Ipswich Hospital,<br />
Ipswich, United Kingdom.<br />
348 SUCCESFUL USE OF LEFLUNOMIDE IN TREATMENT OF<br />
REFRACTORY POLYMYALGIA RHEUMATICA AND GIANT<br />
CELL ARTERITIS<br />
Tochukwu Adizie 1 , Dimitrios Christidis 1 , Bhaskar Dasgupta 1 ,<br />
Mark Williams 1<br />
1.<br />
Southend Hospital , Westcliff-on-sea, United Kingdom.
124 Poster viewing | Thursday 3 May 2012
Exhibition<br />
Exhibition
A STRONG ANALGESIC WITH TWO<br />
MECHANISMS OF ACTION IN ONE MOLECULE 1<br />
Start to unlock severe chronic back pain<br />
with Palexia SR<br />
Palexia SR (tapentadol prolonged release tablets) is indicated <strong>for</strong> the treatment of severe<br />
chronic pain in adults, which can be adequately managed only with opioid analgesics 2<br />
Tapentadol is a Controlled Drug, Schedule 2<br />
visit www.palexia.co.uk <strong>for</strong> more in<strong>for</strong>mation<br />
PALEXIA ® SR and PALEXIA ® Prescribing In<strong>for</strong>mation.<br />
Refer to the Summary of Product Characteristics (SmPCs) be<strong>for</strong>e prescribing.<br />
Presentation: Palexia SR: 50 mg (white), 100 mg (pale yellow), 150 mg (pale pink),<br />
200 mg (pale orange) and 250 mg (brownish red) prolonged-release tablets contain<br />
50 mg, 100 mg, 150 mg, 200 mg and 250 mg of tapentadol (as hydrochloride)<br />
respectively. Palexia: 50 mg (white) and 75 mg (pale yellow) fi lm-coated tablets contain<br />
50 mg and 75 mg of tapentadol (as hydrochloride) respectively. Indication: Palexia<br />
SR is indicated <strong>for</strong> the management of severe chronic pain in adults, which can be<br />
adequately managed only with opioid analgesics. Palexia is indicated <strong>for</strong> the relief of<br />
moderate to severe acute pain in adults, which can be adequately managed only with<br />
opioid analgesics. Dosage and method of administration: Individualise according<br />
to severity of pain, the previous treatment experience and the ability to monitor the<br />
patient. Swallowed whole with suffi cient liquid, with or without food. Palexia SR should<br />
not be divided or chewed. Palexia SR dosage: Initial dose 50 mg twice a day. Switching<br />
from other opioids may require higher initial doses. Titrate in increments of 50 mg<br />
twice a day every 3 days <strong>for</strong> adequate pain control. Total daily doses greater than 500<br />
mg not recommended. Palexia dosage: Initial dose 50 mg every 4 to 6 hours. On the<br />
fi rst day of dosing, an additional dose may be taken 1 hour after the initial dose, if no<br />
pain control. <strong>The</strong> fi rst day’s dose should not exceed 700 mg. Maximum maintenance<br />
daily dose of up to 600 mg. Discontinuation of treatment: Taper dose gradually to<br />
prevent withdrawal symptoms. Renal/hepatic impairment: Not recommended in<br />
severe patients. Caution and dose adjustments with moderate hepatic impairment.<br />
Elderly: May need dose adjustments. Children below 18 years: Not recommended.<br />
Contraindications: Hypersensitivity to ingredients, suspected or having paralytic<br />
ileus, acute alcohol intoxication, hypnotics, centrally acting analgesics or psychotropics.<br />
Not <strong>for</strong> use when mu-opioid receptor agonists are contraindicated (e.g. signifi cant<br />
respiratory depression, acute or severe bronchial asthma or hypercapnia). Special<br />
warnings and precautions: At risk patients may require monitoring due to misuse,<br />
abuse, addiction or diversion. At high doses or in mu-opioid receptor agonist sensitive<br />
patients, dose-related respiratory depression may occur. Caution and monitoring<br />
required with impaired respiratory function. Should not use in patients susceptible to<br />
intracranial effects of carbon dioxide retention (e.g. increased intracranial pressure,<br />
impaired consciousness or coma). Use with caution with head injury, brain tumors,<br />
history or at risk of seizures, moderate hepatic impairment, biliary tract disease or acute<br />
pancreatitis. Not recommended with severe renal or hepatic impairment. Avoid use in<br />
patients who have taken monoamine oxidase inhibitors (MAOIs) within the last 14 days,<br />
due to cardiovascular events. Should not use with hereditary problems of galactose<br />
intolerance, Lapp lactase defi ciency or glucose-galactose malabsorption. Interactions:<br />
Use with benzodiazepines, barbiturates and opioid analgesics, antitussive drugs<br />
and substitutive treatments may enhance the risk of respiratory depression.<br />
Central nervous system (CNS) depressants (e.g. benzodiazepines, antipsychotics,<br />
H1-antihistamines, opioids, alcohol) can enhance the sedative effect and<br />
impair vigilance. Consider dose reduction with respiratory or CNS depressant<br />
agents. In isolated cases, serotonin syndrome has been reported with Palexia<br />
SR/Palexia in combination with serotoninergic medicinal products (e.g. serotonin<br />
re-uptake inhibitors). Care should be taken with mixed mu-opioid agonist/antagonists<br />
or partial mu-opioid agonists due to risk of reducing the analgesic effect. Use<br />
with strong inhibitors of uridine diphosphate transferase isoenzymes (involved in<br />
glucuronidation) may increase systemic exposure of Palexia SR/Palexia. Risk of<br />
decreased effi cacy or adverse events if used with strong enzyme inducing drugs<br />
(e.g. rifampicin, phenobarbital, St John’s Wort). Pregnancy and lactation: Do not<br />
use. Driving and using machines: May have major effect on ability to drive and<br />
use machines, especially at the beginning or change in treatment, in connection<br />
with alcohol or tranquilisers. Undesirable effects: Very common (1/10): dizziness,<br />
somnolence, headache, nausea. Palexia SR only: constipation. Palexia only: vomiting.<br />
Common (1/100,
126 Exhibition | 1-3 May 2012<br />
Exhibitor List<br />
4S Dawn Clinical Software stand 88<br />
A. Algeo Ltd stand 44<br />
Abbott stand 38<br />
ARMA stand 8<br />
Arthritis Care stand 18<br />
Arthritis Research UK stand 56<br />
BARC/BSSA stand 22<br />
BioMarin Europe Ltd stand 70<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong> stand 32<br />
<strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> stand 32<br />
BSR Biologics Register stand 32<br />
Britsol-Myers Squibb Pharmaceuticals stand 114<br />
Cellestis GmbH stand 64<br />
Central Homecare stand 40<br />
Eli Lilly stand 42<br />
Esaote stand 68<br />
Excellence in <strong>Rheumatology</strong> stand 94<br />
Fibromyalgia Association UK stand 13<br />
Genus stand 106<br />
Genzyme stand 110<br />
GlaxoSmithKline/Human genome Sciences stand 60<br />
Grünenthal Ltd stand 74<br />
Healthcare at Home Ltd stand 6<br />
Internis Pharmaceuticals Ltd stand 61<br />
Lupus UK stand 12<br />
Medac stand 52<br />
Miltenyi Biotec Ltd stand 90<br />
Mivenion GmbH stand 48<br />
MSD stand 78<br />
Myositis stand 14<br />
NASS stand 15<br />
NRAS stand 17<br />
Ox<strong>for</strong>d Diagnostic Laboratories stand 46<br />
Pfizer Ltd stand 34<br />
Philips Healthcare stand 50<br />
PMR & GCA stand 11<br />
PSALV stand 20<br />
Pulmonary Hypertension Association UK stand 92<br />
RCN stand 16<br />
Roche Products Ltd stand 98<br />
Rapport stand 104<br />
<strong>Rheumatology</strong> and Ox<strong>for</strong>d University Press stand 62<br />
RAF stand 72<br />
Royal <strong>Society</strong> of Medicine stand 4<br />
Sanofi Aventis stand 63<br />
Savient Pharma Ireland Limited stand 66<br />
Scleroderma <strong>Society</strong> stand 10<br />
Servier Lab Ltd stand 76<br />
SOBI stand 65<br />
TRB Chemedica (UK) Ltd stand 49<br />
UCB stand 26<br />
Vertec Scientific stand 51<br />
Wisepress stand 2
Exhibition floor plan<br />
HALL 5<br />
1-3 May 2012 | Exhibition 127<br />
Poster <strong>View</strong>ing<br />
Poster <strong>View</strong>ing<br />
Disabled<br />
Toilets<br />
Press area<br />
Catering Point<br />
Poster<br />
registration<br />
110 100<br />
114 108<br />
102<br />
98<br />
107<br />
106<br />
104<br />
94<br />
92<br />
90<br />
88<br />
Catering Point<br />
65<br />
63<br />
61<br />
68<br />
60<br />
66<br />
64<br />
62<br />
70<br />
71<br />
76<br />
74<br />
56 52<br />
Cyber<br />
Café<br />
48 49<br />
50<br />
51<br />
78<br />
46 42<br />
44 40<br />
Catering Point<br />
22<br />
20<br />
26<br />
32<br />
34 38<br />
18<br />
17<br />
16<br />
15<br />
14<br />
Exit<br />
8<br />
Registration 6 4 2<br />
10<br />
11<br />
12<br />
13<br />
Entrance<br />
DOOR 5A<br />
DOOR 5B
128 Exhibition | 1-3 May 2012<br />
<strong>Rheumatology</strong> 2012 exhibitors<br />
4S Dawn Clinical Software stand 88<br />
4S DAWN Clinical Software heralds the new era of <strong>Rheumatology</strong><br />
software. DAWN removes the frustration of searching <strong>for</strong> results and<br />
in<strong>for</strong>mation! <strong>The</strong> frustration of filling out <strong>for</strong>ms! <strong>The</strong> fear that some<br />
patients are not being monitored or followed up!<br />
Fall in love with DAWN <strong>Rheumatology</strong> Clinic Software and Embrace<br />
improved safety, quality and productivity. Make your patients feel<br />
cared <strong>for</strong> with printed hand-held records, text-messaging, dictated<br />
letters and so much more...<br />
A. Algeo Ltd stand 44<br />
A.Algeo Ltd (Algeos) are proud suppliers to the podiatry and foot<br />
health sectors. We specialise in foot orthotics, instruments,<br />
diagnostics and podiatry equipment. We also stock a large range of<br />
gel items, com<strong>for</strong>t materials, pharmaceuticals and clinic furniture.<br />
Abbott stand 38<br />
Abbott is a global, broad-based health care company devoted<br />
to discovering new medicines, new technologies and new ways<br />
to manage health. Abbott scientists are applying innovative<br />
monoclonal antibody technology to discover and develop novel<br />
therapies to treat diseases of the immune system including<br />
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,<br />
Crohn’s disease and psoriasis. Tel: 01628 77 33 55<br />
Fax: 01628 64 43 05 Website: www.abbottuk.com<br />
ARMA stand 8<br />
ARMA is the umbrella body <strong>for</strong> the musculoskeletal community<br />
consisting of 37 members including user groups, professional bodies<br />
and research groups. Together with its members, ARMA provides a<br />
<strong>for</strong>um <strong>for</strong> organisations active in the musculoskeletal field to<br />
communicate with each other, co-ordinate their activities and speak<br />
with a collective voice in order to improve the quality of life of people<br />
with musculoskeletal disorders. www.arma.uk.net<br />
Arthritis Care stand 18<br />
Come and visit us at Stand 18 and see how Arthritis Care can<br />
enhance the value of your service. Influencing health policy and<br />
services through campaigning, and providing self management<br />
training courses, to help patients manage their condition. Offering<br />
a free confidential helpline to support your patients throughout their<br />
experience of their condition and providing award winning in<strong>for</strong>mation<br />
enabling patients to make better use of appointments.<br />
Arthritis Research UK stand 56<br />
Arthritis Research UK is the charity leading the fight against arthritis.<br />
Arthritis affects more than 10 million people in the UK. We’re working<br />
to take the pain away <strong>for</strong> sufferers of all <strong>for</strong>ms of the condition and<br />
to help people to remain active. We fund high class research and<br />
provide a comprehensive range of in<strong>for</strong>mation <strong>for</strong> patients, the<br />
public and health professionals. www.arthritisresearchuk.org<br />
BARC stand 22<br />
Birmingham Arthritis Resource Centre (BARC)<br />
Our fundamental aim is to promote ‘self care’ and<br />
‘self-management’, supporting people with chronic and painful<br />
conditions to cope with their problems. We encourage clients to take<br />
an active role in managing their care. <strong>The</strong> Centre is run by a team of<br />
volunteers who are trained as (Patient Educators) and do have a<br />
relevant personal disease experience.<br />
BSSA stand 22<br />
<strong>The</strong> <strong>British</strong> Sjögren's Syndrome Association (BSSA) is a registered<br />
charity which aims to raise awareness of the disease and support<br />
research into its cause and treatment. <strong>The</strong> BSSA supports patients<br />
and carers, educates the public and professionals and raises funds<br />
<strong>for</strong> research into Sjögren’s by providing research grants on an annual<br />
basis. No cure currently exists <strong>for</strong> the condition and the cause<br />
remains unknown. Sjögren’s Syndrome is the second most common<br />
auto immune rheunmatic disease affecting 3-4% of adults in the UK,<br />
but it is under diagnosed and may go untreated. It is characterised<br />
by the degeneration of mucus-secreting glands, particularly the tear<br />
ducts and the saliva glands of the mouth. Other symptoms can<br />
include arthritis and extreme fatigue, disabling joint pain and muscle<br />
aches. http://www.bssa.uk.net/
1-3 May 2012 | Exhibition 129<br />
BioMarin Europe Ltd stand 70<br />
BioMarin Pharmaceutical Inc. develops and commercialises<br />
promising new therapeutics <strong>for</strong> patients with severe and<br />
life-threatening diseases. Headquartered in Novato, Cali<strong>for</strong>nia, the<br />
company operates subsidiary offices in Europe, Latin America and<br />
the Middle East and since it was founded in 1997, the company has<br />
successfully advanced three breakthrough products from bench, to<br />
market, to patients which is a testament to the company's passion<br />
and dedication to patients with serious unmet medical needs.<br />
BioMarin Europe Limited 3rd Floor 164 Shaftesbury Avenue London<br />
WC2H 8HL Tel (Direct): +44 (0)207 420 0800<br />
Fax: +44 (0)207 420 0829 Email: biomarin-europe@bmrn.com<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong> stand 32<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong> (BHPR) unites and<br />
supports members of the multi-disciplinary team in delivering best<br />
quality care which meets the needs of individuals with<br />
musculoskeletal conditions. We have a growing membership,<br />
fast approaching the 500 mark, from many professions: nursing,<br />
physiotherapy, occupational therapy, podiatry, psychology, medicine,<br />
pharmacy and others. Come and visit our stand and learn more<br />
about the work we are doing and how to get involved.<br />
www.rheumatology.org.uk<br />
<strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> stand 32<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> (BSR) promotes excellence in<br />
the treatment of people with arthritis and musculoskeletal conditions,<br />
and supports those delivering it. Come and visit our stand to find out<br />
more about our work and <strong>for</strong> more in<strong>for</strong>mation about becoming a<br />
member. www.rheumatology.org.uk<br />
Bristol-Myers Squibb Pharmaceuticals stand 114<br />
Bristol-Myers Squibb is working to fight serious diseases in<br />
several areas of unmet medical need. Our medications are<br />
helping millions of patients worldwide battle illnesses including<br />
schizophrenia, HIV/AIDS, cancer, chronic hepatitis B,<br />
cardiovascular disease and rheumatoid arthritis. Our mission is<br />
to extend and enhance human life, the opportunities ahead to<br />
combat disease and positively impact people’s lives around the<br />
world have never been more promising.<br />
Cellestis GmbH stand 64<br />
Cellestis is a listed Australian biotechnology company that is a<br />
leader in the detection and control of tuberculosis, with the<br />
development of its breakthrough blood test QuantiFERON®-TB<br />
Gold In-Tube (QFT). Cellestis is focused on developing<br />
diagnostics tests that measure immune function <strong>for</strong> diseases<br />
with an unmet medical need.<br />
Central Homecare stand 40<br />
Central Homecare, a member of Alliance Boots, is a national<br />
provider of clinical homecare services, supporting patients across<br />
a wide range of therapeutic areas Patients are managed by<br />
experienced Patient Co-ordinators who provide a full range of support<br />
services, including arranging patient training by our own therapy<br />
trained nurses. For further in<strong>for</strong>mation, please visit the Central<br />
Homecare stand 40 or visit our web site www.centralhomecare.co.uk<br />
Tel: 01420 453400.<br />
BSR Biologics Registers stand 32<br />
<strong>The</strong> BSR Biologics Registers (BSRBR) track the progress of patients<br />
who are receiving biologic agents, monitoring the safety and<br />
effectiveness of these treatments over the long term. <strong>The</strong> BSRBR<br />
currently manage the Rheumatoid Arthritis (RA) register, which has<br />
been running <strong>for</strong> 10 years and has successful registered over 20,000<br />
patients and continues to grow. This register is based at the Arthritis<br />
Research UK Epidemiology Unit at the University of Manchester and<br />
monitors the safety of seven biologic therapies. <strong>The</strong> Ankylosing<br />
Spondylitis (AS) register launched in April 2012 and is run by the<br />
University of Aberdeen and will monitor the safety of two biologic<br />
therapies. www.rheumatology.org.uk/bsr_biologics_register
130 Exhibition | 1-3 May 2012<br />
Eli Lilly stand 42<br />
Eli Lilly and Company Limited is one of the world's largest<br />
research-based bio-pharmaceutical companies, dedicated to creating<br />
and delivering innovative pharmaceutical healthcare solutions that<br />
enable people to live longer, healthier and more active lives. Our<br />
research and development ef<strong>for</strong>ts constantly strive to address the<br />
world’s growing unmet medical needs in several different clinical<br />
areas. Eli Lilly has a significant presence in the UK at several<br />
locations:<br />
Erl Wood, Surrey: Home to our European HQ and largest R&D<br />
facility outside the US.<br />
Speke, Merseyside: A bulk biotech manufacturing plant which<br />
makes both human and animal health products.<br />
Basingstoke, Hampshire: <strong>The</strong> Headquarters <strong>for</strong> the UK<br />
pharmaceutical business.<br />
For in<strong>for</strong>mation about our products or services, please come and talk<br />
to us at the Lilly stand, or log on to the Eli Lilly website at<br />
www.lilly.com. We look <strong>for</strong>ward to meeting you.<br />
Esaote stand 68<br />
Esaote is one of the world’s leading producers of medical diagnostic<br />
systems and is committed to providing high quality ultrasound &<br />
extremity MRI system solutions. Our systems offer the latest<br />
technologies, unmatched per<strong>for</strong>mance and ease of use.<br />
With systems designed <strong>for</strong> <strong>Rheumatology</strong>, from Point of Care to<br />
High End cart ultrasound and extremity MRI, Esaote offer stunning<br />
image quality allowing you to focus on your patient.<br />
Excellence in <strong>Rheumatology</strong> stand 94<br />
Excellence in <strong>Rheumatology</strong> (EiR) is the annual international<br />
<strong>conference</strong> of the Excellence in <strong>Rheumatology</strong> Institute. <strong>The</strong> 2013<br />
edition will take place in Lisbon, Portugal, 24-27 January 2013 and<br />
will present cutting edge scientific findings as they relate to clinical<br />
practice.<br />
Fibromyalgia Association UK stand 13<br />
FMA UK provides in<strong>for</strong>mation to the general public and medical<br />
professionals on fibromyalgia. Our volunteer led charity lobbies <strong>for</strong><br />
quicker diagnosis and more effective treatment <strong>for</strong> the estimated<br />
1.2m people with fibromyalgia in the UK. <strong>The</strong>re are no approved<br />
guidelines <strong>for</strong> treatment with many people suffering in constant<br />
pain without a diagnosis <strong>for</strong> many years. FMA UK is determined<br />
to improve this unacceptable situation.<br />
Genus Pharmaceuticals Limited stand 106<br />
Genus Pharmaceuticals is a medium sized pharmaceutical company<br />
specialising in supply of <strong>Rheumatology</strong>, Dermatology and Parkinson’s<br />
Disease Medicines. Genus focuses on a number of different therapy<br />
areas to improve the quality of life of patients and works with health<br />
care professionals to enhance patient outcomes and efficiency.<br />
Genzyme stand 110<br />
Genzyme has pioneered the development and delivery of<br />
trans<strong>for</strong>mative therapies <strong>for</strong> patients affected by rare and debilitating<br />
diseases <strong>for</strong> over 30 years. With a focus on rare diseases and<br />
multiple sclerosis, we are dedicated to making a positive impact<br />
on the lives of the patients and families we serve.<br />
GlaxoSmithKline/Human genome Sciences stand 60<br />
Website: www.gsk.com, www.hgsi.com<br />
At GSK we have a challenging and inspiring mission: to improve the<br />
quality of human life by enabling people to do more, feel better and<br />
live longer.<br />
At Human Genome Sciences, we believe that solving critical<br />
medical challenges takes careful planning, relentless resilience,<br />
the best scientific minds, and rigorous clinical trials.<br />
Grünenthal Ltd stand 74<br />
Grünenthal is an independent, family-owned international research<br />
based pharmaceutical company with a focus on the treatment of<br />
pain. Grünenthal has affiliates in 35 countries worldwide, and its<br />
products treat patients in more than 100 countries.<br />
Healthcare at Home Ltd stand 6<br />
<strong>The</strong> UK leader in high-tech clinical homecare and speciality<br />
pharmacy. We also deliver services on-site throughout the NHS and<br />
independent sector. Our 1,000 staff includes over 400 highly skilled<br />
and experienced nurses. With operations throughout the UK, we<br />
provide a vast range of services to over 150,000 patients each year.<br />
Tel: 0870 600 1540 Email: info@hah.co.uk Website: www.hah.co.uk<br />
Internis Pharmaceuticals Ltd stand 61<br />
Founded in 2010, Internis is a pharmaceutical company engaged<br />
in the development and commercialisation of highly effective and<br />
innovative new medicines aimed at the treatment and prevention<br />
of a range of common bone disorders, such as osteoporosis and<br />
vitamin D3 deficiency.
131 Exhibition | 1-3 May 2012<br />
1-3 May 2012 | Exhibition 131<br />
Lupus UK stand 12<br />
LUPUS UK is the only national charity <strong>for</strong> people with lupus offering<br />
support through our voluntary network of over 20 Regional Groups.<br />
Our priorities are to increase lupus awareness amongst the public<br />
and the medical profession, provide support to our members, and<br />
raise funds towards research and Lupus Nurses. Tel: 01708<br />
731251 (24 hour answer phone) website www.lupusuk.org.uk<br />
Medac stand 52<br />
Medac is a German based pharmaceutical manufacturer with a<br />
growing number of branches around the world. Metoject was<br />
launched by Medac in the UK in 2006 as the first range of prefilled<br />
syringes of methotrexate licensed <strong>for</strong> use in rheumatoid arthritis.<br />
Miltenyi Biotec Ltd stand 90<br />
Miltenyi Biotec’s products support basic biomedical research<br />
through to clinical cell isolation and culture, cryopreservation, and<br />
Ig and LDL immunoadsorption therapy.<br />
<strong>The</strong>raSorb <strong>The</strong>rapeutic Apheresis: the treatment option <strong>for</strong><br />
pathogenic immunoglobulin-associated disease (e.g. SLE, Vasculitis,<br />
Scleroderma, Pemphigus, etc.)<br />
CliniMACS® Cell Separation System: clinical grade isolation of<br />
therapeutic cell populations (e.g. TRegs, TolDC’s, MSC’s, etc.)<br />
MACS® GMP Products: culture, differentiation and expansion of<br />
cell therapy products.<br />
Mivenion GmbH stand 48<br />
Mivenion offers Xiralite, a fluorescence-optical system <strong>for</strong> imaging<br />
of rheumatic disorder in the hands. <strong>The</strong> altered microcirculation in<br />
active inflammation is visualized, providing in<strong>for</strong>mation on disease<br />
activity, differential diagnosis, and quantification of treatment<br />
response. It is tailored to the diagnostic needs of rheumatologists,<br />
is easy to use, and allows full integration into the patient workflow,<br />
thus providing fast and reliable in<strong>for</strong>mation <strong>for</strong> treatment decisions.<br />
MSD stand 78<br />
Today's MSD is a global healthcare leader who is working to help<br />
the world be well.<br />
Myositis Support Group stand 14<br />
<strong>The</strong> Myositis Support Group is a UK charity providing advice and<br />
support to individuals and their families affected by Dermatomyositis,<br />
Polymyositis, Inclusion Body Myositis and Juvenile Dermatomyositis.<br />
We also raise funds and promote medical research to improve the<br />
diagnosis, treatment, management and understanding of these<br />
rare illnesses.<br />
NASS stand 15<br />
<strong>The</strong> National Ankylosing Spondylitis <strong>Society</strong> (NASS) was founded<br />
over 30 years ago to provide support and advice <strong>for</strong> patients and<br />
their families. NASS works to raise awareness of AS and provides a<br />
website, publications and in<strong>for</strong>mation as well as running a branch<br />
network of around 95 branches throughout the UK offering regular<br />
supervised exercise sessions. NASS members also participate in<br />
ongoing genetic research into the disease.<br />
NRAS stand 17<br />
<strong>The</strong> National Rheumatoid Arthritis <strong>Society</strong> (NRAS) was launched in<br />
October 2001 and in a relatively short time has become established<br />
as the voice in the UK <strong>for</strong> people with Rheumatoid Arthritis (RA).<br />
NRAS provides assistance to all people in the UK with RA, their<br />
carers and families. We offer a range of services, including support,<br />
in<strong>for</strong>mation, dedicated education <strong>programme</strong>s and peer to peer<br />
support. We also campaign to raise awareness of the disease and<br />
ensure fair treatment <strong>for</strong> all.<br />
Ox<strong>for</strong>d Diagnostic Laboratories stand 46<br />
TB Screening Just Got Easier: Visit Ox<strong>for</strong>d Diagnostic Laboratories<br />
on stand no. 46 to learn about the most Simple, Reliable and Cost<br />
Effective TB Testing Service available in the UK.<br />
Ox<strong>for</strong>d Diagnostic Laboratories is the only national service laboratory<br />
dedicated to running the T-SPOT®.TB IGRA <strong>for</strong> accurate detection<br />
of tuberculosis.<br />
Contact us <strong>for</strong> more in<strong>for</strong>mation:<br />
E-mail: odl@ox<strong>for</strong>dimmunotec.com Tel: 01235 433164<br />
www.tbtestingservices.com<br />
Through our medicines, vaccines, biologic therapies, and consumer<br />
and animal products, we collaborate with human and animal health<br />
professionals across the UK and in more than 140 countries to<br />
deliver innovative health solutions.<br />
Beyond this, we have a commitment to increasing access to<br />
healthcare through far-reaching <strong>programme</strong>s that donate and<br />
deliver our products to people who need them.<br />
For more in<strong>for</strong>mation, please go to www.msd-uk.co.uk.
132 Exhibition | 1-3 May 2012<br />
Pfizer Ltd stand 34<br />
WORKING TOGETHER FOR A HEALTHIER WORLD<br />
At Pfizer, we strive to set the standard <strong>for</strong> quality, safety and<br />
value in the discovery, development and manufacturing of<br />
medicines <strong>for</strong> people. For more than 150 years, Pfizer has<br />
worked to make a difference <strong>for</strong> all who rely on us. In the UK,<br />
Pfizer has its business headquarters in Surrey and is the major<br />
supplier of medicines to the NHS. To learn more about our<br />
commitments, please visit us at www.pfizer.co.uk<br />
RCN stand 16<br />
<strong>The</strong> Royal College of Nurses represents the interests of nurses and<br />
nursing. It aims to educate nurses both academically and<br />
professionally, promoting the art and science of nursing and its<br />
professional practice. <strong>The</strong> rheumatology <strong>for</strong>um aims to promote this<br />
role within the field of rheumatology, providing support and<br />
continuing professional development <strong>for</strong> nurses to ensure they<br />
influence and deliver the best possible care <strong>for</strong> patients with<br />
rheumatological conditions.<br />
Philips Healthcare stand 50<br />
Philips will exhibit its latest plat<strong>for</strong>m of their Vision 2012, iU22<br />
Premium Per<strong>for</strong>mance ultrasound system featuring the very latest<br />
advanced technology on the linear transducer range. <strong>The</strong> transducers<br />
have been expertly optimized to enhance image quality <strong>for</strong> all<br />
musculo-skeletal examinations. Come and visit our stand to discuss<br />
how Philips leading edge Elastography can increase diagnostic<br />
confidence in inflammatory joint conditions.<br />
www.philips.com/healthcare<br />
PMR & GCA stand 11<br />
Polymyalgia Rheumatica and Giant Cell Arteritis Scotland was the<br />
first charity in the UK specifically <strong>for</strong> people with these neglected<br />
conditions. We provide in<strong>for</strong>mation and support through monthly<br />
meetings, our website www.pmrandgca.org.uk, by email<br />
info.scotland@pmrandgca.org.uk, telephone 01382 562 974 and<br />
mail. Through various organisations we raise the profile of these<br />
conditions and try to improve the extremely variable and sometimes<br />
unacceptable standards of care.<br />
PSALV stand 20<br />
PSALV, Psoriasis Scotland, Scotland's only patient-led registered<br />
charity <strong>for</strong> those with psoriasis and psoriatic arthritis, supports<br />
people with these conditions, their families & carers, raises<br />
awareness & provides in<strong>for</strong>mation to all, campaigning, lobbying &<br />
liaising with the Scottish NHS, Scottish Government & clinicians <strong>for</strong><br />
better & more equitable services throughout Scotland. PSALV holds<br />
in<strong>for</strong>mation days, has a website, a newsletter and publishes<br />
literature on psoriasis & PsA.<br />
Pulmonary Hypertension Association UK stand 92<br />
<strong>The</strong> Pulmonary Hypertension Association (PHA UK) is the only charity<br />
in the UK especially <strong>for</strong> people with pulmonary hypertension (PH).<br />
We are committed to helping improve the lives of people with PH,<br />
and supporting the PH community in the UK. We do this by funding<br />
research into PH, raising awareness of the condition, and helping<br />
people in their day-to-day lives.<br />
Roche Products Ltd stand 98<br />
Roche is one of the world’s leading research-focused healthcare<br />
groups in the fields of pharmaceuticals and diagnostics. As a<br />
supplier of innovative products and services <strong>for</strong> the early<br />
detection, prevention, diagnosis and treatment of diseases,<br />
the Group contributes on a broad range of fronts to improving<br />
people’s health and quality of life.<br />
RApport stand 104<br />
RApport: education <strong>for</strong> nurses by nurses<br />
Developed and implemented by a specialist Steering Committee of<br />
healthcare professionals in partnership with Roche Products Limited<br />
and Chugai Pharma UK Limited, RApport is an educational plat<strong>for</strong>m<br />
designed to help the NHS enhance patient care in the field of<br />
rheumatoid arthritis (RA).<br />
Please visit the RApport stand to hear more about the National<br />
Meeting, meet with members of the Steering Committee and gather<br />
in<strong>for</strong>mation to support you in your ongoing clinical audits.<br />
<strong>Rheumatology</strong> and OUP stand 62<br />
<strong>Rheumatology</strong> is the international scientific journal published by<br />
Ox<strong>for</strong>d University Press on behalf of the BSR. This year come and<br />
meet at the Editor at the Stand or find out about the developments<br />
taking place the in the Journal.<br />
Royal Air Force Medical Service stand 72<br />
To succeed in our missions takes more than planes and pilots,<br />
there’s a team of highly skilled people behind every aircraft that takes<br />
to the skies, and that’s where you come in. Come and meet the<br />
team today to find out about the career that could await you as a<br />
RAF Medical Officer.
133 Exhibition | 1-3 May 2012<br />
1-3 May 2012 | Exhibition 133<br />
Royal <strong>Society</strong> of Medicine stand 4<br />
<strong>The</strong> Royal <strong>Society</strong> of Medicine is one of the largest providers of<br />
continuing medical education in the UK. Each year the RSM<br />
organises over 400 CPD accredited <strong>conference</strong>s, courses and<br />
meetings allowing doctors, dentists, veterinary surgeons, including<br />
students of these disciplines, and other healthcare professionals<br />
their continuing freedom to practise.<br />
For more in<strong>for</strong>mation: Email: membership@rsm.ac.uk<br />
Tel: 020 7290 2991 www.rsm.ac.uk<br />
Sanofi stand 63<br />
Sanofi, a global and diversified healthcare leader, discovers, develops<br />
and distributes therapeutic solutions focused on patients’ needs.<br />
Sanofi has core strengths in the field of healthcare with seven growth<br />
plat<strong>for</strong>ms: diabetes solutions, human vaccines, innovative drugs, rare<br />
diseases, consumer healthcare, emerging markets and animal<br />
health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York<br />
(NYSE: SNY).<br />
Savient Pharma Ireland Limited stand 66<br />
Savient Pharma Ireland Limited, a wholly-owned subsidiary of Savient<br />
Pharmaceuticals, is a specialty biopharmaceutical company seeking<br />
regulatory approval <strong>for</strong> KRYSTEXXA® in the European Union <strong>for</strong> the<br />
treatment of refractory chronic gout. KRYSTEXXA is available in the<br />
European Union through a Named Patient Programme and is<br />
currently the only FDA approved product <strong>for</strong> this indication in the<br />
United States.<br />
Scleroderma <strong>Society</strong> stand 10<br />
Come and visit our Stand, we have updated leaflets, Understanding<br />
and Managing Scleroderma booklet used by patients, GP’s and<br />
health professionals. Our latest leaflet “Hospital Checklist” provides<br />
a guide to nursing patients with SSc. Other services we provide<br />
include a free confidential helpline to support your patients<br />
throughout their experience of their condition, new website and<br />
quarterly newsletter. www.sclerodermasociety.co.uk<br />
Servier Lab Ltd stand 76<br />
Servier Laboratories is the UK subsidiary of <strong>The</strong> Servier Research<br />
Group, a French research based pharmaceutical company<br />
established in 1954 by Dr Jacques Servier. Created in 1963 with only<br />
two people, the UK subsidiary was the first subsidiary outside France.<br />
In just over fifty years, <strong>The</strong> Servier Research Group has developed in<br />
stature from a small family-owned, provincial pharmacy employing<br />
nine people to a multi-national operation, established in 140<br />
countries and with over 20,000 employees worldwide.<br />
SOBI stand 65<br />
Swedish Orphan Biovitrum is a Swedish based niche specialty<br />
pharmaceutical company with an international market presence.<br />
<strong>The</strong> company is focused on providing and developing specialist<br />
pharmaceuticals <strong>for</strong> rare disease patients with high medical needs.<br />
<strong>The</strong> portfolio consists of about 60 marketed products and an<br />
emerging late stage clinical development pipe-line. Our current<br />
marketed products in the UK are in the fields of: haematology,<br />
rheumatology, inherited metabolic disorders and emergency<br />
medicine.<br />
TRB Chemedica (UK) Ltd stand 49<br />
We are specialists in bio-synthetic Sodium Hyaluronate. OSTENIL®<br />
is an intra-articular injectable preparation of Sodium Hyaluronate <strong>for</strong><br />
the treatment of degenerative joint disease. OSTENIL® PLUS offers<br />
clinicians and patients the convenience of an effective single<br />
injection option viscosupplement. VISCOSEAL® - a post arthroscopic<br />
synovial fluid replacement - promotes restoration of homeostasis<br />
inside the joint. To find out more please visit our stand at<br />
<strong>Rheumatology</strong> 2012.<br />
UCB stand 26<br />
UCB, Brussels, Belgium (www.ucb.com) is a global<br />
biopharmaceutical company focused on the discovery and<br />
development of innovative medicines and solutions to trans<strong>for</strong>m<br />
the lives of people living with severe diseases of the immune<br />
system or of the central nervous system. With more than 8,500<br />
people in about 40 countries, the company generated revenue<br />
of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels<br />
(symbol: UCB).<br />
Vertec Scientific stand 51<br />
Established in 1985, Vertec Scientific is a leading distributor of<br />
world class systems <strong>for</strong> diagnostic imaging and radiotherapy in the<br />
UK. It’s portfolio features DXA and intraoperative x-ray c-arms from<br />
Hologic, radiotherapy patient immobilisation systems from Klarity<br />
Medical, ultrasound from Zonare, portable CT from Neurologica,<br />
virtual colonoscopy from Viatronix, radiation protection from<br />
Scanflex, ISP Gafchromic dosimetry film and Picsara, a highly<br />
innovative multi-image management system.<br />
Wisepress stand 2<br />
Wisepress.com, Europe's leading <strong>conference</strong> bookseller, has a<br />
complete range of relevant books and journals which can be<br />
purchased at the stand or posted to you. We also have a<br />
comprehensive medical bookshop online with great offers.<br />
bookshop@wisepress.com www.wisepress.com
134 Exhibition | 1-3 May 2012<br />
Abstract reviewers<br />
<strong>The</strong> BSR Heberden Committee was expanded substantially <strong>for</strong> the purposes of abstract<br />
assessment to ensure that every abstract was peer reviewed, blind, by at least three<br />
reviewers. <strong>The</strong> Heberden Committee is extremely grateful <strong>for</strong> the assistance of everyone<br />
who gave up their time to review abstracts and acknowledges them accordingly:<br />
Heberden Committee<br />
Dr Richard Watts (Chair)<br />
Prof Chris Denton<br />
Dr Andrew Keat<br />
Prof Michael Ehrenstein<br />
Prof Costantino Pitzalis<br />
Dr Hoda Mirjafari<br />
Prof Robert Moots<br />
Dr Jacqui Clinch<br />
Dr Michael Backhouse<br />
Dr Lindsay Bearne<br />
Dr Emmanuel George<br />
Dr Jon Packham<br />
Dr Ben Parker<br />
Prof Ian Clark<br />
Prof Elaine Hay<br />
Dr Ed Roddy<br />
Prof Gary Macfarlane<br />
Dr Hector Chinoy<br />
Dr Nicholas Shenker<br />
Dr Karen Walker Bone<br />
Dr Yasmeen Ahmad<br />
Dr Nicole Amft<br />
Dr Marina Anderson<br />
Dr Jacqueline Andrews<br />
Prof Nigel Arden<br />
Dr Eileen Baildem<br />
Dr Lindsay Bearne<br />
Prof Michael Beres<strong>for</strong>d<br />
Dr Rupa Bessant<br />
Dr Fraser Birrell<br />
Dr Cathy Bowen<br />
Dr Simon Bowman<br />
Dr Paul Bowness<br />
Prof Matt Brown<br />
Prof Ian Bruce<br />
Prof Chris Buckley<br />
Dr David Carruthers<br />
Prof Tim Cawston<br />
Prof Kuntal Chakravarty<br />
Prof Ernest Choy<br />
Dr Gavin Clunie<br />
Dr David Collins<br />
Prof Philip Conaghan<br />
Prof Andy Cope<br />
Mrs Trish Cornell<br />
Prof Jane Dacre<br />
Dr Julie Dawson<br />
Prof Chris Deighton<br />
Dr Cristina Estrach<br />
Dr Karl Gaffney<br />
Dr Lyn Goodacre<br />
Dr Caroline Gordon<br />
Dr Celia Gregson<br />
Dr Bridget Griffiths<br />
Ms Elizabeth Hale<br />
Dr Frances Hall<br />
Dr Alison Hammond<br />
Prof Elaine Hay<br />
Dr Philip Helliwell<br />
Prof Sarah Hewlett<br />
Dr Clare Higgins<br />
Dr Neil Hopkinson<br />
Dr Philippa Hulley<br />
Dr Charles Hutton<br />
Dr Kimmie Hyrich<br />
Dr John Ioannou<br />
Prof John Isaacs<br />
Dr Paresh Jobanputra<br />
Dr Jeremy Jones<br />
Prof David Kane<br />
Dr Lesley Kay<br />
Dr Clive Kelly<br />
Dr George Kitas<br />
Dr Ellie Korendowych<br />
Dr Peter Lanyon<br />
Dr Thomas Lawson<br />
Dr Jo Ledingham<br />
Dr Jenny Lewis<br />
Prof Ian McInnes<br />
Dr Chetan Mukhtyar<br />
Dr Fai Ng<br />
Dr Andrew Ostor<br />
Dr John Pauling<br />
Prof George Peat<br />
Dr Ken Poole<br />
Dr Duncan Porter<br />
Dr Elizabeth Price<br />
Dr Elizabeth Rankin<br />
Dr Karim Raza<br />
Dr Ruth Richmond<br />
Prof David L. Scott<br />
Dr Deborah Symmons<br />
Prof Patrick Venables<br />
Ms Karen Vinall<br />
Dr Nikki Walsh<br />
Dr Louise Warburton<br />
Dr Andrew Whallet<br />
Dr Anita Williams<br />
Dr Lyn Williamson<br />
Dr Gerry Wilson<br />
Dr Elspeth Wise<br />
Prof Jane Worthington<br />
Dr Adam Young<br />
If you would be interested in reviewing abstracts <strong>for</strong> next year’s <strong>conference</strong>,<br />
please email events@rheumatology.org.uk letting us know your area of expertise.
1-3 May 2012 | Exhibition 135<br />
Prize and bursary assessors<br />
<strong>The</strong> BSR and BHPR would like to thank all of the judges who have<br />
given up their time to assess the prizes at <strong>Rheumatology</strong> 2012<br />
BSR awards and bursaries<br />
Prof David L Scott, BSR President<br />
Dr Chris Deighton<br />
Prof Kuntal Chakravarty<br />
Dr Simon Bowman<br />
Prof David Isenberg<br />
BSR Heberden Committee<br />
BHPR prizes and bursaries<br />
Mrs Lindsey Hawley, BHPR President<br />
Mr Robert Field<br />
Mrs Patricia Cornell<br />
Dr Michael Backhouse<br />
Dr Jill Firth<br />
Dr Jo Adams<br />
Prof Krysia Dziedzic<br />
Dr Maggie McArthur<br />
Dr Lindsay Bearne<br />
Dr Kristie Haywood<br />
Dr George Peat
136 Exhibition | 1-3 May 2012<br />
Notes<br />
<strong>Rheumatology</strong> 2013 abstract deadline<br />
Wednesday 21 November 2012<br />
www.rheumatology.org.uk/<strong>conference</strong>
1-3 May 2012 | Exhibition 137<br />
www.rheumatology.org.uk/<strong>conference</strong>
138 Exhibition | 1-3 May 2012<br />
www.rheumatology.org.uk/<strong>conference</strong>
1-3 May 2012 | Exhibition 139<br />
www.rheumatology.org.uk/<strong>conference</strong>
140 Exhibition | 1-3 May 2012<br />
www.rheumatology.org.uk/<strong>conference</strong>
1-3 May 2012 | Exhibition 141<br />
www.rheumatology.org.uk/<strong>conference</strong>
142 Exhibition | 1-3 May 2012<br />
www.rheumatology.org.uk/<strong>conference</strong>
1-3 May 2012 | Exhibition 143<br />
www.rheumatology.org.uk/<strong>conference</strong>
144 Exhibition | 1-3 May 2012<br />
<strong>Rheumatology</strong> 2013 abstract deadline<br />
Wednesday 21 November 2012<br />
www.rheumatology.org.uk/<strong>conference</strong>
BSR<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong><br />
Education<br />
Courses<br />
Musculoskeletal Medicine and Pregnancy Course<br />
Ox<strong>for</strong>d | 06 July 2012<br />
Can Biologics Cure Rheumatoid Arthritis?<br />
London | 07 September 2012<br />
Foot and Ankle Course<br />
Leeds | 27 – 28 September 2012<br />
Basic Ultrasound Course<br />
Southend-on-Sea | 19 – 21 October 2012<br />
Core Skills in <strong>Rheumatology</strong> Course<br />
Newcastle | 15 – 16 November 2012<br />
Allied Health Professionals Course in RA<br />
Keele | 21 – 22 November 2012<br />
Advanced Course<br />
Ox<strong>for</strong>d | 03 – 04 December 2012<br />
Advanced Ultrasound Course<br />
Liverpool | 06 – 07 December 2012<br />
of delegates would recommend<br />
91% BSR courses to a colleague<br />
www.rheumatology.org.uk/education
Let’s talk about membership...<br />
Join us at Stand 32 <strong>for</strong> a free coffee and take the<br />
opportunity to discuss your membership, update<br />
your details, and talk about membership issues<br />
with the BSR/BHPR Membership Team!<br />
Interested in<br />
becoming a member?<br />
Please join us at the stand to hear about the<br />
exciting benefits the BSR can offer such as<br />
subscription to our journal <strong>Rheumatology</strong>,<br />
discounted rates <strong>for</strong> the BSR/BHPR annual<br />
<strong>conference</strong> and many more!<br />
Please join us at the stand to hear about the<br />
great benefits BHPR can offer such as high-quality<br />
CPD accredited training, subscription to the<br />
Musculoskeletal Care Journal, discounted rates <strong>for</strong> the<br />
BSR/BHPR annual <strong>conference</strong> and many more!<br />
Contact Details:<br />
Subscriptions Department<br />
18-20 Bride House<br />
Bride Lane<br />
London EC4Y 8EE<br />
T: +44(0)20 7356 0949<br />
E: subscriptions@rheumatology.org.uk